



Driven by
Innovation
Thriving with
Sustainability

About the Report

We are pleased to present our Integrated Annual Report for FY 2024-25 which includes voluntary information to the extent available to us, in accordance with reporting framework developed and designed by **International Integrated Reporting Council (IIRC)**. Our endeavour is to present this information in a manner that is also relevant to all key stakeholders. This report also aligns with the Companies Act, 2013, Indian Accounting Standards and SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.

Reporting Period

The major reporting period for the Integrated Annual Report is **1st April, 2024 to 31st March, 2025.**

However, certain portions of the report provide facts and numbers from prior years in order to give readers a complete picture.

Scope and Boundary

This report provides comprehensive information about the business activities of **Advanced Enzyme Technologies Limited**, suitably communicated through the six capitals as per the guidelines defined by the International Integrated Reporting Council (IIRC). The document encapsulates our business model, overarching performance and corresponding results.

Our Capitals

- Financial Capital
- Manufactured Capital
- Intellectual Capital
- Human Capital
- Natural Capital
- Social and Relationship Capital

Auditor’s Report

To ensure the integrity of facts and information, the financial statements are audited by **MSKA and Associates**, Chartered Accountants and the ‘Independent Auditor’s Report’ has been duly incorporated as part of this report.

Investor Information

₹ 31,265 million
Market capitalisation as on March 31, 2025
L24200MH1989PLC051018
CIN
540025
BSE Code
ADVENZYMES
NSE Code
₹ 4 per share
Interim Dividend Declared
₹ 1.20 per share
Dividend Proposed
July 30, 2025
AGM Date

Forward-Looking Statements

This report contains forward-looking statements that describe our expectations, based on reasonable assumptions and past performances. These are subject to change in light of developments in the industry, geographical market conditions, government regulations, laws and other incidental factors. These statements must not be used as a guarantee of our future performance, as the underlying assumptions could change materially.

Icons to Look for Throughout the Report

- Page Reference
- Online Download Reference
- Weblink Reference

What’s Inside the Report

Corporate Overview006-063

- About Advanced Enzymes	006
- Key Highlights	008
- Value Added Products	010
- Geographic Presence	011
- An Illustrious Legacy	012
- Message from Chairperson	014
- Favourable Opportunities	018
- Value Creation Model	030
- Stakeholder Engagement	032
- Governance	034
- Board of Directors	038
- Management Team	040
- Corporate Information	041
- Financial Capital	042
- Manufactured Capital	046
- Intellectual Capital	050
- Natural Capital	054
- Human Capital	058
- Social and Relationship Capital	062

Statutory Reports064-160

- Management Discussion and Analysis	064
- Board’s Report	093
- Corporate Social Responsibility Report	102
- Corporate Governance Report	108
- Business Responsibility and Sustainability Report	126

Financial Statements161-292

Standalone Financial Statements	
- Independent Auditor’s Report	161
- Balance Sheet	170
- Statement of Profit and Loss	171
- Cash Flow Statement	173
- Notes to Financial Statements	175

Consolidated Financial Statements	
- Independent Auditor’s Report	223
- Balance Sheet	230
- Statement of Profit and Loss	231
- Cash Flow Statement	233
- Notes to Financial Statements	235



Scan the QR code to view the electronic version of this report is available online



Website: www.advancedenzymes.com



In a world grappling with environmental challenges, sustainability is no longer an option. It is cardinal. The choices made today will shape the world that is ultimately passed on to the generations yet to come. At the heart of this journey lies science, holding the key to a better tomorrow.

At Advanced Enzymes, we as a team dedicate our expertise and passion to pioneering solutions that redefine possibilities. Over the years, our Company has harnessed the power of enzymes and probiotics to deliver nature-driven solutions, promoting wellness and enhancing industrial efficiency.

Led by the precision of science and the wisdom of nature, our Company has built a legacy of innovation that spans human nutrition, animal health and industrial processing. With every breakthrough, we push the limits of what is possible in our journey towards a cleaner, healthier and more sustainable world.

From its inception, sustainability has been a responsibility that we strive to fulfil daily. Each enzyme developed and every probiotic formulated is designed in harmony with nature, thereby reducing waste, amplifying efficiency and minimising our Company's environmental footprint. Whether shaping the future with bio-based medicines, enhancing digestion through probiotics or promoting sustainable food systems, our Company's solutions empower industries to grow responsibly.

As Advanced Enzymes steps into the future, remains committed to pushing the boundaries of biotechnology while safeguarding the planet. Backed by global presence, advanced Research and Development (R&D) and a team driven by passion, our Company continues to drive progress. The world is evolving and so are we. Yet, one thing remains unchanged—our steadfast belief that

innovation and sustainability

must go hand in hand. Because in the end, true success is not measured by profits alone, but by the **lives** impacted and the **legacy** created.



What Enzymes

Means to Us

Enzymes are natural protein molecules produced by all living organisms that act as catalysts within cells. They serve as specialised catalysts, speeding up biochemical reactions. Advanced Enzymes utilises enzymes to replace chemicals and improve the efficiency of various industrial processes for our clients.



What Probiotics

Means to Us

Probiotics are live microorganisms that provide health benefits when consumed in sufficient amounts and play a vital role in healthcare. While they are commonly used to treat digestive disorders, their applications go far beyond. Ongoing research is investigating their potential in managing various diseases. Probiotics work by fighting harmful microorganisms and releasing beneficial metabolites into the human and animal systems, promoting overall health. Advanced Enzymes leads the charge in developing and scaling technologies to produce and apply essential probiotics, supporting their growing role in modern healthcare.



What Biocatalysts

Means to Us

Biocatalysts are natural substances that accelerate chemical reactions without being consumed or altered in the process. They play a vital role in biological systems by lowering activation energy and enabling essential biochemical processes such as metabolism and growth. Their specificity and ability to operate under mild conditions make them an eco-friendly alternative to chemical catalysts, reducing toxic by-products and enhancing efficiency. Our Company focuses on developing and applying biocatalysts to optimise industrial processes, contributing to sustainable solutions across various sectors.



What Bio-processing

Means to Us

Bioprocessing involves using living cells or their components, such as enzymes and microorganisms, to facilitate chemical reactions and produce valuable products. It plays a crucial role in industries such as pharmaceuticals, food and beverages and biofuels by enabling the efficient and sustainable production. Compared to conventional chemical methods, bioprocessing offers advantages such as higher specificity, lower energy consumption and reduced environmental footprint. Our Company specialises in developing and scaling up bioprocessing technologies to deliver innovative and eco-friendly solutions that meet the needs of our diverse clientele.

About Advanced Enzymes

Transforming Industries Across the Globe

Since our inception in 1989, Advanced Enzyme Technologies Limited (AETL) has been a frontrunner in enzyme innovation. Headquartered in Thane, Maharashtra, our Company stands as India's largest and one of the world's leading enzyme companies. Our Company specialises in the research, development and manufacturing of high-quality enzymes and probiotics. With over three decades of distinguished expertise, our Company remains committed to creating sustainable and eco-friendly solutions that help transform industries across the globe.

AETL boasts a diverse product portfolio, including over 400 proprietary enzyme formulations, derived from over 65 indigenous enzymes, allowing us to serve a diverse range of industries such as human nutrition, animal nutrition, food processing, textiles, biofuels and environmental applications. Our Company offers customised enzyme solutions that are not only effective but also designed to minimise environmental impact.

Our organisation firmly believes in the transformative power of nature's catalysts. By replacing traditional chemical processes with enzyme-based alternatives, our Company enables the clients to achieve cleaner, greener and more efficient production methods. This approach minimises pollution, reduces energy consumption and significantly lowers the carbon footprint. This steadfast commitment to sustainability serves as our guiding principle, shaping every aspect of our operations, from product innovation to process optimisation.

True progress is driven by collaboration and our Company works closely with its clients to identify unique challenges and develop tailor-made enzyme solutions that enhance efficiency, promote sustainability and contribute to healthier, more sustainable practices. With a passionate team of scientists, engineers and experts, we continue to lead the way in enzyme technology, striving for a future that is cleaner, greener and more efficient for all.



Vision

Our vision at AETL is to become a leading, respected and preferred enzymes and probiotics-based solutions provider in the global market.



Mission

It is our mission to see that every human being is able to utilise the power of enzymes and probiotics, for general well-being, health and improving the quality of life. It is also our mission to see that every possible industry is able to take the advantage of enzymes, to create and produce innovative products, improve the quality of the end-products, reduce energy costs, optimise the use of raw materials and resources and reduce pollution and the overall carbon footprint of the process.



Key Highlights

The Performance Scorecard

FY 2024-25



Financial Capital

₹ 6,369 million

Revenue

₹ 1,944 million

EBITDA

₹ 1,340 million

PAT

₹ 11.72

Earnings per share

Refer page 042



Manufactured Capital

₹ 338 million

Capital expenditure

~60%

Total capacity utilisation

500 m³+

Fermentation capacity

Refer page 046



Intellectual Capital

₹ 248 million

Investments in R&D

17

Patents (filed & granted)**

400+

Proprietary products

Refer page 050



Human Capital

24.75%

Women employed

Zero

Incidences of Fatality

₹ 560 million

Spend towards employees

Refer page 058



Social and Relationship Capital

8

Key Industry Associations

₹ 19 million

Contribution towards

CSR projects

65000+

Shareholders

Refer page 062



Natural Capital

1,163 GJ

Energy consumed through renewable sources

6,307 KL

Reduction in water consumption

165 MT

Reduction in waste generation

Refer page 054

Note: All the data mentioned w.r.t. Human, Social & Relationship and Natural capital is on standalone basis


**Patents includes the filed applications

Value Added Products

Solutions That Go That Extra Mile

At Advanced Enzymes, we maintain an integrated presence across the entire enzyme value chain, seamlessly connecting research and development, commercial-scale manufacturing and marketing.

Our Company's extensive capabilities empower us to deliver bespoke, value-added solutions precisely tailored to the clients' specific requirements. This strategic approach not only fosters robust partnerships but also significantly strengthens our overall business profile.




Geographic Presence

Performance Across the Globe

Our Company has established a strong global presence by remaining true to its commitment to innovation and quality. As a trusted partner across diverse industries, our Company delivers leading-edge enzyme solutions that meet the evolving needs of the customers.

Our organisation's expansive reach and deep technical expertise enable us to drive progress and sustainability at scale. Through continuous innovation and a customer-centric approach, we strive to lead with excellence in the enzyme technology landscape.




An Illustrious Legacy

Strategically Expanding Legacy

We at Advanced Enzymes have strategically grown our legacy. Over the years, we have successfully tapped into new markets and developed high-impact solutions for our global customers.


International acquisitions have further helped our Company to strengthen its worldwide presence, making solutions more accessible and driving long-term growth.



Note : * Through Kotak India Venture Fund I, Kotak Employees Investment Trust and Kotak India Venture (Offshore) Fund

Message from Chairperson

Driving Sustainable Growth Through Innovation



Dear Stakeholders,

It is with pride and optimism that I present the Integrated Annual Report of Advanced Enzyme Technologies Limited for FY 2024–25. The health and wellness landscape continues to evolve rapidly, demanding innovation and sustainable solutions. At Advanced Enzymes, we believe today's choices shape tomorrow's world. We remain committed to building a better future for generations to come.

The past year placed the global economy at a pivotal point amid policy shifts and uncertainty. Yet, we remained resilient—leveraging innovation and strategic focus to deliver consistent performance and maintain our growth trajectory.

Navigating Uncertainty with Focus

Global growth in 2024 was stable but subdued. While moderating inflation offered a positive signal for monetary policies, optimism was tempered by unpredictability—particularly from evolving U.S. trade policies and tariffs that could restructure global markets.

The enzyme and probiotics industry saw modest growth, with companies experiencing varied outcomes. Intense competition from well-funded players with strong R&D and market reach challenged many companies, including us. However, by leveraging our expertise in enzyme-based solutions and targeting niche opportunities, we maintained our competitive edge. Our robust product pipeline positions us well to deliver ongoing value to our consumers.

Financial Performance

Delivering on strategic goals requires sound financial discipline. Our performance in FY 2024–25 reflects our resilience and positions us for future growth. As of March 31, 2025, we recorded consolidated revenue of ₹6,369 million—a two percent year-on-year increase.

Our Animal Nutrition vertical grew 12 percent, contributing 12 percent of total revenue. The Bioprocess vertical, particularly the food business, grew 4 percent. Human Nutrition, contributing 64 percent, remained our largest vertical. Our specialized manufacturing business saw a 30 percent revenue increase, reflecting the success of our diversification efforts.

Subsidiaries played a crucial role in our growth. Scitech Specialities reported a 30 percent revenue increase. JC Biotech and evovx Technologies GmbH advanced our capabilities, with evovx's protein engineering strengthening our R&D capabilities.

Our stable balance sheet and strong cash reserves give us flexibility for strategic investments. As we move 80 percent utilization, from 55 to 60 percent, we anticipate further capacity expansion and acquisition opportunities.

Driving Innovation

Innovation is our foundation and key differentiator. In FY 2024–25, we invested ₹248 million in R&D (four percent of revenue), up from ₹197 million the previous year, representing four percent of revenue. This enabled the development of 15 to 16 new molecules at different stages, many nearing commercialization.

Our strategic R&D focus on biocatalyst enzymes and advanced protein engineering through our German subsidiary evovx Technologies enables us to create enzymes that function effectively under harsh commercial conditions.

We developed extensive enzyme libraries for diverse applications, including sugar, weight management and digestive wellness. In the food business, we introduced baking solutions reducing gluten and sugar use, enhancing fiber and nutrition-meeting the demand for healthier, clean-label products. Our branded and clinically studied nutraceutical ingredients support carbohydrate metabolism and gut health. Future clinical studies will explore enzyme and probiotic applications to meet evolving health needs.

Our U.S. subsidiary established Starya Labs, an independent facility to meet a growing need for third-party testing of enzymes and probiotics. It will serve the increasing demand for regulatory compliance and independent testing certifications for brands in North America.

We also deployed high-throughput and AI-based screening tools, improving enzyme identification and optimization. These technologies enhance product quality, profitability, and health benefits for consumers—empowering innovation-driven growth and exploration of untapped opportunities.

Message from Chairperson contd...

Building a Roadmap for Sustainable Growth

We are deepening our presence in the U.S. nutraceutical market, focusing on high growth sectors such as gut health, protein powders, and pet supplements. Strong brand recognition and targeted marketing are increasing inbound sales and loyalty. To scale further, we are expanding our salesforce and distributor network, prioritising partners with market influence and financial strength.

Strategic acquisitions are key to our growth strategy. With carefully considered acquisitions, we intend to expand our customer base, acquire valuable patents or technology and enhance manufacturing capabilities. Our acquisitions of evoox and Scitech have proven instrumental in strengthening our reach-ensuring value-aligned expansion.

A new R&D facility under development in Nashik, spanning 1,00,000 square feet in its first phase and having already incurred a Capex of ₹469 million (including land acquisition cost), will consolidate research efforts, reduce turnaround time, and accelerate innovation.

Committing to a Greener Future

Sustainability is integral to our ethos. Our enzyme-based solutions replace chemical catalysts across industries, advancing eco-friendly alternatives in healthcare, agriculture, and bioprocessing.

We are proud to have received the Zero Hazardous Discharge Certificate 3.0, reaffirming our commitment to environmentally responsible practices. Our 510 kW solar plant contributed 10% of our electricity in fiscal 2025, marking a major step in our clean energy strategy. We aim to further increase our reliance on renewables.

Our sustainability initiatives also encompass the development of enzymatic solutions for API intermediates, offering cleaner alternatives to chemical methods and helping reduce environmental treatment burdens. These initiatives align with global sustainability goals and promote efficient resource use. We continue to invest in green technologies for biomass hydrolysis and vegetable oil extraction—further proof of our commitment to environmental stewardship and a greener future.

Guided by Vision

Advanced Enzyme Technologies is well-positioned to capture opportunities in the enzyme and probiotics space. Our business model, innovation pipeline, and strategic investments provide a strong foundation for sustained growth.

We recognize global uncertainties and competitive pressures will persist. Our core strengths, innovation and sustainability, coupled with a unwavering focus on market expansion and operational excellence, will continue to drive progress.

With our dedicated team, visionary leadership, and stakeholder trust, I am confident we will continue to deliver science-backed, eco-safe solutions.

My heartfelt gratitude to our dedicated employees, loyal customers, and valued partners and shareholders for their continued support. As we enter the next phase of our journey, we are confident and ready to lead with clarity and purpose.

Sincerely,

V.L. Rathi

Chairperson



Favourable Opportunities

Staying Ahead of the Curve

We closely monitor emerging trends to stay ahead in today's dynamic business environment. With a strategic focus on capitalising on new growth opportunities, our Company positions us to effectively meet changing market demands.

Our agility, robust investments in R&D and operational expertise enable us to consistently expand our product portfolio and maintain a leadership position in the industry.



Favourable Opportunities contd...



Human Nutrition



Personalised Nutrition

The burgeoning personalised nutrition market presents significant growth opportunities, driven by increasing consumer demand for tailored dietary solutions and health-focused products. As awareness grows about individual nutritional needs and the importance of customised approaches to wellness, there is immense potential for expansion. Consumers increasingly seek products that address their specific health concerns, unique physiological requirements and personal wellness goals, positioning this market for substantial development in the coming years.

Our Approach

By leveraging technical expertise, our Company utilises customer-driven insights to analyse specific health concerns and develop customised enzyme formulations tailored to individual needs.



Moving Towards Plant-based Nutrition

As consumers increasingly prioritise health, sustainability and ethical choices, plant-based nutrition is witnessing significant growth. Enzymes are emerging as critical catalysts in this evolution, enhancing sensory properties like taste and texture while improving digestibility, thereby addressing both functional performance and clean-label demands in plant-based food innovation.

Our Approach

We serve as a key enabler of plant-based innovation by partnering with food manufacturers to co-develop enzyme formulations for plant-based dairy, meat and bakery applications.



Metabolic Health

As health consciousness rises globally, growing numbers of consumers are incorporating dietary supplements into their wellness routines to enhance metabolic function. These products play an important role in supporting weight management, blood sugar regulation and other critical aspects of preventive health maintenance.

Our Approach

Leveraging its expertise in enzymes and probiotics, our Company develops integrated metabolic health solutions that combine bioactive ingredients like berberine with precision enzyme blends to optimise nutrient absorption and metabolic efficiency. These formulations are strategically offered through both B2B ingredient partnerships and direct-to-consumer products, addressing diverse wellness needs across markets.



Gut Health and Mental Wellness

Research increasingly demonstrates the critical connection between gut health and mental well-being, driving demand for microbiome-focused solutions. By leveraging R&D capabilities to develop targeted enzyme formulations that support the gut-brain axis, our Company positions itself as a key innovator in this rapidly growing market.

Our Approach

Our Company aims to harness the potential of beneficial probiotic bacteria to improve mood, reduce stress and advance mental health through targeted microbial interventions.



Favourable Opportunities contd...



Biocatalyst



Specialised Enzymes for Green Pharma

Pharmaceutical and biotechnology companies are increasingly shifting away from hazardous chemicals and energy-intensive manufacturing processes toward greener, safer and more sustainable methods of producing medicines. Traditionally, toxic solvents were widely used, generating substantial waste and causing environmental harm. In contrast, enzymes have emerged as a cleaner and more efficient alternative, enabling reactions that require less energy and produce minimal waste.

Our Approach

Our Company's processes not only reduce environmental footprint but also improves operational efficiency, aligning with the industry's growing emphasis on sustainability and corporate responsibility.



Biocatalysis Driving API Innovation

As the demand for biologics and specialty drugs continues to grow, driven by the rising prevalence of chronic diseases, personalised medicine and advancements in therapeutic research, there is increasing interest in high-value biotech Active Pharmaceutical Ingredients (APIs). These APIs are the foundation of cutting-edge treatments such as monoclonal antibodies, gene therapies and targeted biologics. Biotech APIs are often produced through complex biological processes involving living systems, making their development and manufacturing more technically demanding. To streamline the process of API manufacturing, biocatalysis plays a critical role by enabling highly selective, efficient and sustainable synthesis of complex molecules.

Our Approach

At AETL, we are engaged in developing biocatalysis solutions for API manufacturers, offering enzyme-based, target-specific alternatives that significantly reduce energy consumption, processing time and dependency on harsh chemicals, ultimately enabling more sustainable and cost-efficient manufacturing.



Favourable Opportunities contd...



Probiotics



Personalised Probiotics

The probiotic market is experiencing a major shift as consumers seek more personalised, targeted solutions beyond traditional digestive support. Next-gen probiotics are designed to support specific outcomes, from cognitive function to immune health and gut-brain axis balance.

Our Approach

We actively expanding our portfolio by introducing a wider range of probiotic products aimed at supporting immunity development, enhancing gut health, promoting active wellness and addressing diverse nutraceutical applications.



Convenience, Multifunctionality and Holistic Wellness

Modern consumers demand more from probiotics, seeking not just gut health benefits but also convenience, multifunctionality and sensory appeal. This has led to the rise of innovative formats like gummies, protein powders and fermented snack bites that blend probiotics with fibres, botanicals and functional proteins.

Our Approach

Our approach to probiotic development also prioritises consumer convenience, taste and functionality. In line with market trends favouring multifunctional and palatable formats, we co-create solutions that integrate probiotics into functional foods, beverages and supplements.



Favourable Opportunities contd...



Animal Nutrition



Advance Holistic Animal Health

With rising awareness around holistic animal well-being, the nutrition industry is increasingly prioritising comprehensive solutions that go beyond basic feed efficiency. There is growing emphasis on enhancing gut health, maintaining intestinal balance, boosting immune function, improving Feed Conversion Ratio (FCR) and addressing specific challenges like mycotoxin mitigation, joint health and oral hygiene. These focus areas are essential not only for animal productivity but also for meeting the global shift toward antibiotic-free, sustainable animal farming.

Our Approach

We harness our enzyme and probiotic expertise to develop integrated, science-backed formulations that support each of these critical health pillars. The solutions are designed to enhance digestion, modulate gut microbiota, improve nutrient absorption and strengthen the immune system.




Immunity Enhancement

As restrictions on Antibiotic Growth Promoters (AGPs) continue to tighten, the animal nutrition industry is increasingly adopting enzymes and probiotics as natural and effective alternatives.

Our Approach

Our Company develops integrated gut health solutions by combining enzymes with probiotics or prebiotics. These formulations are designed to improve nutrient absorption, strengthen immune function and help manage inflammation.



Favourable Opportunities contd...



Baking



Rising Demand for Gluten Free Food

The growing popularity of gluten-free and ancient grain-based baking is driving demand for improved texture and performance in non-wheat flours, which typically lack the structural properties of gluten. This presents a significant opportunity to develop specialised enzymes that enhance dough elasticity, volume and softness in flours such as rice, millet, sorghum and cassava.

Our Approach

By addressing key functional gaps in gluten-free formulations, such as improving texture, structure and consistency, we position ourselves as a leading provider of high-performing, clean-label baking solutions in this rapidly expanding market.



Need for Shelf Life Enhancement

In India, the shelf life of bakery products poses a significant challenge due to the country's climatic conditions and the limited adoption of advanced preservation methods. Consequently, there is an increasing need to develop specialised enzyme solutions that naturally prolong freshness, preserve softness and delay staling in baked goods.

Our Approach

Leveraging our established expertise in baking enzymes, we address market demand for longer-lasting, high-quality products by offering bakeries a clean-label, cost-effective solution to extend shelf life without compromising taste or texture.



Frozen Dough and Cold Chain

As the global demand for frozen baked goods increases, maintaining product quality after freezing and thawing has become a critical challenge. This presents a growing opportunity to develop freeze-resistant enzyme systems that preserve dough rise, texture and freshness throughout the cold chain.

Our Approach

We provide solutions that are particularly valuable for exporters and food service bakeries, where consistency and extended shelf life are essential.



Value Creation Model

Our Company's Value-Accretive Model Across Six Capitals

Inputs

Financial Capital ₹ 224 million Total equity ₹ 13,985 million Reserves	₹ 16,214 million Total assets
Manufactured Capital 9 Manufacturing facilities	500 m ³ + Fermentation capacity
Intellectual Capital 7 R&D centres	100+ R&D and technology experts
Human Capital 395+ Total employees 40+ Training programs conducted	295+ Total workers ₹ 560 million Total remuneration paid
Social and Relationship Capital ₹ 19 million CSR expenditure 8 Key industry associations ₹ 398 million Contribution to exchequer	65,000+ Shareholders 700+ Customers
Natural Capital 36,800 GJ Total electricity consumption 1,83,238 GJ Total energy consumption	1,36,844 KL Total water consumption

Our Company's Ecosystem

Research and Development

- Application development
- Customisation support
- IP protection
- Process scale-up
- Microbial technology
- Enzyme and probiotic discovery



Manufacturing

- Large capacities
- Highly controlled processes
- Flexible batch sizes
- Flexible down streaming capabilities
- Ability to quickly expand
- Globally competitive cost structure



Marketing and Distribution

- Customised solutions
- Reliability and quality
- Global regulatory expertise
- Value-based selling
- Direct access to end users
- Deep customer insights

Outputs

Financial Capital ₹ 6,369 million Revenue 31 % EBITDA margin	21 % PAT margin
Manufactured Capital 68+ Enzymes and probiotics 400+ Proprietary products	~60% Capacity Utilisation
Intellectual Capital 17 Patents (filed & granted) 15 Food Enzyme Dossiers Filed with EFSA	1 Novel Food Dossier Filed 9 GRAS Dossier Evaluated by the US FDA
Human Capital 108 Women employees and workers Zero Incidences of Fatality 9.29% Employee turnover rate	68% Skill up-gradation training 60% Health and safety measures training
Social and Relationship Capital 1,351 Lives benefitted 45+ Countries Worldwide presence 44 % Dividend pay-out ratio	₹ 4 Dividend Per Share ₹ 1.2 Dividend Proposed
Natural Capital 10.06 % Reduction in electricity consumption 22.31 % Water recycled	14.74 % Reduction in energy consumption

Stakeholders Impacted

Investors Shareholders
Customers Value Chain Partners
Customers Employees
Employees Workers
Communities Customers Shareholders Value chain partners
Communities

SDGs Impacted






















Note: All the data mentioned w.r.t. Human, Social & Relationship and Natural capital is on standalone basis

Stakeholder Engagement

Collaboration at the Core of Progress



Stakeholders	Importance of Stakeholders	Modes of Engagement	Frequency of Engagement	Capital Linkages
↓  Investors and Shareholders	Funds obtained from investors and financial institutions through equity, debt and accruals serve as the key drivers of growth for our Company's financial capital.	↓ Press releases, e-mail, media releases, annual general meeting, stock exchange(s) intimations and website	↓ Quarterly, half- yearly, annual and need-based	↓  
 Employees and Workers	Our Company promotes self-supervision, fair rewards and help employees excel. Their collaboration and expertise play a vital role in driving our Company's growth.	One-on-one interactions, e-mail, senior management meet and internal communication platforms	Quarterly, annually and need-based	  
 Customers	Our customers help generate revenue, build brand reputation, encourage repeat business and inspire innovation through their feedback.	E-mail, SMS, pamphlets, advertisement, website and meetings	Ongoing and need-based	    
 Value Chain Partners	Our valuable chain partners enable us to enhance operational efficiency, reduce costs, promote sustainability and fulfil customer expectations.	E-mail, website and meetings	Ongoing and need-based	 
 Communities	As communities are partners in progress, we at Advanced Enzymes build strong relationships with them.	E-mail, meetings, telecommunications and one-on-one meetings	Ongoing	 

● Financial Capital ● Manufactured Capital ● Intellectual Capital ● Human Capital ● Natural Capital ● Social and Relationship Capital

Governance

Moving Ahead Ethically

We are committed to upholding strong corporate governance principles based on transparency, accountability and ethical conduct. Our governance framework includes a diverse and independent Board supported by various committees to ensure effective oversight and compliance with regulations.

Our Company implements clear policies and mechanisms to promote integrity, manage risks and protect stakeholder interests. Through regular meetings, continuous monitoring and proactive measures, we strive to maintain high standards of governance and build trust with all our stakeholders.

Shareholding Pattern (%)



43.08% - Promoters
20.09% - Institutions
36.83% - Public

Our Company's Policies

Corporate Social Responsibility Policy	Code of Conduct and Ethics	Prohibition of Insider Trading Code	Whistle Blower Policy	Code for Fair Disclosure	Policy on Material Subsidiaries
Policy on Related Party Transactions	Policy on Human Rights and Employee Well-Being	Prevention of Sexual Harassment Policy	Policy on Board Diversity	Dividend Distribution Policy	Nomination and Remuneration Policy

Code of Conduct and Ethics

Our Company committed to the highest standards of integrity and ethical conduct across all business operations. We have implemented a robust compliance programme that includes clear policies and governance frameworks to promote ethical behaviour and ensure adherence to laws and internal regulations. This programme is regularly updated to stay aligned with changing business and regulatory environments.

Our zero-tolerance approach to corruption and bribery is reinforced through a stringent anti-corruption policy and strong internal controls that prevent unethical practices. The policy provides clear guidance on identifying and addressing misconduct. Additionally, we promote employee awareness through regular training and communication, ensuring all team members understand their ethical responsibilities. Through these efforts, AETL fosters a culture of accountability, transparency and trust.



Corporate Framework



Note: *Advanced Enzyme currently holds 95.72% in JC Biotech

Board of Directors

Guiding Success



M ● ● ● ●

Mr. Vasant Rathi
Chairman and Non-Executive Director



C ● ● M ● ● ●

Mr. Mukund Kabra
Whole-time Director



C ● ● M ● ●

Mr. Pramod Kasat
Independent Director



M ● ●

Ms. Rasika Rathi
Non-Executive Director



C ● ● ● ●

Mr. Vinodkumar Hiralal Jajoo
Independent Director



Dr. Sunny Sharma
Non-Executive Director

C Committee Chairman M Committee Member

● Audit Committee ● Nomination and Remuneration Committee ● Stakeholders' Relationship Committee

● Risk Management Committee ● CSR Committee



M ● ● ●

Ms. Rajshree Patel
Independent Director



M ● ● ●

Mr. Nitin Deshmukh
Independent Director



M ● ●

Mrs. Vandana Tilak
Independent Director

Board Diversity


Advanced Enzymes maintains a diverse Board comprising members with varied expertise, experience, perspectives and gender representation. This enables robust decision-making and effective governance, aligning with our Company's commitment to transparency and accountability.

Board Composition



● 55.56% - Independent Directors
● 44.44% - Non-Independent Directors

Board Diversity



● 33.33% - Women Directors

C Committee Chairman M Committee Member

● Audit Committee ● Nomination and Remuneration Committee ● Stakeholders' Relationship Committee

● Risk Management Committee ● CSR Committee

Management Team

Leading from the Front



M ●

Mr. Beni Prasad Rauka

Group CFO and Director - Advanced Bio-Agro Tech Limited, Advanced Enzytech Solutions Limited, JC Biotech Private Limited, SciTech Specialities Private Limited and Saiganesh Enzytech Solutions Private Limited, India



Mr. Dipak Roda

Sr. Vice President - Marketing and Business Development, Director - Advanced Enzytech Solutions Limited, India



M ●

Mr. Sanjay Basantani

Company Secretary and Head Legal



Mr. Harshad Doshi

Chief Financial Officer and Chief Operating Officer of the US subsidiaries



Ms. Martina Doering

Managing Director/Head of Business Development - evoxx technologies GmbH, Germany



Dr. Michael Puls

Managing Director/Head of Research and Development - evoxx technologies GmbH, Germany

C Committee Chairman M Committee Member

● Audit Committee ● Nomination and Remuneration Committee ● Stakeholders' Relationship Committee

● Risk Management Committee ● CSR Committee

Corporate Information

Board Of Directors

Mr. Vasant Rath

Non-Executive Chairman

Mr. Mukund Kabra

Whole-time Director

Ms. Rasika Rath

Non-Executive Director

Mr. Pramod Kasat

Independent Director

Mr. Vinodkumar Jajoo

Independent Director

Dr. Sunny Sharma

Non-Executive Director

Ms. Rajshree Patel

Independent Director

Mr. Nitin Deshmukh

Independent Director

Mrs. Vandana Tilak

Independent Director

Management Team

Mr. Beni Rauka

Chief Financial Officer

Mr. Dipak Roda

Sr. VP. -Marketing & Business Development

Mr. Sanjay Basantani

Company Secretary & Head-Legal

Mr. Harshad Doshi

Chief Financial Officer & Chief Operating Officer of the US subsidiaries

Ms. Martina Doering

Managing Director/Head of Business Development, evoxx technologies GmbH, Germany

Dr. Michael Puls

Managing Director/Head R&D, evoxx technologies GmbH,Germany

Plants

(including subsidiaries)

A-61/62, M.I.D.C. Area, Sinnar, Nashik - 422 103, Maharashtra

SORL, H-17, M.I.D.C, Satpur Area, Nashik - 422 007, Maharashtra

Survey No. 30, Pali, Vasind, Shahpur, Thane - 421 601, Maharashtra

Plot No. B-5-13, SEZ, Pithampur, Dhar - 452 774, Madhya Pradesh

Plot No. 548 to 550, APIIC Growth Centre, Gundlapalli Village, Maddipadu Mandal, Prakasam District, Ongole - 523 211, Andhra Pradesh

Unit I - A-3, Unit II - A-12/13, STICE, Musalgaon, Tal. Sinnar District, Nashik - 422 112, Maharashtra

13591 Yorba Avenue, Chino, California 91710

4880 Murrieta St.,Chino, California 91710

R&D Locations

(including subsidiaries)

A-61/62, M.I.D.C. Area, Sinnar, Nashik - 422 103, Maharashtra

Plot No. A-161, Main Road No. 27, Wagle Industrial Estate, Thane (W) - 400 604, Maharashtra

A-135, Road No. 23, Wagle Industrial Estate, Thane (W) - 400 604, Maharashtra

A-28, STICE, Musalgaon, Sinnar, Nashik - 422 112, Maharashtra

Plot No. 548 to 550, APIIC Growth Centre, Gundlapalli Village, Maddipadu Mandal, Prakasam District, Ongole - 523 211, Andhra Pradesh

Creative-Campus-Allee 12, 40789 Monheim am Rhein, Germany

1406 Lexington Street, Tustin CA 92782

Registered Office

Advanced Enzyme Technologies Limited
CIN: L24200MH1989PLC051018
A - Wing, Sun Magnetica, 5th Floor, LIC Service Road, Louiswadi, Thane (W) - 400 604, Maharashtra
Tel: +91-22-41703200,
Fax: +91-22-25835159
Email: info@advancedenzymes.com
Website: www.advancedenzymes.com

Registrar & Transfer Agent

MUFG Intime India Private Limited (formerly Link Intime India Private Limited)
C-101,1st Floor, 247 Park, Lal Bahadur Shastri Marg, Vikhroli (West), Mumbai - 400 083, Maharashtra
Tel No.: +91 810 811 8484
Fax No.: (022) 4918 6060
Email id: rnt.helpdesk@in.mpms.mufig.com
Website: https://in.mpms.mufig.com

Statutory Auditors

MSKA & Associates
Chartered Accountants
602, Floor 6, Raheja Titanium, Western Express Highway, Geetanjali Railway Colony, Ram Nagar, Goregaon (E), Mumbai - 400063, Maharashtra

Secretarial Auditors

Mr. Shiv Hari Jalan, Shiv Hari Jalan & Co.
Practicing Company Secretary,
1055, Level 10, Hubtown Solaris, N.S. Phadke Marg, Andheri (E), Mumbai - 400 069, Maharashtra

Internal Auditors

Aneja Associates
Chartered Accountants
301, Peninsula Towers, Peninsula Corporate Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai - 400 013, Maharashtra

Bankers

Citi Bank N.A.
HDFC Bank Limited



Financial Capital

Managing Growth through Financial Resilience

Our strong financial capital supports us to drive sustained growth and innovation. We are well-positioned to navigate dynamic market conditions and pursue opportunities with our consistent revenue generation, healthy cash reserves and prudent financial management. Our forward-looking approach is grounded in data and previous performances. It also acknowledges potential risks and uncertainties, while empowering us to invest in enzyme technology, create long-term value and stay resilient in a rapidly evolving business environment.

Stakeholders Impacted

- Employees
- Shareholders

SDGS Impacted



Strong credit rating

CRISIL
An S&P Global Company

Crisil A+/Stable


Long term rating

Crisil A1+

Short term rating


EBITDA

(in ₹ million)




PAT

(in ₹ million)




Net Working Capital

(Days)




Free Cash Flow

(in ₹ million)




Net Worth

(in ₹ million)




Net Debt/Equity

(X)




Fixed Asset Turnover

(X)




ROE

(in %)




ROIC

(in %)



ROCE

(in %)



All the numbers are on Consolidated basis

Net working capital days = ((Trade receivables + inventories - Trade payables)/Net Sales)*365

Net Debt = Long-term debt + short-term debt + current maturities of long-term debt - Cash & Cash Equivalent

ROIC = EBITDA / (Equity + Net Debt)

Return ratio calculated based on average of shareholders' fund and average debt

Financial Summary (Consolidated)

(numbers in ₹ million)

Particulars	FY 2024-25	FY 2023-24	FY 2022-23	FY 2021-22	FY 2020-21
Revenue from Operations (including Export Incentives)	6,369	6,239	5,406	5,294	5,018
Net Sales (excluding Export Incentives)	6,365	6,235	5,404	5,289	5,004
EBITDA	1,944	2,045	1,564	2,014	2,316
Depreciation	366	353	350	349	287
EBIT	1,579	1,692	1,214	1,665	2,029
Finance Charge	36	29	24	18	16
Profit Before Tax and Exceptional Items	1,543	1,663	1,190	1,647	2,013
Exceptional Items	-	151	41	-	-
Profit After Tax and Exceptional Items	1,543	1,512	1,149	1,647	2,013
Other Income	330	367	255	64	88
Profit Before Tax	1,874	1,879	1,404	1,711	2,101
Tax	534	509	365	473	588
Profit After Tax Including Minority Interest (PAT)	1,340	1,370	1,039	1,238	1,513
Profit After Tax and Allocation of Minority Interest	1,311	1,333	1,056	1,196	1,459
Paid-Up Capital - Equity	224	224	224	224	223
Reserves and Surplus	13,985	13,018	12,127	10,662	94,86
Shareholders' Fund	14,209	13,241	12,351	10,886	9,709
Minority Interest	478	470	491	518	617
Long-Term Borrowings (including Current Maturities)	92	70	78	81	99
Working Capital Finance	111	176	50	19	38
Short-Term Borrowings	12	6	5	9	54
Total Debt	215	251	132	109	191
Current Liabilities (excluding Short-Term Borrowings and Current Maturities)	844	882	721	576	584
Other Liabilities	467	511	523	587	461
Tangible Fixed Assets (property, plant and equipment) (net)*	3,146	3,073	2,888	2,718	2,510
Intangible Assets (net)	523	583	609	663	747
Goodwill on Consolidation	3,334	3,253	3,209	2,961	2,887
Current Assets	8,799	8,097	7,221	6,044	5,160
Other Assets	411	349	292	290	222
Net Worth	14,209	13,241	12,351	10,886	9,709
Total Outside Liabilities (TOL)	2,005	2,113	1,868	1,790	1,852

Note: Book value and EPS are based on face value of ₹ 2 per share

*Based on Net sales

#Return ratio calculated based on average shareholders' fund and average debt

(numbers in ₹ million)

Particulars	FY 2024-25	FY 2023-24	FY 2022-23	FY 2021-22	FY 2020-21
Growth Indicators					
Net Sales	2%	15%	2%	6%	13%
EBITDA	-5%	31%	-22%	-13%	14%
EBIT	-7%	39%	-27%	-18%	15%
PAT	-2%	32%	-16%	-18%	14%
Key Operating Ratio*					
Gross Margin	76%	77%	76%	79%	80%
EBITDA Margin - EBITDA/Net Sales	31%	33%	29%	38%	46%
EBIT Margin - EBIT/Net Sales	25%	27%	22%	31%	41%
PAT Margin - PAT/Net Sales	21%	22%	19%	23%	30%
Financial Leverage					
Net Debt/Equity	0.02	0.02	0.01	0.01	0.02
Interest Coverage	44.39	58.34	50.57	92.68	126.07
Debt/EBITDA	0.11	0.12	0.09	0.05	0.08
Return Ratios#					
RoE (PAT/Shareholders' Fund)	10%	11%	9%	12%	17%
RoCE (EBIT/ (Shareholders' Fund + Total Debt))	11%	13%	10%	16%	22%
RoIC (EBITDA)/ (Equity+ Total Debt- Cash and Cash equivalent)	15%	18%	15%	26%	32%
Other Ratios					
Turnover to Tangible Assets (Net)	2.02	2.03	1.87	1.95	1.99
TOL to Net Worth Ratio	0.14	0.16	0.15	0.16	0.19
Book Value/Share (₹)	127.00	118.41	110.45	97.37	86.90
EPS (Basic)	11.72	11.92	9.45	10.70	13.09
EPS (Diluted)	11.71	11.92	9.45	10.68	13.07
Working Capital Cycle (No. of Days)*					
Inventory Turnover	90	87	84	83	68
Accounts Receivable	66	58	69	61	63
Accounts Payable	10	9	17	12	11
Net Working Capital	146	135	135	132	120
R&D Spends					
Capital Expenditure	32	24	50	16	54
Recurring Expenditure	216	173	173	150	124
R&D Spends	248	197	223	166	178
As % of Net Sales	4%	3%	4%	3%	4%




Manufactured Capital Progressing through Cutting-edge Manufacturing Acumen

We understand the importance of manufacturing capital in driving our operations. Our specialised facilities are equipped with advanced machinery and cutting-edge technology to enable smoother production of enzymes. Consistent investment in these capabilities highlights our commitment to quality, innovation and growth. We ensure the reliable delivery of high-quality enzyme solutions across diverse industries by continuously enhancing our manufacturing infrastructure. This strategic focus reinforces our leadership in the sector and fuels ongoing advancements in enzyme technology.

Stakeholders Impacted

- Customers
- Suppliers
- Communities
- Government and Regulatory bodies

SDGS Impacted




- Human Nutrition - 64%
- Industrial Bioprocessing - 16%
- Animal Nutrition - 12%
- Specialised Manufacturing - 8%

Human Nutrition

We are a trusted partner in the pharmaceutical and nutraceutical industries across major global markets in Asia (including India), North America and Europe. Our diverse product portfolio enhances the nutritional value of food and delivers customised offerings to meet the demands of our customers. We are transforming probiotic development by adopting advanced technologies such as 'Directed Evolution' acquired through evocx technologies GmbH in Germany, ushering in a new generation of healthcare solutions.

Revenue Split

(in ₹ million)




Industrial Bio-processing

We are at the forefront of industrial bio-processing by leveraging micro-organisms to develop sustainable solutions across various sectors, including agriculture and polymers. Our expertise reduces environmental impact by lowering the dependence on chemicals and decreasing the consumption of energy. Through advanced technologies like consolidated bio-processing, we promote circular economy principles and drive eco-friendly innovation. We deliver cost-effective manufacturing solutions, strengthening our position to build a greener future for diverse industries.

Revenue Split

(in ₹ million)



Food Processing


Our enzymes play a key role in improving the product quality and nutritional value within the food processing industry. We specialise in safe and natural enzyme solutions to encourage manufacturers to create healthier food and beverage options. Through advanced enzymatic technology, we help develop food products that meet consumer demands.

13%

Share of revenue

Revenue Split

(in ₹ million)



Non-food Processing


Our enzymes serve as vital bio-catalysts in different industries, driving greater process efficiency and environmental sustainability. AETL provides a portfolio of eco-friendly enzyme solutions designed specifically for non-food sectors like textiles, leather, detergents and paper and pulp. By optimising manufacturing workflows and reducing the use of energy and waste, these solutions enhance operational performance and deliver cost savings.

3%

Share of revenue

Revenue Split

(in ₹ million)




Animal Nutrition

We have adopted a holistic and innovative approach to animal nutrition with enzyme-based feed additives and advanced probiotic solutions. These innovations are designed to improve nutrient absorption and better digestion, support growth and strengthen the immunity. On the business front, it offers the benefits of low feed costs and reduced environmental impact. Our probiotics, enriched with advanced metabolites, enhance overall wellness of animals and strengthen operational profitability. With a strong focus on sustainability and innovation, we seamlessly integrate digestive health, feed optimisation and environmental responsibility in modern animal husbandry.

Revenue Split

(in ₹ million)




Specialised Manufacturing

Our specialised manufacturing division leverages modern technology to develop tailored products for a wide range of industries, including health supplements, baking, pharmaceuticals, cleaning solutions and other niche segments. This advanced technology ensures rapid dissolution and improved product effectiveness, meeting consumer and industrial needs. Our strategic partnerships and cutting-edge innovation enables us to deliver high-quality and customised solutions that align with evolving market demands within the enzyme industry.

Revenue Split

(in ₹ million)



Our Manufacturing Facilities

Our robust manufacturing infrastructure is the backbone of our operations. It enables us to deliver high-quality enzyme and probiotic solutions across the globe. Strategically located in various regions of India and the United States, our facilities are equipped with advanced technologies for fermentation, formulation, recovery and blending.

Certifications

- Food Safety System Certifications (FSSC) 22000
- Global Organic Textile Standard (GOTS)
- ISO 9001:2015
- ISO 14001:2015
- Halal Certification
- Kosher Certification
- WHO-GMP Certification
- GMP Plus Certification
- Written Confirmation Certification
- Export Inspection Agency Certification
- Input for Organic Processing/ Production

Highly controlled processes

Large capacities

Globally competitive cost structure

Flexible downstream capabilities



Flexible batch sizes

Ability to expand quickly

Global Expansion with a Customer-centric Focus

Our global expansion strategy is driven by the understanding of our customer needs and meeting their demand in various regions. As we enter new markets and strengthen our presence in the existing ones, we prioritise delivering tailored enzyme solutions that ensure customer satisfaction. We refine our offerings by maintaining close client relationships and incorporating their feedback into our products. This helps us to stay aligned with the local demands and industry dynamics. We are also exploring strategic acquisitions, joint ventures and partnerships to enhance our capabilities and expand our global footprint. This integrated approach opens up new growth opportunities and reinforces our position as a trusted global-leader in the industry.





Intellectual Capital Empowering Growth with Intellectual Prowess

We recognise that research and development (R&D) is fundamental in achieving a sustained and long-term growth. Our R&D efforts are strategically aligned with market-specific complexities, enabling us to customise our product portfolio according to the diverse geographical needs. With a forward-looking approach, we are continuously exploring new opportunities and accelerating the development of innovative products, particularly within our bio-catalyst and bio-processing businesses. By adopting advanced technological tools and systems, we enhance the efficiency and impact of our pipeline, ensuring timely, market-relevant solutions.

Stakeholders Impacted

-  Shareholders
-  Communities
-  Employees
-  Customers

SDGS Impacted



Our R&D Process

Enzymes and Probiotics Development

- Strengthens the enzyme engineering part of R&D
- Facilitates the precise design of enzyme sets, tailored to specific target applications

Product Development and Customisation

- Undertakes upscaling of fermentation
- Enhances efficiency of downstream processes
- Aims to improve recovery and purification yields

Proteomics and Applied Microbiology

- Specialises in the purification and characterisation of enzymes and probiotics
- Generates crucial data for regulatory dossier filings
- Focuses on enhancing the efficiency of downstream processes

Application Development

- Innovates in developing cutting-edge enzyme and probiotics solutions for various food and non-food processing industries
- Offers assistance in valuable lab trials to test and optimise enzyme and probiotics applications

Our Research Facilities

Our research laboratories focus on the enzyme production and applications across various sectors. With specialised labs for fermentation, strain development, therapeutic formulations and industrial applications, we deliver innovative solutions to meet the needs of various industries, from food processing to life sciences.

1. Process Development Lab

This lab focuses on improving production efficiencies in the fermentation process and enhancing the organisation's downstream processing capabilities, including projects aimed at boosting recovery and purification yields.

2. Applied Microbiology Lab

This lab specialises in strain development using advanced molecular biology techniques. It utilises both classical mutagenesis and site-directed mutagenesis methods to achieve its objectives.

3. Life Sciences Application Lab

This lab develops therapeutic enzyme formulations for both human and animal nutrition. Its primary goal is to create effective, side-effect-free treatments for a range of common and complex health conditions.

4. Food Applications Development Lab

This lab specialises in developing enzyme applications for the food processing industry. Its focus is on creating innovative solutions that enhance product quality and process efficiency in the human food consumption sector.

5. Industrial Applications Development Lab

This lab specialises in developing enzyme applications for the non-food processing industries. Its primary focus is on creating innovative solutions that enhance product quality and improve process efficiency.



₹ 248 million

Total R&D spend in
FY 2024-25

7

R&D units (India-5, USA-1, Germany-1)

400+

Proprietary Products

68+

Enzymes and Probiotics

17*

Patents

9**

GRAS Dossier evaluated by US FDA

15#

Food Enzyme Dossiers filed with EFSA

1##

Novel Food Dossier filed with EFSA

30+

Years of fermentation experience

100+

Scientists, Microbiologists, Engineers,
Food Technologists, Biotechnologists

Our Research Facilities

Advanced Bio-catalyst Enzymes

We have developed novel bio-catalyst enzymes through advanced protein engineering, ensuring high performance even under the harsh conditions of typical commercial processes.

Diverse Enzyme Libraries

We have created diverse enzyme libraries tailored for various applications, including bio-catalysis, human nutrition such as sugar management and protein digestion, animal nutrition and the food industry. These libraries have enabled the development of new products and advanced application studies across multiple sectors.

Innovative Food Industry Solutions

We have introduced bakery products such as whole wheat bread and chemical-free baked goods, addressing the growing demand for healthier, sustainable options.

We have developed products that significantly reduce sugar content in baked goods, offering healthier alternatives to consumers.



We are committed to improving health and wellness by reducing gluten allergenicity in our products, making them more accessible to individuals with sensitivities.

Sustainable Biomass Processing

We have pioneered new products that enhance biomass hydrolysis, providing sustainable solutions for industries dependent on biomass processing.

Optimising Oil Extraction

We have developed innovative products that improve the efficiency of vegetable oil extraction processes.

Innovative Health and Wellness Solutions

- We have introduced products that enhance carbohydrate metabolism and support gut microbiota, supporting overall wellness.
- We have developed new clinical indications and formulations for enzymes and probiotics to address evolving health needs.

Collaboration and Knowledge Excellence

We harness the power of collaborative innovation by building strategic alliances with leading academic institutions, research organisations and industry pioneers. These partnerships provide access to a wide spectrum of expertise and resources, accelerating technological progress. We also maintain a strong focus towards knowledge management, equipping our teams with the tools and insights needed to effectively gather, interpret and apply critical information.

Advancing Growth through Innovation

We are also focused on strengthening our research and development capabilities, as reflected in our continued investments in this area. This shows our drive to promote innovation and accelerate technological progress across our operations. We prioritise the integration of advanced technologies and scientific tools, to enhance our problem-solving capabilities, keeping us ahead of the competition.

New Tech, System and Method Development

- We have expanded and developed a diverse range of expression systems, enabling the successful production of commercially viable proteins for a wide variety of industrial applications.
- We have pioneered an innovative enumeration method for sporulating probiotics, allowing precise quantification of individual strains, even in complex mixtures. This

advancement significantly improves the effectiveness of our probiotic formulations.

- We have created an industry-grade product specifically engineered to enhance both the quality and yield of oil, offering a superior solution for industries that depend on this vital ingredient.
- The industrial solution developed for whole wheat bread production enables bakeries to produce fibre-rich, nutritious baked goods that meet the growing demand for healthier options. It also improves shelf life, softness and overall acceptability, helping manufacturers maintain consistent quality and remain competitive.
- We have developed a cutting-edge nutraceutical product which is aimed at improving carbohydrate metabolism and promoting gut health in humans. This scientifically validated solution supports digestive well-being.
- Building on our expertise, we have designed advanced digestion models that offer insights into digestive processes in both humans and animals.
- We have introduced a nutraceutical product specifically formulated to help manage and alleviate allergy symptoms.

Driving Efficiency by Integrating Advanced and Sustainable Technology

We strategically integrate data analytics and sustainable technologies across our

operations to drive smarter decisions and reduce our environmental footprint. We gain actionable insights into market trends, customer behaviour and operational performance by leveraging big data and machine learning. Simultaneously, our focus on sustainable development is reflected in the use of renewable energy and eco-friendly materials in our operations.

We are also dedicated to developing innovative enzymatic solutions that simplify the production of Active Pharmaceutical Ingredient (API) intermediates. By leveraging our expertise in enzymatic and microbial technologies, we pursue initiatives to address challenges in Environmental Treatment Plants (ETP), delivering sustainable products that enhance operational efficiency for our clients.

Improving Customer Service through Technology

We are committed to acquiring state-of-the-art equipment that support high-throughput screening, allowing us to accurately evaluate key variants. By leveraging artificial intelligence-based tools for in-silico screening, we identify the most promising candidates, which are then validated and optimised through rigorous wet lab testing.

Our products are specifically designed to tackle current challenges in food processing, enhancing product quality and increase profitability for our partners. We also focus on delivering holistic health benefits, ensuring our innovations contribute to consumer well-being while addressing the evolving demands of the industry.

* Patents includes the filed applications

**No question letter received for 7 Dossier, 1 is self-affirmed & another 1 is under evaluation

#Food Dossier filed with EFSA, out of which positive R&D opinion is received for 9 Dossiers & 6 are under evaluation

Novel food dossier has been filed with EFSA is under evaluation

All the numbers are as per IndAs



Natural Capital Embedding Sustainability in Every Action

Our approach to growth is deeply rooted in sustainable principles and practices. We believe that embracing sustainable practices unlocks better opportunities for long-term value creation. This is reflected in our strategic business decisions, which consistently prioritise environmental responsibility. By integrating eco-conscious measures across our operations, we work towards minimising our environmental footprint, which is a core principle embedded in our organisational ethos.

Stakeholders Impacted

- Employees
- Suppliers
- Communities
- Customers

SDGS Impacted



Note: All the details mentioned w.r.t. Natural Capital are on standalone basis

Zero Discharge of Hazardous Chemicals (ZDHC) Manufacturing Restricted Substances List (MRSL) level 3.0 conformance

Energy Management

Enhancing Operational Efficiency Through Smarter Energy Use

We strive to optimise energy efficiency across all aspects of our operations with the dual aim to reduce our environmental footprint and managing operational costs. A range of measures have been implemented to support this goal, including the deployment of a Steam Condensate Recovery System to enhance heat utilisation, installation of energy-efficient air conditioning systems using CFC-free refrigerants, and the use of VFD-grade motors in fermenter agitation systems to improve energy efficiency. We have also installed cold insulation for the ducts of Air Handling (AHU) system to minimise heat transfer into cold air ducts to improve energy efficiency and prevent heat gain. Regular preventive maintenance of all critical and utility equipment and dynamic balancing of blowers further help in maximising energy performance.

We are embedding renewable energy solutions into our processes by integrating solar power into our energy mix, thereby reducing reliance on fossil fuels and reinforcing our shift towards more sustainable energy practices.

*510 kW includes 160 kW installed during FY 2024

1,163 GJ

Energy consumption from renewable sources

510 KW*

Solar plant system installed

We have installed hot insulation on steam and utility systems to minimise heat loss.

85 kg/hr

Reduction of steam consumption

We have incorporated measures to optimise the electrical current utilisation of blowers.

2-15 Amp/hr

Reduction in power consumption from blowers

We have implemented enhancements in the chilled water generation system to recover heat, reducing the steam requirement.

25 kg/hr

Reduction in steam requirement for chilled water generation

Through improved fuel efficiency, we have reduced our fuel consumption and carbon emissions.

4%

Generator kWh to Fuel ratio achieved




Reducing Carbon Footprint

Future-Proofing Through Decarbonisation

We are formulating and executing a comprehensive strategy to reduce its carbon footprint and align with the broader global ambition of achieving 'net zero' emissions. Recognising the urgency of climate change, we are undertaking a phased and region-specific approach to decarbonisation. We are also exploring opportunities for carbon offsetting, improving process efficiencies, and integrating low-emission alternatives in our value chain. These efforts are aimed at facilitating environmental resilience while meeting regulatory expectations and stakeholder aspirations for a greener future.

Scope 1 GHG Emissions* (Metric tonnes of CO₂ equivalent)



Responsible Waste Stewardship

Managing Waste Right

We follow a holistic and compliant approach to waste management, ensuring all types of waste, including plastics and hazardous materials which are handled with the highest standards of responsibility. Our efforts are rooted in strict adherence to environmental regulations and include the use of authorised disposal channels approved by the State Pollution Control Board. We also focus on in-house waste processing, resource optimisation and efficiency-enhancing practices across our facilities to minimise environmental impact.

165 MT
Reduction in waste generation

150 MT
Waste recycled

356 MT
Waste re-used

*GHG: Green House Gas Emission

Water Recovery System

Driving Circular Water Management

We follow a Zero Liquid Discharge (ZLD) approach at our facilities, using a three-stage evaporation system to ensure no wastewater is released into the environment. The setup includes an Effluent Treatment Plant (ETP), Mechanical Vapour Recompression (MVR) system, and a dryer. Steam generated during wastewater treatment is condensed and reused in boilers, compressors and cooling towers. The residual slurry is dried and repurposed for non-pharmaceutical applications, supporting resource recovery and sustainable operations.

6,950 KL
Treated water discharge

17,447 KL
Reduction in water withdrawal

30,533 KL
Water recycled in FY 2025



Human Capital Nurturing Talent through Comprehensive Development

Our employees are at the core of our sustained achievement, playing a significant role in driving the Company's growth and innovation. We focus on nurturing a future-ready workforce by providing continuous learning opportunities through advanced training programmes aligned with evolving business needs. Our inclusive and equitable work environment supports the culture of respect, recognition and empowerment, encouraging employees to perform at their best and lead transformative change. Guided by strong ethical values, we uphold fair HR practices and maintain a strict zero-tolerance stance against any form of discrimination, ensuring a workplace where every individual can thrive.

Stakeholders Impacted



Employees

Communities


Government and
regulatory body

SDGS Impacted



Employees

396



298 - Male

98 - Female

Talent Management

Building Capabilities for Growth and Leadership

We believe that talent development is essential to driving long-term growth and innovation. Our efforts span the entire employee journey from hiring young professionals and equipping them with core skills, to encouraging continuous learning and building leadership capabilities.

86%

Employee
retention rate

Training and Development

Unlocking Potential to Drive Growth

We believe that the growth of an organisation is directly tied to the growth of its people. We focus on strengthening employee capabilities through a range of structured training and development initiatives. From recruitment to career progression, we provide extensive on-the-job and internal training programmes designed to build core competencies and leadership potential. These efforts aim to empower employees, promote continuous learning and support their long-term professional development.

40+

Training and awareness
programmes conducted

100%

Performance and career
development review

Recruiting and Developing Future Talent

We recruit fresh graduates and postgraduates, equipping them with comprehensive training programmes designed to build essential professional skills and prepare them for long-term career growth.

Shaping Future Leaders

We focus on cultivating leadership capabilities at all levels, ensuring a strong pipeline of future-ready leaders through targeted development initiatives.

Diversity, Equity and Inclusion

Ensuring Equal Opportunity for All

We are focused towards promoting an empowering and inclusive workplace through our Equal Opportunity Policy. We ensure fair and respectful treatment for all individuals, irrespective of gender, age, abilities, beliefs, religion, sexual orientation, ethnicity, caste or any other attribute.

To support employees with disabilities, we provide necessary accessibility arrangements tailored to the requirements of different departments and office spaces. We deeply value the diverse perspectives and unique contributions of our workforce, recognising that this diversity drives innovation, excellence and performance. Through a culture of mutual respect and collaboration, we continue to nurture talent, enabling holistic growth and development across the organisation.

24.75%

Female employees

Employee Safety and Well-being

Building a Safe and Supportive Workplace

We have established a robust Occupational Health and Safety (OHS) management system across all our units, showing our responsibility to maintaining a safe and supportive work environment. Comprehensive fire safety protocols, including regular inspections, training and emergency drills, are in place to ensure preparedness and risk mitigation.

Beyond physical safety, we promote a culture rooted in mutual trust and respect, supported by a structured grievance redressal mechanism. To further promote overall well-being, we offer a range of health and wellness initiatives, such as annual medical check-ups, doctor consultations, remote work flexibility and targeted training programmes to support employee growth, engagement and productivity.

Employee Engagement

Inspiring Commitment Through Appreciation

We recognise that employee motivation and engagement are key drivers of organisational growth. To promote a culture of appreciation and high performance, we have designed and implemented comprehensive reward and recognition programmes. These initiatives aim to celebrate both individual excellence and team achievements, encouraging employees to go above and beyond in their roles. By acknowledging contributions in a timely and meaningful manner, we boost morale, reinforce our core values and promote a sense of belonging. These programmes serve as a strategic tool to enhance employee satisfaction, retain top talent and drive long-term business performance.

60%+

Employees trained on health and safety

65%+

Employees trained on skill upgradation

ISO 45001:2018

OHS management system certification

9.29%

Employee turnover rate

Policies to Promote Safe Work Culture

Commitment to Workplace Safety


We have implemented a comprehensive set of policies that promote ethical conduct, safeguard employee rights and create a secure and supportive work environment. These policies serve as guiding frameworks to reinforce our values and ensure a harmonious, compliant and high-performing workplace.

Zero

Lost time injury frequency rate

100%

Employees covered under accidental insurance





Social and Relationship Capital

Driving Inclusive Growth for Lasting Impact

We are focused towards inclusive and holistic growth and contribute to societal well-being by engaging with diverse stakeholders and promoting enduring partnerships. Our business philosophy integrates the principle of shared progress, where uplifting communities is not only integral to our values but also essential for building a resilient and equitable society. Through strategic collaborations with registered trusts, societies and social organisations, we continue to strengthen our efforts to create lasting, positive impact.

Stakeholders Impacted

- Employees
- Media
- Suppliers
- Communities
- Customers

SDGS Impacted



Note: All the details mentioned w.r.t. Social and Relationship Capital are on standalone basis

1351

Total beneficiaries

90%+

Beneficiaries from vulnerable and marginalised groups

We are focussed towards making a meaningful impact in the lives of local communities, with a strong focus on empowering disadvantaged and marginalised groups. Guided by our comprehensive Corporate Social Responsibility (CSR) policy, we undertake diverse initiatives aimed at promoting sustainable livelihoods and advancing human development. Recognising the unique challenges faced by various communities, we prioritise key areas such as healthcare and education to improve overall quality of life and promote a more inclusive society. To bring these initiatives to life, we collaborate with trusted and registered trusts and societies to fund and implement impactful programmes. These include vocational training for individuals with disabilities, nutrition support to fight malnutrition, improved educational access for tribal children, life-saving medical treatment for thalassemia patients, and educational assistance.

₹ 19 million

Total CSR spend

Contribution for Inclusive Social Progress

Empowering Progress for All



Healthcare Initiatives

Recognising the urgent need for accessible healthcare, we support a range of medical initiatives focused on delivering treatment to underprivileged

individuals. These efforts have significantly improved access to essential health services, strengthening our resolve to creating meaningful, lasting impact in the lives of those who need it most.

₹ 3 million


Healthcare initiative funding

Care for Thalassemia Patients

We have extended our support to the Arpan Thalassemia Society in Nashik, focusing on improving healthcare access for individuals affected by genetic blood disorder. Our initiative includes the provision of essential medical resources to aid in the effective management of Thalassemia. This effort has significantly enhanced the quality of life for many patients and their families, offering them renewed hope and better health outcomes.

Assistance for Medical Treatment

We have directly engaged with patients in need for medical treatment for spine and pancreas to support them financially. This has enabled them to carry out their treatment effectively and with quality. We have also extended support to the Shri Laxminarayan Rathi Bahuuddeshiya Seva Sanstha (SLRBSS) in Nashik for medical treatment, surgeries and preventive healthcare needs.



Education Initiatives

We believe that building a developed economy starts with providing every individual access to basic education and skill development. To support this vision, we are committed to empowering economically challenged youth, women and individuals by helping them gain literacy and develop skills. Our goal is to enable them to earn a living and achieve self-reliance.

₹ 16 million

Financial contribution towards infrastructure development

Infrastructure Development


We have extended support to the Shri Laxminarayan Rathi Bahuuddeshiya Seva Sanstha (SLRBSS) in Nashik, Maharashtra. Our efforts include funding the infrastructure development of a centre in Yeola Taluka, transforming the space to host educational, skill-building, and vocational training programmes. This initiative aims to equip individuals with the skills necessary for gainful employment, thereby improving livelihoods and enabling sustained socio-economic progress within the community.

Promoting Education and Skill Building

Through Spread A Smile Foundation, for promotion of education, literacy campaigns and provided special education, including academic support for students from economically disadvantaged backgrounds. Additionally, we offer vocational training and skill development programs for youth and women. We have also directly supported marginalised students in pursuing degrees such as Bachelor of Design and B.Tech.



Management Discussion & Analysis



Economic Environment

Global Economic Overview¹

The global economy in CY 2024 navigated complex challenges, balancing growth with technological change and geopolitical tensions. Global GDP growth moderated at 3.3% in a year marked by moderating inflation, rising uncertainties, policy divergence and structural economic shifts across regions.


Economic performance across regions varied significantly with the US achieving 2.8% growth, owing to a strong consumer spending and a dynamic labour market while the Eurozone struggled due to political and economic uncertainties in Germany and Italy. Emerging markets, particularly India and Southeast Asia, outperformed the advanced economies maintaining a growth rate above 4%. China’s economy exhibited decline due to overcapacity issues and weak consumer confidence.

¹IMF, World Economic Outlook April 2025

Global inflation declined to 5.7% in CY 2024 from 6.7% in CY 2023 as supply chains improved and energy prices normalised. Central banks in emerging markets, such as Brazil, India and Japan carefully balanced growth stimulus against currency-related inflation risks. A stronger US dollar created repayment difficulties and capital outflows from some emerging economies markets. However, recent uncertainty regarding the escalation of reciprocal tariffs between countries reversed the performance of the US\$ with respect to other currencies.

The Red Sea crisis and Panama Canal drought also affected global trade severely, increasing shipping costs and causing delays. Many nations responded by strengthening regional supply chains and implementing manufacturing subsidies. The exodus of investments from the US bond market has caused the price of gold to rise significantly as investors seek liquidity in an uncertain economic landscape. Global Mergers and Acquisitions deal value reached US\$ 3.4 trillion, driven by private equity investments in distressed European assets and horizontal consolidation in the biologics sector.²

Global Growth in CY 2024 (in %)



Source: IMF, World Economic Outlook April 2025; CY: Calendar Year; AE: Advanced Economy; EMDE: Emerging Markets and Developing Economies

Outlook

Global growth is projected to remain modest at 2.8 % for CY 2025 and 3% for CY 2026. Disinflationary trends are expected to sustain, directed by a labour market cool down, decline in Chinese demand and descending oil prices due to production expansion by the US and the Middle East. This will enable Central Banks around the world to adopt a more flexible approach to promote economic activity.

With the new regime in US expected to impose additional tariffs on imported goods, an elevation in the inflation level is expected. The implementation of protectionist trade policies will impact global trade as seen in the downward revision of projected trade volumes for the next two calendar years.

²McKinsey M&A Annual Report.


³RBI Bulletin April 2025

⁴TOI report, February 02, 2025

Meanwhile European economy will have to rely on its strong industrial base in fundamental sectors and domestic demand for recovery. The economy of Germany is planning to undertake historic reforms allowing the government to increase its public spending to restore momentum to the economy and overcome stagnation.

Emerging markets and Developed Economies are expected to sustain their dynamic growth trajectory guided by technological advancements and favourable demographic conditions. The evolution of supply chain resilience in a dynamic global landscape bears opportunity for the Emerging Markets and Developed Economies (EMDEs) to establish themselves as key drivers in the global value chains. However, these economies will need to navigate an increasingly complex trade environment and heightened geo-economic fragmentation.

Global GDP Forecast (CY 2025 Growth %)



Source: World Economic Outlook (IMF, April 2025)

Indian Economic Overview³

India remained one of the fastest growing economies with an estimated 6.5% GDP growth in FY 2024-25. This growth was fuelled by a dynamic services sector, rising urbanisation and transition towards renewable energy and robust domestic demand. The strategic reforms of the government, represented by the Production Linked Incentive (PLI) scheme and increased budget of ₹ 10.2 trillion on infrastructure spending, are aimed at stimulating activity in the economy.⁴ Under the Union Budget, the government approved an additional outlay of ₹ 10 billion each for the Revised National Programme for Dairy Development (NPDD) and the Revised Rashtriya Gokul Mission (RGM), emphasising the role of the agricultural sector as a crucial driver of economic growth.

The RBI managed liquidity deficits via Open Market Operations (OMO) and forex swaps, stabilising the market amid foreign portfolio outflows. Additionally, income tax reforms introduced in the union budget is likely to drive further consumer spending.

India maintained a strong export performance in advanced manufacturing categories, such as electronics, semiconductors, defence equipment and pharmaceuticals demonstrating the country's integration within international supply networks and global value chains. Although, trade tensions and tariff uncertainties impacted input costs for manufacturing industries pressurising their margins. India's R&D expenditure lagged at 0.6%-0.7% of GDP, below the global average of ~2%.⁵ However, India ranked 6th globally in terms of intellectual property filings, indicating a thriving innovation ecosystem.⁶

Outlook

India's economy is poised to sustain its upward growth trend in the long-term. Inflation is expected to remain manageable with the waning of core pressures. Although, ongoing trade tensions dampen the investors' sentiments leading to a downward revision of growth projections in the near-term. However, with ongoing structural reforms, the nation is strategically positioned to navigate the uncertain global landscape by strengthening its bilateral relations thereby benefitting the export industry.


With the government's impetus on manufacturing, the sector is anticipated to exhibit renewed vigour. The passing of the BioPharma Act in the US aims to reduce the dependence on China within the biotechnology supply chains, creating new opportunities for India. As countries look to reinforce their supply chains by adopting a 'China plus one' strategy, India, with its stable policy framework and favourable business environment is set to emerge as a global manufacturing hub for key industries.

Declining inflation is expected to allow the RBI to persist with an expansionary policy injecting liquidity in the economy and thereby stimulating activity. In January 2025, the central bank had cut the interest rates by 25 basis points with further 25 basis points cut in April. Combined with the income tax reliefs announced in the Union Budget for salaried individuals,

discretionary spending is expected to rise in the near term improving the nation's growth prospects.

Bolstered by a strong domestic foundation, the outlook for the Indian economy remains positive despite global macroeconomic challenges as the nation continues on its journey to establishing itself as a developed economy by 2047.

India's Real GDP growth (in %)



*Second Advance Estimates

**Projected

Source: [RBI Bulletin April 2025](#)



Industry Overview

Global Enzymes Market

Enzymes are proteins that act as biological catalysts by expediting chemical reactions. Recently, enzymes are witnessing heightened demand from human & animal healthcare, food processing industries such as baking, dairy, oils & fats, brewing & malting, flavours & fragrances etc. and non-food industrial processing such as textile, leather, pulp & paper, detergents, biofuels, etc. due to rising sustainability concerns and advancements in biotechnology.

In 2024, the global enzymes market size was valued at US\$ ~14 billion. The market is expected to experience a Compound Annual Growth Rate (CAGR) of 7.8% during 2024-29, reaching US\$ 20.4 billion by 2029.⁷ Enzymes play a vital role in the synthesis of Active Pharmaceutical Ingredients (APIs) and the production of biologics. This increases their demand in the healthcare industry. Enzymes also find application in the nutraceuticals and sports supplements. Several industries and key markets across the world are increasingly integrating enzymes in their operations owing to their versatility and eco-friendly nature.




⁷[Markets and Markets](#)

⁸[Research and Markets](#)

⁹[Research and Markets](#)

Global Enzymes Market Outlook (2024-2029)

US\$ Billion



Source: [MarketsandMarkets](#)


Indian Enzymes Market

The market encompasses various types of enzymes including carbohydrases, proteases, lipases, polymerases, nucleases and others, utilised across industrial and specialty sectors. In India, the market for enzymes is primarily being propelled by the growth of food and beverage industry, ascending demand for biofuels and breakthroughs achieved in biotechnology.

The Indian enzymes market is valued at US\$ 448.62 million and is expected to expand at a CAGR of 6.08% through 2030.⁸ India's enzyme market benefits from a booming pharmaceutical sector (3rd globally) and a growing food processing industry. Government initiatives like 'Make in India' aims to augment domestic production, reducing the reliance on imports. While the market remains fragmented, regional growth aligns with Asia-Pacific's 14.6% CAGR in industrial enzymes.⁹

Indian Enzymes Market Outlook

US\$ Million



Source: [Research and Markets](#)

⁵ [TOI Report, November 29, 2024](#)

⁶ [World Intellectual Property Organisation](#)

Demand Drivers for Indian Enzymes Market



Industrial Growth

The extension of crucial industries, such as pharmaceuticals, nutraceuticals, animal feeds, food processing, manufacturing of baking and brewing & malting products, dairy products, detergents & cleaning products, textile processing, paper & pulp processing, leather processing, leather processing and many such industries is driving the demand of enzymes in India.



R&D Investments

Indian enzyme manufacturers are stepping up their research and development efforts to enhance enzyme performance and broaden their scope of application across various industrial sectors.



Sustainable Production Processes

Heightened emphasis on cleaner and more efficient production processes is promoting the adoption of enzymes to reduce energy consumption, minimise chemical use and increase yields.



Environmental Considerations

Growing awareness and inclination towards eco-conscious technologies is augmenting the application of enzymes in industrial processes, particularly in generation of biofuels and other renewable energy sources.



Personal Care Product Expansion

The rising prominence of enzyme-based products in personal care and cleaning products is another factor which is playing a crucial role in driving the growth of the market.



Government Support

Strong support from the Government of India towards innovation in the field of biotechnology is creating an environment conducive to the continued growth of the domestic enzymes market.

Emerging Trends

The Indian enzymes market is witnessing several emerging trends, including:

- Tailor-Made Enzymes:** Development of customised enzymes for specific applications to improve efficiency and performance.
- Combination Approaches:** Enzymes are being used with other biocatalysts to improve efficiency in various industrial processes.
- Sustainable Applications:** Enzymes are being increasingly used in wastewater treatment and biofuel production as part of sustainable practices.

Global Human Healthcare Enzymes Market¹⁰

The human healthcare enzymes market is a crucial segment within the broader enzymes industry. This market specifically focuses on applications of enzymes in pharmaceutical, digestive supplements and diagnostic sectors. The pharmaceutical sector remains a key contributor. This contribution is facilitated by the heightened investment which is being directed towards drug production aimed at combating chronic diseases. Digestive supplements have also been gaining popularity in recent years fuelled by the rising demand for eco-friendly and organic solutions. These supplements aid in improving gut health and providing relief from ailments such as gut irritation and heartburn. As of 2024, the global human healthcare market was valued at US\$ 4.11 billion and is projected to grow at a CAGR of 6.52% and is estimated to reach US\$ 7.73 billion by 2034.


¹⁰[Precedence Research](#)

Human Healthcare Enzyme Market Outlook

US\$ billion

CAGR

6.52% ↑




Source: [Precedence Research](#)

Regional Analysis

North America commands the largest share of the healthcare specialty enzymes market, accounting for US\$ 1.64 billion in 2024. This market share is further expected to grow at a CAGR of 6.67% during the forecast period of 2024-34. The US alone accounted for US\$ 1.15 billion in 2024 and is predicted to reach US\$ 2.21 billion by 2034, with a CAGR of 6.75%.

The region's dominance is attributed to its comprehensive and well-structured healthcare infrastructure, advanced research facilities, pharmaceutical companies and diagnostic laboratories. Additionally, the growing prevalence of chronic diseases, such as cancer, cardiovascular disorders and metabolic diseases in North America augments the demand for specialty enzymes used in diagnosis, treatment and management of these diseases.

Healthcare Enzyme Region-wise Market Share (2023)



Source: [Precedence Research](#)

¹¹[Statista](#)

¹²[IMARC Group](#)

Indian Human Healthcare Enzymes Market

The Indian human healthcare enzymes market is witnessing an elevation in demand for sports and dietary supplements. This demand is mainly propelled by the increasing health awareness, aging population, growing incidence of chronic diseases, rising discretionary income, accelerated urbanisation and rising preference for organic and natural supplements.

The market size of dietary supplements has reached ₹ 826.83 million in 2025 and is expected to rise with a CAGR of 6.39% till 2029.¹¹ This growth trajectory provides significant room for the expansion of digestive supplement enzymes.

Indian Biocatalyst Market

A biocatalyst is an enzyme or microbe that has the capability to initiate or catalyse chemical reactions inside a living body. Biocatalysts find application in the pharmaceutical industry to manufacture statins, antibodies, amino acids and vitamins.

The Indian biocatalyst market size is valued at US\$ 316.3 million in 2024 driven by significant growth in the field of biotechnology. The market expected to witness a CAGR of 5.97% during 2025-2033 reaching US\$ 547.4 million by 2033.¹²




Global Feed Enzymes Market

Feed enzymes are crucial additives utilised in animal nutrition that enhance digestion, nutrient absorption, mycotoxin binders and reduce the environmental impact of animal husbandry. They help in resolving the harmful effects of anti-nutritional factors present in feed raw materials, enhancing overall animal performance and promoting long-term health.

The feed enzymes market has been growing at a notable pace, fuelled by a heightened demand for enhanced animal nutrition and more efficient feed. In 2024, the global feed enzymes market was valued at US\$ 1.86 billion and is projected to reach US\$ 2.02 billion in 2025, demonstrating a CAGR of 8.6%. In the years ahead, the market is expected to expand to US\$ 2.68 billion by 2029, with a CAGR of 7.4% during the forecast period.¹³ Phytases, which improve phosphorus absorption in livestock lead in terms of usage (~50% share).¹⁴ The Asia-Pacific region leads in demand due to rising meat consumption, while the North American market is driven by sustainable feed solutions.

Global Feed Market Outlook

Market Size (in US\$ billion)



Source: [The Business Research Company](#)

Growth Drivers

Several factors are responsible for the growth of the feed enzymes market such as:



Rising Meat Consumption

An ascending global demand for meat-based products is promoting the need for more efficient animal production. For instance, per capita turkey consumption in the US is predicted to grow from 14.60 pounds in 2022 to 15.40 pounds by 2033, while broiler chicken consumption is expected to increase from 98.90 pounds to 107.50 pounds during the same period.¹⁵



Alternatives to Antibiotics

With increasing restrictions being placed on antibiotic use in animal production, enzymes offer a natural alternative to promote animal health and performance.



Focus on Sustainable Farming

Growing emphasis on eco-conscious agricultural practices is heightening the integration of enzymes into agricultural practises. The enzymes reduce waste and improve feed conversion efficiency.



Technological Advancements

Continued Research and Development (R&D) in enzyme technology is resulting in the development of more effective and specialised feed enzyme products.

¹³[The Business Research Company](#)

¹⁴[Mordor Intelligence](#)

¹⁵[The Business Research Company](#)



India Feed Enzymes Market¹⁶


India’s feed enzymes market presents a significant growth opportunity. The market size is estimated at US\$ 42.70 million in 2025 and projected to reach US\$ 53.99 million by 2030, with a CAGR of 4.80%.

The nation’s feed enzymes industry has undergone substantial transformation in recent years, with feed enzymes accounting for approximately 3.5% of the total feed additives market value in 2022. Technological advancements have led to the development of heat-stable enzymes that can withstand the feed pelleting process, improving enzyme stability and efficacy.

Carbohydrases dominate India’s feed enzymes market due to their crucial role in breaking down complex carbohydrates and improving nutrient absorption.

Indian Feed Enzymes Market Outlook

US\$ million



Source: [Mordor Intelligence](#)

¹⁶[Mordor Intelligence](#)

¹⁷[Mordor Intelligence](#)

¹⁸[IMARC](#)

Demand Drivers for Indian Feed Enzymes Market

1. Growing Livestock Production:

India's compound feed market is growing substantially. Projections indicate that it will reach US\$ 38.85 billion by 2030, with a CAGR of 6.10% from 2025-30. This expansion will be directed by the country's large livestock population, particularly in the dairy sector. India is the world’s leading milk producer, accounting for almost a quarter of the production. Dairy production in India experienced a CAGR of 5.62% over the past decade (till FY2024).

Within animal husbandry, India ranks 2nd in egg production and 5th in meat production in the world. Egg production in the country is experienced a CAGR of 6.87% while meat production in the country witnessed a CAGR of 4.85% over the past 10 years (till FY2024). In 2023, India's bovine population reached 307.5 million. This rise in population will further enable growth of enzymes in the compound feed industry.¹⁷

2. Aquaculture Expansion:

The aquaculture sector in India continues to exhibit considerable growth, thereby, elevating the demand for specialised feeds and enzymes. According to recent data, India's aqua-feed market reached 1.9 million tonnes in 2024 and is further expected to grow at a CAGR of 8.13% to reach 4.0 million tonnes by 2033.¹⁸ This growth expected to be supported by increasing demand of seafood, both domestic and international and government initiatives promoting aquaculture development.

3. Improved Distribution Networks:

Manufacturers have established strong partnerships with local feed mills and integrators, enhancing market penetration and service delivery.

4. Regulatory Framework Development:

The Bureau of Indian Standards (BIS) and Food Safety and Standards Authority of India (FSSAI) have implemented stringent quality control measures. This has helped in establishing greater confidence among end-users, thereby contributing to market expansion.

5. Vertical Integration:

Major players are establishing manufacturing facilities in vital agricultural regions to ensure better supply chain management and product availability.

Global Industrial Enzymes Market


Industrial enzymes serve as specialised biological catalysts derived from microorganisms, plants, or animals that expedite chemical reactions in various industrial processes. Their applications span food production, pharmaceuticals, biofuels, textiles and other sectors where they optimise process efficiency, reduce energy consumption and support eco-conscious practices.

The global industrial enzymes market has grown consistently. The market valued at US\$ 7.95 billion in 2024, is projected to reach US\$ 15.50 billion by 2034, with a 6.90% Compound Annual Growth Rate (CAGR).¹⁹ Carbohydrases (e.g., amylases, cellulases) hold 45% of the total market share with respect to enzyme type with lipases and esterases segment. Proteolytic enzymes and oxidoreductases segment form the rest of the market. With respect to the source of enzymes, microbial-sourced enzymes account for 68% of production followed by plant and animal-sourced segments.²⁰

Global Industrial Enzymes Market Outlook

US\$ billion

CAGR




Source: [Precedence Research](#)

Regional Analysis

North America currently dominates the industrial enzymes market, commanding ~37% of the global market share in 2023.²¹ The US market alone is projected to grow from US\$ 2.06 billion in 2024 to US\$ 4.05 billion by 2034. This dominance can be attributed to the presence of several end-use industries including food and beverage, pharmaceuticals, laundry detergent, personal care and cosmetics sectors in the region. The region's advanced technological framework and substantial investments in Research and Development (R&D) further reinforce its market position.

Asia Pacific is rapidly establishing itself as crucial centre of growth influenced by accelerated industrialisation, increase in manufacturing and a growing demand for eco-friendly and sustainable solutions. Countries, such as China, India and Japan are witnessing a rise in end-user industries, such as food and beverages, textiles, detergents and biofuels, contributing significantly to the demand for industrial enzymes.

Industrial Enzymes Region-wise Market Share (2024)



Source: [Precedence Research](#)

Global Food Enzymes Market


Food enzymes are used in bakery products, brewing & malting, beverages, dairy products, oils & fats extraction, flavours & fragrances, functional foods, nutraceuticals and various other fields. The notable growth of the bakery industry has served as a major growth driver for the market. Food enzymes play a crucial role in enhancing the taste, texture, flavour and shelf life of the bakery items across various stages of production, including dough preparation, fermentation, and baking.

The global baking enzymes market size is expected to demonstrate a CAGR of 5.5% during 2025 to 2034, reaching around US\$ 1484.5 Mn by 2034, from US\$ 869.1 Mn in 2024. The growth of the bakery industry has been driven by the increasing consumption of processed and ready-to-eat baked products.²²

Global Food Enzymes Market Outlook

US\$ million

CAGR



Source: [Precedence Research](#)

Demand Drivers for Global Food Enzymes Market



Growing Consumer Awareness and Health-Conscious Trends

Growing knowledge of nutrition, health concerns and changing dietary patterns among global consumers has led to the market expansion of digestive enzymes.



Technological Advancements

Advancements in biotechnology are enabling the production of more efficient enzymes. Food preservation and waste reduction capabilities of these enzymes are attracting manufacturers. This is leading to the rise in R&D investments focused on the creation of novel enzyme solutions.



Lifestyle and Demographic Factors

An expanding population of professionals who have less time for meal preparation and the rising number of nuclear families have increased the demand for processed food.



Market Expansion and Product Benefits

Enzymes improve texture, flavour, aroma and shelf-life of food products and add nutritional value driving market expansion. In addition, food enzymes are witnessing increased demand from alcoholic and non-alcoholic beverage industries.



¹⁹[Precedence Research](#)

²⁰[Mordor Intelligence](#)

²¹[Grand View Research](#)

²²[Market.us](#)

Global Non-Food Enzymes Market

Enzymes are increasingly being utilised in varied industries, such as textiles, leather processing and pulp and paper, owing to their eco-friendly properties and their ability to augment efficiency. In textiles, enzymes offer sustainable alternatives to traditional chemicals, improving fabric quality and reducing environmental impact. Bio-based, enzyme-powered cleaning agents find application across industries such as healthcare, pharmaceuticals and manufacturing in removal of organic residues like proteins, fats, and starches. Across domestic segment, demand is growing for sustainable, biodegradable cleaning solutions along with stringent sanitation regulations in public places. Further, the leather industry is utilising enzymes to reduce utilisation of hazardous chemicals and enhance product quality, while conserving water and minimising pollution. In the pulp and paper sector, enzymes are being used to heighten production efficiency, reduce costs and decrease environmental pollution. Overall, this augmentation in enzyme utilisation is propelled by a growing demand for sustainable practices and more efficient manufacturing processes.

Indian Industrial Enzymes Market

In 2024, India’s industrial enzymes market was valued at US\$ 250 million. The market is expected to grow at a CAGR of 5.95% from 2024 till 2030, reaching US\$ 350 million.²³ Proteases, a type of enzyme that breaks down proteins, commands the

largest market share in this segment. Due to their versatility, Proteases are utilised in various industries, such as, food and beverages, textiles, pharmaceuticals and detergents.

Regional Analysis

Northern India has established a clear dominance in the Indian Industrial Enzymes Market due to its several strategic advantages. The strong agricultural sector in Punjab, Haryana and Uttar Pradesh generates substantial enzyme demand for crop protection, animal feed and biofuel applications. Northern India also houses significant manufacturing hubs across Delhi, Haryana and Uttar Pradesh. In addition, the region has a strong presence of enzyme-dependent industries, such as, food processing, textiles and pharmaceuticals.

Indian Food Enzymes Market

India’s food enzyme market represents a specialised segment focusing on enzymes used in food processing to improve quality, shelf life and nutritional content. The bakery sector currently boasts the most extensive utilisation of food enzymes in India.

Market Segmentation

The market is segmented by enzyme type (carbohydrase, protease and lipase) and application (bakery, confectionery, dairy and frozen desserts, meat poultry and seafood products, beverages and other applications).

Demand Drivers for Indian Food Enzyme Market



Processed Food Demand

The demand for processed food is on the rise. This rise can be attributed to accelerated urbanisation and changing lifestyles. The demand for processed food is a key factor propelling the food enzyme market in India.



Food and Beverage Industry Growth

The expanding food and beverage industry in India is creating a strong demand for enzymes used in food processing, beverage production and other food manufacturing applications.



Health Awareness

Increasing consumer awareness of health and wellness is driving demand for food products with improved nutritional profiles. Enzymes play a central role in these nutritional enhancements.



Government Initiatives

The promotion of food processing by the government is supporting market growth by creating a favourable regulatory environment for enzyme application in food production.

²³[Research and Markets](#)

Emerging Trends

The Indian food enzyme market is witnessing several emerging trends:



Clean Label and Natural Ingredients

Growing consumer preference for food products with simple, recognisable ingredients is driving demand for enzymes that can replace artificial additives and preservatives.



Functional Food Applications

Enzymes play a crucial role in functional foods, offering specific health benefits. The rising prominence of these products is driving growth in the food enzyme market.



Customised Enzyme Solutions

Development of bespoke enzyme blends for specific food applications is an emerging trend in the market.



E-commerce Expansion

The rapid growth of e-commerce platforms has made it easier for consumers to purchase food enzymes and enzyme-fortified products, thereby expanding market reach.



Digital Technology in Feed Formulation

Integration and utilisation of digital technology in feed formulation is enabling more precise and efficient use of enzymes in food production.

Indian Non-Food Enzymes Market

The non-food enzymes market in India is experiencing steady growth, directed by increased adoption across manufacturing sectors. In paper and pulp applications, enzymes , such as xylanase and cellulase are utilised for improving pulp brightness, reducing chemical usage and enhancing paper strength. The leather processing industry utilises proteases and lipases during soaking, unhairing, bating and degreasing stages, significantly reducing environmental pollution compared to traditional chemical methods. In textile processing, enzymes facilitate critical processes including de-sizing, bio-polishing and bleaching. Along with the growing Indian detergent and cleaning industry, demand for high quality and eco-conscious cleaning solutions has augmented notably among consumers. Enzymes can replace harsh chemicals and reduce wash temperature. Additionally, the benefits of enzymes in detergents include better cleaning and stain removal, shorter washing time, reduced water and energy consumption and minimal environmental impact.

Demand Drivers

Several factors are driving the growth of India's non-food enzymes market. Stringent environmental regulations are compelling industries to adopt cleaner enzyme-based technologies that reduce chemical waste and pollution. Technological advancements in enzyme engineering have created more stable and efficient enzymes tailored to India's industrial conditions. The expansion of end-use industries, particularly in South India, has created new markets for enzyme applications. Additionally, growing awareness of the benefits such as sustainability and cost efficiency of enzymes is driving businesses to replace conventional chemical processes with enzyme-based alternatives. The shift toward green manufacturing and resource efficiency continues to support market growth across industrial sectors.



Global Probiotics Market

Probiotics are live microorganisms. When consumed in appropriate amounts, it benefits health by maintaining a healthy microbial balance in the intestines. They promote proper digestion, enhance immune function and help address various health concerns including digestive disorders, mental health issues and infections.


The global probiotics market has experienced explosive growth, influenced by heightened consumer awareness of gut health and its connection to overall wellness. The global probiotics market was valued at US\$ 99.98 billion in 2024 and is projected to reach US\$ 374.57 billion by 2034, expanding at a notable CAGR of 14.12%.²⁴

Global Probiotics Market Outlook

US\$ billion

CAGR

14.12% ↑



Source: [Precedence Research](#)

Demand Drivers for the Global Probiotics Market

The probiotics market is driven by several key factors:



Rising Awareness of Gut Health

Scientific research highlighting the gut microbiome’s crucial role in maintaining well-being, immune function and digestive health has led more consumers to incorporate probiotics into their daily routines.



Preventative Healthcare Trends

Heightened inclination of consumers towards preventative healthcare coupled with the development of effective probiotic strains, is augmenting market growth.

²⁴[Precedence Research](#)


²⁵[Precedence Research](#)

Regional Analysis

Asia Pacific dominated the global probiotics market with a 38.81% share in 2024, valued at US\$ 38.80 billion. The market is further expected to reach US\$ 145.52 billion by 2034, with a CAGR of 14.13%.²⁵ The region is witnessing substantial growth in consumer awareness. This is evident from the strong demand stemming from countries, such as India, China and Australia.

The market of North America is expected to grow considerably during the forecast period of 2024-34. Heightened investments from manufacturers in the food and beverage and pharmaceutical industries and continued research and development to launch new products targeting various age groups and genders are some of the factors that will direct the growth in the market.

Probiotics Market Region-wise Market Share



Source: [Precedence Research](#)

Global Human Probiotics Market

Human probiotics market is expected to grow to ~ US\$ 93 billion by 2028.²⁶ This growth is expected to be driven by elevated consumer awareness of gut health, preventative healthcare and the benefits of probiotics in improving digestion, immunity and overall well-being. Asia-Pacific dominates the market, accounting for over 38% of the global share in 2024. This dominance is directed by ascending disposable incomes, technological advancements like microencapsulation and strong demand in countries such as India and China.²⁷ Key trends in the global human probiotics market include personalised probiotics, probiotic beverages and therapies based on micro-biome. These trends are further supported by innovations in probiotic formulations and expanding e-commerce platforms leading to market expansion.

Indian Human Probiotics Market

Probiotics in India are finding increased application across various sectors, including food and beverages, dietary supplements and pharmaceuticals. The market encompasses probiotic curd, drinks, yogurt and other formulations distributed through various channels including convenience stores, supermarkets, hypermarkets, specialty stores and online platforms.

The Indian probiotics market has witnessed exceptional growth in recent years. This growth can be attributed to heightened health consciousness and awareness of gut health benefits. The market was valued at US\$ 2.2 billion in 2024 and is projected to reach US\$ 10.0 billion by 2033, demonstrating an impressive CAGR of 17.8% during 2025-2033.²⁸

Dietary supplements dominate, with tablets/softgels holding 40.22% share, while chewables grow fastest.²⁹ The dairy sector drives demand, with probiotic yogurt sales projected to grow from US\$ 920.21 million in 2023 to US\$ 2,033.04 million by 2032, with a Compound Annual Growth Rate (CAGR) of 9.20%.³⁰



²⁶Global Probiotics Market 2024-2028, Technavio


²⁷[Precedence Research](#)

²⁸[IMARC Group](#)

²⁹[Grand View Research](#)


³⁰[Credence Research](#)

Demand Drivers for Indian Probiotics Market




Rising Prevalence of Gastrointestinal Disorders

The heightened incidence of conditions, such as constipation, irritable bowel syndrome, diarrhoea and colorectal cancer is driving demand for probiotics that can help manage these conditions.




Growing Geriatric Population

India’s aging population, which is more susceptible to developing gastrointestinal ailments, is contributing to increased probiotic consumption.




Health Consciousness

With increasing health awareness among consumers, there has been a significant shift toward healthier food products, including functional foods and beverages containing probiotics.




Immunity Concerns

The escalating demand for immunity-boosters, dietary supplements and fortified food products, particularly following the COVID-19 pandemic, has accelerated the adoption of probiotics.




Product Innovation

Leading manufacturers are offering innovative product variants, including dairy-free, allergen-free and sugar-free formulations, to expand their consumer base and gain a competitive edge.




Changing Lifestyles

Factors, such as the expanding working population, on-the-go food culture, hectic lifestyles, rising incomes and rapid urbanisation are creating a favourable market environment for probiotics.




E-Commerce Growth

The rise in prominence of quick-commerce applications that facilitate free doorstep delivery of probiotics coupled with secure payment gateways, is bolstering market growth.



Nutrient Deficiencies

Changing dietary patterns resulting in nutrient deficiencies are elevating demand for probiotics to aid absorption of micronutrients in the body.



Government Incentives

Favourable incentives implemented for investment and growth of the food and beverage industry by the Government of India are stimulating market growth.

Global Pet Probiotics Market

The global pet probiotics market is expanding steadily, with the pet probiotics supplements segment projected to grow from US\$ 780 million in 2024 to US\$ 1.1 billion by 2034 at a CAGR of 3.5%.³¹ Elevated pet ownership and growing awareness of pet health are fuelling the demand for probiotic-enriched pet food. These products address digestive issues, boost immunity and improve coat quality. Innovations in probiotic strains and delivery systems, such as chewable tablets and liquid supplements, are enhancing product accessibility and effectiveness. Leading companies are investing in R&D to develop targeted solutions for different pet species and age groups. Additionally, premiumisation trends and multifunctional formulations combining probiotics with prebiotics and vitamins are shaping the future of this market.



³¹Future Market Insights

Global Nutraceutical Market

The global nutraceuticals market represents a growing sector within the health and wellness industry, encompassing functional foods, functional beverages and dietary supplements. This market is demonstrating strong growth potential as consumers increasingly prioritise preventive healthcare approaches and seek products that offer specific health benefits beyond basic nutrition. The nutraceuticals industry is constantly evolving with continued product innovation and expanding distribution channels. Further, the e-commerce platforms have enhanced product accessibility worldwide. In 2024, the global nutraceutical market was valued at US\$ ~400 billion.³²

Regional Analysis

North America is the dominant regional market for nutraceuticals. This dominance stems from high consumer awareness and substantial demand for fortified food products. Further, advanced healthcare infrastructure, stringent regulatory framework and high-income levels have contributed to the growth of the market in the area. Europe represents another significant market with strong growth potential, particularly in natural and organic nutraceutical segments. The Asia-Pacific region is emerging rapidly due to heightened health consciousness, rising disposable incomes and growing urbanisation across developing economies in the region. Further, Latin America, the Middle East and Africa are presenting promising opportunities as health awareness increases and distribution networks expand.

Demand Drivers for the Global Nutraceutical Market



Health and Wellness Consciousness

Increasing awareness of the importance of proper nutrition and preventive healthcare is influencing market growth. This is further leading to widespread use of dietary supplements, vitamins and minerals to support overall wellbeing.



Rising Fitness Trends

Growing consumption of sports nutrition products for endurance and muscle recovery is leading to the market growth of specialised nutraceuticals which target performance enhancement.



Demographic Shifts

Aging population in developing countries is augmenting the demand for health-supporting products which particularly cater to joint health, cognitive functions, etc.



Economic Factors

Rising per capita income is enabling greater spending on premium health products, especially in the Asia-Pacific region.



Healthcare Economics

Consumers are increasingly adopting a preventive approach towards healthcare. This shift is mainly due to the considerable rise in healthcare costs. This shift has heightened the use of nutraceuticals, thereby influencing the growth of the market.



Weight Management Concerns

Growing prevalence of obesity is creating demand for weight management supplements as customers gravitate toward healthy lifestyles and incorporate nutraceuticals into their daily routine.



Retail Expansion

Proliferation of e-commerce platforms and specialised retail outlets are improving product accessibility leading to market expansion.

³²Press Information Bureau

Indian Nutraceutical Market

Nutraceuticals, which include dietary supplements, functional foods and beverages and protein supplements, have gained significant traction in India due to enhanced consumer attention to fitness and health, rising disposable incomes and a heightened focus on preventive healthcare.

The Indian nutraceutical market has emerged as one of the fastest-growing segments within the broader health and wellness industry. The nutraceuticals market size is expected to increase to US\$ 18 billion in 2025.³³

The Indian nutraceutical market presents significant growth opportunities. With continued innovation and expanding distribution networks, the market is poised for substantial expansion in the coming years.

Market Segmentation

The Indian nutraceutical market can be segmented into:

- 1. **Dietary Supplements:** Including vitamins, minerals, proteins and herbal supplements
- 2. **Functional Foods and Beverages:** Products fortified with nutrients, probiotics and other bioactive compounds
- 3. **Protein Supplements:** Including whey protein, plant-based proteins and amino acid supplements

Dietary supplements currently dominate the market, accounting for approximately 65% of the total nutraceutical market in India, followed by functional foods and beverages and protein supplements.³⁴

Emerging Trends

The Indian nutraceutical market is witnessing several emerging trends:

- 1. **Personalised Nutrition:** Growing demand for customised nutraceutical solutions based on individual health needs, genetic profiles and lifestyle factors.
- 2. **Plant-Based Supplements:** Increasing preference for plant-derived nutraceuticals, driven by the rising trend of vegetarianism and veganism.
- 3. **Clean Label Products:** Growing consumer demand for nutraceuticals with minimal processing, organic ingredients and transparent labelling.
- 4. **Integration with Traditional Medicine:** Combination of modern nutraceutical science with traditional Ayurvedic and herbal ingredients to create unique product offerings.
- 5. **Digital Health Integration:** The integration of nutraceutical products with digital health platforms, apps and wearable devices for personalised health monitoring and supplementation.

**Enzyme Industry: SWOT Analysis**

Strengths

Robust Market Growth and Size

The enzyme industry exhibits strong growth potential, with the global market projected to expand significantly with a CAGR of 7.8% till 2029. Heightened application of enzymes spanning sectors, such as food processing, pharmaceuticals, biofuels and industrial manufacturing is contributing to this robust growth.

Technological Innovation and Advancements

The enzyme industry benefits from cutting-edge innovations in biotechnology and enzyme engineering. Platforms guided by machine-learning have reshaped enzyme design and optimisation processes, expediting the development of specialised biocatalysts. Advanced breakthroughs in synthetic biology tools, high-throughput screening technologies and computational modelling have further enhanced enzyme performance characteristics, such as stability, activity and substrate specificity.

Diverse Application Portfolio

Enzymes are highly versatile and find applications across multiple industries:

- 1. **Food Processing:** Enzymes enhance texture, flavour, shelf life and nutritional profiles of food products
- 2. **Biofuels:** Enzymes, such as cellulases and amylases play a vital role in converting biomass into ethanol biofuel
- 3. **Pharmaceuticals:** Specialty enzymes are integral to drug synthesis and biopharmaceutical production
- 4. **Textile and Leather Processing:** Enzymatic solutions reduce environmental impact while improving production efficiency.

This diversity of application mitigates market volatility and provides multiple growth vectors.

Sustainability Alignment

Enzymes are increasingly being utilised as eco-conscious alternatives to traditional chemical processes. They reduce energy consumption and waste generation across industries, such as biofuels, textiles, detergents and food processing. This alignment with global target of reducing environmental impact positions the industry favourably amid increasing regulatory pressures.

Weaknesses

High Production Costs

Enzyme manufacturing requires advanced biotechnology processes, specialised equipment and skilled personnel, leading to high production costs. These costs may limit the accessibility of enzymes for small-scale industries or price-sensitive markets.

Regulatory Challenges

The enzyme industry faces stringent regulatory requirements across regions:

- In the US, enzymes classified as food additives or GRAS (Generally Recognized As Safe) substances must undergo stringent safety evaluations by the U.S. Food and Drug Administration (USFDA).
- In Europe, food enzymes are regulated under Regulation EC No 1332/2008 but face delays owing to harmonisation issues among member states.

Managing these complex regulatory landscapes requires substantial resources and can delay product development.

Sensitivity to Environmental Conditions

Enzymes are highly sensitive to temperature, pH levels and other environmental factors. This sensitivity necessitates

Demand Drivers for Indian Nutraceutical Market

**Increasing Health Awareness**

Growing consciousness about preventive healthcare and wellness is driving consumers to incorporate nutraceuticals into their daily regimen.

**Rising Prevalence of Lifestyle Diseases**

The heightened incidence of conditions, such as diabetes, obesity and cardiovascular diseases has prompted consumers to seek preventive health solutions.

**Growing Geriatric Population:**

India's aging population, which is more susceptible to nutritional deficiencies and chronic diseases, is contributing to increased nutraceutical consumption.

**Shift Towards Preventive Healthcare**

The COVID-19 pandemic has expedited the transition from curative to preventive healthcare, elevating the demand for immunity-enhancing supplements.

**Urbanisation and Changing Lifestyles**

Rapid urbanisation, sedentary lifestyles and changing dietary patterns have led to nutritional gaps that consumers are trying to address through nutraceuticals.

**E-Commerce Growth:**

The proliferation of online retail platforms has made nutraceutical products accessible to a broader consumer base, particularly in tier-2 and tier-3 cities.

**Government Initiatives:**

Supportive government policies promoting the nutraceutical industry and increasing investments in healthcare infrastructure are driving market growth. The government has allowed a FDI of 100% under this segment.

**Product Innovations:**

Continuous development of new formulations, delivery formats and targeted solutions is expanding the market potential.

³³Ministry of Food Processing Industries

³⁴Invest India

precise control during industrial processes, adding complexity and cost to their application.

Dependence on Specific Raw Materials

The production of enzymes often relies on specific microorganisms or plants as raw materials. Variability in supply due to environmental factors or geopolitical issues can impact production consistency.

Opportunities

Expansion into Emerging Markets

Emerging economies, such as India, China, Brazil and South Africa represent significant growth opportunities for the enzyme industry due to rapid industrialisation and increasing demand for processed foods and pharmaceuticals. Brazil leads the South American market, supported by strong demand for biofuels and animal feed enzymes. In Asia-Pacific, India is projected to be the fastest-growing market due to its expanding food processing sector.

Rising Demand for Specialty Enzymes

Specialty enzymes tailored for specific applications such as gluten-free baking or lactose-free dairy products are gaining traction among health-conscious consumers. The specialty enzymes market is expected to witness steady growth driven by advancements in biotechnology research.

Increasing Use in Biofuel Production

Governments worldwide are promoting biofuel adoption as part of their sustainability initiatives. Enzymes like cellulases play a crucial role in converting biomass into renewable energy sources such as ethanol biofuel.

Advancements in Biotechnology

Technological advancements such as machine learning-guided platforms enable rapid development of novel enzymes with enhanced characteristics. These innovations open up new possibilities for enzyme applications across industries ranging from pharmaceuticals to green chemistry.

Threats

Intense Competition from Substitutes

Chemical catalysts often serve as cost-effective alternatives to enzymes in certain applications. The enzyme industry must continuously innovate to demonstrate superior performance and sustainability benefits over traditional methods.

Price Volatility of Raw Materials

Fluctuations in raw material prices due to geopolitical issues or environmental factors can impact production costs and profitability for enzyme manufacturers.

Economic Downturns

Global economic turbulences can reduce industrial production and consumer spending, impacting demand for enzymes across sectors such as food processing or pharmaceuticals.

Public Perception Challenges


Negative public perception regarding Genetically Modified Organisms (GMOs) used in enzyme production can hinder market acceptance. Transparent communication about safety measures is crucial for addressing consumer concerns.



The enzyme industry demonstrates significant potential driven by robust growth dynamics, technological innovations, diverse applications, sustainability alignment, established leadership structures, strategic investments and emerging opportunities in global markets. However, challenges related to high production costs, regulatory compliance barriers, environmental sensitivities, competition from substitutes, raw material dependencies, economic downturns and public perception issues must be addressed proactively.

The global enzyme industry can capitalise on the opportunities while mitigating threats through:

1. Investments in R&D focusing on developing cost-effective production methods
2. Strategic partnerships with end-user industries to promote innovation
3. Regulatory harmonisation efforts
4. Consumer education campaigns which can help build trust around GMO-derived products
5. Diversification into emerging markets to ensure sustained growth despite economic uncertainties.



Advanced Enzymes is a research-centric company and holds a global leadership position in enzymes & probiotics manufacturing. It is the largest Indian enzymes & probiotics company engaged in research and development, manufacturing and marketing of 400+ proprietary products developed from over 65 indigenous enzymes and probiotics. The Company is devoted to providing eco-conscious solutions to industries ranging from human health care and nutrition, animal nutrition, baking, fruit and vegetable processing, brewing and malting, grain processing, protein modification, dairy processing, speciality applications, textile processing, leather processing, etc.


The Company aims to augment the accessibility of healthcare without side-effects, help farmers enhance nutrition for animals and also to help the industry replace traditional thermal-chemical-mechanical processes into enzyme integrated processes. Having pioneered the production of enzymes in India, it continues to lead the research and development of new applications for the use of enzymes across various industries.

The Company operates state-of-the-art manufacturing facilities and research and development centres across India, US and the Europe. Following the acquisition of evovx Technologies GmbH, a German R&D company, Advanced Enzymes has elevated its R&D capabilities with state-of-the-art 'Directed Evolution' technology creating any desired enzyme molecule.

The Company has justified its robust profit margins by leveraging strategic benefits such as low overheads, in-house development of fermenters and over three decades of technical knowledge and market know-how.

Advanced Enzymes with three wholly owned direct subsidiaries, four direct subsidiaries and five step-down wholly owned subsidiaries has geographical presence in more than 45 countries worldwide. The Company strives to build enduring relationships with its customers through customised and effective enzyme solutions coupled with the best technical advice and superior service.

The Company's mission is to ensure that every possible industry is able to take advantage of enzymes to create and produce innovative products, improve the quality of their end products, reduce energy costs, optimise the use of raw materials and resources, reduce pollution and overall carbon footprint.



Subsidiaries

Advanced Enzymes USA (AEU)

Advanced Enzymes USA Inc. (“AEU”) is engaged in the research, development and marketing of innovative, effective and all-natural enzyme solutions of the highest quality. As a wholly owned direct subsidiary of Advanced Enzyme Technologies Ltd., it primarily serves the North American and Latin American markets through its subsidiaries: Cal-India Foods International (doing Business as Specialty Enzymes and Biotechnologies), Advanced Supplementary Technologies Corporation and Enzyme Innovation. In FY 2024-25, AEU recorded consolidated revenue of ₹ 2,342 million and a Profit After Tax (PAT) of ₹ 714 million.

Advanced Supplementary Technologies Corporation (AST)

Operating as a wholly owned subsidiary of Advanced Enzymes USA, AST stands as a premier manufacturer of professional, enzyme-based strength supplements supporting cardiovascular, anti-inflammatory, joint, digestion and colon health. The Company exclusively utilises non-genetically modified and natural ingredients which undergo rigorous testing by a team of leading scientists and industry specialists. AST assists customers in attaining a healthy lifestyle through enzyme supplements formulated and produced in-house, guaranteeing the highest quality, activity, purity and safety standards.

Cal-India Foods International (doing Business as Specialty Enzymes and Biotechnologies) [SEB]

Cal-India Foods International (doing Business as Specialty Enzymes and Biotechnologies) [“SEB”], a wholly owned subsidiary of Advanced Enzymes USA (AEU), was established in 1985. Since its inception, it has established itself as a prominent producer of enzymes in the Western Hemisphere. A subsidiary of Advanced Enzymes USA, this subsidiary provides comprehensive enzyme solutions for healthcare and nutrition, catering to the North American and Latin American markets. It excels in the development of custom enzyme blends right from inception to completion and also offers a range of well-established, highly effective enzyme products.

Enzyme Innovation Inc. (EI)

Enzyme Innovation Inc. (“EI”) functions as a wholly owned subsidiary of Specialty Enzymes and Biotechnologies, USA, focused on marketing and business development of industrial enzymes throughout the American continent. EI caters to various industries including Baking and Milling, Brewing and Malting, Craft Brewing and Distilling, Fruit and Vegetable processing, Animal Feed, Protein Modification, Grain Alcohol, Paper and Pulp, Waste Management, Wine and Detergents and Cleaning aids. Enzyme Innovations excels in delivering customised solutions to meet specific industry needs.

Starya Labs Inc.

During the year under review, the Board of Directors of AEU, a wholly owned subsidiary of the Company, accorded its approval for formation of a new corporation in California (US), named Starya Labs, Inc (“Starya Labs”), as wholly owned subsidiary of AEU. Cal-India Foods International USA, a step-down wholly owned subsidiary of the Company (“SEB”) to spin-off and transfer its enzyme/probiotic laboratory testing services (“SEB Lab”) together with certain assets and liabilities related to the said SEB Lab into Starya Labs. Starya Labs was incorporated on December 09, 2024 and will focus on laboratory testing services and enzyme / probiotic product testing.

Advanced Bio Agro Tech Limited (ABTL)

Incorporated in 2007, Advanced Bio-Agro Tech Limited, as a public limited company and a subsidiary (60%) of the Company. It concentrates exclusively on animal nutrition by developing, manufacturing and marketing enzyme-based solutions for industries such as poultry and cattle. ABTL has positioned itself as a leader in poultry enzyme solutions throughout the Indian sub-continent and provides solutions to the notable Southeast Asian markets of Vietnam, Thailand, Malaysia and Philippines. In FY 2024-25, ABTL’s revenue stood at ₹ 479 million, while its PAT was ₹ 36 million.

Advanced Enzytech Solutions Limited (AESL)

AESL is a leading provider of eco-safe enzyme solutions for industries including textiles, leather, paper, detergents and cleaning aids. AESL also strives to substitute traditional harsh chemical processes in these industries with newer, eco-conscious, yet cost-effective alternatives utilising enzymes, micro-organisms and bio-degradable chemicals. Founded in 2008, AESL operates as a wholly owned subsidiary of the Company. AESL’s revenue for FY 2024-25 was ₹ 183 million and its PAT for the same period was ₹ 22 million.

JC Biotech Private Limited (JC Biotech)

JC Biotech was incorporated in 1991 with the mission of manufacturing nutraceuticals, bio-pharmaceuticals and bio-chemicals. As of December 1st, 2016, JC Biotech became a subsidiary of Advanced Enzyme Technologies Ltd. The Company further increased its stake in JC Biotech by 5.89% during the previous financial year, increasing the total shareholding to 95.72%. Beyond its ongoing development and manufacturing of bio-pharmaceutical molecules, JC Biotech also aims to produce algae DHA in the coming years. In FY 2024-25, JC Biotech reported revenues reaching ₹ 600 million and a PAT of ₹ 12 million.

Scitech Specialities Private Limited (Scitech)

SciTech functions as a specialty products manufacturing unit established by Pharma Technocrats. The Company acquired 51% stake in SciTech on January 11, 2021. SciTech serves as suppliers of Effervescent based products and has presence in India, Southeast Asia, Middle East and North Africa (MENA), Eastern Europe, USA, Canada and Australia. In FY 2024-25, SciTech’s revenue stood at ₹ 542 million, while its PAT was ₹ 37 million.

Saiganesh Enzytech Solutions Private Limited (Saiganesh Enzytech)

Saiganesh Enzytech specialises in extracting Latex from papaya, purifying it and supplying the finished papain enzyme in liquid form (agricultural extraction of Papain enzyme). Papain ranks as one of the essential digestive enzymes utilised in formulated solutions for human health/nutrition and the food industry. Saiganesh Enzytech was incorporated on November 1, 2022 and is located in Burhanpur, Madhya Pradesh. The Company had acquired 50% stake in Saiganesh Enzytech on January 03, 2023. In FY 2024-25, Saiganesh Enzytech generated revenue of ₹ 213 million and a PAT of ₹ 16 million.

Advanced Enzymes Europe B.V., Amsterdam (Netherlands) (AEE BV)

Advanced Enzymes Europe B.V. (“AEE BV”) is a wholly owned subsidiary of your Company. In FY 2024-25, on a consolidated basis, AEE BV’s revenue stood at ₹ 214 million as compared to ₹ 230 million in FY 2023-24. AEE BV is registered with the Chamber of Commerce and serves as a special purpose vehicle for the European market, holding 100% equity in evovx technologies GmbH. In December 2024, the Company increased its investment in AEE BV through fresh issuance of equity shares by AEE BV for a consideration of ₹ 478.18 million.

evovx Technologies GmbH (evovx)

evovx technologies, a wholly owned subsidiary of Advanced Enzymes Europe B.V., operates as an industrial biotech company that specialises in the development and production of enzymes and the development of oligosaccharides and polysaccharides primarily intended for food applications. The Company specifically targets ingredients offering health benefits to consumers. evovx maintains a team of team of scientists and technicians to focus on developing best-in-class ingredients that offer consumer health benefits. In FY 2024-25, evovx generated revenue of ₹ 214 million.

Research and Development

The Company's R&D strategy involves identification of product gaps and development of new enzymes, probiotics and solutions. This helps in expanding competencies in enzymes and probiotics, discovery and genetic engineering. The Company owns and operates 7 state-of-the-art R&D facilities including 5 in India, 1 in the US and 1 in Germany.

The Company is dedicated to the procurement of advanced instruments that support high-throughput screening methods, enabling efficient and precise evaluation of key variants. It leverages AI-based tools for in silico screening to identify the most promising variants, which are then further assessed in the wet lab for validation and optimisation.

The Company's ongoing development of diverse expression systems has enabled it to successfully produce commercially viable proteins, making them suitable for a wide range of applications across various industries. The products it develops are designed to address current industrial challenges in food processing, driving improvements in product quality and enhancing profitability for our partners. Additionally, its innovations are focused on offering holistic health benefits,



contributing to the well-being of consumers while meeting the evolving needs of the industry.

It has pioneered a new enumeration method for sporulating probiotics, which allows for precise quantification of each strain, even when multiple probiotics are present in a mixture. This advancement enhances the Company's ability to create effective probiotic formulations.

The Company has developed an industrial-grade product specifically designed to improve both the quality and yield of the oil, providing a better solution for industries that rely on this ingredient. It has also developed an industrial product for whole wheat bread production which provides an innovative solution to create fiber-rich, nutritious baked goods, helping bakeries cater to the increasing demand for healthier options. Additionally, it enhances the shelf life, softness, resilience and overall acceptability of baked products, empowering manufacturers to maintain consistent quality and stay competitive in the market.

Its innovative nutraceutical product is designed to enhance carbohydrate metabolism and promote gut health in humans, offering a scientifically backed solution for digestive well-being. Building on this foundation, the Company has developed advanced digestion models that provide deeper insights into digestive processes in both humans and pets, enabling the creation of more personalised and effective health solutions for all. It has also developed a nutraceutical product designed to help manage and alleviate allergy symptoms, providing individuals with a natural and effective way to improve their quality of life.

The Company also partners with customers to develop innovative enzymatic solutions for API intermediates preparation, replacing traditional chemical processes. Its enzymatic and microbial technologies address Environmental Treatment Plant challenges while delivering sustainable products that enhance efficiency and reduce environmental footprint for its customers. Through these initiatives, the Company continues to drive advancements in biotechnology, contributing to the development of healthier, more sustainable products across various industries.

During FY 2024-25:

3

Patents filed

1

EFSA Dossier filed

2

GRAS Dossiers filed

Overall:

17

Patents filed ³⁵

15

Food Enzyme Dossiers filed with EFSA ³⁶

9

GRAS Dossier filed with the US FDA ³⁷

Manufacturing Facilities

The Company operates nine world-class manufacturing facilities globally. These production plants have large-scale fermentation, recovery, purification, and formulation capacity, catering to various industries including animal nutrition, nutraceuticals, pharmaceuticals, poultry products, cosmetics, and other specialty industries. The plants are ISO and WHO cGMP certified, following the highest standards of quality and safety. In the US, the Company's plants are primarily involved in the mixing and blending of enzymes and probiotics. The Company has increased fermentation capacity of more than 500 m³.

Business-wise Performance

The enzyme libraries of the Company have been specifically crafted for diverse application in biocatalysis, human nutrition (such as sugar management and protein digestion), animal nutrition and the food industry. These libraries have paved the way for the development of new products, advancing application studies across these sectors.

Human Nutrition

Enzymes

The Company is catering to the nutraceuticals market through Systematic Enzymes which include Blood related, Bronchitis and Fibroids. These enzymes are used as supplements by supplement manufactures to get rid of the bloating caused by protein supplements. The Company works with the R&D teams

of health capsule manufacturers, MLM, sports nutrition, API and pharma formulators.

The Company has focused on reducing potential gluten allergenicity in products, to make them suitable for use by individuals with sensitivity. It has developed new clinical indications for enzymes and probiotics, along with their respective formulations, to address the evolving health needs. Specialty Enzymes has introduced a new solution in sports nutrition, which is a potent blend of proteolytic enzymes, five probiotic strains and a prebiotic, uniquely capable of supporting the optimal digestion of a high-protein diet.

For the Indian market the Company has introduced a brand, Wellfa. The brand focuses on human health, well-being and nutrition. Under this brand, the Company produces a wide range of innovative and scientifically-backed products, in compliance with RDA guidelines set by FSSAI. The products are aimed at supporting overall wellness of consumers. These products are free from harmful chemicals, heavy metals, pesticides and are non-GMO. The products offered by Wellfa focus on improving digestive health, boosting immunity along with a range of other solutions.

Probiotics

In probiotics business, the Company has put in significant effort in research, particularly on cancer treatment. Although the market is considerably sized, strain replacement is difficult for customers, providing advantage to competitors with bigger strains. The Company is planning to develop new applications for probiotics to stay ahead of the fierce competition in the probiotics business.

Biocatalysts

The Company uses protein engineering to structure catalysts such as (R)-isomer or (S)-isomer. These catalysts are solvent proof, more specific and reduce the number of steps and chemical concentration required in the overall chemical reaction.



³⁵Includes filed applications

³⁶Positive opinion received on 9 dossiers, 6 are under evaluation

³⁷No question letter received for 7 dossiers, 1 is self-affirmed and another 1 is under evaluation

Superior cost-efficient characteristics of bio-catalysis presents an opportunity for market creation in India. The Company is strategically positioning itself to take advantage of the favourable government policies and the ongoing relocation of manufacturing from China to India.

During the year under review, the Company has successfully developed new biocatalyst enzymes through advanced protein engineering. These enzymes are designed to perform effectively under the harsh conditions of commercial processes. This innovation is tailored to enhance various applications across multiple industries.

Animal Nutrition

The Company supplies nutrition and digestive enzymes to feed manufacturers and formulators. These businesses are approached directly or through distributors. Under this business, the Company aims to introduce new molecules/ products/formulations in market. In addition, it is also getting into new product range for ruminants and aqua-culture. Enzyme solutions are able to promote animal health and productivity in poultry, ruminants, aquatic animals and pets through improved digestion and nutrient uptake. Phytases, in particular, are essential in releasing phosphorus from plant materials, while carbohydrases such as amylase and xylanase improve carbohydrate digestion. Proteases facilitate protein digestion, and NSP (Non-Starch Polysaccharides) enzymes facilitate fiber breakdown, lowering viscosity and overall feed efficiency.

Overall animal nutrition enzymes enhance feed absorption and digestion, enabling better nutrient utilisation and growth. They support the animals' immunity and gut health by promoting a balanced microbiome and reducing harmful pathogens. Further, these enzymes contribute to joint and muscle health by improving nutrient delivery and reducing inflammation, supporting overall animal well-being.

The Company aims to increase its market share in animal nutrition with plans for expansion into Asian and the South American market in the years ahead.

Bioprocessing

Food Processing

Under food processing, the Company caters to businesses, formulators and distributors. The current revenue mix comprises Baking and Malting and Breweries. The Company is also running pilot with certain potential customers in the category of flavours and fragrances for tea and coffee. The Company is aiming to develop a new market among bakeries in India by increasing the shelf life of bread through enzymes.


While Europe and the US provide a market for extension of the shelf life of breads using enzymes, there is generally a longer approval time in these regions.

In the global food industry, the Company has developed innovative bakery products, such as, whole wheat bread and chemical-free baked goods. This helps in meeting the increasing demand for healthier and sustainable options. In addition, the Company has created products focused on reducing the high sugar content in baked goods, offering healthier alternatives to consumers.

In the vegetable oil extraction process, the Company has developed new products that optimise extraction efficiency. It has also introduced ground breaking products that enhance carbohydrate metabolism and improve gut microbiota, contributing to better overall health.

Non-Food Processing

Advanced Enzymes provides enzymatic solutions to non-food processing industries, such as textiles, leather and paper manufacturing, offering eco-conscious alternatives to traditional chemical methods. In FY 2024-25, the Company expanded its bio-catalysis initiatives for API intermediates, developing targeted enzymatic processes that reduce energy consumption and chemical usage in pharmaceutical manufacturing. Recent developments include advanced trials of enzyme-based solutions for API manufacturers and enhanced R&D investments to strengthen industrial bio-processing capabilities. The Company has also pioneered new products aimed at improving biomass hydrolysis, providing sustainable solutions for industries relying on biomass processing.



Developments During FY 2024-25

Established Starya Labs:

The Board of Directors of Advanced Enzymes USA have accorded its approval for formation of new corporation in the California (US) under the name of Starya Labs Inc. The enzyme/probiotic laboratory testing services of Cal-India Foods International USA will be spun off into the said new corporation. This laboratory is dedicated to the evaluation and testing of enzyme and probiotic formulations.

ESG Initiatives:

- The Company established and made operational a 350kW solar power plant in November 2024 to increase its cumulative clean energy capacity to 510kW.
- The Company received ZDHC MRSL level 3.0 conformance certificate [Zero Discharge of Hazardous Chemicals (ZDHC) Manufacturing Restricted Substances List (MRSL)] which represents the highest assurance of chemical formulation safety and demonstrates its commitment to eliminating hazardous substance in operations.

European Food Safety Authority, EU ("EFSA") / Generally Recognized as Safe, USFDA ("GRAS")

- The Company has submitted a food enzyme dossier to the European Food Safety Authority (EFSA). This enzyme is intended for use in baking and the production of refined edible fats and oils

- Two GRAS (Generally Recognized as Safe) dossiers have been filed with the U.S. Food and Drug Administration (USFDA). These applications support the use of food processing enzymes in baking, brewing, starch processing, and oligosaccharide production
- Additionally, the Company has filed three patent applications focused on sugar management technologies



Financial Performance

Revenue from Operations

The Company's revenue from operations on a consolidated basis was ₹ 6,369 million in FY 2024-25 from ₹ 6,239 million in FY 2023-24. The total revenue includes international sales of ₹ 3,464 million (₹ 3,133 million in FY 2023-24), Increase of 11% and domestic sales of ₹ 2,905 million (₹ 3,106 million in FY 2023-24), a decrease of 6%. During FY 2024-25, domestic sales accounted for about 46% of the Company's revenue, down from 50% in FY 2023-24. In FY 2024-25, international sales accounted for 54% of revenue from operations versus 50% in FY 2023-24.

Financial Costs

Financial costs were ₹ 35 million in FY 2024-25 as compared to ₹ 29 million in FY 2023-24.

Profit

Earnings Before Interest, Taxes, Depreciation and Amortisation excluding other income (EBITDA) for FY 2024-25 was marked at ₹ 1,944 million compared to ₹ 2,045 million in FY 2023-24. During FY 2024-25, profit before tax registered ₹ 1,874 million. Profit after tax changed by (2)% to ₹ 1,340 million in FY 2024-25 from ₹ 1,370 million in FY 2023-24.

Other Income

Other income for FY 2024-25 was ₹ 330 million in comparison to ₹ 366 million in FY 2023-24.

Depreciation and Amortisation

Depreciation and amortisation for FY 2024-25 changed to ₹ 365 million as compared to ₹ 352 million in FY 2023-24.

Net Worth and Returns

As of March 31, 2025, the net worth of the shareholders was ₹ 14,209 million compared to ₹ 13,241 million the previous year. Return on Equity (ROE) for FY 2024-25 was 10% compared to the 11% previous year. (Return ratio is calculated based on average shareholders’ funds).

Cash and Cash Equivalents

Cash and cash equivalents in FY 2024-25 stood at ₹ 1,077million as opposed to ₹ 1,269 million in FY 2023-24.



Details of significant changes (i.e. change of 25% or more as compared to the immediately preceding financial year) in key financial ratios, along with detailed explanation:

Ratio	FY 2024-25	FY 2023-24	Variance	Reason for Variance
Debtors Turnover Ratio	5.52	6.33	-13%	NA
Inventory Turnover Ratio	4.05	4.20	-4%	NA
Interest Turnover Ratio	44.39	58.34	-24%	NA
Current Ratio	9.09 times	7.61 times	19%	NA
Debt Equity Ratio	0.02 times	0.02 times	0%	NA
Operating Profit Margin (%)	31%	33%	-6%	NA
Net Profit Margin (%)	21%	22%	-5%	NA

Outlook

The Company is intent on building its business in Human Nutrition, Animal Nutrition and Bio-Processing through the build-up of its enzymes and probiotics portfolio and development of innovative products in targeted markets. Ongoing development of new molecules in enzymes, probiotics and biocatalysts underlies this strategy, bolstered by strong internal capabilities and continued capital expenditures.

For Human Nutrition, the Company is using its proven B2C model from the U.S. as a platform to drive India growth, rolling out products across weight and sugar management, immunity and gut health. Launching the Wellfa brand and digital platform increases reach to a full breadth of supplements designed to meet consumers' needs through digital channels to exploit shifting market opportunities.

In Animal Nutrition, the Company remains committed to improving feed efficiency and animal health by providing high-quality nutritional solutions. Continual trials and product registrations, and focused expansion in the U.S., MENA, and

Asian regions, are accompanied by an expanding distribution network and sales force.

Substantial investments in cutting-edge R&D facilities are allowing the Company to expand its product pipeline and create new applications across industries. The growth of the R&D staff highlights the Company’s focus on innovation and portfolio expansion.

The Company has a history of making strategic, zero-debt acquisitions to enhance marketing, increase its geographic presence and strengthen its B2C business with the aim to maintain this strategy for future growth.

Product development activities consist of probiotics for human as well as animal health to bolster immunity, digestion, and wellness, and food processing and bio-catalytic enzymes. Progress in regulatory filing and advanced plant-level trials demonstrate the Company's emphasis on offering effective, sustainable solutions for the world markets.

Risk Mitigation Strategy

Risk	Impact	Mitigation Strategy
 Macro-Economic	Prevailing geo-economic uncertainties and possibility of global economic downturn, pose risk to the Company's international and domestic business.	The Company relies on technological innovation and a robust operational strategy to mitigate possible inflationary pressures by ensuring cost efficiencies across functions.
 Supply Chain	Geopolitical turbulences disrupting crucial supply chains can result in operational delays and impact costs.	The Company is constantly enhancing its supply chain management, by maintaining good relations with its suppliers, thereby reducing the dependency on a particular supplier, thus allowing flexibility.
 Regulatory	The enzymes and probiotics industry is subjected to specific regulations in many countries including stringent safety, quality and labelling requirements.	The Company proactively follows and ensures alignment with the applicable regulatory norms, maintaining industry compliance.
 Competition	The Company faces several competition risks that can impact its operations and profitability both domestically and internationally. In addition, the expansion of the Company into new geographies will invite challenge from established players.	To mitigate this risk, the Company relies on innovation and ensures its alignment to the market trends, enabling it to stay ahead of its competitors.
 Technological	The Company may face technological risks due to its operation within a research-intensive industry. In order to stay aligned to the evolving trends, continued technological advancement and investment in R&D is necessary.	The Company is undertaking substantial investments in state-of-the-art R&D centre. The Company plans on expanding its portfolio across various industries through formulation of new applications and new use cases.
 Intellectual Property	Enzymes and probiotics companies have to protect their significant investments in R&D and product development through patents, trademarks and trade secrets.	The Company ensures timely filing of patents to protect itself from competitors.
 Consumer Demand	Consumer preferences towards enzymes or probiotics may shift in response to changing trends or unforeseen events.	The Company is continually focussing on strengthening its R&D capabilities to keep pace with the evolving consumer demand. It is committed to innovating and enhancing its products to better cater to the consumers' needs.
 Product Quality	Enzyme and probiotic businesses need to maintain high quality and safety standards to make their products safe for consumption by humans and animals. Lack of compliance can result in recalls, liabilities and reputational damage.	The Company implements constant product improvement measures, which includes multiple stages of R&D and maintaining a strict adherence to the globally accepted quality standards.
 Foreign Exchange	Currency fluctuations pose a risk of diminishing the Company's margins and impacting export demand.	To manage this risk, the companies may need to implement strategies, including hedging, diversification and monitoring market developments. The Company is taking necessary steps to mitigate the forex risk and the currency fluctuations.

Internal Control Systems and their Adequacy

Advanced Enzyme Technologies maintains a strong internal control system to ensure efficient operations. This system helps identify risks and meet legal requirements. The Company maintains dual flow of communication—from leaders to teams and back—to address internal and external factors promptly.

The company's risk management approach ensures proper controls and monitoring for smooth business operations. The process involves identifying, measuring and addressing various risks. Internal auditors review this framework regularly, while departments create risk registers documenting issues and planned solutions.

The IT team continuously improves systems both proactively and in response to security challenges. The company evaluates internal controls by setting targets and making corrections when needed. Given its size and operations, Advanced Enzyme Technologies maintains appropriate internal control and financial systems, which both internal and external auditors regularly test and certify.

Material Developments in Human Resources/ Industrial Relations

The Company recognises the value of its people by nurturing talent and developing a positive workplace culture. With ongoing business expansion, the Company is focusing on attracting skilled professionals and supporting their growth through several development initiatives. Employees are provided with ample opportunities for learning, well-being, and collaboration and various other resources needed to succeed. The Company prioritises safe and healthy workspaces,

while also encouraging a mind-set geared toward progress and adaptability.

The Company promotes inclusivity across all levels, encouraging open communication and valuing diverse perspectives. Regular initiatives are undertaken to strengthen team cohesion and develop a sense of belonging among employees. The Company remains abreast of the evolving industry requirements, ensuring the employees are well-equipped to meet future challenges. Through these comprehensive efforts, the Company aims to sustain a motivated workforce and achieve organisational success.

Currently, your Company has more than 395 employees (standalone basis) with diverse backgrounds.

Cautionary Statement

In this Management Discussion and Analysis Report, certain forward-looking statements may be made based on various assumptions about the Company's present and future business strategies, the environment in which it operates and other factors. Risks and uncertainties may cause actual results and information to differ materially from those stated or implied. Among these risks and uncertainties are the effects of economic and political conditions in India and abroad, volatility in interest rates and the securities market, new Government regulations and policies that may impact the Company's businesses and its ability to implement its strategies. The information contained herein, is as of the date referenced and the Company has no obligation to update it. Market data and other information have been obtained from sources deemed trustworthy by the Company or it has been estimated internally, but the accuracy or completeness can't be guaranteed.



BOARD'S REPORT

for the financial year ended March 31, 2025

Dear Members,

Your Board of Directors (“Board”) is pleased to present the 36th Annual Report of Advanced Enzyme Technologies Limited (“Company”) along with the Audited financial statements for the financial year ended March 31, 2025.

FINANCIAL HIGHLIGHTS

The financial performance of your Company for the financial year ended March 31, 2025 is summarized below:

(₹ in million)

Particulars	Standalone		Consolidated	
	Year ended March 31, 2025	Year ended March 31, 2024	Year ended March 31, 2025	Year ended March 31, 2024
Revenue from operations	3,514	3,655	6,369	6,239
EBITDA	706	1,052	1,944	2,045
Less:				
Finance Cost	2	2	35	29
Depreciation and Amortisation	114	109	365	352
Add:				
Other income	615	588	330	366
Profit before exceptional items and Tax	1,205	1,529	1,874	2,030
Exceptional items	0	189	0	151
Profit Before Tax (PBT)	1,205	1,340	1,874	1,879
Less: Provision for Taxation				
Current tax	169	270	495	566
Deferred tax	12	(11)	39	(53)
MAT credit entitlement	-	-	(2)	(4)
Tax adjustment for earlier years	-	-	2	-
Tax expenses	181	259	534	509
Profit for the year	1,024	1,081	1,340	1,370
Surplus Brought Forward from the Previous Year	4,696	4,175	10,795	10,023
Amount Available for Appropriations	5,147	5,256	12,135	11,393
Earnings Per Share (Amount in ₹)				
Basic	9.16	9.67	11.72	11.92
Diluted	9.15	9.66	11.71	11.92

RESULTS FROM OPERATIONS

Revenue – Consolidated

Your Company's revenue from operations on a consolidated basis increased to ₹ 6,369 million in the financial year 2024-25 (“FY25”) from ₹ 6,239 million in the financial year 2023-24 (“FY24”), a growth rate of 2%. The total revenue comprises international sales amounting to ₹ 3,464 million (FY24 - ₹ 3,133 million), an increase of 11% and domestic sales amounting to ₹ 2,905 million (including Export Incentives of ₹ 4 million) (FY24 - ₹ 3,106 million (including Export Incentives of ₹ 4 million), decrease of 6%.

Your Company's domestic sales constitute about 46% of revenue from operations during FY25 as compared to 50% of revenue from operations during FY24. International sales were 54% of revenue from operations as compared to 50% of revenue from operations during FY24.

Revenue - Standalone

Your Company's revenue from operations on a standalone basis were ₹ 3,514 million in FY25 from ₹ 3,655 million in FY24, a decrease of 4%. The total revenue comprises international sales of ₹ 1,270 million (FY24 - ₹ 1,134 million), an increase of 12% and domestic sales at ₹ 2,244 million (including Export Incentives of ₹ 4 million) (FY24 - ₹ 2,520 million (including Export Incentives of ₹ 4 million), a decrease of 11%.

The domestic sales constitute 64% of revenue from operations during FY25 as compared to 69% of revenue from operations during FY24. International sales were 36% of revenue from operations during FY25 as compared to 31% of revenue from operations during FY24.

Profits - Consolidated

EBITDA (Earnings before interest, tax, depreciation & amortisation excluding other income) during FY25 was ₹ 1944 million (31%) as compared to ₹ 2,045 million (33%) during FY24, a decrease of 5%.

Profit before tax stood at ₹ 1,874 million (29%) during FY25 as against ₹ 1,879 million (30%) in the previous year, a decrease of 0.3%. Profit after tax stood at ₹ 1,340 million during FY25 as compared to ₹ 1,370 million during FY24, a decrease of 2%.

Profits - Standalone

EBITDA during the year under review was at ₹ 706 million (20%) as compared to ₹ 1,052 million (29%) in FY24. Profit before tax stood at ₹ 1,205 million during FY25 as compared to ₹ 1,340 million in FY24, a decrease of 10%. Profit after tax stood at ₹ 1,024 million during FY25 as compared to ₹ 1,081 million during FY24, a decrease of 5%.

DIVIDEND

During the financial year under review, the Board of Directors of your Company had declared an Interim Dividend @ 200% i.e. ₹ 4/- per Equity Share of face value of ₹ 2/- each for the financial year 2024-25, aggregating to about ₹ 447.30 million (subject to deduction of taxes, as applicable).

Pursuant to the Dividend Distribution Policy of the Company, the Board of Directors recommends a final Dividend @ 60% i.e. ₹ 1.20/- per Equity Share of face value of ₹ 2/- each for the financial year 2024-25 (“**FY25**”), aggregating to about ₹ 134.26 million (subject to deduction of taxes, as applicable) i.e. an increase of 9.10% on the previous year final Dividend.

The final Dividend payout is subject to approval of the Members at 36th Annual General Meeting (“AGM”) of your Company.

Further, the Board of Directors of your Company declared an Interim Dividend @ 200% i.e. ₹ 4/- per Equity Share of face value of ₹ 2/- each for the financial year 2025-26 (“**FY26**”), aggregating to about ₹ 447.52 million (subject to deduction of taxes, as applicable).

The Dividend Distribution Policy of the Company is available on the website of the Company at www.advancedenzymes.com/investors/corporate-governance/#codes-and-policies.

The Dividend Distribution Tax payable by domestic companies on declaration of dividend has been abolished w.e.f. April 01, 2020. Pursuant to this amendment and consequential amendments brought vide Finance Act, 2020, as the dividend by the companies is taxable in the hands of the shareholders, the Company would be under an obligation to deduct tax at source (“TDS”) in accordance with the provisions of the Income Tax Act, 1961 (as amended from time to time).

RESERVES

During the FY25, your Company has not transferred any amount to the General Reserves.

EMPLOYEES STOCK OPTION PLAN

The Members of the Company approved Advanced Enzyme Technologies Limited – Employees Stock Option Scheme 2022 (“**ESOP Scheme 2022**”) and related matters on August 19, 2022 at the 33rd Annual General Meeting of the Company. Your Company has received the In-principle approval from BSE Limited (BSE) and National Stock Exchange of India Limited (NSE).

During the reporting period, the Company allotted 57,075 Equity Shares of face value of ₹ 2 per share pursuant to the Exercise of Options under ESOP Scheme 2022.

Consequent to the said allotment, the paid-up share capital of the Company increased from ₹ 223,648,150 comprising of 111,824,075 Equity Shares of ₹ 2 each to ₹ 223,762,300 comprising of 111,881,150 Equity Shares of ₹ 2 each.

During the reporting period, the Nomination & Remuneration Committee of the Company vide its circular resolution passed on March 27, 2025 approved the Grant of 512,500 stock Options in aggregate having face value of ₹ 2 each to the eligible Employees, under the ESOP Scheme 2022.

The Company has received a certificate from Mr. Shiv Hari Jalan, Proprietor of Shiv Hari Jalan & Co., Practicing Company Secretaries that ESOP Scheme 2022 has been implemented in accordance with the Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 [“**SEBI SBEB Regulations**”] and the resolutions passed by the Members in the General meeting. The certificate will be placed at the ensuing AGM for inspection by the Members of the Company.

The disclosure pertaining to the said ESOP Scheme 2022 as required under the Act and SEBI SBEB Regulations are provided on the website of the Company under the tab ‘Details of Employees Stock Option’ at www.advancedenzymes.com/investors/shareholder-information

FINANCIAL STATEMENTS

The financial statements of your Company for the year ended March 31, 2025 are prepared in accordance with the Indian Accounting Standards (“**IND AS**”), read with the provisions of Section 129 and other applicable provisions, if any, of the Companies Act, 2013 (“**the Act**”), rules framed thereunder and Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (including any statutory modification(s) or re-enactments thereof for the time being in force) [“**SEBI Listing Regulations**”] and forms part of this Integrated Annual Report.

The estimates and judgments relating to the financial statements are made on a prudent basis, so as to reflect in a true and fair manner, the form and substance of transactions and reasonably present the Company's state of affairs, profits and cash flows for the year ended March 31, 2025.

SUBSIDIARIES

Your Company has 12 (Twelve) subsidiaries as on March 31, 2025 as listed below:

Domestic Subsidiaries:

- Advanced Bio-Agro Tech Limited (60%) [“**ABAT**”];
- Advanced EnzyTech Solutions Limited (100%) [“**AESL**”];
- JC Biotech Private Limited (95.72%) [“**JCB**”];
- SciTech Specialities Private Limited (51%) [“**SciTech**”]
- Saiganesh Enzytech Solutions Private Limited (50%) [“**Saiganesh**”]

In terms of the financial performances:

- ABAT's revenue for FY25 was ₹ 479 million (previous financial year [“FY24”] - ₹ 448 million), and Profit after Tax for FY25 was ₹ 36 million (FY24 - ₹ 40 million).

- AESL's revenue for FY25 was ₹ 183 million (FY24 - ₹ 153 million), and Profit after Tax for FY25 was ₹ 22 million (FY24 - ₹ 19 million).
- JCB's revenue for FY25 was ₹ 600 million (FY24 - ₹ 626 million), and Profit after Tax for FY25 was ₹ 12 million (FY24 - ₹ 18 million).
- SciTech's revenue for FY25 was ₹ 542 million (FY24 - ₹ 418 million), and Profit after Tax for FY25 was ₹ 37 million (FY24 - ₹ 37 million).
- Saiganesh's revenue for FY25 was ₹ 213 million (FY24 - ₹ 267 million), and Profit after Tax for FY25 was ₹ 16 million (FY24 - ₹ 26 million).

International Subsidiaries:

- Advanced Enzymes USA (100%)
 - Advanced Supplementary Technologies Corporation (100% Subsidiary of Advanced Enzymes USA) ;
 - Cal-India Foods International (doing Business as Specialty Enzymes and Biotechnologies) (100% Subsidiary of Advanced Enzymes USA);
 - Enzyme Innovation Inc. (100% Subsidiary of Cal-India Foods International);
 - Starya Labs Inc. effective from December 09, 2024 (100% Subsidiary of Advanced Enzymes USA)*

*Note: (iii)The Board of Directors of Advanced Enzymes USA (“AEU”), a wholly owned subsidiary of the Company, has accorded its approval for formation of a new corporation in California (US), Starya Labs, Inc (“Starya Labs”). Cal-India Foods International USA, a step-down wholly owned subsidiary of the Company (“SEB”), to spin-off and transfer its enzyme/probiotic laboratory testing services (“SEB Lab”) together with certain assets and liabilities related to the said SEB Lab into Starya Labs. The aggregate value of the assets to be transferred by SEB to Starya Labs, including any liabilities, contracts, intellectual property, and personnel, not exceeding US \$500,000

In terms of the consolidated financial performance of Advanced Enzymes USA, the revenue for FY25 was ₹ 2,342 million (FY24 - ₹ 2,128 million), and Profit after Tax for FY25 was ₹ 714 million (FY24 - ₹ 616 million).

- Advanced Enzymes Europe B.V. (100%) [“**AEE**”]

In terms of the consolidated financial performance (including its subsidiary, evoxx technologies, GmbH), AEE's revenue for FY25 was ₹ 214 million (FY24 - ₹ 230 million), and profit for FY25 was ₹ 30 million (which includes about ₹ 13 million of operational loss, ₹ 123 million of other income, ₹ 9 million of deferred tax reversal, ₹ 59 million of amortization expense and ₹ 31 million of finance cost) as compared to loss of ₹ 78 million for FY24.

- evoxx technologies GmbH [100% subsidiary of AEE] [“**evoxx**”]

For FY25, the revenues for evoxx was ₹ 214 million (FY24 - ₹ 230 million) and had a negative impact on the bottom line by ₹ 39 million including operational loss of ₹ 27 million (FY24 - negative impact on the bottom line by ₹ 26 million including operational loss of ₹ 15 million) and charge of ₹ 9 million (FY24 - ₹ 11 million) of an amortization expense.

The Policy for determining Material Subsidiaries is available on the website of the Company: www.advancedenzymes.com/investors/corporate-governance. During the year under review, JC Biotech Private Limited in India and Cal-India Foods International in USA were Material Subsidiaries of your Company based on the criteria specified in the SEBI Listing Regulations.

A separate statement containing the salient features of the financial performance of subsidiaries in the prescribed Form AOC-1 is annexed to the financial statements of the Company. The Audited Consolidated financial statements together with Auditors' Report forms an integral part of the Annual Report.

The individual financial statements and other reports of the Company's subsidiaries have not been attached to the financial statements of the Company for FY25. Pursuant to the provisions of Section 136 of the Act read with the SEBI Listing Regulations, the financial statements of the subsidiaries and related information are uploaded on the website of your Company and can be accessed on the web link, www.advancedenzymes.com/investors/quarterly-updates/financial-results and also available for inspection, during working hours at the registered office of the Company on working days except Saturdays and Sundays, up to the date of 36th AGM of the Company. Any Member desirous of conducting inspection and/or of seeking information on the Annual financial statements of the Company's subsidiaries may write and intimate in advance, to the Company Secretary.

SUBSIDIARIES, JOINT VENTURE AND ASSOCIATE COMPANIES

During the year under review:

- Based on the approval of the Board of Directors of your Company, a further investment of ₹ 478.18 million [Euro 5.36 million] in Advanced Enzymes Europe B.V., wholly owned subsidiary [“AEE”] through acquisition/subscription to the issue of 3,623,163 Equity Shares of AEE at Euro 1.48 per Equity Share was completed by your Company on December 19, 2024. The said investment was utilized by AEE to retire interest bearing debt borrowed earlier by AEE from Advanced Enzymes USA, a wholly owned subsidiary of your Company. AEE continues to be the wholly owned subsidiary of the Company and there was no change in the percentage shareholding (100%) of the Company in AEE pursuant to said further investment.
- The Board of Directors of your Company approved a collaboration of the Company with a developer engaged in the development of group captive solar power project, for setting up a solar power plant through its Special Purpose Vehicle, to avail and meet the power/ electricity requirement through solar for the Plants of the Company at Sinnar, Nashik. In such case, the developer would undertake the group captive solar power plant project through a Special Purpose Vehicle company (“SPV”) wherein the buyer of the solar power is required to invest in at least 26% of the said SPV as per the requirement of the applicable laws. In view of this, once the developer/in-principle terms are finalized and the requisite agreements formalized, the Company will be required to invest in 26% Equity shares of such SPV, with the total investment amount in the said Equity Shares not to exceed ₹ 10 million.
- The Board of Directors of Advanced Enzymes USA (“AEU”), a wholly owned subsidiary of your Company, accorded its

approval for formation of a new corporation in California (US), Starya Labs, Inc (“Starya Labs”). Cal-India Foods International USA, a step-down wholly owned subsidiary of the Company (“SEB”) to spin-off and transfer its enzyme/probiotic laboratory testing services (“SEB Lab”) together with certain assets and liabilities related to the said SEB Lab into Starya Labs. The said new corporation, Starya Labs was incorporated and become a wholly owned subsidiary of AEU on December 09, 2024. The aggregate value of the assets to be transferred by SEB to Starya Labs, including any liabilities, contracts, intellectual property, and personnel, not to exceed US \$500,000

The details are available on the website of the Company at www.advancedenzymes.com/investors/announcements-notice

Except as mentioned above, no other entity has become or ceased to be a Subsidiary, Joint Venture or Associate of the Company during the year under review.

MANAGEMENT DISCUSSION AND ANALYSIS

A detailed review of the operations, performance and future outlook of your Company, Subsidiaries and its Business including Risks, Opportunities and Threats are given in the Management Discussion and Analysis, as required under the SEBI Listing Regulations, which is provided in separate section and forms an integral part of this Report.

DIRECTORS' RESPONSIBILITY STATEMENT

Pursuant to the provisions of Section 134 of the Companies Act, 2013, the Directors, to the best of their knowledge and belief and based on the information and explanations provided to them, confirm that:

- in the preparation of the annual accounts for the year ended March 31, 2025, the applicable accounting standards read with requirements set out under Schedule III to the Act, have been followed and there are no material departures from the same;
- appropriate accounting policies have been selected and applied consistently and judgments and estimates are made reasonably and prudently so as to give a true and fair view of the state of affairs of the Company as at March 31, 2025 and of the profit of the Company for the year ended on that date;
- Proper and sufficient care has been taken for the maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;
- the annual accounts have been prepared on a 'going concern' basis;
- Proper internal financial controls are devised to ensure compliance with all the provisions of the applicable laws and that such internal financial controls are adequate and are operating effectively; and
- Proper systems are devised to ensure compliance with the provisions of all applicable laws and that such systems are adequate and operating effectively.

RISK MANAGEMENT

Your Company understands that controlling risks through a formal program is a necessary component and an integral

cornerstone of Corporate Governance. Your Company has adopted Risk Assessment & Management policy which embeds the vision that a robust Risk Management system ensures commensurate controls and monitoring mechanism for smooth and efficient management of Business. The Policy outlines the framework for identification, measurement, evaluation, monitoring and mitigation of various risks. The Management has also reviewed the Risk Management framework of the Company. The Risk Registers are prepared by the concerned departments wherein the respective risks are identified along with its current control activities and the mitigation plans. Thereafter, the registers are reviewed.

The Risk Management Committee constituted by the Board of Directors of your Company (“Board”) assists the Board in monitoring and review of Risk Management Policy of the Company including associated systems, processes, controls & strategies thereto, various risks exposures of the Company, on a periodic basis and then inform the Board about the risks assessed, their concerns and action plan with strategy for mitigation of the risks and such other functions related to risk management & mitigation as may be required by the Board, from time to time.

RELATED PARTY TRANSACTIONS

During the year under review, all transactions with the Related Parties were placed before the Audit Committee for its approval. An omnibus approval from the Audit Committee was obtained for the Related Party transactions which are repetitive in nature. The Audit Committee and the Board, reviewed all the transactions entered into pursuant to the omnibus approvals on a quarterly basis. All the transactions with Related Parties, entered into during the year under review, were in the ordinary course of business and on arms' length basis in accordance with the provisions of the Act, Rules made thereunder and the SEBI Listing Regulations. Approval of the Members of the Company is also obtained in case any Related Party transaction exceeds the prescribed limits and as good corporate governance practice as there may be few transactions that may be carried out in the long-term interest of the Company. The transactions of the Company with its wholly-owned subsidiaries as per the terms mentioned in the Act and the SEBI Listing Regulations, are exempted from the approval of the Members, and hence such approvals are not obtained by the Company.

The Policy on Related Party Transactions (as reviewed and revised by the Board effective February 08, 2025) is available on the Company's website and can be accessed at www.advancedenzymes.com/investors/corporate-governance

As prescribed under Section 134(3)(h) of the Companies Act, 2013 read with Rule 8(2) of the Companies (Account) Rules, 2014, particulars of contracts/arrangements with Related Parties are given in Form AOC-2, annexed as Annexure I to this Report.

TRANSFER TO INVESTOR EDUCATION AND PROTECTION FUND (IEPF)

Pursuant to Section 124(6) of the Companies Act, 2013, all shares in respect of which Dividend has not been paid or claimed for seven consecutive years or more shall be transferred by the company in the name of Investor Education and Protection Fund (“IEPF”). Your Company transferred 9,663 unclaimed Equity Shares pertaining to financial year 2016-17 to the Demat account of IEPF during November 2024. The details of the said shares are provided on the website of the Company at www.advancedenzymes.com/investors/shareholder-information

During the year under review, the Company transferred unclaimed Dividend of ₹ 181,186 for the financial year 2016-17. As on March 31, 2025, the total amount lying in the Unpaid Dividend accounts of the Company in respect of the last seven years was around ₹ 1.49 million. In addition, the total amount lying in the Unpaid (Interim) Dividend account of the Company for FY25 is around ₹ 0.79 million. Details of unclaimed Dividend and Shares due for transfer with due dates and procedure to claim the same are provided in the Notes to the Notice convening 36th AGM of the Company (“AGM Notice” / “Notice of 36th AGM”) and briefly in the Corporate Governance Report which forms an integral part of this Report.

Details of Nodal Officer are displayed on the Company's website at:

www.advancedenzymes.com/investors/shareholder-information

CORPORATE SOCIAL RESPONSIBILITY (“CSR”)

The Annual Report on Corporate Social Responsibility (“CSR”) activities/project is provided in Annexure II and the report along with all the details thereto, forms an integral part of this Report. The Composition of CSR Committee is disclosed in the said Annual Report on CSR Activities and in the Corporate Governance report section.

The CSR policy of the Company intends to focus on certain projects which include initiatives in the field of education, skill development/vocational training, health care, sanitation, safe drinking water, environment sustainability, women empowerment and rural development which will *inter alia* enable creation of a sustainable livelihood in the society and better human capital. The CSR policy covers the potential CSR activities in line with the provisions of Section 135 of the Companies Act, 2013 (as amended) and Schedule VII thereto.

The Corporate Social Responsibility Policy may be accessed on the Company's website at www.advancedenzymes.com/investors/corporate-governance.

POLICY ON CRITERIA FOR APPOINTMENT / REMOVAL OF DIRECTORS AND SENIOR MANAGEMENT PERSONNEL AND REMUNERATION OF DIRECTORS, KEY MANAGERIAL PERSONNEL AND EMPLOYEES

As per the Nomination & Remuneration Policy of the Company (“Policy”), the Nomination and Remuneration Committee *inter alia* recommends the appointment of Directors, Key Managerial Personnel (KMP) and Senior Management Personnel. The Policy lays down the criteria for such appointments and the framework in relation to remuneration of Directors including Managerial Personnel, KMPs and employees of the Company. The Nomination & Remuneration Committee oversees the matter of remuneration to the Executive Directors, KMPs and Senior Management Personnel and recommends to the Board, revision, if any, in the remuneration of the said Directors / Personnel subject to limits as may be approved by the Members.

The Nomination and Remuneration Policy may be accessed on the website of the Company at www.advancedenzymes.com/investors/corporate-governance.

The Board affirms that the remuneration paid to the Directors is as per the terms laid out in the Nomination and Remuneration Policy of the Company.

DIRECTORS AND KEY MANAGERIAL PERSONNEL

During the year under review, there has been no change in the composition of Board and Key Managerial Personnel of the Company.

DECLARATION BY THE INDEPENDENT DIRECTORS

All Independent Directors of the Company have given the following declarations stating that:

- they meet the 'criteria of Independence' as defined under Regulation 16(1) of the SEBI Listing Regulations and Section 149(6) of the Companies Act, 2013 read with Schedule IV and the relevant Rules made thereunder;
- they have complied with the provisions of the Code of Conduct & Ethics of the Company. The Independent Directors have confirmed that they are not aware of any circumstance or situation which exist or may be reasonably anticipated, that could impair or impact their ability to discharge their duties with an objective independent judgment and without any external influence.
- they have complied with the provisions of Rule 6(1) and 6(2) of the Companies (Appointment and Qualifications of Directors) Rules, 2014 (as amended) with regards to the registration on the Independent Directors' databank.

None of the Directors of the Company are disqualified for being appointed as Directors as specified in Section 164(2) of the Companies Act, 2013 and Rule 14(1) of the Companies (Appointment and Qualification of Directors) Rules, 2014 (as amended).

The Board is of the opinion that the Independent Directors of the Company possess requisite qualifications, experience and expertise and they hold highest standards of integrity.

The Independent Directors of your Company have registered on the Independent Directors' Databank pursuant to the provisions of Section 149 of the Companies Act, 2013 and the applicable rules thereunder (“Act”). The Independent Directors, as on March 31, 2025, have informed the Company, that they have either claimed exemption or passed the online proficiency test prescribed under the Act.

RETIREMENT BY ROTATION

In accordance with the provisions of Section 152 of the Companies Act, 2013 read with Rules made thereunder and the Articles of Association of the Company, Mr. Mukund Kabra (DIN: 00148294), Whole-time Director, retires by rotation at the ensuing AGM and being eligible offers himself for re-appointment. The Board recommends the said re-appointment of Mr. Mukund Kabra at the 36th AGM and his brief profile is provided in the Notice convening the said AGM of the Company.

AUDITORS AND AUDITORS' REPORT

STATUTORY AUDITORS

Pursuant to provisions of Section 139 of the Companies Act, 2013 read with the Companies (Audit and Auditors) Rules, 2014 (as amended), M/s. MSKA & Associates, Chartered Accountants [Firm's Registration No: 105047W] were appointed as Statutory Auditor for a term of five consecutive years to hold office from the conclusion of 32nd AGM up to the conclusion of the 37th AGM. The Auditors' Report to the Members on the financial statements of the Company for the year ended March 31, 2025 forms a part of the Annual Report and the Auditors' Report does not contain any qualification, reservation or adverse remark.

COST RECORDS AND AUDIT

The Company has maintained Cost records in accordance with the provisions of Section 148(1) of the Companies Act, 2013, during the year under review.

In terms of Section 148 of the Companies Act, 2013 read with Companies (Cost Records and Audits) Rules, 2014, as amended (“Act”), the Company is not required to have the audit of cost records conducted by the Cost Accountant in practice, for the financial year 2025-26 (“FY26”). During the year under review, based on the recommendations of the Audit Committee, the Board of your Company approved the appointment of M/s. Shilpa & Co., Cost Accountants, Nashik (Firm Registration No. 100558) as the Cost Auditors of the Company to carry out the Cost Audit of the cost records of the Company for FY25. The remuneration of the Cost Auditors was ratified by the Members of the Company in its previous Annual General Meeting held on July 25, 2024.

As per the applicable provisions of the Act, the Cost Auditor is required to forward the Cost Audit Report to the Company within 180 days from the end of the financial year. Once the Cost Audit Report is received and as may be approved by the Board, the same shall be filed by the Company within the timelines prescribed under the Act.

SECRETARIAL AUDITOR / AUDITORS REPORT

Pursuant to the provisions of Section 204 of the Companies Act, 2013 read with the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 (as amended), the Board appointed Mr. Shiv Hari Jalan, Practicing Company Secretary (FCS No. 5703 C.P. No. 4226) to undertake the Secretarial Audit of the Company for the financial year 2024-25 (“FY25”). The Secretarial Audit Report for the FY25 is annexed as Annexure III (A) and forms an integral part of this Report. The Secretarial Audit Report for the year ended March 31, 2025 does not contain any qualification, reservation or adverse remark.

Further, pursuant to the provisions of Regulation 24A of the SEBI Listing Regulations, the Secretarial Audit Report of JC Biotech Private Limited, Material Unlisted Subsidiary for the financial year 2024-25 is annexed as Annexure III (B) and forms an integral part of this Report. The Secretarial Audit Report of JC Biotech Private Limited for the year ended March 31, 2025 does not contain any qualification, reservation or adverse remark.

Pursuant to the provisions of Regulation 24A of the SEBI Listing Regulations (as amended), the aforesaid provisions of the Companies Act, 2013 and based on the recommendations of the Audit Committee and subject to the approval of the members of the Company, the Board has appointed Mr. Shiv Hari Jalan, Proprietor of Shiv Hari Jalan & Co., Company Secretary in practice (FCS No. 5703; C.P. No. 4226) as the Secretarial Auditor of the Company for a term of 5 (Five) consecutive years to hold office from the conclusion of ensuing AGM till the conclusion of 41st AGM to be held for the financial year 2029-30 i.e. to conduct the Secretarial Audit from the financial year 2025-26 to the financial year 2029-30.

Brief profile of the said proposed Secretarial Auditor is separately provided in the Notice of ensuing AGM. Mr. Shiv Hari Jalan has given his consent to act as the Secretarial Auditor of the Company and confirmed that: (i) the aforesaid appointment, if made, would be within the prescribed limits under the Act & Rules made thereunder and SEBI Listing Regulations; and (ii) he is not disqualified to be appointed as the Secretarial Auditor in terms of provisions of the Act, Rules made thereunder and SEBI Listing Regulations.

CORPORATE GOVERNANCE REPORT

The Report on Corporate Governance and the Certificate of the Practicing Company Secretary regarding compliance of the conditions of Corporate Governance as required pursuant

to the provisions of the SEBI Listing Regulations, are enclosed as Annexure IV. Declaration signed by the Whole-time Director affirming compliance with the Code of Conduct by the members of the Board and Senior Management Personnel also forms part of this Report.

BUSINESS RESPONSIBILITY AND SUSTAINABILITY REPORT

Pursuant to the provisions of Regulation 34 of the SEBI Listing Regulations (as amended), the Business Responsibility and Sustainability Report (“BRSR Report”) for FY25 is provided in a separate section of this Annual Report FY25 and may be accessed on the website of the Company at <https://www.advancedenzymes.com/investors/stock-exchange-compliance/#other-compliance>

COMMITTEES OF THE BOARD

As per the Companies Act, 2013 and the SEBI Listing Regulations, during the year under review, the Board has five statutory Committees viz., Audit Committee, Nomination and Remuneration Committee, Corporate Social Responsibility Committee, Stakeholders Relationship Committee and the Risk Management Committee. The details of the composition of these Committees along with number of meetings held and attendance at the meetings are provided in the Corporate Governance Report, which forms an integral part of this Report.

VIGIL MECHANISM

Your Company had adopted Whistle Blower Policy / Vigil Mechanism Policy pursuant to the provisions of Section 177(9) of the Companies Act, 2013 and the Companies (Meetings of Board and its Powers) Rules, 2014 and Regulation 22 of the SEBI Listing Regulations. Details on the Vigil Mechanism of your Company have been outlined in Corporate Governance Report, which forms an integral part of this Report.

The Whistle Blower Policy may be accessed on your Company's website at www.advancedenzymes.com/investors/corporate-governance

MEETINGS OF THE BOARD

During the year, 4 (four) meetings of the Board of Directors were held. The requisite details of the Board Meetings and the details of the Directors present are provided in the Corporate Governance Report, which forms part of this Report.

SECRETARIAL STANDARDS

During the year under review, the Company has complied with the provisions of applicable Secretarial Standards issued by the Institute of Company Secretaries of India with respect to the Board and General Meetings, as notified by the Ministry of Corporate Affairs of India.

EVALUATION OF PERFORMANCE OF BOARD, ITS COMMITTEES AND DIRECTORS

Pursuant to the provisions of the Companies Act, 2013 and the SEBI Listing Regulations, the Board has undertaken an Annual Evaluation of its own performance, its various Committees and individual Directors. The manner in which the performance evaluation has been carried out has been given in the Corporate Governance Report, annexed to this Report. The Board expressed its satisfaction of the evaluation process and outcome.

The Board Evaluation policy can be accessed on your Company's website at www.advancedenzymes.com/investors/corporate-governance.

FAMILIARIZATION PROGRAM FOR INDEPENDENT DIRECTORS

Pursuant to provisions of Regulation 25(7) of the SEBI Listing Regulations, the details of familiarization program is available on the website of your Company at www.advancedenzymes.com/investors/corporate-governance. Further, upon appointment of an Independent Director, the Company issues a letter of appointment outlining his / her role, function, duties and responsibilities. The format of the letter of appointment is available on the Company's website at: www.advancedenzymes.com/investors/corporate-governance

CODE OF CONDUCT FOR PROHIBITION OF INSIDER TRADING

Your Company has in place a Code of Conduct for Prohibition of Insider Trading (known as the AETL Insider Trading Code), which lays down the process for trading in securities of the Company by the Designated Persons and to regulate, monitor and report trading by the employees of the Company either on his/her own behalf or on behalf of any other person, on the basis of Unpublished Price Sensitive Information.

The aforementioned Code, as amended, is available on the website of the Company at www.advancedenzymes.com/investors/corporate-governance

INTERNAL CONTROL AND ITS ADEQUACY

Your Company has adopted procedures and systems for ensuring the orderly and efficient conduct of its Business, including adherence to the Company's policies, safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of financial disclosures. Your Company maintains appropriate and adequate Internal Control System / Internal Financial Control commensurate to its size and nature of operations. Your Company's Internal Control systems are tested and certified by the Internal Auditors and Statutory Auditors of the Company.

The Audit Committee periodically reviews the report(s) of the independent Internal Auditors along with the adequacy and effectiveness of Internal Control systems.

SIGNIFICANT AND MATERIAL ORDERS

During the year under review, there were no significant and material orders passed by the Regulators or Courts or Tribunals impacting the going concern status and its future operations.

CHANGE IN THE NATURE OF BUSINESS, IF ANY

There was no change in the nature of Business of your Company during the year under review affecting the financial position of the Company.

MATERIAL CHANGES FROM THE DATE OF END OF FINANCIAL YEAR TILL THE DATE OF THIS REPORT

Except as otherwise mentioned in this report, there are no material changes and commitments affecting the financial position of the Company which have occurred between the end of the Financial year of the Company to which the financial statements relates and the date of this report.

PARTICULARS OF LOANS GIVEN, INVESTMENTS MADE, GUARANTEES GIVEN AND SECURITIES PROVIDED

The details of Loans and Investments under Section 186 of the Act read with the Companies (Meetings of Board and its Powers) Rules, 2014 (as amended), for the FY25 are given in the Standalone financial statements (Note No. 55 to the Standalone

financial statements). Your Company has not provided any guarantee or security under Section 186 of the Act during the year under review.

ANNUAL RETURN

Pursuant to Section 92(3) read with Section 134(3)(a) of the Act, the Annual Return of the Company as on March 31, 2025 is available on the website of the Company at www.advancedenzymes.com

CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION, FOREIGN EXCHANGE EARNINGS AND OUTGO

Information pertaining to conservation of energy, technology absorption, foreign exchange earnings and outgo as required under Section 134 of the Act read with Rule 8(3) of the Companies (Accounts) Rules, 2014 (as amended) is furnished in Annexure V and forms part of this Report.

PARTICULARS OF EMPLOYEES AND RELATED DISCLOSURES

Pursuant to Section 197(12) of the Act read with Rule 5 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, as amended (“Rules”), the details are disclosed in Annexure VI to this report. In terms of Section 136(1) of the Act read with second proviso to the Rule 5 of the said Rules, the Integrated Annual Report with Annexure VI is being sent to the Members excluding the statement of particulars of employees under Rule 5(2) and (3) of the Rules (“Information”), which forms part of this report. The Annexure VI / Information under Rule 5(2) and (3) is available for inspection by the Members at the registered office of the Company during business hours on all working days except Saturdays and Sundays up to the date of the AGM. Any Member interested in conducting inspection and/or obtaining a copy of the said Annexure/Information may write to the Company Secretary at the Registered Office address of your Company.

DEPOSITS

During the year under review, your Company did not invite or accept any Deposits covered under Chapter V of the Act. There were no outstanding deposits within the meaning of Sections 73 and 74 of the Act, read together with the Companies (Acceptance of Deposits) Rules, 2014 (as amended), at the end of the year under review or the previous financial year.

CREDIT RATING

During the year under review, there was no change in the Credit Rating obtained by the Company in terms of the Long-Term rating which remained at CRISIL A+/Stable (Reaffirmed). The Short-Term rating was upgraded from CRISIL A1 to CRISIL A1 + for outstanding Bank facilities (outstanding facilities), by Credit Rating Information Services of India Limited (CRISIL).

GENERAL DISCLOSURES

During the year under review:

- The Whole-time Director of your Company has not received any remuneration or commission from any of the subsidiaries.
- Your Company has not issued Shares with Differential Rights as to Dividend, Voting or otherwise.
- Your Company has devised a policy on Prevention of Sexual Harassment to comply with the provisions

- of the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013. The said policy is hosted on the Company's website at www.advancedenzymes.com. During the year under review, there were no cases / grievances reported or pending and the Company has complied with provisions relating to the constitution of Internal Complaints Committee under the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013.
- d. There are no details to be disclosed under Section 134(3) (ca) of the Act as there has been no such fraud reported by the Auditors under Section 143(12) of the Act.
- e. There are no applications made by or any proceedings pending against the Company under the Insolvency and Bankruptcy Code, 2016.
- f. The details regarding the difference in valuation between a one-time settlement and valuation for obtaining loans from banks or financial institutions, along with reasons, are not applicable.

ACKNOWLEDGEMENTS

Your Directors acknowledge with gratitude the support received by the Company from the Banks, Government agencies/ organizations and employees of your Company.

Your Directors also acknowledge with thanks the faith reposed by the Investors in the Company and look forward to their continued support for times to come.

For and on behalf of the Board of Directors of

Advanced Enzyme Technologies Limited

Mukund Kabra
Whole-time Director
DIN: 00148294
Place: Thane
Date: May 13, 2025

Vinodkumar Jajoo
Director
DIN: 08224980
Place: Nashik

ANNEXURE I

FORM NO. AOC-2

(Pursuant to clause (h) of sub-section (3) of Section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014)

FORM FOR DISCLOSURE OF PARTICULARS OF CONTRACTS/ARRANGEMENTS ENTERED INTO BY THE COMPANY WITH RELATED PARTIES REFERRED TO IN SUBSECTION (1) OF SECTION 188 OF THE COMPANIES ACT, 2013 INCLUDING CERTAIN ARM'S LENGTH TRANSACTIONS UNDER THIRD PROVISIO THERETO.

1. Details of contracts or arrangements or transactions not at Arm's Length basis: NIL
- (a) Name(s) of the related party and nature of relationship: Not Applicable
- (b) Nature of contracts/arrangements/transactions: Not Applicable
- (c) Duration of the contracts/arrangements/transactions: Not Applicable
- (d) Salient terms of the contracts or arrangements or transactions including the value, if any: Not Applicable
- (e) Justification for entering into such contracts or arrangements or transactions: Not Applicable
- (f) Date(s) of approval by the Board: Not Applicable
- (g) Amount paid as advances, if any: Not Applicable
- (h) Date on which the Special Resolution was passed in general meeting as required under first proviso to Section 188: Not Applicable
2. Details of material contracts or arrangements or transactions at arm's length basis:

Sr. No.	Particulars	Transaction – Sales / Purchase
a)	Name(s) of the related party and Nature of relationship	JC Biotech Private Limited (“JC Biotech”) Subsidiary (95.72%)
b)	Nature of contracts / arrangements / transactions	Sales / Purchase of Goods
c)	Duration of the contracts/ arrangements/ transactions	Transactions during the year ended March 31, 2025
d)	Salient terms of the contracts or arrangements or transactions including the value, if any	Total (Sales & Purchase of goods): ₹ 593 million (Sales : ₹ 5 million Purchase : ₹ 588 million) Shareholders’ approval received in the Annual General Meeting held on (i) August 12, 2023 for aggregate limit of Sales and Purchase of ₹ 750 million (annual limit) for the period from October 01, 2023 to September 30, 2024 and (ii) July 25, 2024 for aggregate limit of Sales and Purchase of ₹ 800 million (annual limit) for the period from October 01, 2024 to September 30, 2025.
e)	Date(s) of approval by the Board, if any	May 13, 2023 and May 11, 2024
f)	Amount paid as advances, if any	Advances, if any and as may be paid by the Company, during the year, were only towards the supply of goods by JC Biotech to the Company, under the limits as mentioned above

Notes:

The above disclosure of material related party transaction(s) is based on the aggregate transaction value exceeding 10% of annual consolidated turnover of the Company pursuant to the provisions of the Securities and Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015 and Policy on Related Party Transactions of the Company, as amended from time to time.

For and on behalf of the Board of Directors of

Advanced Enzyme Technologies Limited

Mukund Kabra
Whole-time Director
DIN: 00148294
Place: Thane
Date: May 13, 2025

Vinodkumar Jajoo
Director
DIN: 08224980
Place: Nashik

ANNEXURE II

ANNUAL REPORT ON

CORPORATE SOCIAL RESPONSIBILITY (CSR) ACTIVITIES

1) A brief outline of the CSR policy of the Company:

The CSR policy of the Company intends to focus on certain long term projects which includes initiatives in the field of Education, Skill development/Vocational training, Health Care, Sanitation, Safe Drinking Water, Environment Sustainability, Women Empowerment and Rural Development which will *inter alia* enable creation of a sustainable livelihood in society and better human capital culture.

The CSR policy of the Company covers the proposed CSR activities in line with the provisions of Section 135 of the Companies Act, 2013 (as amended) and Schedule VII thereto. The CSR Policy of the Company including the overview of projects or programme may be accessed from the website of the Company, at www.advancedenzymes.com/investors/corporate-governance

2) The Composition of the CSR Committee is as under:

Sr. No.	Name of Director	Designation / nature of Directorship	Number of meetings of CSR Committee held during the year	Number of meetings of CSR Committee attended during the year
1.	Mr. Mukund Kabra*	Whole-Time Director & Chairman of Committee	1	1
2.	Mr. Vasant Rathi	Non-Executive Director	1	1
3.	Ms. Rajshree Patel	Independent Director	1	1

* Appointed as the Chairperson of the Committee effective from May 11, 2024.

3) Provide the web-link where Composition of CSR committee, CSR Policy and CSR projects approved by the Board are disclosed on the website of the company: www.advancedenzymes.com/investors/corporate-governance

4) Provide the executive summary along with web-link(s) of Impact assessment of CSR projects carried out in pursuance of sub-rule (3) of Rule 8 of the Companies (Corporate Social Responsibility Policy) Rules, 2014, if applicable (attach the report): Not Applicable

- 5) (a) Average net profit of the company as per sub-section (5) of section 135: ₹ 961,805,256
(b) Two percent of average net profit of the company as per sub-section (5) of section 135: ₹ 19,236,105
(c) Surplus arising out of the CSR projects or programmes or activities of the previous financial years: NIL
(d) Amount required to be set off for the financial year, if any: NIL
(e) Total CSR obligation for the financial year [(b) + (c) - (d)]: ₹ 19,236,105

- 6) (a) Amount spent on CSR Projects (both Ongoing Project and other than Ongoing Project): ₹ 84,68,173
(b) Amount spent in Administrative Overheads: NIL
(c) Amount spent on Impact Assessment, if applicable: NIL
(d) Total amount spent for the Financial Year [(a) + (b) + (c)]: ₹ 84,68,173
(e) CSR amount spent or unspent for the Financial Year:

Total Amount Spent for the Financial Year. (in ₹)	Amount Unspent (in ₹)				
	Total Amount transferred to Unspent CSR Account as per subsection (6) of section 135		Amount transferred to any fund specified under Schedule VII as per second proviso to sub-section (5) of section 135		
	Amount	Date of transfer	Name of the Fund	Amount	Date of transfer
84,68,173	2,500,000	April 04, 2025	-	-	-
	8,267,932	April 22, 2025			

(f) Excess amount for set-off, if any:

Sr. No	Particulars	Amount (in ₹)
(1)	(2)	(3)
(i)	Two percent of average net profit of the company as per sub-section (5) of section 135	Not Applicable
(ii)	Total amount spent for the Financial Year	
(iii)	Excess amount spent for the Financial Year [(ii)-(i)]	
(iv)	Surplus arising out of the CSR projects or programmes or activities of the previous Financial Years, if any	
(v)	Amount available for set off in succeeding Financial Years [(iii)-(iv)]	

7) Details of Unspent Corporate Social Responsibility amount for the preceding three Financial Years:

1.	2.	3.	4.	5.	6.		7.	8.
Sr. No.	Preceding Financial Year	Amount transferred to Unspent CSR Account under subsection (6) of Section 135 (in ₹)	Balance Amount in Unspent CSR Account under subsection (6) of section 135 (in ₹) *	Amount spent in the Financial Year (in ₹)	Amount transferred to a Fund as specified under Schedule VII as per second proviso to subsection (5) of section 135, if any		Amount remaining to be spent in succeeding financial years (₹)	Deficiency, if any
					Amount	Date of transfer		
1.	2021-22	11,019,640	160,142	160,142	-	-	-	-
2.	2022-23	12,319,425	434,704	434,704	-	-	-	-
3.	2023-24	4,306,977	4,306,977	4,306,977	-	-	-	-

*Note: Unspent balance as on April 2024

Whether any capital assets have been created or acquired through Corporate Social Responsibility amount spent in the Financial Year:

Yes No✓

If Yes, enter the number of Capital assets created/ acquired: NIL

Furnish the details relating to such asset(s) so created or acquired through Corporate Social Responsibility amount spent in the Financial Year: Not Applicable

Sr. No.	Short particulars of the property or asset(s) [including complete address and location of the property]	Pincode of the property or asset(s)	Date of Creation	Amount of CSR amount spent	Details of entity/ Authority/ beneficiary of the registered owner		
(1)	(2)	(3)	(4)	(5)	(6)		
					CSR Registration Number, if Applicable	Name	Registered address
-	-	-	-	-	-	-	-

9) Specify the reason(s), if the company has failed to spend two per cent of the average net profit as per as per subsection (5) of section 135.: Not Applicable

For and on behalf of the Board of Directors of

Advanced Enzyme Technologies Limited

Mukund Kabra
Whole time-Director & Chairman of CSR Committee
DIN :00148294
Place: Thane
Date : May 13, 2025

Vinodkumar Jajoo
Director
DIN :08224980
Place: Nashik

ANNEXURE III (A)

FORM NO. MR-3
SECRETARIAL AUDIT REPORT

FOR THE FINANCIAL YEAR ENDED 31ST MARCH, 2025

[Pursuant to Section 204(1) of the Companies Act, 2013 and Rule No. 9 of the Companies
(Appointment and Remuneration Personnel) Rules, 2014]

To,
The Members,
Advanced Enzyme Technologies Limited
Sun Magnectica, 5th Floor,
Near LIC Service Road, Louis Wadi,
Thane- 400604.

I, Shiv Hari Jalan, Proprietor of Shiv Hari Jalan & Co., Company Secretary in practice have conducted the Secretarial Audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by **Advanced Enzyme Technologies Limited** (hereinafter called the “Company”). Secretarial Audit was conducted in a manner that provided me a reasonable basis for evaluating the corporate conducts/ statutory compliances and expressing my opinion thereon.

Based on my verification of books, papers, minute books, forms and returns filed and other records maintained by the Company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, I hereby report that in my opinion, the company has, during the audit period covering the financial year ended on 31.03.2025 complied with the statutory provisions listed hereunder and also that the Company has proper Board-processes and compliance-mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

I have examined the books, papers, minute books, forms and returns filed and other records maintained by the Company for the financial year ended on 31st March, 2025 according to the provisions of:

- (i) The Companies Act, 2013 (the Act) and the rules made thereunder;
- (ii) The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the rules made thereunder;
- (iii) The Depositories Act, 1996 and the Regulations and Bye-laws framed thereunder;
- (iv) Foreign Exchange Management Act, 1999 and the rules and regulations made thereunder to the extent of Foreign Direct Investment, Overseas Direct Investment and External Commercial Borrowings;
- (v) The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ('SEBI Act'):-
 - (a) The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;
 - (b) The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015;
 - (c) The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018; (Not applicable to the company during the review period)

- (d) The Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021;
- (e) The Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015;
- (f) The Securities and Exchange Board of India (Issue and Listing of Non-Convertible Securities) Regulations, 2021; (Not applicable to the company during the review period)
- (g) The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993 regarding the Companies Act and dealing with client; (Not applicable to the company during the period under review)
- (h) The Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2021; (Not applicable to the company during the review period)
- (i) The Securities and Exchange Board of India (Buyback of Securities) Regulations, 2018; (Not applicable to the company during the review period)
- (j) The Securities and Exchange Board of India (Depositories and Participant) Regulations, 2018;
- (vi) Other laws applicable specifically to the Company namely:
 - (a) Factories Act, 1948;
 - (b) The Contract Labour (Regulation and Abolition) Act, 1970 and Rules made thereunder;
 - (c) Air (Prevention and Control of Pollution) Act, 1981 and Rules made thereunder;
 - (d) Environment Protection Act, 1986
 - (e) Water (Prevention and Control of Pollution) Act, 1974 and Rules made thereunder;
 - (f) The Petroleum Act, 1934;
 - (g) Drugs & Cosmetics Act, 1940;
 - (h) Food Safety and Standard Act, 2006 & rules made thereunder;

I have also examined compliance with the applicable clauses of the Secretarial Standards issued by The Institute of Company Secretaries of India.

During the period under review, the Company has complied with the provisions of the Act, Rules, Regulations, Guidelines, Standards etc. mentioned above.

I further report that:

The Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors and Independent Directors. During the period under review there was no changes in the composition of the Board of Directors.

Adequate notice is given to all directors to schedule the Board Meetings, agenda and detailed notes on agenda were sent in advance in accordance with the provisions of Companies Act, 2013 and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meeting.

As per the minutes, the decisions at the Board Meetings were taken unanimously.

I further report that there are adequate systems and processes in the company commensurate with the size and operations of the company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.

I further report that during the audit period the company had no specific actions having a major bearing on the company's affairs in pursuance of the above referred laws, rules, regulations, guidelines, standards, etc. referred to above.

Place: Mumbai
Date: 13.05.2025

For Shiv Hari Jalan & Co.
Company Secretaries
UDIN: F005703G000329840
FRN: S2016MH382700

Shiv Hari Jalan
Proprietor
FCS No: 5703
C.PNO: 4226
PR No. 1576/2021

This report is to be read with my letter of even date which is annexed as Annexure 'A' and forms an integral part of this report.

‘Annexure A’

To,
The Members,
Advanced Enzyme Technologies Limited
Sun Magnectica, 5th Floor,
Near LIC Service Road, Louis Wadi,
Thane - 400604.

My Report of even date is to be read along with this letter.

- Maintenance of Secretarial record is the responsibility of the management of the Company. My responsibility is to express an opinion on these secretarial records based on my audit.
- I have followed the audit practices and process as were appropriate to obtain reasonable assurance about the correctness of the contents of the secretarial records. The verification was done on test basis to ensure that correct facts are reflected in secretarial records. I believe that the process and practices, I followed provide a reasonable basis for my opinion.
- I have not verified the correctness and appropriateness of financial records and books of accounts of the company.
- Where ever required, I have obtained the management representation about the compliance of laws, rules and regulations and happening of events etc.
- The Compliance of provision of Corporate and other applicable laws, rules, regulations, standard is the responsibility of management. My examination was limited to the verification of procedure on test basis.
- The secretarial Audit report is neither an assurance as to the future viability of Company nor of the efficacy of effectiveness with which the management has conducted the affairs of the company.

Place: Mumbai
Date: 13.05.2025

For Shiv Hari Jalan & Co.
Company Secretaries
UDIN: F005703G000329840
FRN: S2016MH382700

Shiv Hari Jalan
Proprietor
FCS No: 5703
C.PNO: 4226
PR No.: 1576/2021

ANNEXURE III (B)

Form No. MR-3
SECRETARIAL AUDIT REPORT

FOR THE FINANCIAL YEAR ENDED 31ST MARCH 2025

[Pursuant to Sub Section (1) of the Section 204 of the Companies Act, 2013 and Rule 9 of the Companies (Appointment and Remuneration Personnel) Rules, 2014] Applicable pursuant to Company being material unlisted subsidiaries as per LODR

To
The Members,
JC BIOTECH PRIVATE LIMITED
8-2-269/S/3/A, Plot No.3,
Sagar Society, Road No.2,
Banjara Hills, Hyderabad 500034

I have conducted the secretarial audit of the compliance of applicable statutory provisions and adherence to good corporate practices by JC BIOTECH PRIVATE LIMITED - CIN U65993TG1991PTC013624 (hereinafter called the Company) as stated herein below. Secretarial Audit was conducted in a manner that provided me a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing my opinion thereon.

Based on my verification of the Company's Books, Papers, Minutes Book, Forms and Returns filed and other Records maintained by the Company and also the information provided by the Company, its officers and authorized representatives during the conduct of secretarial audit, I hereby report that in my opinion, the Company has, during the audit period covering the financial year ended on 31st March 2025 complied with the statutory provisions listed hereunder and also that the Company has proper Board - processes and compliance mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

I have examined the books, papers, minute books, forms and returns filed and other records maintained by the Company for the financial year ended on 31st March 2025 according to the provisions of:

- (I) The Companies Act, 2013 ("the Act") and the rules made thereunder;
- (II) The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the rules made thereunder;
- (III) The Depositories Act, 1996 and the Regulations and Bye-laws framed thereunder;
- (IV) Foreign Exchange Management Act, 1999 and the rules and regulations made there under, to the extent of Foreign Direct Investment, Overseas Direct Investment and External Commercial Borrowings;
- (V) The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ('SEBI Act'):-
 - a. The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011; **{Not Applicable};**
 - b. The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015; **{Not Applicable};**
 - c. The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2009; **{Not Applicable as the Company has not issued any further share capital during the period under review};**

- d. The Securities and Exchange Board of India (Share Based Employee Benefits) Regulations, 2014; **{Not Applicable as the Company has not issued any ESOPS during the period under review};**
- e. The Securities and Exchange Board of India (Issue and Listing of Debt Securities) Regulations, 2008 **{Not Applicable as the Company has not issued and listed any debt securities during the financial year under review};**
- f. The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993, regarding the Companies Act and dealing with client **{Not Applicable as the Company is not registered as Register to Issue and Share Transfer Agent during the financial year under review};**
- g. The Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009 **{Not Applicable as there was no reportable event during the period under review};**
- h. Securities and Exchange Board of India (Buy Back of Securities) Regulations, 1998 **{Not Applicable as there was no reportable event during the period under review}**
- (VI) The Management has identified and confirmed the following laws as specifically applicable to the Company:
 - 1. The Drugs and Cosmetics Act, 1940;
 - 2. The Prevention of Food Adulteration Act, 1954;
 - 3. Air Prevention &Control of Pollution Act, 1981
 - 4. The Patents Act, Copyright Act& Rules made thereunder
 - 5. Customs Act, 1962
 - 6. Environment Protection Act, 1986
 - 7. Explosive Act 1984 & the petroleum Act
 - 8. Gas Cylinder Rules, 1981
 - 9. Indian Boilers Act 1923 and the rules made thereunder
 - 10. Prevention of Food Adulteration Act, 1974
 - 11. Protection of Human Rights Act, 1994
 - 12. Water (Prevention & Control of Pollution) Act, 1974
 - 13. The Factories Act 1948 and the rules made thereunder
 - 14. The Labour Welfare Fund Act
 - 15. The Contract Labour (Rules & Regulations) Act 1970
 - 16. The Employees State Insurance Act, 1948
 - 17. The Employees Provident Fund & Miscellaneous Provisions Act 1952
 - 18. The Industrial employment (Standing Order), Act

- 19. The Industrial Disputes Act, 1947
- 20. The Minimum Wages Act, 1948
- 21. The Maternity Benefits Act
- 22. The Payment of Bonus Act, 1965
- 23. The Payment of Gratuity Act, 1972
- 24. The Workmen Compensation Act, 1923
- 25. The Trade Unions Act, 1926
- 26. The Equal Remunerations Act, 1976
- 27. Food Safety & Standard Act 2006 & Rules made thereunder
- 28. The Income Tax Act, 1961 mainly the provisions regarding Deduction of tax at source and payment thereof, Rule 6 DD
- 29. Property Tax Act
- 30. The Sexual Harassment of Women at Workplace (Prevention, Prohibitions & Redressal) Act, 2013 & rules made thereunder
- 31. Conditions stipulated in any approvals, license, consents granted to the Company under any of the aforesaid Acts and Rules

During the period under review the Company has complied with the provisions of the Act, Rules, Regulations, Guidelines, Standards etc.

I further report that

- The Board of Directors of the Company is duly constituted. The changes in the composition of the Board of Directors that took place during the period under review were carried out in compliance with the provisions of the Act.
- Adequate notice is given to all Directors to schedule the Board Meetings, agenda and detailed notes to agenda were sent seven days in advance and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaning participation at the meeting.

- All the decisions of the Board and Committees thereof were carried out with requisite majority.

I further report that there are adequate systems and processes in the Company commensurate with the size and operations of the Company to monitor and ensure compliances with applicable laws, rules, regulations and guidelines.

I further report that during the audit period there were no instances of:

- (i) Public/Right/Preference issue of shares/debentures sweat equity, etc;
- (ii) Redemption/buy-back of Securities;
- (iii) Major decisions taken by the members in pursuance to Section 180 of the Companies Act, 2013
- (iv) Merger/amalgamation/reconstitution, etc;
- (v) Foreign technical collaborations.

I have relied on the representation made by the Company and its Officers for systems and mechanism formed by the Company for compliances under other applicable Acts, Laws and Regulations to the Company.

I have not verified the correctness and appropriateness of financial records and books of accounts of the Company.

Wherever required, I have obtained the management's representation about the compliance of Laws, rules and regulations and happening events, etc.

The Secretarial Audit report is neither an assurance as to the future viability of the Company nor of the efficacy or effectiveness with which the management has conducted the affairs of the Company.

Thanking You,

Riddhi Krunal Shah
Practicing Company Secretary
(Membership No. 20168, PCS No.17035 PR No. 2037/2022)
UDIN: A020168G000258001
Place: Mumbai
Date: 03/05/2025

ANNEXURE IV

CORPORATE GOVERNANCE REPORT

COMPANY'S PHILOSOPHY ON CODE OF GOVERNANCE

Corporate Governance is about maximizing shareholders value legally, ethically and sustainably with a goal to ensure fairness for every stakeholder. We are dedicated to ensure to adopt and attain the best practices in Corporate Governance. The Company believes in ensuring corporate fairness, transparency, professionalism, accountability and propriety in the functioning of the Company and believes that these are pre-requisites for attaining sustainable growth in this competitive corporate world.

BOARD OF DIRECTORS

Composition of the Board of Directors as on March 31, 2025

The Board of Directors of the Company (hereinafter referred as "the Board") comprises an optimum combination of Executive and Non-Executive Directors. As on March 31, 2025, the Board comprised 9 (Nine) Directors i.e. 1 (One) Executive Director and 8 (Eight) Non-Executive Directors, out of which 5 (Five) were Independent Directors (including 2 (Two) Women Independent Director). The Chairman of the Board is a Non-Executive Director (Promoter) and more than half of the Board members are Independent. The composition of the Board is in line with requirements of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (hereinafter referred as the "SEBI Listing Regulations"). The Independent Directors do not have any material pecuniary relationship or transactions with the Company, Promoters or Management, which may affect their judgment in any manner. Further, in the opinion of the Board, the Independent Directors fulfill the conditions specified in the SEBI Listing Regulations and are independent of the management. The Board members are eminently qualified and experienced professionals in business, finance and / or corporate management.

The relevant details of composition of the Board are as follows:

Sr. No.	Name	Director Identification Number	Category
1.	Mr. Vasant L. Rath	01233447	Chairman & Non-Executive Director (Promoter)
2.	Mr. Mukund Kabra	00148294	Whole-time Director
3.	Ms. Rasika Rath	08300682	Non-Executive Director (Promoter Group Member)
4.	Mr. Pramod Kasat	00819790	Independent Director
5.	Mr. Vinodkumar Jajoo	08224980	Independent Director
6.	Dr. Sunny Sharma	02267273	Non-Executive Director
7.	Ms. Rajshree Patel	08761022	Independent Director
8.	Mr. Nitin Deshmukh	00060743	Independent Director
9.	Mrs. Vandana Tilak	10048021	Independent Director

Note: During the year under review, all the recommendations of the Committees of the Board, which are mandatorily required, were approved by the Board.

None of the Directors of the Company are related to any other Director on the Board in terms of the definition of 'Relative' under the Companies Act, 2013 read with the corresponding Rules framed thereunder ("Act") except Ms. Rasika Rath who is a daughter of Mr. Vasant Rath.

Number of Board or Board Committees of which a Director is a member or Chairperson; the names of Other Listed entities where the Directors of the Company are Directors and the Category of their Directorship:

Sr. No.	Name of Directors	No. of Directorship held in other companies (\$)	No. of Committee members-hip in other companies(*)	No. of Committees in which Director is a Chairperson (other companies) (*)	Name of the listed entities where the person is a Director (Category of Directorship)
1.	Mr. Vasant Rath	-	-	-	-
2.	Mr. Mukund Kabra	5	1	-	-
3.	Ms. Rasika Rath	1	-	-	-
4.	Mr. Pramod Kasat	5	6	2	Natural Capsules Limited, Fermenta Biotech Limited and Sai Silks (Kalamandir) Limited (Independent Director)
5.	Mr. Vinodkumar Jajoo	-	-	-	-
6.	Dr. Sunny Sharma	1	1	-	Marksans Pharma Limited (Non-Executive Director)
7.	Ms. Rajshree Patel	-	-	-	-
8.	Mr. Nitin Deshmukh	4	3	-	-
9.	Mrs. Vandana Tilak	-	-	-	-

\$ Excludes Directorship in private companies, foreign companies and Section 8 companies.

* Audit Committee and Stakeholders' Relationship Committee in listed and unlisted public limited companies have been considered.

Attendance of each Director at the Board Meetings and the last Annual General Meeting

During the financial year 2024-25 ("FY25"), the meetings of the Board of Directors of the Company was held four (4) times i.e. on May 11, 2024 (No. 02/2024), August 10, 2024 (No. 03/2024), November 09, 2024 (No. 04/2024) and

February 08, 2025 (No. 01/2025). The maximum gap between any two Board meetings was less than 120 days, as stipulated under Regulation 17(2) of the SEBI Listing Regulations. Details of attendance at the Board meetings and General Meeting as the Directors of the Company, during the year under review, are as follows:

Sr. No.	Name	No. of the Board Meetings attended		Attended - last AGM held on July 25, 2024
		Held	Attended	
1.	Mr. Vasant Rath	4	4	Yes
2.	Mr. Mukund Kabra	4	4	Yes
3.	Mr. Pramod Kasat	4	4	No
4.	Ms. Rasika Rath	4	4	Yes
5.	Mr. Vinodkumar Jajoo	4	4	Yes
6.	Dr. Sunny Sharma	4	3	Yes
7.	Ms. Rajshree Patel	4	2	No
8.	Mr. Nitin Deshmukh	4	4	Yes
9.	Mrs. Vandana Tilak	4	3	No

SKILLS, EXPERTISE AND COMPETENCIES OF THE BOARD

The Board comprises of qualified personnel who have the key skills, competencies and expertise required for the Board members' effective contribution to the Board & its Committees and also for the Board to function effectively. Following is the chart / matrix setting out the requisite skills/competencies/expertise of the Board:

SKILLS/COMPETENCIES/EXPERTISE OF THE BOARD OF DIRECTORS OF THE COMPANY	
Experience in the enzyme business / industry	The experience in the enzyme business / industry is seen as most critical, considering the nature of business of the company
Leadership	Extensive leadership experience of an organization for practical understanding of the organization, its processes, strategic planning, risk management for driving change and long-term growth
Finance	Finance field skills/competencies/expertise is seen as important for intricate and high quality financial management and financial reporting processes
Legal	In order to strengthen and maintain the governance levels & practices in the organization
Understanding of Global Business	Owing to presence across the globe, the understanding of global business & markets is seen as pivotal

The aforementioned skills are only indicative and not possessing any skill/competency/expertise need not be seen as a disqualifying ability. The nominations to the Board was made

on the recommendations of the Nomination and Remuneration Committee, which may consider various other factors.

Following is the chart/matrix setting out the Name of the Directors of the Company possessing the requisite skills/competencies/expertise:

Name of Directors	Skills/Competencies/expertise (to be read along with profile as provided elsewhere in the Annual report under the heading "Board of Directors")
Mr. Vasant Rath	Immense experience in Enzyme business / industry, Business strategic planning & development, Finance, Leadership with experience of business at global level and international markets
Mr. Mukund Kabra	Experience in Enzyme business, Business Strategy, Sales, Marketing, Leadership with understanding of global business and markets
Ms. Rasika Rath	Experience in Enzyme business, Legal including Risk Management, Leadership and understanding of global business
Mr. Pramod Kasat	Finance with rich experience in Investment Banking, Leadership and understanding of global business
Mr. Vinodkumar Jajoo	Finance with rich experience in Direct/ Indirect Taxation and Audit
Dr. Sunny Sharma	Finance, rich experience in Investment Banking/Fund, Leadership and understanding of global business
Ms. Rajshree Patel	Prolific Organizational, Strategy and Executive Leadership Consultant
Mr. Nitin Deshmukh	Dynamic experience in Investment Banking/Private equity, Advisory, Leadership skills, understanding of global business.
Mrs. Vandana Tilak	Social entrepreneur and visionary with exceptional sales, fundraising and marketing skills.

CERTIFICATION FROM THE COMPANY SECRETARY IN PRACTICE

Mr. Shiv Hari Jalan, Company Secretary in Practice (FCS No.: 5703), has issued a certificate as required under the SEBI Listing Regulations that none of the Directors on the Board of the Company have been debarred or disqualified from being appointed or continuing as a Director of Companies by SEBI / Ministry of Corporate Affairs or any such statutory authority. The Certificate is enclosed as an Annexure to this report.

AUDIT COMMITTEE

Brief Description of term of reference

The terms of reference of Audit Committee articulates the roles, responsibilities and powers of the Audit Committee under Regulation 18(3) read with Schedule II (Part C) of the SEBI Listing Regulations and Section 177 of the Companies Act, 2013 (hereinafter referred to as "the Act"). The Role of the Audit Committee is as prescribed under Regulation 18 read with Part C of Schedule II of the SEBI Listing Regulations.

The role of the Audit Committee *inter alia* includes the following:

- Oversight of Company's financial reporting process and the disclosure of its financial information to ensure that the financial statement is correct, sufficient and credible;
- Recommendation for the appointment, remuneration and terms of appointment of auditors of the Company;
- Approval of payment to Statutory Auditors for any other services rendered by the Statutory Auditors;
- Review with the management, the annual financial statements and Auditor's Report thereon before submission to the Board for approval, with particular reference to:
 - Matters required to be included in the Directors' Responsibility Statement to be included in the Board's report in terms of clause (c) of sub-section (3) of Section 134 of the Act;
 - Changes, if any, in accounting policies and practices and reasons for the same;
 - Major accounting entries involving estimates based on the exercise of judgment by management;
 - Significant adjustments made in the financial statements arising out of audit findings;
 - Compliance with listing and other legal requirements relating to financial statements;
 - Disclosure of any related party transactions; and
 - Modified opinion(s) in the draft audit report.
- Review with the management, the quarterly financial statements before submission to the Board for approval;
- Review with the management, the statement of uses / application of funds, if any, raised through an issue (public issue, rights issue, preferential issue, etc.), the statement of funds utilized for purposes other than those stated in the offer document/prospectus/notice and the report submitted by the monitoring agency monitoring the utilization of proceeds of a public or rights issue, and making appropriate recommendations to the Board to take up steps in this matter;
- Review and monitor the auditor's independence and performance, and effectiveness of audit process;
- Approval or any subsequent modification of transactions of the Company with related parties;
- Scrutiny of inter-corporate loans and investments;
- Valuation of undertakings or assets of the Company, wherever it is necessary;
- Evaluation of Internal Financial Controls and Risk Management Systems;
- Review with the management, performance of statutory and internal auditors, and adequacy of the internal control systems;
- Review the adequacy of internal audit function, if any, including the structure of the internal audit department, staffing and seniority of the official heading the department, reporting structure coverage and frequency of internal audit;
- Discussion with internal auditors of any significant findings and follow up there on;

- Review the findings of any internal investigations by the internal auditors into matters where there is suspected fraud or irregularity or a failure of internal control systems of a material nature and reporting the matter to the Board;
- Discussion with Statutory Auditors before the Audit commences, about the nature and scope of audit as well as post-audit discussion to ascertain any area of concern;
- Review the reasons for substantial defaults, if any, in the payment to the depositors, debenture holders, shareholders (in case of non-payment of declared dividends) and creditors;
- Review the functioning of the whistle blower mechanism;
- Approval of appointment of Chief Financial Officer after assessing the qualifications, experience and background, etc. of the candidate;
- Carry out any other function as is mentioned in the terms of reference of the Audit Committee under the Act and the SEBI Listing Regulations.
- Review the utilization of loans and/ or advances from/ investment by the holding company in the subsidiary exceeding Rupees 100 crore or 10% of the asset size of the subsidiary, whichever is lower including existing loans / advances / investments existing as on the date of coming into force of this provision
- Consider and comment on rationale, cost-benefits and impact of schemes involving merger, demerger, amalgamation etc., on the listed entity and its shareholders

Composition, Name of Members and Chairman, Meetings of the Committee and Attendance during the year

In accordance with the provisions of Regulation 18 of the SEBI Listing Regulations read with Section 177 of the Act, the Audit Committee of the Board comprises 3 (Three) Independent Directors and 1 (One) Non-Executive Director as on March 31, 2025. All the members of the Audit Committee are financially literate. The Committee invites the representatives of the Statutory and Internal Auditors. Further, the Chief Financial Officer also attends the Audit Committee meetings. The Company Secretary acts as a Secretary to the Audit Committee.

During the FY25, the Audit Committee met 4 (Four) times i.e. on May 11, 2024 (No. 02/2024), August 10, 2024 (No. 03/2024), November 09, 2024 (No. 04/2024) and February 08, 2025 (No.01/2025).

The composition of the Audit Committee along with the details of the meetings held and attended during the aforesaid period, is detailed below:

Name of Members	Designation	No. of Committee Meetings	
		Held	Attended
Mr. Vinodkumar Jajoo #	Chairman	4	4
Mr. Pramod Kasat	Member	4	4
Mrs. Vandana Tilak \$	Member	2	1
Mr. Vasant Rathi	Member	4	4

#Appointed as the Chairperson of the Audit Committee effective from May 11, 2024

\$Appointed as the member of the Audit Committee effective from August 10, 2024

NOMINATION AND REMUNERATION COMMITTEE

Brief Description of terms of reference

The terms of reference of the Nomination and Remuneration Committee are in line with Regulation 19 read with Part D of Schedule II of the SEBI Listing Regulations and Section 178 of the Act:

- To guide the Board in relation to appointment and removal of Directors, Key Managerial Personnel and Senior Management.
- To evaluate the performance of the members of the Board and provide necessary report to the Board for further evaluation.
- To recommend to the Board on Remuneration payable to the Directors, Key Managerial Personnel and Senior Management.

The role of the Nomination and Remuneration Committee *inter alia* includes the following:

- Formulation of the criteria for determining qualifications, positive attributes and independence of a Director and recommend to the Board a policy relating to the remuneration of the Directors, Key Managerial Personnel and other employees;
- Formulation of criteria for evaluation of performance of Independent Directors and the Board;
- Devising a policy on diversity of the Board;
- Identifying persons who are qualified to become Directors and who may be appointed in senior management in accordance with the criteria laid down, and recommend to the Board their appointment and removal.
- Whether to extend or continue the term of appointment of the Independent Director, on the basis of the report of performance evaluation of Independent Directors.
- Recommend to the Board, the remuneration, in whatever form, payable to the senior management.

Composition, Name of Members and Chairman, Meetings of the Committee and Attendance during the year

During the FY25, Nomination and Remuneration Committee met Once i.e. on May 11, 2024 (No. 02/2024).

The composition of the Nomination and Remuneration Committee as on March 31, 2025 along with the details of the meetings held and attended during the aforesaid period, is detailed below:

Name of Members	Designation	No. of Committee Meetings	
		Held	Attended
Mr. Pramod Kasat	Chairman	1	1
Mr. Vasant Rathi	Member	1	1
Ms. Rajshree Patel	Member	1	0
Mr. Nitin Deshmukh	Member	1	1

Familiarization Programme for Independent Directors

The Familiarization programme for the Directors during the year covered topics such as Operations, Financials, Plant visits, Performance, Annual Budget and update on amendment of statutory & regulatory laws.

The details of the Familiarization programme are available on the website of the Company at: www.advancedenzymes.com/investors/corporate-governance

Performance Evaluation of Board and Individual Directors

The Board has adopted a formal policy for evaluating the performance of its Board, Committees and Directors, including the Chairman of the Board ("Board Evaluation Policy"). The said evaluation typically examines the role of the Board and the entailing responsibilities and assesses their effectiveness by the Board. The effectiveness of the Board depends on various factors, some of which are derived from the functions of the Board. A structured performance evaluation exercise was carried out based on criteria such as Board / Committee compositions, dynamics and functioning of the Board, Business Strategy, Governance & Monitoring role, Financial reporting, Internal Audit, Internal Controls and Advisory role etc.

Pursuant to provisions of the Act, SEBI Listing Regulations and Board Evaluation Policy, the Directors of the Company carried out annual performance evaluation of the Board as a whole, Committees of the Board and the Independent Directors (excluding the Director being evaluated), as per evaluation forms circulated to them. The evaluation of Independent Directors was conducted on the basis of the parameters which included the participation & contribution at the Board & Committee meetings, understanding of the governance, regulatory, financial, fiduciary and ethical requirements of the Board & Committees, standards of ethics & integrity, ability to exercise objective independent judgment in the best interests of the Company and its stakeholders.

A meeting of Independent Directors of the Company was held through video conference on March 29, 2025 to: (a) review the performance of Chairperson, Non-Independent Directors and the Board as a whole; (b) assess the quality, quantity and timeliness of flow of information between the Company management and the Board. The results of the performance evaluation were placed for review at the meeting of the Independent Directors, Nomination and Remuneration Committee and the Board.

REMUNERATION OF DIRECTORS

There were no pecuniary relationships or transactions between the Non-Executive Directors (including Independent Directors) and the Company, except the following:

1. Sitting fees to the Independent Directors for attending the meetings of the Board, Committee(s) thereof and Independent Directors' Meeting.
2. Commission to the Non-Executive Directors of the Company.

Criteria for making payment to Non-Executive Directors

The Company has formulated a Nomination and Remuneration Policy, which indicates criteria for making payment to Non-Executive Directors. As per the said Policy, the remuneration / commission to Non-Executive Directors shall be in accordance with the statutory provisions of the Act, and the rules made thereunder for the time being in force. The Non-Executive / Independent Directors may receive remuneration by way of sitting fees for attending meetings of Board or Committees thereof. Provided that the amount of such fees shall not exceed the maximum amount as provided in the Act per meeting of the Board or Committees. Limits of Remuneration / Commission to be paid shall be within the monetary limits as approved by Members, and not exceeding 1% of the net profits of the Company computed as per the applicable provisions of the Act.

The said Policy is available on the website of the Company. The web-link for the same is www.advancedenzymes.com/investors/corporate-governance.

Details of Remuneration to Directors:

Remuneration to Executive Director

The details of the Remuneration of Mr. Mukund Kabra, Whole-time Director of the Company, for the year ended March 31, 2025 is as follows:

Particulars		(in ₹)
Basic Salary	A	73,64,448
Other Allowances		1,62,55,178
Bonus		6,13,704
	B	1,68,68,882
Sub-total	(A+B)	2,42,33,330
Contribution to :		
Provident fund		9,57,378
Super Annuation Fund		7,36,445
Gratuity		3,54,060
	C	20,47,883
Total	(A+B+C)	2,62,81,213
Commission for FY25	D	5,108,230
Grand Total	(A+B+C+D)	31,389,443
*Stock Options		290,225

Note: The aforesaid amount is on payable basis and is excluding leave encashment.

* During the year under review, Mr. Mukund Kabra exercised 1,250 Stock Options out of 25,000 Options granted to him last year, at an average exercise price of ₹ 174/- per Option, in accordance with the provisions of Advanced Enzyme Technologies Limited – Employees Stock Option Scheme 2022 of the Company. Based on this, 1,250 Equity Shares were allotted to him.

Further, during the FY25, Nomination and Remuneration Committee of the Board of Directors of the Company vide Circular Resolution passed on March 27, 2025 has granted 25,000 Options to Mr. Mukund Kabra, as per the provisions of Advanced Enzyme Technologies Limited – Employees Stock Option Scheme 2022 of the Company. The said Options are yet to be vested and exercised.

Remuneration and Shareholding (as on March 31, 2025) of the Non-Executive Directors

The Independent Directors receive remuneration by way of sitting fees for attending meetings of the Board/Committees and for meeting of the Independent Directors. The details of Sitting Fees / Commission paid/payable to Independent Directors and Non-Executive Directors for the FY25 along with the Shareholding of the Non-Executive Directors as on March 31, 2025 are as under:

Names of Directors	Category of Non-Executive Directorship	Sitting Fees (Note 1) (₹ In million)	Commission (Note 2) (₹ In million)	No. of Shares (Face Value ₹ 2/- each)	% of Shareholding
Mr. Vasant Rathi	Non Executive Non-Independent	-	0.99	3,71,23,702*	33.18
Ms. Rasika Rathi	Non-Executive Non-Independent	-	0.59	26,65,825	2.38
Dr. Sunny Sharma	Non-Executive Non-Independent	-	0.30	NIL	NIL
Mr. Pramod Kasat	Independent Director	0.29	0.89	5000^	0.004
Mr. Vinodkumar Jajoo	Independent Director	0.34	1.09	NIL	NIL
Ms. Rajshree Patel	Independent Director	0.10	0.30	NIL	NIL
Mr. Nitin Deshmukh	Independent Director	0.22	0.59	NIL	NIL
Mrs. Vandana Tilak **	Independent Director	-	-	NIL	NIL

* Including 75,00,000 Equity Shares held by Vasant and Prabha Rathi Generation Trust and shown/clubbed basis PAN of Mr. Vasant Rathi. Mr. Vasant Rathi and Mrs. Prabhavati Rathi are the trustees and the settlor of the Trust and Ms. Rasika Rathi, Ms. Reshma Rathi & Ms. Rachana Rathi are the beneficiaries of the Trust.

^ Holding 5000 Equity Shares on behalf of Pramod Kasat HUF.

** Mrs. Vandana Tilak (DIN: 10048021) has voluntarily waived the receipt of the sitting fees, and the Commission (FY25) amounting to ₹ 0.13 million and ₹ 0.40 million respectively.

Note 1: During the year under review, ₹ 35,000/- was paid/ payable for each Board Meeting thereafter and ₹ 25,000/- was paid/payable for each Committee Meeting and Independent Directors' Meeting.

Note 2: Commission payable to Non-Executive Directors is pursuant to the approval of the Members at the 34th Annual General Meeting held on August 12, 2023. The amount of commission is determined and approved by the Board in proportion to the number of meetings of the Board and its Committees thereto attended by the respective Non-Executive Director(s) during the financial year 2024-25. The total amount of commission to Non-Executive Directors is within the limit of 1% of the Net profits of the Company for the year under review, calculated as per the provisions of the Act.

Details of service contracts, notice period and severance fees of the Executive Director

Name of Director	Mr. Mukund Kabra, Whole-time Director
Date of contract	October 06, 2021
Term of contract	Five years w.e.f April 01, 2022
Notice Period	Three Months
Severance Fees	-

Particulars of Senior Management including the changes therein since the close of the previous Financial Year

Details of Senior Management Personnel(s) including Key Managerial Personnel (KMP) as on March 31, 2025, are as follows:

Sr. No.	Name	Designation
1.	Mr. Beni P Rauka	Chief Financial Officer (KMP)
2.	Mr. Sanjay Basantani	Company Secretary & Head –Legal (KMP)
3.	Mr. Dipak Roda	Sr. VP – Marketing & Business Development
4.	Mr. Satish Pagar	Plant Manager, Sinnar / Head Operations
5.	Mr. Pradeep Bhosale	Plant Manager, Indore

Kindly note that there have been no changes in the Senior Management Personnel(s) since the close of the previous financial year.

STAKEHOLDERS' RELATIONSHIP COMMITTEE

Pursuant to the provisions of Section 178 of the Act and Regulation 20 of the SEBI Listing Regulations read with Part D of Schedule II thereto, the Company has in place, a Stakeholders' Relationship Committee ("SRC"). The SRC comprises 2 (Two) Independent Directors and the Whole-time Director as on March 31, 2025. The Chairman of the Committee is an Independent Director. The Company Secretary acts as a Secretary to the Committee.

During the FY25, Stakeholders' Relationship Committee met once i.e. on August 10, 2024 (No. 01/2024).

Following is the constitution of the Stakeholders' Relationship Committee along with the meeting and attendance during the year:

Name of Members	Type of Membership	No. of Committee Meetings	
		Held	Attended
Mr. Vinodkumar Jajoo *	Chairman	1	1
Mr. Mukund Kabra	Member	1	1
Mr. Nitin Deshmukh *	Member	1	1

*Effective from April 01, 2024, Mr. Vinodkumar Jajoo, Member of the Committee had been appointed as a Chairman of Stakeholders' Relationship Committee and Mr. Nitin Deshmukh had been appointed as a Member of Stakeholders' Relationship Committee.

The role of the Stakeholders' Relationship Committee is in accordance with Section 178 of the Act and as per Regulation 20 and Part D of Schedule II of the SEBI Listing Regulations and *inter alia* includes:-

- Resolving the grievances of the security holders of the listed entity including complaints related to transfer/ transmission of shares, non-receipt of annual report, non-receipt of declared dividends, issue of new/duplicate certificates, general meetings etc.
- Review of measures taken for effective exercise of voting rights by shareholders.

- Review of adherence to the service standards adopted by the listed entity in respect of various services being rendered by the Registrar & Share Transfer Agent
- Review of the various measures and initiatives taken by the listed entity for reducing the quantum of unclaimed dividends and ensuring timely receipt of dividend warrants/ annual reports/statutory notices by the shareholders of the company.
- Other matters as may be required for aforesaid purposes.

Name and Designation of Compliance Officer

Mr. Sanjay Basantani - 'Company Secretary & Head - Legal'

Status Report of Investor Complaints for the year ended March 31, 2025

No. of Complaints as on April 01, 2024	- NIL
No. of Complaints Received during the year	- 1
No. of Complaints Resolved during the year	- 1
No. of Complaints not resolved to the satisfaction of the shareholders	- NA
No. of Complaints Pending as on March 31, 2025	- NIL

All valid requests for dematerialization wherein the complete documentation was received during the year have been acted upon and no such valid dematerialization request is pending for more than prescribed period.

CORPORATE SOCIAL RESPONSIBILITY COMMITTEE (CSR COMMITTEE)

In line with the provisions of Section 135 of the Act read with the corresponding Rules framed thereunder, as on March 31, 2025, the CSR Committee comprises 1 (One) Independent Director, a Non-Executive Director and the Whole-time Director. The Company Secretary as a Secretary to the Committee.

During the FY25, the CSR Committee has met once i.e. on May 11, 2024 (No. 01/2024).

Constitution of the CSR Committee along with the number of meetings held during the year and attendance is as follows:

Name of Members	Type of Membership	No. of Committee Meetings	
		Held	Attended
Mr. Mukund Kabra *	Chairman	1	1
Mr. Vasant Rathi	Member	1	1
Ms. Rajshree Patel	Member	1	1

*Appointed as the Chairman of the CSR Committee effective from May 11, 2024

The terms of reference of the Corporate Social Responsibility Committee is in accordance with Section 135 of the Act and *inter alia* includes:

- To formulate and recommend to the Board, a CSR Policy (including any modification thereto) which shall indicate the framework within which the proposed CSR activities would be undertaken;

- b) To formulate and recommend to the Board, the Annual Action Plan, which shall include the following:
- o the list of CSR projects or programmes that are approved to be undertaken in areas or subjects specified in Schedule VII of the Act;
 - o the manner of execution of such projects or programmes as specified in Rule 4(1) of the Rules
 - o the modalities of utilization of funds and implementation schedules for the projects or programmes;
 - o monitoring and reporting mechanism for the projects or programmes; and
 - o details of need and impact assessment, if any, for the projects undertaken by the Company:
- Provided that Board may alter such plan at any time during the financial year, as per the recommendation of its CSR Committee, based on the reasonable justification to that effect
- c) To monitor the implementation of the CSR Policy from time to time and take such other action as it may deem fit in pursuance of the CSR Vision of AETL; and
- d) Any other role, as may be specified in the Act/Rules from time to time and as may be required by the Board.

RISK MANAGEMENT COMMITTEE

Pursuant to the provisions of Regulation 21 of the SEBI Listing Regulations, constitution of Risk Management Committee is mandatory for top 1000 listed entities determined on the basis of the market capitalization as at the end of the immediate previous financial year. Pursuant to the composition of the Risk Management Committee prescribed under the provisions of Regulation 21 of the SEBI Listing Regulations, the Risk Management Committee, as on March 31, 2025, comprises an Independent Director, Whole-time Director, a Non-Executive Director, Chief Financial Officer and Company Secretary.

During the FY25, the Risk Management Committee met twice i.e. on May 17, 2024 (No. RMC 01/2024) and on December 06, 2024 (No. RMC 02/2024).

Following is the constitution of the Risk Management Committee along with number of meetings held and attendance during the year:

Name of Members	Type of Membership	No. of Committee Meetings	
		Held	Attended
Mr. Vinodkumar Jajoo	Chairman	2	2
Mr. Mukund Kabra	Member	2	2
Ms. Rasika Rathi	Member	2	2
Mr. Beni Prasad Rauka	Member	2	2
Mr. Sanjay Basantani	Member	2	2

The terms of reference of the Risk Management Committee *inter alia* includes:

- a) To monitor & review Risk Management Policy of the Company including associated systems, processes, controls & strategies thereto;

- b) To monitor & review various risks exposures of the Company, on a periodic basis and then inform the Board about the risks assessed, their concerns and action plan with strategy for mitigation of the risks;
- c) To assist Audit Committee in assessment of internal financial controls, monitoring of the risk management plan, overview of processes for identification & assessment of the risks, reviewing the outcomes of risk management processes and for advising the Committee, as may be necessary, from time to time;
- d) To perform such other functions related to risk management & mitigation as may be required by the Board of Directors and/or SEBI Listing Regulations, from time to time;
- e) To formulate a detailed risk management policy which shall include:
- A framework for identification of internal and external risks specifically faced by the listed entity, in particular including financial, operational, sectoral, sustainability (particularly, ESG related risks), information, cyber security risks or any other risk as may be determined by the Committee.
 - Measures for risk mitigation including systems and processes for internal control of identified risks.
 - Business continuity plan.
- f) To ensure that appropriate methodology, processes and systems are in place to monitor and evaluate risks associated with the business of the Company;
- g) To monitor and oversee implementation of the risk management policy, including evaluating the adequacy of risk management systems;
- h) To periodically review the risk management policy, at least once in two years, including by considering the changing industry dynamics and evolving complexity;
- i) To keep the Board of Directors informed about the nature and content of its discussions, recommendations and actions to be taken;
- j) The appointment, removal and terms of remuneration of the Chief Risk Officer (if any) shall be subject to review by the Risk Management Committee.

GENERAL BODY MEETINGS

Details of location, time and date of last three Annual General Meetings, are provided below:

Financial Year	Date	Location			Time
2023-24 (FY24)	July 25, 2024 (35 th AGM)	Through Video Conference (“VC”) or Other Audio Visual Means (“OAVM”) (deemed venue: Registered office of the Company at Thane (W) – 400604, Maharashtra, India) 400604			10:00 a.m.
2022-23 (FY23)	August 12, 2023 (34 th AGM)	Through Video Conference (“VC”) or Other Audio Visual Means (“OAVM”) (deemed venue: Registered office of the Company at Thane (W) – 400604, Maharashtra, India) 400604			3:00 p.m.

Financial Year	Date	Location			Time
2021-22 (FY22)	August 19, 2022 (33 rd AGM)	Through Video Conference (“VC”) or Other Audio Visual Means (“OAVM”) (deemed venue: Registered office of the Company at Thane (W) – 400604, Maharashtra, India) 400604			10:00 a.m.

Special Resolutions passed in the previous three Annual General Meetings (AGMs)

During the Annual General Meetings held in the last 3 years i.e. for FY22 to FY24 approvals of the Members were obtained by passing special resolutions in AGMs, as follows:

Sr. No.	Special Resolutions	Date of Meeting
1.	Appointment of Ms. Vandana R. Tilak (DIN: 10048021) as an Independent Director of the Company for the period of five years effective from July 01, 2023	August, 12, 2023
2.	Re-Appointment of Mr. Vinodkumar Hiralal Jajoo (DIN: 08224980) as an Independent Director of the Company for the period of five years effective from February 09, 2024	August, 12, 2023
3.	Re-Appointment of Ms. Rajshree Patel (DIN: 08761022) as an Independent Director of the Company for the period of three years effective from June 12, 2023	August, 12, 2023
4.	Continuation of Directorship of Mr. Vasant Rathi, Non-Executive Director (DIN: 01233447) in terms of Regulation 17(1A) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)	August, 19, 2022
5.	Appointment of Mr. Nitin Jagannath Deshmukh (DIN: 00060743) as an Independent Director of the Company for the period of five years effective from July 01, 2022	August, 19, 2022
6.	Approval of AETL - Employee Stock Option Scheme 2022	August, 19, 2022
7.	Grant of stock options to the employees of the Subsidiaries of the Company under AETL – Employee Stock Option Scheme 2022	August, 19, 2022

Resolutions passed through postal ballot & details of voting pattern

During the year under review, no resolution was passed through postal ballot.

MEANS OF COMMUNICATION

The Board believes that effective communication of information is an essential component of Corporate Governance. The Company regularly interacts with Members through multiple channels of communication such as results announcement and Newspaper publications, Annual Report, media releases, website of the Company and specific communications to the Stock Exchanges, where the Equity Shares of the Company are listed.

Quarterly Results

The unaudited quarterly financial results of the Company were published in English and regional newspaper. The financial results were not sent individually to the Members.

Newspapers wherein results are normally published

The results are normally published in an English Newspaper viz. The Free Press Journal / the Financial Express and a Regional Newspaper viz. Navshakti / Mumbai Lakshadeep.

Website

The Company has in place a website addressed as www.advancedenzymes.com. The Website contains the basic information about the Company viz. details of its Business, financial information, Annual Reports, Company's policies & Code of Conduct & Ethics as required under the Act and the SEBI Listing Regulations, Shareholding Pattern, Compliance with Corporate Governance report, contact information of the Designated official of the Company, who is responsible for assisting and handling Investor Grievances and such other details as may be required under sub Regulation (2) of Regulation 46 of the SEBI Listing Regulations. The Company ensures that the contents of this website are periodically updated. In addition, the Company publishes official news release and presentations, if any, made to institutional investors /analysts on its website.

GENERAL SHAREHOLDER INFORMATION

Annual General Meeting Date, Time and Venue	36 th Annual General Meeting (AGM) July 30 th , 2025, Wednesday, at 10:00 a.m. IST Through Video Conference or Other Audio Visual Means with Registered Office of the Company deemed to be the venue for the proceedings of the AGM
Financial Year	April 01 to March 31
Schedule (Tentative) for declaration of financial results during the FY26	First quarter - Up to August 14, 2025 Second quarter - Up to November 14, 2025 Third quarter - Up to February 14, 2026 Annual & fourth quarter - Up to May 30, 2026 Annual General Meeting - Up to September 30, 2026
Dividend Payment Date	On or after August 01, 2025 (subject to declaration of dividend by the Members at the 36 th AGM)
Listing on Stock Exchanges	Company's Equity Shares are listed at: BSE Limited (BSE) Phiroze Jeejeebhoy Towers Dalal Street Mumbai- 400001 National Stock Exchange of India Limited (NSE) Exchange Plaza, Bandra-Kurla Complex, Mumbai-400051 The Company hereby confirms that it has made the payment of Annual Listing Fees to BSE Limited and National Stock Exchange of India Limited.
Registrar & Share Transfer Agent	MUFG Intime India Private Limited C 101, 247 Park, L.B.S. Marg, Vikhroli (West), Mumbai - 400083. Tel: +91 810 811 8484 Fax: (022) 49186060 Email ID: rnt.helpdesk@in.mpms.mufg.com Website: https://in.mpms.mufg.com

Share Transfer System

In terms of Regulation 40(1) of the SEBI Listing Regulations, as amended from time to time, the Securities of the listed entity can be transferred only in dematerialized form. The operational guidelines for transfer and dematerialization of re-lodged physical shares were laid down by SEBI vide circular SEBI/HO/MIRSD/RTAMB/CIR/P/2020/236 dated December 02, 2020.

Further, SEBI vide its circular SEBI/HO/MIRSD/MIRSD_RTAMB/P/CIR/2022/8 dated January 25, 2022 has mandated that the listed entities shall henceforth issue Securities in dematerialized (demat) form while processing the following requests:

- i. Issue of duplicate securities certificate
- ii. Claim from Unclaimed Suspense Account
- iii. Renewal/Exchange of securities certificate
- iv. Endorsement
- v. Sub-division / Splitting of securities certificate
- vi. Consolidation of securities certificates/folios
- vii. Transmission
- viii. Transposition

Members holding Equity Shares of the Company in physical form are requested to consider converting their holdings to dematerialized form. Transfers of Equity Shares in electronic form are effected through the depositories with no involvement of the Company. SEBI also vide its circular No. SEBI/HO/MIRSD/MIRSD_RTAMB/P/CIR/2022/65 dated 18th May 2022 and circular No. SEBI/HO/MIRSD/MIRSD_RTAMB/P/CIR/2022/70 dated May 25, 2022 has simplified the procedure and standardized the format of documents for transmission of securities & issuance of duplicate securities certificates respectively.

Further, SEBI vide its Master Circular No. SEBI/HO/MIRSD/POD-1/P/CIR/2023/70 dated May 17, 2023 and further amended by Master Circular No. SEBI/HO/MIRSD/POD-1/P/CIR/2024/37 dated May 07, 2024 (“SEBI Circulars”) has mandated that the Securities pursuant to the transmission shall be issued in demat mode only, and also mandated that duplicate share certificates shall be issued in demat mode only by way of issue of Letter of Confirmation.

Updation of PAN, KYC and Nomination details:

As per Master Circular no. SEBI/HO/MIRSD/POD-1/P/CIR/2023/70 dated May 17, 2023 and further amended by Master Circular No. SEBI/HO/MIRSD/POD-1/P/CIR/2024/37 dated May 07, 2024 (“SEBI Circulars”) and the FAQs released by the SEBI has provided common and simplified norms for processing investor’s service request by RTAs and norms for furnishing PAN, KYC and Nomination details. As per the said SEBI Circular, the Members holding shares in physical form and who have not updated their KYC details (viz. PAN; Choice of Nomination; Contact Details; Mobile Number; Bank Account Details and signature) against their folio with MUFG Intime India Private Limited, Registrar and Transfer Agent of the Company (“RTA”), their dividend shall be withheld by the Company and the same shall be immediately released electronically, upon updation of KYC. In this regard, the Company through its RTA have sent the letter during March / April 2024 to its physical Members for updating their KYC details as mentioned above.


The certificate received from a Practicing Company Secretary pursuant to the provisions of Regulation 40(9) of the SEBI Listing Regulations (as amended) is submitted by the Company to the Stock Exchanges, on an annual basis. The Certificate was received from a Practicing Company Secretary and submitted to the Stock Exchanges, on a quarterly basis, with respect to timely dematerialization of shares of the Company and reconciliation of the share capital of the Company, as required under the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018.

The Company has designated the e-mail ID: investor.grievances@advancedenzymes.com, for addressing the investors' grievances.

Shareholding Pattern of the Company as on March 31, 2025:

Category of Shareholder	No. of Shares held	% of holding
Promoter and Promoter Group:		
-Indian	22,09,100	1.97
-Foreign	4,59,90,885	41.11
Sub-Total (A)	4,81,99,985	43.08
Public:		
Institutions:		
-Mutual Funds	59,91,978	5.36
-Alternate Investment Fund	31,68,272	2.83
-Foreign Portfolio Investors	1,33,10,458	11.90
-Financial Institutions/Banks	0.00	0.00
Non Institutions:		
-Individuals	2,49,53,442	22.30
-HUF/ NRI/ Trust/ Bodies Corporate/ IEPF/ Clearing Members/ Others	1,62,54,515	14.53
NBFCs registered with RBI	2,500	0.00
Sub-Total (B)	6,36,81,165	56.92
Grand Total (A+B)	11,18,81,150	100.00

Shareholding Pattern As on March 31, 2025



Distribution of Shareholding as on March 31, 2025:

Shareholding (Range)	No. of Shareholders	%	Shares	%
up to 500	60,226	90.39	46,38,578	4.15
501 to 1000	3,063	4.60	23,19,655	2.07
1001 to 2000	1,618	2.43	23,79,637	2.13
2001 to 3000	546	0.82	13,68,689	1.22
3001 to 4000	285	0.43	10,22,175	0.91
4001 to 5000	193	0.29	8,96,611	0.80
5001 to 10000	352	0.53	25,51,048	2.28
10001 and above	344	0.52	9,67,04,757	86.44
Total	66,627	100.00	11,18,81,150	100.00

Note: The above distribution summary of Shareholding Pattern is folio based and not PAN based.

Dematerialization of shares and liquidity

As on March 31, 2025, 99.81 % of shareholding was held in Dematerialized form with National Securities Depository Limited and Central Depository Services (India) Limited.

Note: Trading in the Equity Shares of the Company is permitted only in Dematerialized form in accordance with the circular issued by SEBI.

Particulars of Unclaimed Dividend of the Company

Financial Year	Type of Dividend	Date of Declaration	Due date to transfer to IEPF
2017-2018	Final Dividend	September 14, 2018	October 16, 2025
2018-2019	Final Dividend	August 08, 2019	September 13, 2026
2019-2020	Final Dividend	July 15, 2020	August 20, 2027
2020-2021	Final Dividend	September 08, 2021	October 09, 2028
2021-2022	Final Dividend	August 19, 2022	September 22, 2029
2022-2023	Final Dividend	August 12, 2023	September 13, 2030
2023-2024	Interim Dividend	May 13, 2023	June 15, 2030
2023-2024	Final Dividend	July 25, 2024	August 26, 2031
2024-2025	Interim Dividend	May 11, 2024	June 13, 2031

The Company will transfer the Unclaimed dividend to Investor Education and Protection Fund (IEPF) within thirty (30) days from the aforesaid due dates.

Equity Shares lying with the Company in Suspense Account

Pursuant to the provisions of Regulation 39(4) read with Schedule V (F) of the SEBI Listing Regulations, details of Equity Shares in Advanced Enzyme Technologies Limited – Unclaimed Securities Suspense Account as on March 31, 2025 are as follows:

Particulars	No. of Shareholders	No. of Equity Shares
Opening Balance	10	32,700
Aggregate number of shareholders and the outstanding shares in the suspense account lying as on April 01, 2024		
Number of shareholders who approached listed entity for transfer of shares from suspense account during the year	2	4200
(Less) Number of shareholders to whom shares were transfer red from suspense account during the year	(2)	(4200)
(Less) Number of shareholders whose shares got transferred from suspense account to the IEPF Authority during the year	(3)	(5,000)
Closing Balance	5	23,500
Aggregate number of shareholders and the outstanding shares in the suspense account lying as on March 31, 2025		

All the corporate benefits, if any, against the above shares like bonus shares, split, etc., are also required to be transferred to Unclaimed Suspense Account of the Company. While the dividend for the shares which are lying in Unclaimed Suspense Account would be credited back to the relevant dividend accounts of the Company, the voting rights on shares lying in Unclaimed Suspense Account shall remain frozen till the rightful owner claims the shares.

Pursuant to Section 124(6) of the Companies Act, 2013, all Shares in respect of which Dividend has not been paid or claimed for seven consecutive years or more shall be transferred by the company in the name of Investor Education and Protection Fund (“IEPF”). The details are provided on the website of the Company at www.advancedenzymes.com/investors/shareholder-information

Further, the Company has not issued any Global Depository Receipt / American Depository Receipt / Warrant or any convertible instrument, which is likely to have impact on the Company's Equity.

Commodity price risk or foreign exchange risk and hedging activities

The Company does not trade in commodities. The relevant details of foreign exchange exposure & risk / hedging activities are provided in Note No. 41 of Standalone financial statements

Custodian Fees

The Company has paid custodian fees for folios maintained by National Securities Depository Limited and Central Depository Services (India) Limited for the FY25, as per the Invoices received.

Plant Locations of the Company

1. A-61/62, M.I.D.C. Area, Sinnar, Nashik - 422 103, Maharashtra
2. SORL, H-17, M.I.D.C, Satpur Area, Nashik – 422 007, Maharashtra
3. Survey No.30, Pali, Vasind, Shahpur, Thane – 421 601, Maharashtra
4. Plot No. B-5-13, SEZ, Pithampur, Dhar - 452774, Madhya Pradesh

Address for Correspondence

Advanced Enzyme Technologies Limited
5th Floor, 'A' wing, Sun Magnetica, LIC Service Road, Louiswadi, Thane (W), Maharashtra - 400604, India
Phone: +91-22-4170 3200, Fax: +91-22-2583 5159
Email Id: investor.grievances@advancedenzymes.com
Website: www.advancedenzymes.com

Company Secretary and Compliance Officer / Nodal Officer
Mr. Sanjay Basantani

Company Secretary & Head - Legal
5th Floor, 'A' wing, Sun Magnetica, LIC Service Road, Louiswadi, Thane, Maharashtra - 400604, India
Phone: +91-22-4170 3200, Fax: +91-22-2583 5159
Email Id: sanjay@advancedenzymes.com
Website: www.advancedenzymes.com

Registrar & Transfer Agent

MUFG Intime India Private Limited
C 101, 247 Park, L.B.S. Marg, Vikhroli (West), Mumbai - 400083.
Tel: +918108118484; Fax: (+91 22) 49186060
Email ID: rnt.helpdesk@in.mpms.mufg.com
Website: <https://in.mpms.mufg.com>

CREDIT RATING

Your Company has received a long term rating of CRISIL A+ / Stable (Reaffirmed) and a short term rating of CRISIL A1+ (upgraded from “CRISIL A1”) for outstanding Bank loan facilities (outstanding facilities), by Credit Rating Information Services of India Limited (CRISIL).

OTHER DISCLOSURES

Materially Significant Related Party Transactions

During the year under review, the Related Party Transactions were done on an arm's length basis and in ordinary course of business. The Company presents a statement of the Related Party Transactions before the Audit Committee on a quarterly basis specifying *inter alia* the nature and value of the transactions. The transactions with Related Parties were conducted in a transparent manner in the interest of the Company, were approved by the Audit Committee and had no potential conflict with the interest of the Company at large. There were no significant Related Party transactions, monetary transactions or relationships between the Company and Directors, the Management, Subsidiaries or Relatives except as disclosed in the Note No. 42 of the Standalone financial statements for the year ended March 31, 2025 and AOC - 2 annexed as Annexure II to this Board’s report.

Whistle Blower Policy

The Board had adopted Vigil Mechanism/Whistle Blower Policy pursuant to the provisions of Section 177(9) of the Act and the Companies (Meetings of Board and its Powers) Rules, 2014 as amended and Regulation 22 of the SEBI Listing Regulations, in order to establish a Vigil Mechanism for the Directors and Employees to report the genuine concerns in such manner as may be prescribed.

Your Company believes in the conduct of the affairs of its various constituents in a fair and transparent manner, by adopting the highest standards of professionalism, honesty, integrity and ethical behavior and open communication. Accordingly, the Whistle Blower Policy has been formulated with a view to provide a mechanism for associates of the Company to approach the Chairperson of the Audit Committee of the Company to, *inter alia*, report to the management, instances of unethical behaviour, actual or suspected fraud or violation of the Company's policy. No personnel was denied access to the Audit Committee of the Company.

Details of Utilization of Funds Raised through Preferential allotment or Qualified Institutions placement as specified under Regulation 32(7) of SEBI Listing Regulations

The Company has not raised any funds through preferential allotment or qualified institutions placement during the year under review.

Disclosure of Loans and advances in the nature of loans to firms/companies in which Directors are interested by name and amount

The Company and its Subsidiaries have not given any loans and advances in the nature of loans to firms/companies in which Directors are interested.

Details of total fees paid to the Statutory Auditors

The details of total fees for all services paid by the Company and its Subsidiaries, on a consolidated basis, to the Statutory Auditor and all entities in the network firm/network entity of which the Statutory Auditor is a part, are as follows:

(₹ in million)	
Particulars	Year ended March 31, 2025
Company to Statutory Auditors:	
Statutory Audit	2.26
Limited review	1.49
Certification work	0.10
Transfer pricing	-
Reimbursement of expenses	0.64
Advisory Services	-
Total	4.49
Company to network entity of Statutory Auditors	
Issuing Form 3CEB	-
Transfer Pricing Report for FY 2023-24	-
Reimbursement of expenses	-
Total	-
Subsidiaries	-

Compliance with mandatory / Non-mandatory requirements

The Company has complied with the mandatory Corporate Governance requirements under the SEBI Listing Regulations.

The provisions of Schedule V Part C read with Schedule II Part E, further states that the non-mandatory requirements adopted by the Company be highlighted in the Corporate Governance Report. Accordingly, the Company has complied with the following non-mandatory requirements:

- During the year, the Office of Chairman and the Whole-Time Director or CEO was held by distinct individuals.
- The Internal Auditors have direct access to the Audit Committee and present their Internal Audit observations to the Audit Committee.

Disclosures in relation to the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013

Sr. No.	Particulars	No.
1.	Number of Complaints filed during the financial year	NIL
2.	Number of Complaints disposed of during the financial year	NA
3.	Number of Complaints pending as on the end of the financial year	NA

Disclosures

The Company has a Risk Management Policy. Minutes of Risk Management Committee meetings held during the year under review, were placed before the Board.

During the last three years, there were no instances of non-compliance reported by the Company and no penalties or strictures were imposed on the Company by the Stock Exchange(s) or the SEBI or any statutory authority, on any matter related to the capital markets.

Pursuant to Regulation 17(8) read with Part B of Schedule II of the SEBI Listing Regulations, the Whole-time Director and the Chief Financial Officer have submitted a certificate to the Board of Directors for the financial year ended March 31, 2025. The Certificate has been reviewed by the Audit Committee and taken on record by the Board.

The Company is in compliance with the requirements stipulated under Regulation 17 to 27 read with Schedule V and clauses (b) to (i) of sub-regulation (2) of Regulation 46 of the SEBI Listing Regulations, as applicable, with regard to corporate governance. The Certificate of the Practicing Company Secretary regarding compliance of the conditions of Corporate Governance for the

year ended March 31, 2025 by the Company, as stipulated in Regulations 17 to 27, clauses (b) to (i) of regulation 46(2) and para C and D of Schedule V of the SEBI Listing Regulations is annexed to this report and forms an integral part of this Report.

Web link for Policy for determining Material Subsidiaries and Related Party Transactions

In accordance with the requirements of the SEBI Listing Regulations, the Company has formulated a Policy for determining Material Subsidiary and Policy on Related Party Transactions. These policies, as amended, are hosted on the website of the Company at: www.advancedenzymes.com/investors/corporate-governance

Details of Material Subsidiaries; including the date and place of incorporation and the name and date of appointment of the statutory auditors of such subsidiaries

- 1) Cal-India Foods International (SEB) incorporated on March 25, 1985, State of California (US) was the material subsidiary of the Company during the year under review. The law of the country of its incorporation does not mandatorily requires to get its Standalone financial statements audited and hence the details of its Statutory Auditors are not applicable.
- 2) JC Biotech Private Limited (JCB) – Subsidiary incorporated on December 31, 1991, Hyderabad – India was the material subsidiary of the Company, during the year under review. The subsidiary had appointed M/s. N A C and Associates LLP as the Statutory Auditors in its Annual General Meeting held on August 05, 2023.

Shareholders' Right

The Quarterly / Half-Yearly / Annual Results of the Company were published in English and Vernacular newspapers and have been displayed on the Company's website, www.advancedenzymes.com and at the website of the Stock Exchanges, where the shares of the Company are listed / traded, as soon as the results were approved by the Board. These were not sent individually to the Members.

Disclosure of certain types of Binding Agreements

Pursuant to Regulation 30(A)(5) of SEBI Listing Regulations, no such agreements were disclosed to Stock Exchanges and accordingly the same is not applicable.

Auditors' Report

The Auditors' Report to the Members on the financial statements of the Company for the year ended March 31, 2025 does not contain any qualification, reservation or adverse remark.

**DECLARATION ON ADHERENCE WITH COMPANY'S
CODE OF CONDUCT & ETHICS**
[Pursuant to Regulation 34(3) and Schedule V of Securities and
Exchange Board of India
(Listing Obligations and Disclosure Requirements)
Regulations, 2015]

To,

The Members of

Advanced Enzyme Technologies Limited

This is to confirm that the Company has adopted Code of Conduct and Ethics for all the Members of Board of Directors, Senior Management/Officers of the Company as stipulated under Regulation 17(5) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, and the members of Board of Directors, Senior Management / Officers of the Company have affirmed compliance with this Code of Conduct & Ethics for the financial year ended on March 31, 2025.

For Advanced Enzyme Technologies Limited

**Place: Thane
Date : May 13, 2025**

**Mukund Kabra
Whole-time Director
DIN: 00148294**

CERTIFICATION ON CORPORATE GOVERNANCE

To,

The Members of **Advanced Enzyme Technologies Limited**

I, Shiv Hari Jalan, Proprietor of Shiv Hari Jalan & Co., Company Secretary in practice have examined the compliance of conditions of Corporate Governance by **Advanced Enzyme Technologies Limited** ('the Company') for the year ended March 31, 2025 as stipulated in Regulations 17 to 27 and clauses (b) to (i) and (t) of sub-regulation (2) of regulation 46 and para C and D of Schedule V of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations').

The compliance of conditions of Corporate Governance is the responsibility of the management. My examination was limited to procedures and implementation thereof adopted by the Company for ensuring the compliance of the conditions of corporate governance. It is neither an audit nor an expression of opinion on the financial statements of the Company.

I have examined the books of account and other relevant records and documents maintained by the Company for the purposes of providing reasonable assurance on the compliance with Corporate Governance requirements by the Company.

Based on my examination of the relevant records and according to the information and explanations provided to me and the representations provided by the Management, I certify that the Company has complied with the conditions of Corporate Governance as stipulated in Regulations 17 to 27 and clauses (b) to (i) and (t) of sub-regulation (2) of regulation 46 and para C and D of Schedule V of the Listing Regulations during the year ended March 31, 2025.

I further state that such compliance is neither an assurance as to the future viability of the Company nor the efficiency or effectiveness with which the management has conducted the affairs of the Company.

Restriction on use

This certificate is issued solely for the purpose of complying with the aforesaid regulations and may not be suitable for any other purpose.

**Place: Mumbai
Date: 13.05.2025
UDIN: F005703G000329675**

**For Shiv Hari Jalan & Co.
Company Secretaries
FRN: S2016MH382700**

**(Shiv Hari Jalan)
Proprietor
FCS No: 5703
C.P.NO: 4226
PR No. 1576/2021**

CERTIFICATE OF NON-DISQUALIFICATION OF DIRECTORS

*(Pursuant to Regulation 34(3) and Schedule V Para C clause (10)(i) of the SEBI
(Listing Obligations and Disclosure Requirements) Regulations, 2015)*

To,

The Members of
Advanced Enzyme Technologies Limited

Sun Magnetica, 5th Floor,
Near LIC Service Road,
Louis Wadi, Thane- 400604.

I, Shiv Hari Jalan, Proprietor of Shiv Hari Jalan & Co., Company Secretary in practice have examined the relevant registers, records, forms, returns and disclosures received from the Directors of Advanced Enzyme Technologies Limited having CIN L24200MH1989PLC051018 and having registered office at Sun Magnectica, 5th Floor, Near LIC Service Road, Louis Wadi, Thane- 400604 (hereinafter referred to as 'the Company'), produced before me by the Company for the purpose of issuing this Certificate, in accordance with Regulation 34(3) read with Schedule V Para-C clause 10(i) of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

In my opinion and to the best of my information and according to the verifications (including Directors Identification Number (DIN) status at the portal www.mca.gov.in) as considered necessary and explanations furnished to me by the Company & its officers, I hereby certify that none of the Directors on the Board of the Company as stated below for the Financial Year ending on 31st March, 2025 have been debarred or disqualified from being appointed or continuing as Directors of companies by the Securities and Exchange Board of India, Ministry of Corporate Affairs or any such other Statutory Authority.

Sr. No.	Name of Director	DIN	Date of Appointment in Company *
1	Mr. Vasant Rath	01233447	05/03/1993
2	Mr. Mukund Kabra	00148294	04/09/1999
3	Mr. Pramod Kasat	00819790	14/12/2016
4	Mr. Vinodkumar Jajoo	08224980	09/02/2019
5	Ms. Rasika Rath	08300682	08/01/2019
6	Mr. Sunny Sharma	02267273	02/11/2019
7	Ms. Rajshree Patel	08761022	12/06/2020
8	Mr. Nitin Deshmukh	00060743	01/07/2022
9	Mrs. Vandana Tilak	10048021	01/07/2023

*The date of appointment is as per the MCA Portal.

Ensuring the eligibility for the appointment / continuity of every Director on the Board is the responsibility of the management of the Company. My responsibility is to express an opinion on these based on my verification. This certificate is neither an assurance as to the future viability of the Company nor of the efficiency or effectiveness with which the management has conducted the affairs of the Company.

**Place: Mumbai
Date: 13.05.2025
UDIN: F005703G000329774**

**For Shiv Hari Jalan & Co.
Company Secretaries
FRN: S2016MH382700**

**(Shiv Hari Jalan)
Proprietor
FCS No: 5703
C.P.NO: 4226
PR No. 1576/2021**

INFORMATION UNDER SECTION 134(3)(M) OF THE COMPANIES ACT, 2013 READ WITH RULE 8(3) OF THE COMPANIES (ACCOUNTS) RULES, 2014 AND FORMING PART OF THE BOARD'S REPORT FOR THE YEAR ENDED MARCH 31, 2025

A) CONSERVATION OF ENERGY

(I) Steps taken for conservation of energy:

1. Installation of the Solar power plant for an additional 350KW. With this, the total Solar power installed capacity is 510 KW
2. Steam Condensate used as the feed hot water to the Boiler resulting in reduction in fuel consumption. Scheduled Preventive maintenance and cleaning of Boilers at reduced intervals
3. Scheduled D check maintenance conducted for the Diesel Generator (DG) sets to improve its energy efficiency
4. Installation of the Energy Efficient Air conditioning system using CFC free clean refrigerant gas
5. Installed and operated Energy Efficient & VFD grade motors for Fermenter Agitation
6. Installation of LED lamps/lights at various sections in the Plant
7. Implementation of Preventive Maintenance Plan to enhance Energy Efficiency for all the Critical and Utility Equipment. Carried out preventive maintenance of Electrical Substation and Power Distribution network to enhance electrical power efficiency
8. Scheduled Preventive Maintenance and dynamic balance checking of blowers to achieve maximum energy efficiency
9. Cold Insulation provided for the ducts of Air Handling (AHU) system of Spray Dryer Plant
10. Energy audit of equipment carried out for better performance and use
11. Pumping trap in Spray dryer for improving equipment performance. Replacements of old cooling unit and air conditioner
12. Installation of an extra capacitor bank to maintain Power factor. Soft Starter use in cooling tower fan motor

(II) Impact of measures taken:

1. Roof-top renewable Solar power electricity generation up to 323,192 units in the financial year
2. Energy saving due to cold insulation was 5-8 KWH/day
3. Diesel Generator set D-Check maintenance resulted in stable KWH to Fuel ratio at around 3.84%
4. Hot insulation of steam and utility systems resulting in stabilization of steam consumption @ 85 kg/hour
5. Chilled water generation system heat recovery improvement resulted in reduction of 25 kg/hr steam requirement

6. Electrical Current Utilisation of Blowers reduced by 2-15 Amp / hour
7. Preventive maintenance of the Critical and Utility equipment enhanced the performance of the equipment and resulted in the reduction in the power and fuel consumption. Efficient performance of Electrical equipment
8. Power bill Incentive and other rebates received from MSEDCL was ₹ 16.31 lakhs
9. By installation of LED light, lighting power consumption reduced by around 8-10% and it resulted in the reduced maintenance cost
10. By installation of the pumping trap in the spray dryer, the temperature reaching time was reduced, steam consumption reduced and having good condensate recovery (under observation)
11. By installation of the capacitor bank, the power factor 0.999 was maintained and results in the efficient performance of the Electrical equipment
12. Replacement of the old R-22 gas air conditioner with new R-32 Gas/Inverter AC. It reduces energy consumption and maintenance cost. Soft starter reduces the initial torque of motor, smoother motor acceleration and extend equipment lifespan and energy efficiency.

(III) The steps taken by the Company for utilizing alternate sources of energy:

Completed installation of solar power unit for an additional 350KW.

(IV) The capital investment on energy conservation equipment:

Sr. No.	Particulars	Amount (₹ in million)
1.	Installation of an additional 350 KW Solar Power Plant	17.03
2.	Diesel Generator set D-check preventive maintenance	1.39
3.	Energy Efficient lights fixture	1.73
4.	Energy efficient Frequency Drive and Motors procurement	0.60
5.	CFC free Gas Air Conditioners procurement	0.84
6.	Capacitor for maintaining Power factor	0.11
7.	Cold Insulation provided	0.75
8.	Energy audit	0.23
9.	Pumping trap in Spray Dryer	0.19
10.	Cooling unit / Air Conditioner unit	0.28
11.	Soft starter use as mentioned above	0.04
Total		23.19

ANNEXURE V

B) TECHNOLOGY ABSORPTION

(I) Efforts in brief made towards technology absorption:

1. Upgradation of the virtual laboratory for the efficient engineering of the proteins.
2. With focus on high throughput screenings, various enzyme assays were scaled down to suit the screening.
3. Technologies to produce and commercialize enzymes for industrial applications, biocatalysts, human & pet nutrition and animal feed were developed.

(II) Benefits derived as a result of the above efforts:

1. Updated virtual screening methods led to reducing the lead time of the projects on development and engineering of biocatalysts for production of API (Active Pharmaceutical Ingredient) intermediates.
2. The engineered enzymes developed using the above virtual screening methods are advantageous as they reduce the wet lab load.
3. Human & pet nutrition: New enzymes/probiotics formulations developed as the holistic health solutions. With more self-awareness towards health and health care supplements, it is expected that the demand for nutraceuticals may grow further.

(III) Imported technology:

Technology imported: NIL

1. the details of technology imported: Not Applicable
2. Year of Import: Not Applicable
3. Has the technology been fully absorbed: Not Applicable
4. If not fully absorbed areas where absorption has not taken place, and the reasons thereof: Not Applicable

(IV) Benefits derived as a result of the above efforts pertaining to Imported Technology: Not Applicable

(V) Expenditure incurred on Research and Development:

(₹ in million)

Sr. No.	Particulars	2024-25	2023-24
(a)	Capital	31.87	18.86
(b)	Recurring	296.52	255.21
(c)	Total	328.39	274.07
(d)	Total R&D expenditure as a % of Net Sales of the Company	10.41%	7.50%

Notes: Net Sales of ₹ 3,154.11 million (previous year ₹ 3,654.69 million)

On consolidated basis, the Research and Development expenditure for FY 2024-25 was ₹ 248 million (3.86% of Net sales) and for FY 2023-24 was ₹ 197 million (3.15% of Net sales).

C) FOREIGN EXCHANGE EARNINGS AND OUTGO

(₹ in million)

Sr. No.	Particulars	2024-25	2023-24
(a)	Foreign Exchange Earnings	1,204.43	1,096.62
(b)	Foreign Exchange Outgo	704.79	594.36

For and on behalf of the Board of Directors of

Advanced Enzyme Technologies Limited

Mukund Kabra
Whole-Time Director
DIN: 00148294
Place: Thane
Date : May 13, 2025

Vinodkumar Jajoo
Director
DIN: 08224980
Place: Nashik

ANNEXURE VI

DISCLOSURE IN BOARD'S REPORT PURSUANT TO SECTION 197(12) OF THE COMPANIES ACT, 2013 READ WITH THE COMPANIES (APPOINTMENT AND REMUNERATION OF MANAGERIAL PERSONNEL), RULES, 2014

Sr. No.	Requirements	Disclosure		
1.	The ratio of the remuneration of each Director to the median remuneration of the employees of the Company for the Financial Year	Name of the Directors	Remuneration (₹ in million)	Ratio to median remuneration
		Mr. Vasant L. Rathī (Chairman & Non-Executive Director)	0.99	1.77
		Mr. Mukund M. Kabra (Whole-time Director)	26.28	46.93
		Refer notes below		
		Ms. Rasika Rathī (Non-Executive Director)	0.59	1.05
		Mr. Pramod Kasat (Independent Director)	0.89	1.59
		Mr. Vinodkumar H. Jajoo (Independent Director)	1.09	1.95
		Dr. Sunny Sharma (Non-Executive Director)	0.30	0.54
		Ms. Rajshree Patel (Independent Director)	0.30	0.54
		Mr. Nitin Deshmukh (Independent Director)	0.59	1.05
		Mrs. Vandana Tilak (Independent Director)	-	-
		Refer notes below		

Notes:

- (i) The median remuneration of employees of the Company was ₹ 0.56 million.
- (ii) The Commission for financial year 2024-25 (FY25) payable to Directors is also included in the total remuneration.
- (iii) For this purpose, the sitting fees have not been considered as remuneration.
- (iv) Figures have been rounded off wherever necessary.
- (v) The remuneration of Mr. Mukund Kabra as mentioned above is on payable basis and excludes leave encashment and Stock Options under the provisions of Advanced Enzyme Technologies Limited – Employees Stock Option Scheme 2022 (“ESOP Scheme 2022”).
- (vi) Mrs. Vandana Tilak has voluntarily waived the receipt of commission (₹ 0.40 million for FY25) and accordingly amount is show as Nil under the above field of Remuneration.

Sr. No.	Requirements	Name of the Directors and Key Managerial Personnel	Designation	% change (to be read with notes)
2.	The percentage increase in remuneration of each Director, Chief Financial Officer and Company Secretary in the financial year (Name with % change in the financial year 2024-25) (To be read with notes)	Mr. Vasant L. Rathī	Chairman & Non-Executive Director	(12.39)
		Mr. Mukund M. Kabra	Whole-time Director	10.00
		Mr. Pramod Kasat	Independent Director	2.30
		Ms. Rasika Rathī	Non-Executive Director	126.92
		Mr. Vinodkumar H. Jajoo	Independent Director	25.29
		Dr. Sunny Sharma	Non-Executive Director	(14.29)
		Ms. Rajshree Patel	Independent Director	(42.31)
		Mr. Nitin Deshmukh	Independent Director	34.09
		Mrs. Vandana Tilak	Independent Director	NA
		Mr. Beni P Rauka	Chief Financial Officer	10.00
		Mr. Sanjay Basantani	Company Secretary and Head-Legal	13.88

Notes:

- (i) The % increase in remuneration of Mr. Mukund Kabra, Whole-time Director is determined after excluding commission, leave encashment and Stock Options.
- (ii) The percentage change in remuneration of Mr. Vasant Rathī and Ms. Rasika Rathī as shown in the above table are from the standalone perspective (i.e. commission payable). In addition, pursuant to the resolution passed by the Members of the Company in its meeting held on July 15, 2020, recommendation of the Nomination & Remuneration Committee and approval of the Board, as Mr. Vasant Rathī heads the US Operations and Ms. Rasika Rathī is Vice President, General Counsel & Secretary there, they were paid remuneration aggregating to ₹ 46.51 million (excluding commission of ₹ 7.11 million from US Subsidiary) and ₹ 17.76 million respectively for FY25 by the Company’s subsidiary in US for the services rendered.
- (iii) The amount of commission as mentioned above is determined and approved by the Board in proportion to the number of meetings of the Board and its Committees thereto attended by the respective Non-Executive Director(s) during the financial year 2024-25.
- (iv) The % increase in remuneration of Mr. Beni P Rauka, CFO and Mr. Sanjay Basantani, Company Secretary and Head-Legal of the Company, is determined after excluding the annual incentives, leave encashment and stock Options under the ESOP Scheme 2022.

3.	The percentage increase in the median remuneration of employees in the financial year	During financial year 2024-25, the percentage increase in the median remuneration of employees as compared to previous year was approximately 9.80%
4.	The number of permanent employees on the rolls of company (As on March 31, 2025)	338
5.	Average percentage increase already made in the salaries of employees other than the Managerial Personnel in the last Financial Year and its comparison with the percentage increase in the Managerial Remuneration and justification thereof and point out if there are any exceptional circumstances for increase in the Managerial Remuneration.	Average increase in remuneration is around 10.96% for employees other than Managerial Personnel and around 10% for Managerial Personnel.

Note: The average percentage increase was based on the financial performance of the Company as summarised in the Board’s Report including the relevant factors mentioned in the Nomination and Remuneration Policy of the Company.

6.	Affirmation that the remuneration is as per the remuneration policy of the Company	Pursuant to Rule 5(1)(xii) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, it is affirmed that the remuneration paid to the Directors, Key Managerial Personnel and Senior Management is as per the Remuneration Policy of your Company.
7.	Pursuant to Section 197(12) of the Act read with Rule 5 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, as amended (“Rules”), the details are disclosed in this Annexure VI. In terms of Section 136(1) of the Act read with second proviso to the Rule 5 of the said Rules, the Annual Report with Annexure VI is being sent to the Members excluding the statement of particulars of employees under Rule 5(2) and (3) of the Rules (“Information”), which forms part of this report. The Annexure VI / Information under Rule 5(2) and (3) is available for inspection by the Members at the registered office of the Company during business hours on all working days except Saturdays and Sundays up to the date of the AGM. Any Member interested in conducting inspection and/or obtaining a copy of the said Annexure/Information may write to the Company Secretary at the Registered Office address of your Company.	

For and on behalf of the Board of Directors of
Advanced Enzyme Technologies Limited

Mukund Kabra
Whole-time Director
DIN: 00148294
Place: Thane
Date: May 13, 2025

Vinodkumar Jajoo
Director
DIN: 08224980
Place: Nashik

BUSINESS RESPONSIBILITY & SUSTAINABILITY REPORT (BRSR)

SECTION A: GENERAL DISCLOSURES

I. Details of the listed entity

1.	Corporate Identification Number (CIN) of the Listed Entity	L24200MH1989PLC051018
2.	Name of the Listed Entity	Advanced Enzyme Technologies Limited (“AETL”)
3.	Year of Incorporation	1989
4.	Registered office address	5 th Floor, ‘A’ wing, Sun Magnetica, LIC Service Road, Louisswadi, Thane (W) - 400 604, Maharashtra, India
5.	Corporate office address	
6.	E-mail	info@advancedenzymes.com
7.	Telephone	+91-22-4170 3200
8.	Website	www.advancedenzymes.com
9.	Financial year for which the reporting is done	FY 2024-25 (April 01, 2024 to March 31, 2025)
10.	Name of the Stock Exchange(s) where shares are listed	BSE Limited (BSE) & National Stock Exchange of India Limited (NSE)
11.	Paid-up Capital	₹ 223.76 million (as of March 31, 2025)
12.	Name and contact details (telephone, email address) of the person who may be contacted in case of any queries on the BRSR report	Mr. Ronak Saraf, Manager-Investor Relations ir@advancedenzymes.com; +91 22-4170 3200
13.	Reporting Boundary - Are the disclosures under this report made on a standalone basis (i.e. only for the entity) or on a consolidated basis (i.e. for the entity and all the entities which form a part of its consolidated financial statements, taken together)	Disclosures under this report are made on a standalone basis for Advanced Enzyme Technologies Limited
14.	Name of assurance provider	NA
15.	Type of assurance obtained	NA

II. Products/services

16. Details of business activities (accounting for 90% of the turnover)

S. No.	Description of main activity	Description of business activity	% of turnover of the entity
1.	Manufacturing	Chemical and chemical products; pharmaceuticals; medicinal chemical and botanical products	100%

17. Products/Services sold by the entity (accounting for 90% of the entity's turnover)

S. No.	Product/service	NIC Code	% of total turnover contributed
1.	Enzymes and Probiotics	21001	100%

III. Operations

18. Number of locations where plants and/or operations/offices of the entity are situated

Location	Number of plants	Number of offices	Total
National (India)	4	2	6
International	-	-	-

Note: AETL has 2 R&D laboratories

19. Markets served by the entity:

a. Number of locations

Locations	Number
National (No. of states)	PAN India presence across all 28 states and 8 Union Territories
International (No. of countries)	Exported to 47 countries across 5 continents

Note: During FY 2024-25, the Company dispatched its materials to 20 states and 4 Union Territories

b. What is the contribution of exports as a percentage of the total turnover of the entity?

Exports account for 36.23% of the revenues.

c. A brief on types of customers

The Company provides proprietary enzymes & probiotics products and customized solutions to Human Nutrition, Animal Nutrition, Bio-Processing Industry (Food & Non-Food processing).

IV. Employees

20. Details as at the end of financial year: 2024-25

a. Employees and Workers (including differently abled)

S. No.	Particulars	Total (A)	Male		Female	
			No. (B)	% (B/A)	No. (C)	% (C/A)
Employees						
1.	Permanent (D)	290	215	74.14%	75	25.86%
2.	Other than permanent (E)	106	83	78.30%	23	21.70%
3.	Total employees (D + E)	396	298	75.25%	98	24.75%
Workers						
4.	Permanent (F)	48	48	100.00%	0	0.00%
5.	Other than permanent (G)	249	239	95.98%	10	4.02%
6.	Total workers (F + G)	297	287	96.63%	10	3.37%

Note: In FY 2025, there were 86 trainees who are included in ‘Other than permanent’ above.

b. Differently abled Employees and Workers

S. No.	Particulars	Total (A)	Male		Female	
			No. (B)	% (B/A)	No. (C)	% (C/A)
Differently Abled Employees						
1.	Permanent (D)	1	1	100.00%	0	0
2.	Other than permanent (E)	0	0	0	0	0
3.	Total differently abled Employees (D + E)	1	1	100.00%	0	0
Differently Abled Workers						
4.	Permanent (F)	0	0	0	0	0
5.	Other than permanent (G)	0	0	0	0	0
6.	Total differently abled Workers (F + G)	0	0	0	0	0

21. Participation/Inclusion/Representation of women

Particulars	Total (A)	No. and Percentage of Females	
		No. (B)	% (B/A)
Board of Directors	9	3	33.33%
Key Management Personnel (KMP)	2	0	0%

Note: KMP includes Chief Financial Officer (CFO) and Company Secretary (CS)

22. Turnover rate for permanent employees and workers

Particulars	FY 2024-25			FY 2023-24			FY 2022-23		
	Male	Female	Total	Male	Female	Total	Male	Female	Total
Permanent Employees	6.68%	17.02%	9.29%	11.21%	12.40%	11.49%	10.50%	30.09%	14.52%
Permanent Workers	3.01%	0	2.94%	7.69%	0	7.69%	1.83%	0	1.83%

V. Holding, Subsidiary and Associate companies (including joint ventures)**23. Names of Holding/Subsidiary/Associate companies/Joint Ventures**

S. No.	Name of the Holding / Subsidiary / Associate companies / Joint ventures (A)	Indicate whether Holding / Subsidiary / Associate / joint venture	% of shares held by listed entity	Does the entity indicated at column A, participate in the business responsibility initiatives of the listed entity? (Yes/No)
1.	JC Biotech Private Limited	Subsidiary	95.72%	No, the subsidiaries are separate entities, and hence they follow Business Responsibility initiatives as per the laws as may be applicable to them.
2.	Advanced Bio-Agro Tech Limited	Subsidiary	60%	
3.	Advanced EnzyTech Solutions Limited	Subsidiary	100%	
4.	Advanced Enzymes USA	Subsidiary	100%	
5.	Cal-India Foods International	Subsidiary (Step-down)	100%	
6.	Advanced Supplementary Technologies Corporation	Subsidiary (Step-down)	100%	
7.	Enzyme Innovation Inc.	Subsidiary (Step-down)	100%	
8.	Starya Labs Inc*	Subsidiary (Step-down)	100%	
9.	Advanced Enzymes Europe B.V.	Subsidiary	100%	
10.	evox technologies GmbH	Subsidiary (Step-down)	100%	
11.	SciTech Specialities Private Limited	Subsidiary	51%	
12.	Saiganesh Enzytech Solutions Private Limited	Subsidiary	50%	

Note: *During the financial year 2024-25, the Board of Directors of Advanced Enzymes USA (“AEU”), a wholly owned subsidiary of the Company has accorded its approval for formation of a new corporation in California (US), Starya Labs, Inc (“Starya Labs”). As a result, Starya Labs, Inc. became a subsidiary (step down) of the Company, effective December 9, 2025.

VI. CSR Details

- 24. i. Whether CSR is applicable as per section 135 of Companies Act, 2013:** Yes
- ii. **Turnover (in million) :** ₹ 3,514.11 million (on standalone basis)
- iii. **Net worth (in million) :** ₹ 6,293.41 million (on standalone basis)

VII. Transparency and Disclosures compliances**25. Complaints/Grievances on any of the principles (Principles 1 to 9) under the National Guidelines on responsible business conduct (“NGRBC”) :**

Stakeholder group from whom complaint is received	Grievance Redressal Mechanism in Place (Yes/No) (If yes, then provide a weblink to the grievance redress policy)	FY 2024-25			FY 2023-24		
		Number of complaints filed during the year	Number of complaints pending resolution at the close of the year	Remarks	Number of complaints filed during the year	Number of complaints pending resolution at the close of the year	Remarks
Communities	No	NIL	NIL		NIL	NIL	
Investors (other than Shareholders)	No	NIL	NIL		NIL	NIL	
Shareholders	Yes*	1	NIL		NIL	NIL	
Employees and workers	Yes	NIL	NIL		NIL	NIL	
Customers	Yes	31	NIL		34	NIL	
Value chain partners	No	5	NIL		1	NIL	
Other (please specify)	No	NIL	NIL		NIL	NIL	

Note: Value Chain Partners include entities with which the organisation has a direct or indirect business relationship and which either (a) supply products or services that contribute to the organisation's own products or services or (b) receive products or services from the organisation.

Weblink of all the policies: www.advancedenzymes.com/investors/corporate-governance/#codes-and-policies

*The Grievance Redressal Mechanism is as per the applicable regulations

26. Overview of the entity's material responsible business conduct issues

Please indicate material responsible business conduct and sustainability issues pertaining to environmental and social matters that present a risk or an opportunity to your business, rationale for identifying the same, and approach to adapt or mitigate the risk along with its financial implications, as per the following format:

S. No.	Material issue identified	Indicate whether risk or opportunity (R/O)	Rationale for identifying the risk/opportunity	In case of risk, approach to adapt or mitigate	Financial implications of the risk or opportunity (indicate positive or negative implications)
1.	Climate risk	Risk	The Company may face significant changes in its operating environment due to climate change, such as disruptions in production, shifts in customer preferences, and other potential impacts	The Company stays up to date with the latest developments and implements necessary risk mitigation strategy. This may include analysing and assessing the potential consequences that could impact the business	Negative Increased production costs for adaptation
		Opportunity	The Company may consider climate change an opportunity since addressing it will necessitate the development of new and improved products across the globe	The Company is preparing to adapt to the evolving market conditions due to climate change	Positive Increased revenue from new product development and market adaptation
2.	Environmental impact	Risk	As a manufacturing company, the plants run by AETL always carry the risk of having a negative impact on the environment	The Company has a strong system in place for establishing its 'Standard Operating Procedures' with a key focus on protecting the environment. E.g. the complete range of enzymes produced by the Company is eco-friendly	Negative Potential fines, remediation costs, and damage to reputation
3.	Energy conservation	Opportunity	The Company conserves energy, which results in using less energy to achieve the same or even higher output, reducing costs and significantly reducing environmental impact	The Company consistently implements measures to conserve energy, such as installing more energy-efficient technology and products	Positive Cost savings from reduced energy consumption and environmental benefits.
4.	Carbon emissions	Risk	Scientific studies have shown that industry carbon emissions contribute significantly to the greenhouse effect, which is the primary cause of global climate change	The Company is developing a strategy to decrease its emissions and conform to the 'net zero' goals within its specific regions	Negative As the Company is a manufacturing concern, carbon emission will remain a certain part of operations for certain time period but never the less the Company endeavours for Cost savings from emission reduction

S. No.	Material issue identified	Indicate whether risk or opportunity (R/O)	Rationale for identifying the risk/opportunity	In case of risk, approach to adapt or mitigate	Financial implications of the risk or opportunity (indicate positive or negative implications)
5.	Water usage and management	Opportunity	Using and managing water efficiently results in lower costs and also aids in reducing the adverse effects of groundwater depletion and water pollution	The Company understand its responsibility towards water usage and its efficient usage. Hence, a system is in place to recycle wastewater, that can be used in different operations. Water usage monitoring across various facilities enables us to strategize the reduction efforts	Positive Cost savings from reduced water consumption and environmental benefits
		Risk	There is a great degree of dependency on uninterrupted supply of water for continued operations. Therefore, water management becomes crucial for the Company's operations. With changing climate and drought like conditions, water availability is increasingly becoming a risk across different geographies.		Negative High dependency on uninterrupted water supply creates risk for plant operations
6.	Waste reduction	Opportunity	Minimising waste involves an all-encompassing approach of utilising fewer materials to decrease waste production. Such a practice results in conserving natural resources and cost savings	The Company is dedicated to minimising waste to attain environmental and economic advantages	Positive Cost savings from reduced waste disposal and resource conservation
7.	Material handling	Risk	Being an industrial manufacturer, the Company deals with material handling, which involves transporting and storing materials and products. This encompasses several stages: raw material handling, manufacturing processes, warehousing, and distribution	The Company employs industry-leading practices to manage both raw materials and finished products, ensuring the most efficient and effective material handling	Negative Increased operational costs and potential damages from mishandling
8.	Supply chain management	Risk	External and internal events may result in challenges related to the sourcing and transporting of raw materials and finished products, potentially leading to missed business opportunities and revenue losses	The Company continuously strives to optimise cost-effectiveness and timely deliveries. To ensure delivery timelines, raw materials are procured from reputable manufacturers. The Company also maintains adequate buffer stock to prevent potential delivery delays	Negative Increased costs from supply chain disruptions and potential revenue losses
9.	Customer experience	Risk	The survival and success of any business heavily rely on its customers. A decrease or discontinuation in customer demand can negatively impact the Company's revenue and profitability	The Company has been proactively improving the quality and consistency of the customer experience while also diversifying its client base, thereby reducing business risks	Negative Decreased revenue from declining customer demand and potential loss of market share

S. No.	Material issue identified	Indicate whether risk or opportunity (R/O)	Rationale for identifying the risk/opportunity	In case of risk, approach to adapt or mitigate	Financial implications of the risk or opportunity (indicate positive or negative implications)
10.	Health & safety	Risk	Due to the nature of its operations, the Company must contend with risks that could potentially threaten the health and safety of its employees and customers. This necessitates objectively assessing potential hazards that may lead to harm, injury, illness, or even death of employees or customers	The Company has 'zero tolerance' for any compromise or deviation from accepted norms and everyone is expected to abide with them. The Company also endeavors and strives to fulfil all applicable compliance requirements related to health and safety. The health and safety of our people and customers was, is and will continue to be our topmost priority	Negative Increased costs from workplace accidents, legal liabilities, and damage to reputation
11.	Employee engagement	Opportunity	Employee engagement is the assessment of the commitment, enthusiasm, and interest employees feel towards their job and overall responsibilities within the organisation. It presents an opportunity for the Company as studies have shown that employees who are more engaged tend to be more conscientious about their work and the Company's performance	The Company is dedicated to creating a work environment that encourages and supports its employees to excel by implementing employee engagement programmes. The Management is focused on providing employees with better tools, technology, and techniques to optimise their potential and improve teamwork	Positive Increased productivity, morale, and retention lead to cost savings and revenue growth
12.	Community engagement	Opportunity	In order to foster resilience in business and establish a positive, sustainable, long-term relationship with the community, organisations must have a clear vision and work collaboratively. The individuals who are directly or indirectly connected with the Company are significant stakeholders	The Company strives to monitor its initiatives aimed at benefiting the community. The senior management regularly reviews and evaluates the programmes and their progress	Positive Enhanced brand reputation, customer loyalty, and potential revenue growth
13.	Data privacy & security	Risk	Data privacy has become a significant risk factor in the modern world, but it can also be a valuable source of competitive advantage if managed properly. Despite this, effective information and data management continues to pose compliance challenges, which may lead to reputation risks	The Company has a strong framework in place to identify cybersecurity risks. Recognising the growing significance of data privacy concerns, the Company takes a comprehensive and coordinated approach to information security and data privacy systems	Negative Financial losses from data breaches, legal penalties, and damaged reputations
14.	Product quality and safety	Opportunity	Improving product quality and safety and meeting customer expectations can attract more customers and subsequently increase revenue	By ensuring high product quality, the company can build a strong reputation for delivering reliable and effective enzymes which can lead towards attracting and retaining customers. Quality and safety measures also minimize product recalls, warranty claims, and customer complaints, leading to cost savings	Positive Increased customer satisfaction, reduced warranty claims, and improved brand reputation

S. No.	Material issue identified	Indicate whether risk or opportunity (R/O)	Rationale for identifying the risk/opportunity	In case of risk, approach to adapt or mitigate	Financial implications of the risk or opportunity (indicate positive or negative implications)
	Product quality and safety	Risk	The retention of customers is heavily reliant on maintaining high levels of product quality and safety. Any shortcomings in meeting customer expectations can negatively impact revenue	The Company follows quality control and quality assurance processes to ensure that each product manufactured meets the high quality standards established by the Company	Negative Can lead to product withdrawals, recalls, regulatory action, decreased sales, reputational risk, increased litigation followed by increase in litigation cost
15.	Corporate governance	Opportunity/ Risk	Ensuring robust corporate governance is fundamental to fulfilling the objectives of the organization, as any risks have the potential to erode the trust of the stakeholders, dent the reputation of the organization, and may disrupt its business	The Board effectiveness is enhanced by selecting the right mix of individuals to serve on the Board, with the requisite qualifications, expertise and experience, who can collectively serve the best interests of all stakeholders, maintain board and management accountability and drive corporate ethics, values and sustainability	Positive Improved stakeholder trust and potential revenue growth Negative Decreased trust leading to loss of investors or customers
16.	Investment in R&D	Opportunity	To attain operational excellence and generate value for our stakeholders, we aim to bolster our research capabilities by utilizing state-of-the-art technologies and establishing world-class laboratories	The Company has wide talent pool for every division it operated in. By adopting new technological innovations, Advanced Enzymes can gain a competitive edge and explore new opportunities for sustainable growth in the long run	Positive Potential for new product development and revenue growth
		Risk	The Company operates in highly volatile & evolving industry that needs continuous and efficient R&D. Many a times R&D takes more than expected time & resources, leading to the cost escalation. At times, despite quality research the Company may not get the desired output which may lead to the delayed product launch resulting in the lower ROI from R&D		Negative Cost escalation due to elongated R&D timeline and revenue loss due to delayed product launch
17.	Regulatory compliance	Risk	The enzymes and probiotics industry is subject to extensive regulation, and the regulatory framework is continuously evolving in response to the impacts of globalization, the emergence of new markets, the introduction of new technologies, and the increasing expectations of patients, investors, and regulators	Maintaining the highest standards of quality and adhering to applicable regulatory requirements are top priorities for us. Our facilities located nationwide follow Good Manufacturing Practice (GMP) guidelines	Negative Fines, penalties, and potential revenue losses due to non-compliance.

SECTION B: MANAGEMENT AND PROCESS DISCLOSURES

This section is aimed at helping businesses demonstrate the structures, policies and processes put in place towards adopting the NGRBC principles and core elements referred as P1-P9 as given below:

P1 - Businesses should conduct and govern themselves with integrity in a manner that is Ethical, Transparent and Accountable.

P2 - Businesses should provide goods and services in a manner that is sustainable and safe.

P3 - Businesses should respect and promote the well-being of all employees, including those in their value chains.

P4 - Businesses should respect the interests of and be responsive to all its stakeholders.

P5 - Businesses should respect and promote human rights.

P6 - Businesses should respect and make efforts to protect and restore the environment.

P7 - Businesses, when engaging in influencing public and regulatory policy, should do so in a manner that is responsible and transparent.

P8 - Businesses should promote inclusive growth and equitable development.

P9 - Businesses should engage with and provide value to their consumers in a responsible manner.

S. No.	Disclosure questions	P 1	P 2	P 3	P 4	P 5	P 6	P 7#	P 8	P 9
Policy and management processes										
1.	a. Whether the entity's policy/policies cover each principle and its core elements of the NGRBCs. (Yes/No)	Y	Y	Y	Y	Y	Y	N	Y	Y
	b. Has the policy been approved by the Board? (Yes/No)	Y	Y	Y	Y	Y	Y	N	Y	Y
	c. Weblink of the policies, if available	www.advancedenzymes.com/investors/corporategovernance/#codes-and-policies								
2.	Whether the entity has translated the policy into procedures. (Yes/No)	Y	Y	Y	Y	Y	Y	N	Y	Y
3.	Do the enlisted policies extend to your value chain partners? (Yes/No)*	Y	Y	Y	Y	Y	Y	N	Y	Y
4.	Name of the national and international codes/certifications/labels/standards (e.g. Forest Stewardship Council, Fairtrade, Rainforest Alliance, Trustea) standards (e.g. SA 8000, OHSAS, ISO, BIS) adopted by your entity and mapped to each principle	ISO 9001:2015	Food Safety System Certifications (FSSC) 22000, ISO 9001:2015, Halal , Kosher, WHO-GMP , GMP Plus, Written Confirmation, Input for Organic Processing / Production, Export Inspection Agency, Global Organic Textile Standard (GOTS)	ISO 45001:2018	ISO 9001:2015	Halal Certification, Kosher Certification	ISO 14001:2015, ZDHC MRSL level 3.0 conformance certificate	Export Inspection Agency, Written Confirmation	-	WHO-GMP Certification, Food Safety System Certifications (FSSC) 22000
5.	Specific commitments, goals and targets set by the entity with defined timelines, if any	N	N	N	N	N	N	NA	N	N

6. Performance of the entity against the specific commitments, goals and targets alongwith reasons in case the same are not met.	The Company uses eco-friendly methods to create sustainable products, making it a comprehensive offering for both customers and end users. The Company is currently working on establishing emission targets that align with the Science Based Targets initiative, which offers a specific plan for companies to decrease their carbon emissions.
	<ul style="list-style-type: none">The Company has implemented a human rights policy distributed to all its employees. The employees are fully informed about workplace ethics, labor laws, and other relevant policies through various means of communication such as display boards, handbooks, and other forms of communication. The Company takes measures to prevent the use of forced or child labor within the workplace and conduct thorough compliance audit to ensure this policy is upheld.The Company takes measures to abide by the laws and regulations in India and in other countries where it conducts business. Additionally, a Whistle Blower Policy is in place that enables directors and employees to report any concerns without fear of retaliation.The Company strives to strengthen its relationships with stakeholders by actively seeking their perspectives on topics that are important to them. This includes issues related to the environment, society, and the economy that may impact the Company ability to generate value. By gaining these insights, the Company can better understand how the stakeholders perceive value, pinpoint emerging trends, identify potential risks and opportunities, and develop appropriate strategic responses.
Governance, leadership and oversight	
7. Statement by the director responsible for the business responsibility report, highlighting ESG-related challenges, targets and achievements	In our Annual Report and Business Responsibility and Sustainability Report, we have addressed all crucial matters concerning business responsibility and sustainability at Advanced Enzyme Technologies Limited. However, I would like to take this opportunity to articulate our unchanging values and strategic priorities regarding business resilience and sustainability. These times are challenging for everyone in various ways, as humanity grapples with combating climate change, eradicating violent conflict, fostering community development, and conducting ethical, transparent, and responsible business. We must prioritize inclusive growth and sustainable development without sacrificing the unique developmental requirements of different regions and the welfare of the poor and marginalized. We have consistently endeavored to include all stakeholders in our journey of growth and progress. It is imperative that we always conduct our business responsibly and sustainably, with trust and transparency. We also encourage and support our suppliers, vendors, distributors, partners, and other stakeholders to adopt the same principles. On behalf of the board and management, I would like to express our commitment to continue conducting our business ethically and responsibly, with the interests of all stakeholders guiding our conduct
8. Details of the highest authority responsible for implementing and overseeing the Business Responsibility policy(ies)	Mr. Vasant Rath Chairman & Non-Executive Director DIN: 01233447
9. Does the entity have a specified Committee of the Board/Director responsible for decision-making on sustainability related issues? (Yes/No). If yes, provide details	Yes. Mr. Mukund Kabra Whole-time Director DIN: 00148294

10. Details of Review of NGRBCs by the Company:																		
Subject for Review	Indicate whether the review was undertaken by Director/Committee of the Board /Any other Committee									Frequency (Annually/Half yearly/Quarterly/ Any other – please specify)								
	P 1	P 2	P 3	P 4	P 5	P 6	P 7#	P 8	P 9	P 1	P 2	P 3	P 4	P 5	P 6	P 7#	P 8	P 9
Performance against the above policies and follow-up action	Board Members or senior leadership team review the effectiveness of policies and procedures and recommend necessary changes.									Periodic or need-based								
Compliance with statutory requirements of relevance to the principles, and, rectification of any non-compliances	Senior management reviews and issues a Statutory Compliance Certificate to the Board of Directors.									Periodic or need-based								
11. Has the entity carried out an independent assessment/ evaluation of the working of its policies by an external agency? (Yes/No). If yes, provide the name of the agency																		
										P 1	P 2	P 3	P 4	P 5	P 6	P 7#	P 8	P 9
										The independent assessment has not been carried out by the Company. However, an internal evaluation is carried out on a periodical basis.								
12. If the answer to question (1) above is 'No' i.e. not all principles are covered by a policy, reasons to be stated:																		
Questions										P 1	P 2	P 3	P 4	P 5	P 6	P 7#	P 8	P 9
The entity does not consider the Principles material to its business (Yes/No)																		
The entity is not at a stage where it is in a position to formulate and implement the policies on specified principles (Yes/No)																		
The entity does not have the financial or/human and technical resources available for the task (Yes/No)										Not Applicable								
It is planned to be done in the next financial year (Yes/No)																		
Any other reason (please specify)																		
*Note: Presently, AETL is not engaged in influencing public and regulatory policy.																		
* The value chain partners are encouraged to adhere to these policies, as applicable or expected from responsible businesses.																		

SECTION C: PRINCIPLE-WISE PERFORMANCE DISCLOSURE

This section is aimed at helping entities demonstrate their performance in integrating the Principles and Core Elements with key processes and decisions. The information sought is categorised as ‘Essential’ and ‘Leadership’. While the essential indicators are expected to be disclosed by every entity mandated to file this report, the leadership indicators may be voluntarily disclosed by entities which aspire to progress to a higher level in their quest to be socially, environmentally and ethically responsible.

Principle 1: Businesses should conduct and govern themselves with integrity and in a manner that is Ethical, Transparent and Accountable

Essential Indicators

1. Percentage coverage by training and awareness programmes on any of the Principles during the financial year

Segment	Total number of training and awareness programmes held	Topics/principles covered under the training and it's impact	% age of persons in respective category covered by the awareness programmes
Board of Directors	8	The Company acquaints its director(s) operations, financials, risk management framework, business, annual budget and other important information update, primarily during the Board and Committee meetings / presentation by Marketing & Business team on the Company Business Model and Subsidiaries plant visit	100%
Key Managerial Personnel	8	Programs for familiarisation as mentioned above including Prevention of Sexual Harassment awareness training	100%
Employees other than BoD & KMPs	42	Leadership Workshop, Prevention of Sexual Harassment, Data Integrity, Labour law-new labour codes, fire safety training, pharma regulations codes, Awareness regarding FSSC 22000 Ver. 6.0	65.43%
Workers	48	Labour law-new labour codes, fire safety trainings, pharma regulations codes, Awareness regarding FSSC 22000 Ver. 6.0, Awareness of ISO standards, current Good Manufacturing Practices (CGMP), Good Distribution Practices (GDP) HALAL etc.	76.09%

2. Details of fines / penalties / punishment / award / compounding fees / settlement amount paid in proceedings (by the entity or by directors/KMPs) with regulators / law enforcement agencies/ judicial institutions, in the financial year, in the following format:

Monetary					
	NGRBC principle	Name of the regulatory/enforcement agencies/ judicial institutions	Amount (in ₹)	Brief of the case	Has an appeal been preferred? (Yes/No)
Penalty/fine	1	Income Tax Department	11,81,716	The Authority has considered the differential amount of R&D expenses claim u/s 35(2AB)as under reported income and levied penalty	Yes
		Food Safety and Standards Authority of India	32,450	Delayed filing of Annual return by Pithampur plant	No
Settlement	-	-	-	-	-
Compounding fee	1	Nashik Metropolitan Region Development Authority	10,54,500	Voluntary scrutiny for the regularization pertaining to the existing construction on the purchased Land situated at Mouza - Lakhalgaon	No

Non-Monetary				
	NGRBC principle	Name of the regulatory/enforcement agencies/judicial institutions	Brief of the case	Has an appeal been preferred? (Yes/No)
Imprisonment				
Punishment				

3. Of the instances disclosed in Question 2 above, details of the Appeal/Revision preferred in cases where monetary or non-monetary action has been appealed.

Case details	Name of the regulatory/enforcement agencies/ judicial institutions
The Authority has considered the differential amount of R&D expenses claim u/s 35 (2AB) as under reported income and levied penalty	Commissioner of Income Tax, Appeals

4. Does the entity have an anti-corruption or anti-bribery policy? If yes, provide details in brief and if available, provide a web-link to the policy:

Yes, AETL has a robust anti-corruption and anti-bribery policy outlined in its Code of Conduct and Ethics Policy. The policy applies to the Board of Directors, senior management personnel, and all employees. It strictly prohibits the acceptance or offering of gifts, donations, remuneration, or any other benefits to influence business favours. Bribery, whether direct or indirect, is strongly discouraged, aligning with the Prevention of Corruption Act, 1988, and other relevant legislation globally.

www.advancedenzymes.com/investors/corporate-governance#codes-and-policies

5. Number of Directors / KMPs / employees / workers against whom disciplinary action was taken by any law enforcement agency for the charges of bribery / corruption:

	FY 2024-25	FY 2023-24
Directors	NIL	NIL
KMPs		
Employees		
Workers		

6. Details of complaints with regard to conflict of interest:

	FY 2024-25		FY 2023-24	
	Number	Remarks	Number	Remarks
Number of complaints received in relation to issues of conflict of interest of the Directors	NIL		NIL	
Number of complaints received in relation to issues of conflict of interest of the KMPs				

7. Provide details of any corrective action taken or underway on issues related to fines/penalties/action taken by regulators/law enforcement agencies/judicial institutions, on cases of corruption and conflicts of interest.

Not Applicable

8. Number of days of accounts payables ((Accounts payable *365) / Cost of goods/services procured) in the following format:

	FY 2024-25	FY 2023-24
Number of days of accounts payables	36.86	37.71

9. Open-ness of business

Provide details of concentration of purchases and sales with trading houses, dealers, and related parties along-with loans and advances & investments, with related parties, in the following format:

Parameter	Metrics	FY 2024-25	FY 2023-24
Concentration of Purchases	a. Purchases from trading houses as % of total purchases	-	-
	b. Number of trading houses where purchases are made from	-	-
	c. Purchases from top 10 trading houses as % of total purchases from trading houses	-	-
Concentration of Sales	a. Sales to dealers/distributors as % of total sales	23.57%	23.39%
	b. Number of dealers/distributors to whom sales are made	88	84
	c. Sales to top 10 dealers/distributors as % of total sales to dealers/ Distributors	71.04%	71.33%
Shares of RPT in	a. Purchases (Purchases with related parties/Total purchases)	33.30%	34.12%
	b. Sales (Sales to related parties/Total sales)	27.67%	24.87%
	c. Loans & advances (Loans & advances given to related parties/Total loans & advances)	-	-
	d. Investments (Investments in related parties/Total investments made)	87.36%	80.15%

Leadership Indicators

1. Awareness programmes conducted for value chain partners on any of the Principles during the financial year:

Total number of awareness campaign held	Topics/Principles covered under the training	% age of value chain programme partners covered (by value of business done with such partners) under the awareness programmes
No		

2. Does the entity have processes in place to avoid/ manage conflict of interests involving members of the Board? (Yes/No). If yes, provide details of the same:

Yes, AETL implements stringent measures to prevent and manage conflict of interest among its Board members, senior management personnel, and employees. The Code of Conduct and Ethics policy prohibits Board members from engaging in activities conflicting with the Company’s interests. Independent Directors are granted freedom in their professional endeavours, while ensuring transparency. Specific scenarios leading to conflicts, such as interference with duties or investments compromising responsibility, are outlined. Transactions involving related parties are disclosed to the Board as per legal requirements, with ordinary business dealings exempted.

Principle 2: Businesses should provide goods and services in a manner that is sustainable and safe

Essential Indicators

1. Percentage of R&D and capital expenditure (capex) investments in specific technologies to improve the environmental and social impacts of product and processes to total R&D and capex investments made by the entity, respectively:

	FY 2024-25	FY 2023-24	Details of improvements in environmental and social impacts
R&D	100%	100%	• Developed next-generation engineered proteins • Developed Enzymes and probiotics. Enzymes can often replace chemicals or processes that present safety or environmental issues.
Capex	100%	100%	

2.

a. Does the entity have procedures in place for sustainable sourcing (Yes/No)

Yes, the Company sources its raw materials locally, thereby reducing its carbon footprint. The Company has established a supplier sustainability criterion and implemented a process for vendor selection. This encompasses adhering to the Safety, Health, and Environment Policy, complying with legal requirements, and obtaining ISO certification, among others. Additionally, the Company makes a sincere effort to procure raw materials from suppliers who comply with regulatory requirements.

b. If yes, what percentage of inputs were sourced sustainably?

Approximately 90% of sourcing is procured sustainably.

3. Describe the processes in place to safely reclaim your products for reusing, recycling and disposing at the end of life, for (a) Plastics (including packaging) (b) E-waste (c) Hazardous waste and (d) other waste.

- Plastics, E-waste, Hazardous waste, and other waste are disposed of through authorised scrap dealers registered with the State Pollution Control Board
- Hazardous waste generated in the process is reprocessed in-house at one of the plants and used as one of the raw materials in the manufacturing of other application products
- Liquid waste from the R&D centre is treated according to the State Pollution Control Board protocol, and the treated waste is used for watering plants

4. Whether Extended Producer Responsibility (EPR) is applicable to the entity’s activities (Yes/No). If yes, whether the waste collection plan is in line with the Extended Producer Responsibility (EPR) plan submitted to Pollution Control Boards? If not, provide steps taken to address the same.

No, given the nature of business, Extended Producer Responsibility (EPR) is not applicable to the Company.

Leadership Indicators

1. Has the entity conducted Life Cycle Perspective/Assessments (LCA) for any of its products (for manufacturing industry) or for its services (for service industry)? If yes, provide details in the following format?

NIC code	Name of Product/ Service	% of total turnover contributed	Boundary for which the Life Cycle Perspective/ Assessment was conducted	Whether conducted by an independent external agency (Yes/No)	Results communicated in the public domain (Yes/No) If yes, provide the weblink
No					

2. If there are any significant social or environmental concerns and/or risks arising from production or disposal of your products/ services, as identified in the Life Cycle Perspective/Assessments (LCA) or through any other means, briefly describe the same along-with action taken to mitigate the same.

Name of the Product / Service	Description of the risk / concern	Action / taken
NA		

3. Percentage of recycled or reused input material to total material (by value) used in production (for manufacturing industry) or providing services (for service industry).

Indicate input material	Recycled or reused input material to total material (%)	
	FY 2024-25	FY 2023-24
Raw Material*	13.79	22.10

Note: Reused input material was only considered for Nashik plant in FY 2023-24

* As multiple raw materials are consumed during the process, the name of each raw material is not mentioned

4. Of the products and packaging reclaimed at end of life of products, amount (in metric tonnes) reused, recycled, and safely disposed, as per the following format:

	FY 2024-25			FY 2023-24		
	Reused	Recycled	Safely disposed	Reused	Recycled	Safely disposed
Plastics (including packaging)	NIL	NIL	NIL	NIL	NIL	NIL
E-waste	NIL	NIL	NIL	NIL	NIL	NIL
Hazardous waste	NIL	NIL	NIL	NIL	NIL	NIL
Other waste	NIL	NIL	NIL	NIL	NIL	NIL

5. Reclaimed products and their packaging materials (as percentage of products sold) for each product category.

Indicate product category	Reclaimed products and their packaging materials as % of total products sold in the respective category
NIL	

Principle 3: Businesses should respect and promote the well-being of all employees, including those in their value chains

Essential Indicators

1. a. Details of measures for the well-being of employees:

Category	% of employees covered by										
	Total (A)	Health insurance		Accident insurance		Maternity benefits		Paternity benefits		Day care facilities	
		Number (B)	% (B/A)	Number (C)	% (C/A)	Number (D)	% (D/A)	Number (E)	% (E/A)	Number (F)	% (F/A)
Permanent Employees											
Male	215	144	66.98%	215	100%	NA	NA	71	33.02%	NA	NA
Female	75	13	17.33%	75	100%	75	100%	NA	NA	NA	NA
Total	290	157	54.14%	290	100%	75	100%	71	33.02%	NA	NA
Other than Permanent Employees											
Male	83	63	75.90%	83	100%	NA	NA	20	24.10%	NA	NA
Female	23	10	43.48%	23	100%	23	100%	NA	NA	NA	NA
Total	106	73	68.87%	106	100%	23	100%	20	24.10%	NA	NA

- b. Details of measures for the well-being of Workers:

Category	% of workers covered by										
	Total (A)	Health insurance		Accident insurance		Maternity benefits		Paternity benefits		Day care facilities	
		Number (B)	% (B/A)	Number (C)	% (C/A)	Number (D)	% (D/A)	Number (E)	% (E/A)	Number (F)	% (F/A)
Permanent workers											
Male	48	48	100%	48	100%	NA	NA	NA	NA	NA	NA
Female	0	0	0	0	0	NA	NA	NA	NA	NA	NA
Total	48	48	100%	48	100%	NA	NA	NA	NA	NA	NA
Other than Permanent workers											
Male	239	239	100%	239	100%	NA	NA	NA	NA	NA	NA
Female	10	10	100%	10	100%	10	100%	NA	NA	NA	NA
Total	249	249	100%	249	100%	10	100%	NA	NA	NA	NA

- c. Spending on measures towards well-being of employees and workers (including permanent and other than permanent) in the following format:

	FY 2024-25	FY 2023-24
Cost incurred on well-being measures as a % of total revenue of the company	0.12%	13.77%

2. Details of retirement benefits, for current financial year and previous financial year:

Benefits	FY 2024-25			FY 2023-24		
	No. of employees covered as a % of total employees	No. of workers covered as a % of total workers	Deducted and deposited with authority (Y/N/NA)	No. of employees covered as a % of total employees	No. of workers covered as a % of total workers	Deducted and deposited with authority (Y/N/NA)
PF	91.67%	92.93%	Y	100%	100%	Y
Gratuity	91.41%	16.16%	Y	100%	100%	Y
ESI	17.68%	80.81%	Y	100%	100%	Y
Others - Super Annuation	15.66%	0%	Y	20.05%	0%	Y

3. Accessibility of workplaces:

Are the premises / offices of the entity accessible to differently abled employees and workers, as per the requirements of the Rights of Persons with Disabilities Act, 2016? If not, whether any steps are being taken by the entity in this regard.

Yes, Depending on the accessibility requirement of an employee under different departments of our premises / offices, the arrangements are done accordingly. In compliance with the requirements of the Rights of Persons with Disabilities Act, 2016, the plants and offices are accessible by differently abled persons.

4. Does the entity have an equal opportunity policy as per the Rights of Persons with Disabilities Act, 2016? If so, provide a web-link to the policy:

Yes. AETL is committed to maintaining an Equal Opportunity Policy aimed at nurturing an inclusive workplace environment. The Company provides equal employment opportunities and ensures fair treatment for all employees, regardless of gender, age, physical ability, beliefs, religion, sexual orientation, ethnicity, caste, or any other discriminatory factor. The Company values the diversity within its workforce and actively supports the development and growth of talent within the organisation. Moreover, AETL believes that optimal performance is achieved when there is an environment of mutual trust and collaboration among all employees.

Weblink: www.advancedenzymes.com/investors/corporate-governance/#codes-and-policies

5. Return to work and retention rates of permanent employees and workers that took parental leave:

Gender	Permanent Employees		Permanent Workers	
	Return to work rate	Retention rate	Return to work rate	Retention rate
Male	100%	100%	NIL	NIL
Female	75%	75%	NIL	NIL
Total	86%	86%	NIL	NIL

6. Is there a mechanism available to receive and redress grievances for the following categories of employees and worker? If yes, give details of the mechanism in brief:

AETL prioritises fostering a work culture based on mutual trust and respect. Recognising that grievances may arise regarding supervisors, co-workers, or working conditions, the Company has implemented a well-defined, structured, and hierarchical procedure for addressing such concerns. Employees are encouraged to first raise their grievances with their reporting managers and HR representatives. If the grievances remain unresolved, they have the option to escalate the matter to AETL’s senior management team. Furthermore, the Company regularly reviews and adjusts this process as needed based on evolving circumstances and the specific needs of different employee categories.

	Yes/No (If yes, then give details of the mechanism in brief)
Permanent Workers	Yes (as mentioned above)
Other than Permanent Workers	
Permanent Employees	
Other than Permanent Employees	

7. Membership of Employees and Workers in association(s) or Unions recognised by the listed entity:

Category	FY 2024-25			FY 2023-24		
	Total Employees/Workers in the respective category (A)	No. of Employees/Workers in the respective category who are part of association(s) or Union (B)	% (B/A)	Total employees/workers in the respective category (C)	No. of employees/workers in the respective category who are part of association(s) or Union (D)	% (D/C)
Total Permanent Employees	290	NIL	NIL	273	NIL	NIL
- Male	215	NIL	NIL	207	NIL	NIL
- Female	75	NIL	NIL	66	NIL	NIL
Total Permanent Workers	48	48	100%	50	50	100%
- Male	48	48	100%	50	50	100%
- Female	NA	NA	NA	NA	NA	NA

8. Details of training given to Employees and Workers:

Category	FY 2024-25					FY 2023-24				
	Total (A)	On health and safety measures		On skill upgradation		Total (D)	On Health and safety measures		On skill upgradation	
		No. (B)	% (B/A)	No. (C)	% (C/A)		No. (E)	% (E/D)	No. (F)	% (F/D)
	Employees									
Male	298	188	63.09%	193	64.77%	278	195	70.14%	180	64.75%
Female	98	58	59.18%	66	67.35%	85	62	72.94%	68	80.00%
Total	396	246	62.12%	259	65.40%	363	257	70.80%	248	68.32%
	Workers									
Male	287	220	76.66%	152	52.96%	265	210	79.25%	158	59.62%
Female	10	6	60.00%	6	60.00%	07	05	71.43%	05	71.43%
Total	297	226	76.09%	158	53.20%	272	215	79.04%	163	59.93%

9. Details of performance and career development reviews of employees and workers:

Category	FY 2024-25			FY 2023-24		
	Total (A)	No. (B)	% (B/A)	Total (C)	No. (D)	% (D/C)
Employees						
Male	298	298	100%	278	278	100%
Female	98	98	100%	85	85	100%
Total	396	396	100%	363	363	100%
Workers						
Male	287	287	100%	265	265	100%
Female	10	10	100%	07	07	100%
Total	297	297	100%	272	272	100%

10. Health and safety management system:

a. Whether an occupational health and safety management system has been implemented by the entity? (Yes/No). If yes, the coverage such system?

Yes. AETL has established a robust occupational health & safety management system certified under ISO 45001, meeting the requirements for an Occupational Health & Safety (OH&S) management system across all its units. The system covers all employees, including regular staff and contractors, encompassing 100% of the organisation. Additionally, the Company adheres to legal regulations, such as the Factories Act, the Indian Boilers Act, the Environment Protection Act, and other relevant government mandates, ensuring comprehensive compliance with health & safety standards.

b. What are the processes used to identify work-related hazards and assess risks on a routine and non-routine basis by the entity?

AETL is committed to fostering a safe and healthy work environment across its premises, prioritising the prevention of safety incidents and work-related illnesses. The Company has established an organised and systematic procedure for identifying potential hazards, evaluating associated risks, and implementing measures to mitigate and control them effectively. Moreover, the Company’s approach focusses on taking appropriate actions to eliminate or minimise risks, while creating awareness among all staff and workers to actively participate in maintaining workplace safety.

c. Whether you have processes for workers to report the work related hazards and to remove themselves from such risks. (Y/N)

Yes, AETL actively promotes a culture of reporting near-miss incidents among its employees to identify potential risks and prevent future incidents. Additionally, each site has a dedicated procedure for reporting work-related hazards, injuries, unsafe conditions, and acts, ensuring that any concerns are promptly addressed and appropriate measures are implemented to maintain a safe working environment.

d. Do the employees/worker of the entity have access to non-occupational medical and healthcare services? (Yes/No)

Yes, AETL ensures the well-being of its employees by conducting periodic medical check-ups and providing personal accident insurance coverage.

11. Details of safety related incidents, in the following format:

Safety Incident/Number	Category*	FY 2024-25	FY 2023-24
Lost Time Injury Frequency Rate (LTIFR) (per one million-person hours worked)	Employees	NIL	NIL
	Workers		
Total recordable work-related injuries	Employees		
	Workers		
No. of fatalities	Employees		
	Workers		
High-consequence work-related injury or ill-health (excluding fatalities)	Employees		
	Workers		

* including the contract workforce

12. Describe the measures taken by the entity to ensure a safe and healthy work place:

AETL has established an EHS Committee at the plant level, comprising both management and worker representatives, to oversee environmental, health, and safety (EHS) initiatives. Regular meetings of the EHS Committee are held to address various issues, including identifying training needs, reviewing Hazard Identification and Risk Assessment (HIRA), and proposing enhancements. Following these discussions, necessary corrective and preventive measures are implemented to maintain a secure and healthy work environment. Additionally, comprehensive fire safety arrangements are in place, ensuring a safe and healthy workplace for all employees & workers.

13. Number of complaints on the following made by employees and workers:

	FY 2024-25			FY 2023-24		
	Filed during the year	Pending resolution at the end of the year	Remarks	Filed during the year	Pending resolution at the end of the year	Remarks
Working conditions	NIL			NIL		
Health & safety						

14. Assessments for the year:

	% of your plants and offices that were assessed (by entity or statutory authorities or third parties)
Health and safety practices	100% of the plants were assessed as follows: - Nashik: Entire plant assessment as per ISO 45001:2018, assessment by Jt. Director Health and Safety
Working conditions	- Pithampur: Entire plant has been assessed by IR class as per FSSAI guidelines - As per FSSC 22000 certification

15. Provide details of any corrective action taken or underway to address safety-related incidents (if any) and on significant risks/ concerns arising from assessments of health & safety practices and working conditions.

Not Applicable

Leadership Indicators

1. Does the entity extend any life insurance or any compensatory package in the event of the death of (A) Employees (Y/N) (B) Workers (Y/N):

(A) Employees – Yes, AETL provides either in form of mediclaim or accidental death insurance policy and other benefits.

(B) Workers – Yes

2. Provide the measures undertaken by the entity to ensure that statutory dues have been deducted and deposited by the value chain partners:

AETL commits to complying with current regulations by withholding and depositing all applicable statutory dues related to its transactions. This adherence undergoes rigorous examination as part of internal statutory audits.

3. Provide the number of employees/workers having suffered high consequence work-related injury/ill-health/fatalities (as reported in Q11 of Essential Indicators above), who have been are rehabilitated and placed in suitable employment or whose family members have been placed in suitable employment:

	Total number of affected Employees/ Workers		Number of Employees/Workers that are rehabilitated and placed in suitable employment or whose family members have been placed in suitable employment	
	FY 2024-25	FY 2023-24	FY 2024-25	FY 2023-24
Employees	NIL	NIL	NIL	NIL
Workers				

4. Does the entity provide transition assistance programmes to facilitate continued employability and the management of career endings resulting from retirement or termination of employment? (Yes/No)

No

5. Details on assessment of value chain partners:

	% of value chain partners (by value of business done with such partners) that were assessed
Health and safety practices	NIL
Working conditions	

6. Provide details of any corrective actions taken or underway to address significant risks / concerns arising from assessments of health and safety practices and working conditions of value chain partners:

NIL

Principle 4: Businesses should respect the interests of and be responsive to all its stakeholders

Essential Indicators

1. Describe the processes for identifying key stakeholder groups of the entity:

AETL considers anyone or any entity directly or indirectly influencing its operations or business chain as a crucial stakeholder. This includes customers, shareholders, suppliers, communities, government and regulatory bodies, and employees. The Company conducts periodic mapping exercises to identify and engage with these stakeholders effectively.

2. List stakeholder groups identified as key for your entity and the frequency of engagement with each stakeholder group:

Stakeholder group	Whether identified as vulnerable & marginalised group (Yes/ No)	Channels of communication (Email, SMS, Newspaper, Pamphlets, Advertisement, Community Meetings, Notice board, Website), Other	Frequency of engagement (Annually/ Half yearly/ Quarterly/ others – please specify)	Purpose and scope of engagement, including key topics and concerns raised during such engagement
Employees	No	One-on-one interactions, e-mail, senior management meet and internal communication platforms	Quarterly, annually and need-based	Career development, salary and other perquisites, work ethics, policy communication and team building
Shareholders	No	Press releases, e-mail, media releases, annual general meeting, stock exchange(s) intimations and website	Quarterly, half-yearly, annual and need-based	Financial performance, key risks and mitigation, operational highlights, share price appreciation and dividend distribution
Customers	No	E-mail, SMS, pamphlets, advertisement, website and meetings	Ongoing & need-based	Superior customer service throughout the life cycle
Suppliers	No	E-mail, website and meetings	Ongoing and need-based	Timely delivery, payment terms & conditions and the quality of goods procured
Communities	Yes	E-mail, meetings, telecommunications, and one- on-one meetings	Ongoing	CSR, community complaints, awareness programme and community development
Media	No	Press meets, management interviews, conference calls, newspaper, advertisement, and website	Quarterly or need-based	Business and industry updates and quarterly results
Governments and Regulatory bodies	No	Meetings and visits	Need-based	Compliance, governance practices and regulatory approvals

Leadership Indicators

1. Provide the processes for consultation between stakeholders and the Board on economic, environmental, and social topics or if consultation is delegated, how is feedback from such consultations provided to the Board.

AETL employs multiple communication channels to actively engage with its diverse stakeholders. This indomitable dedication to ongoing, proactive dialogue with key stakeholders empowers the Company to consistently enhance its strategies and performance. Priority is given to crafting policies and programmes that uphold principles of equity and transparency, fostering a well-rounded approach that considers the interests of all stakeholders.

2. Whether stakeholder consultation is used to support identifying and managing environmental and social topics (Yes/No). If so, provide details of instances as to how the inputs received from stakeholders on these topics were incorporated into policies and activities of the entity.

Yes, AETL actively collaborates with a diverse range of stakeholders to gain profound insights into their expectations and benchmark its practices against industry standards. Continuously and actively striving to understand the impact of its sustainability strategy and future priorities, the Company engages in regular consultations with both internal and external stakeholders. These consultations play a pivotal role in shaping the Company’s CSR agenda and sustainability initiatives, ensuring alignment with stakeholder needs and preferences.

3. Provide details of instances of engagement with, and actions taken to, address the concerns of vulnerable/marginalised stakeholder groups.

AETL is dedicated to enhancing the well-being of marginalised and disadvantaged groups in society, emphasising sustainable livelihoods and nurturing a robust human capital ethos. Through its Corporate Social Responsibility (CSR) policy, the Company directs its efforts across various sectors, including education, skills development, healthcare, sanitation, environmental sustainability, women’s empowerment, and rural development. By concentrating on specific areas requiring improvement, AETL strives to elevate living standards and contribute to overall societal advancement through the following initiatives:

- Collaborating with trusts and NGOs to allocate resources for CSR activities
- Initiating specific initiatives, such as vocational training for differently-abled adults, addressing malnutrition and educational deficiencies among tribal children, treating thalassemia patients, and supporting educational endeavours
- Prioritisng assistance to children, the elderly, women, differently-abled individuals, and impoverished communities

Principle 5: Businesses should respect and promote Human Rights

Essential Indicators

1. Employees and workers who have been provided training on human rights issues and policy(ies) of the entity in the following format:

Category	FY 2024-25			FY 2023-24		
	Total (A)	No. of Employees/ Workers covered (B)	% (B/A)	Total (C)	No. of Employees/ Workers covered (D)	% (D/C)
Employees						
Permanent	290	290	100%	273	273	100%
Other than permanent	106	106	100%	90	90	100%
Total Employees	396	396	100%	363	363	100%
Workers						
Permanent	48	48	100%	50	50	100%
Other than permanent	249	249	100%	222	222	100%
Total Workers	297	297	100%	272	272	100%

In FY 2025, 86 trainees and in FY 24, 84 trainees are categorised above under ‘other than permanent’

2. Details of minimum wages paid to employees and workers in the following format:

Category	FY 2024-25					FY 2023-24				
	Total (A)	Equal to Minimum wage		More than Minimum wage		Total (D)	Equal to Minimum wage		More than Minimum wage	
		No. (B)	% (B/A)	No. (C)	% (C/A)		No. (E)	% (E/D)	No. (F)	% (F/D)
Employees										
Permanent										
Male	215	17	7.91%	198	92.09%	207	15	07.25%	192	92.75%
Female	75	12	16.00%	63	84.00%	66	14	21.21%	52	78.79%
Other than permanent										
Male	83	10	12.05%	73	87.95%	71	08	11.27%	63	88.73%
Female	23	12	52.17%	11	47.83%	19	14	73.68%	05	26.32%
Workers										
Permanent										
Male	48	00	00	48	100%	50	50	100%	-	-
Female	00	00	00	00	00	-	-	-	-	-
Other than permanent										
Male	239	239	100%	00	00	215	215	100%	-	-
Female	10	10	100%	00	00	07	07	100%	-	-

3. Details of remuneration/salary/wages, in the following format:

- a. Median remuneration/wages: (in ₹ million)

	Male		Female	
	Number	Median remuneration/salary/ wages of the respective category	Number	Median remuneration/salary/ wages of the respective category
Board of Directors (BoD)	5	0.89	3	0.40
Key Managerial Personnel	3	14.34	0	0
Employees other than BoD and KMP	295	0.53	98	0.56
Workers	48	0.93	0	0
Contractual Workers	239	0.23	10	0.23

Notes:

1. The Commission payable to Board members as of March 31, 2025, has been considered to determine the median remuneration of BoD. Sitting fees paid to Independent Directors have not been considered.
2. For the purpose of the above disclosure, the remuneration (excluding Commission) of Mr. Mukund Kabra (Whole-Time Director & KMP) has been considered to determine the median remuneration for KMPs.
3. The median remuneration calculated for KMPs excludes the Commission/Annual Incentives, Leave encashment, gratuity and ESOP (as may be/wherever applicable).

b. Gross wages paid to females as % of total wages paid by the entity, in the following format:

	FY 2024-25	FY 2023-24
Gross wages paid to females as % of total wages	16.77%	17.78%

4. Do you have a focal point (individual/committee) responsible for addressing human rights impacts or issues caused or contributed to by the business? (Yes/No)

Yes, the Human Resources Department, Board and Senior Management hold responsibility for addressing human rights issues at AETL. The Company's human rights policy extends its applicability to all relevant stakeholders.

5. Describe the internal mechanisms in place to redress grievances related to human rights issues:

The core principle at the Company is that any stakeholder should be able to raise their grievances and should be able to report any breach or perceived violation, with complete confidence and trust, confidentially and anonymously and without fear of retaliation. They should be able to report any breach of policies and procedures in the Company. The grievance can be reported in the following manner, a) General Human Right Grievances – To be addressed to Human Resource Department, Immediate supervisor, team lead of the department, with adequate arrangement for escalation, b) Any Sexual Harassment related incidents should be reported to Prevention of Sexual Harassment Committee (i.e. Internal Complaints Committee), Head - Human Resources / the Board.

6. Number of complaints on the following made by employees and workers:

	FY 2024-25			FY 2023-24		
	Filed during the year	Pending resolution at the end of the year	Remarks	Filed during the year	Pending resolution at the end of the year	Remarks
Sexual harassment	NIL			NIL		
Discrimination at workplace						
Child labour						
Forced Labour/Involuntary Labour						
Wages						
Other human rights-related issues						

7. Complaints filed under the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013, in the following format:

	FY 2024-25	FY 2023-24
Total complaints reported under Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 (POSH)	NIL	NIL
Complaints on POSH as a % of female employees/workers		
Complaints on POSH upheld		

8. Mechanisms to prevent adverse consequences to the complainant in discrimination and harassment cases:

AETL is committed to maintaining a safe and secure workplace, free from violence, harassment, intimidation, or any other unsafe or disruptive conditions stemming from internal or external threats. Responsibility for preventing negative repercussions for those reporting discrimination or harassment is shared by the Head of Human Resources, departmental team leads/managers, Management and the Board, supported by appropriate escalation procedures. This dedication extends to interactions with third-parties during business operations. Furthermore, employees are encouraged to express their opinions openly.

9. Do human rights requirements form part of your business agreements and contracts? (Yes/No)

Yes, the human rights requirements is covered in detail in AETL Code of Conduct. The 'AETL Code of Conduct and Ethics' is available at: www.advancedenzymes.com/investors/corporate-governance/#codes-and-policies

10. Assessments for the year:

	% of your plants and offices that were assessed (by the entity or statutory authorities or third parties)
Child labour	100% (Assessed during various audits)
Forced/Involuntary Labour	
Sexual Harassment	
Discrimination at workplace	
Wages	
Others – please specify	

11. Provide details of any corrective actions taken or underway to address significant risks/concerns arising from the assessments at Question 10 above.

Not Applicable

Leadership Indicators

1. Details of a business process being modified / introduced as a result of addressing human rights grievances / complaints.

Despite no grievances or complaints regarding human rights issues, AETL remains proactive in implementing measures to uphold and protect the rights of all employees and workers. The Company's human rights policy is publicly accessible. It encompasses several essential principles, including the prohibition of child labour and forced labour, the promotion of a harassment-free workplace, ensuring non-discrimination through equal opportunity practices, fostering diversity and freedom of association, providing compensation above legal requirements, and adhering to standard working hours as mandated by relevant laws.

2. Details of the scope and coverage of any human rights due-diligence conducted:

Not Applicable

3. Is the premise/office of the entity accessible to differently abled visitors, as per the requirements of the Rights of Persons with Disabilities Act, 2016?

Yes, AETL ensures that the accessibility needs of visitors are accommodated at its offices or premises. In accordance with the Rights of Persons with Disabilities Act, 2016, the Company's plants and offices are designed to be accessible to individuals with different abilities.

4. Details on assessment of value chain partners:

	% of value chain partners (by value of business done with such partners) that were assessed
Sexual Harassment	Nil, the Company holds its value chain partners to the same high standards of corporate values, ethical principles, and human rights that it adheres to in all of its business operations. Although no specific evaluation regarding value chain partners has been conducted, this is an ongoing commitment.
Discrimination at workplace	
Child labour	
Forced Labour/Involuntary Labour	
Wages	
Others – Please specify	

5. Provide details of any corrective actions taken or underway to address significant risks / concerns arising from the assessments at Question 4 above.

Not Applicable

Principle 6: Businesses should respect and make efforts to protect and restore the environment

Essential Indicators

1. Details of total energy consumption (in joules or multiples) and energy intensity in the following format:

Parameter	FY 2024-25	FY 2023-24
From renewable sources (in GJ)		
Total electricity consumption (A)	1,163	445
Total fuel consumption (B)	-	-
Energy consumption through other sources (C)	-	-
Total energy consumed from renewable sources (A+B+C)	1,163	445
From non-renewable sources (in GJ)		
Total electricity consumption (D)	35,637	40,475
Total fuel consumption (E)	1,46,437	1,73,985
Coal	1,28,970	1,39,650
Furnace oil & LDO	15,960	32,773
Diesel	1,507	1,561
Energy consumption through other sources (F)	-	-
Total energy consumed from non-renewable sources (D+E+F)	1,82,074	2,14,460
Total energy consumed (A+B+C+D+E+F)	1,83,238	2,14,904
Energy intensity per rupee of turnover (Total energy consumption/Revenue from operations)	5.21 * 10 ⁻⁵ GJ/₹	5.88 * 10 ⁻⁵ GJ/₹
Energy intensity per rupee of turnover adjusted for Purchasing Power Parity (PPP)* (Total energy consumed/Revenue from operations adjusted for PPP)	1.08 * 10 ⁻³ GJ/\$	1.32 * 10 ⁻³ GJ/\$
Energy intensity in terms of physical output	4.02 * 10 ⁻² GJ/kg	4.89 * 10 ⁻² GJ/kg
Energy intensity (optional) – the relevant metric may be selected by the entity	-	-

*PPP: INR Revenue X PPP Factor (US\$/INR) PPP Factor = 20.66; World Economic Outlook (April 2025) - Implied PPP conversion rate (imf.org). IMF PPP conversion rate (22.4), available for March 2024, was used for total income PPP adjusted value for FY 2023-24. Intensity calculation for FY 2023-24 has been changed as per the applicable SEBI circular.

Note: Indicate if any independent assessment/evaluation/assurance has been carried out by an external agency? (Y/N)
If yes, the name of the external agency.:

Independent assessment was not carried out by any external agency.

2. Does the entity have any sites/facilities identified as designated consumers (DCs) under the Performance, Achieve and Trade (PAT) Scheme of the Government of India? (Y/N) If yes, disclose whether targets set under the PAT scheme have been achieved. In case targets have not been achieved, provide the remedial action taken, if any:

No

3. Provide details of the following disclosures related to water in the following format:

Parameter	FY 2024-25	FY 2023-24
Water withdrawal by source (in kilolitres)		
(i) Surface water	NIL	NIL
(ii) Groundwater	NIL	NIL
(iii) Third-party water - Municipal Corporation	136,844	154,291
(iv) Seawater/desalinated water	NIL	NIL
(v) Others	NIL	NIL
Total volume of water withdrawal (in kilolitres) (i + ii + iii + iv + v)	136,844	154,291
Total volume of water consumption (in kilolitres)	136,844	154,291
Water intensity per rupee of turnover (water consumed/turnover)	3.89 * 10 ⁻⁵ Kilo litres/₹	4.22 * 10 ⁻⁵ Kilo litres/₹
Water intensity per rupee of turnover adjusted for Purchasing Power Parity (PPP)* (Total water consumption/Revenue from operations adjusted for PPP)	8.05 * 10 ⁻⁴ Kilo litres/\$	9.46 * 10 ⁻⁴ Kilo litres/\$
Water intensity in terms of physical output	3.00 * 10 ⁻² Kilo litres/Kg	3.51 * 10 ⁻² Kilo litres/Kg
Water intensity (optional) – the entity may select the relevant metric	-	-

*PPP: INR Revenue X PPP Factor (US\$/INR) PPP Factor = 20.66; World Economic Outlook (April 2025) - Implied PPP conversion rate (imf.org). IMF PPP conversion rate (22.4), available for March 2024, was used for total income PPP adjusted value for FY 2023-24. Intensity calculation for FY 2023-24 has been changed as per the applicable SEBI circular.

Note: Indicate if any independent assessment/evaluation/assurance has been carried out by an external agency? (Y/N)
If yes, the name of the external agency.:

No, independent assessment was carried out by any external agency.

4. Provide the following details related to water discharged:

Parameter	FY 2024-25	FY 2023-24
Water discharge by destination and level of treatment (in kilolitres)		
(i) To surface water		
No treatment	NIL	NIL
With treatment – please specify level of treatment	NIL	NIL
(ii) To groundwater		
No treatment (Potable water use for Gardening)	6,480	7,750
With treatment – (Toilet wash water - Passed through brick-bite Soak Pits)	6,950	6,700
(iii) To seawater		
No treatment	NIL	NIL
With treatment – please specify level of treatment	NIL	NIL
(iv) Sent to third-parties		
No treatment	NIL	NIL
With treatment – please specify level of treatment	NIL	NIL
(v) Others		
No treatment	NIL	NIL
With treatment – please specify level of treatment	NIL	NIL
Total water discharged (in kilolitres)	13,430	14,450

Note: Indicate if any independent assessment/evaluation/assurance has been carried out by an external agency? (Y/N)
If yes, the name of the external agency.:

No

5. Has the entity implemented a mechanism for Zero Liquid Discharge? If yes, provide details of its coverage and implementation:

Yes, AETL has implemented a mechanism for Zero Liquid Discharge (ZLD), featuring a three-stage forced feed evaporation plant. This sytem efficiently treats both process effluent and equipment wash water, generating steam that is condensed to create recycled water suitable for various utilities like boilers, water-cooled compressors, and cooling towers.

After the evaporation process, resulting slurry and sludge undergo further treatment by drying them in a cage mill. This step yields a non-hazardous powder used as a raw material for non-pharmaceutical application products, ensuring minimal waste generation.

This ZLD system, operational since 2003, highlights its longstanding effectiveness and reliability. It comprises key components, such as an Effluent Treatment Plant (ETP), Mechanical Vapor Recompression Evaporator (MEE), and a dryer. Together, these components form a closed-loop system that efficiently manages liquid waste, while minimising environmental impact.

6. Please provide details of air emissions (other than GHG emissions) by the entity in the following format:

Parameter	Please specify unit	FY 2024-25	FY 2023-24
NOx	Mg/Nm3	28.28	32.41
SOx	Mg/Nm3	24.22	24.53
Particulate matter (PM)	Mg/Nm3	88.46	73.83
Persistent organic pollutants (POP)	Mg/Nm3	2.98	2.10
Volatile organic compounds (VOC)	Mg/Nm3	1.23	2.33
Hazardous air pollutants (HAP)	Mg/Nm3	39.86	51.24
Others – please specify	Mg/Nm3	NA	NA

Note: Indicate if any independent assessment/evaluation/assurance has been carried out by an external agency? (Y/N) If yes, the name of the external agency.:

Yes

- Ashwamedh Engineers & Consultants- Laboratory services division, Nashik
- Azis Labs, Pithampur, Madhya Pradesh

7. Provide details of greenhouse gas emissions (Scope 1 and Scope 2 emissions) & its intensity in the following format:

Parameter	Unit	FY 2024-25	FY 2023-24
Total Scope 1 emissions (Break-up of the GHG into CO ₂ , CH ₄ , N ₂ O, HFCs, PFCs, SF ₆ , NF ₃ , if available)	Metric tonnes of CO ₂ equivalent	20,232	23,083
Total Scope 2 emissions (Break-up of the GHG into CO ₂ , CH ₄ , N ₂ O, HFCs, PFCs, SF ₆ , NF ₃ , if available)	Metric tonnes of CO ₂ equivalent	7,210	-
Total Scope 1 and Scope 2 emissions per rupee of turnover	Metric tonnes of CO ₂ equivalent	7.81 * 10 ⁻⁶ MT/₹	6.32 * 10 ⁻⁶ MT/₹
Total Scope 1 and Scope 2 emission intensity per rupee of turnover adjusted for Purchasing Power Parity (PPP)* (Total Scope 1 and Scope 2 GHG emissions/Revenue from operations adjusted for PPP)	Metric tonnes of CO ₂ equivalent	1.61 * 10 ⁻⁴ MT/\$	1.41 * 10 ⁻⁴ MT/\$
Total Scope 1 and Scope 2 emission intensity in terms of physical output	Metric tonnes of CO ₂ equivalent	6.03 * 10 ⁻³ MT/Kg	5.25 * 10 ⁻³ MT/Kg
Total Scope 1 and Scope 2 emission intensity (optional) - - the entity may select the relevant metric		-	-

*PPP: INR Revenue X PPP Factor (US\$/INR) PPP Factor = 20.66; World Economic Outlook (April 2025) - Implied PPP conversion rate (imf.org). IMF PPP conversion rate (22.4), available for March 2024, was used for total income PPP adjusted value for FY 2023-24. Intensity calculation for FY 2023-24 has been changed as per the applicable SEBI circular.

Note: Indicate if any independent assessment/evaluation/assurance has been carried out by an external agency? (Y/N)
If yes, the name of the external agency.:

Pristine International, Pithampur, Madhya Pradesh for Pithampur Plant

8. Does the entity have any project related to reducing Green House Gas emission? If yes, then provide details:

Yes, AETL has undertaken several projects to reduce greenhouse gas emissions as part of its commitment to environmental sustainability. Some of these initiatives include:

- **Solar Power Installations:** Installation of the Solar power plant for an additional 350KW. With this, the total Solar power installed capacity is 510 KW, reducing reliance on fossil fuels for electricity
- **Steam Condensate Recovery:** Implemented steam condensate recovery systems, to recycle hot water to feed boilers, thereby reducing the need for additional energy input and minimising greenhouse gas emissions associated with boiler operations
- **Energy Efficient Systems:** Invested in energy-efficient air conditioning systems that utilise CFC-free refrigerant gas, reducing both energy consumption and the release of ozone-depleting substances into the atmosphere
- **Cold Insulation:** Implemented cold insulation for the ducts of the Air Handling Unit (AHU) system in the Spray Dryer Plant to prevent heat gain, control condensation, improve energy efficiency, and reduce noise
- **LED Lighting:** Deployed LED lamps throughout the plant reduce electricity consumption compared to traditional lighting systems, consequently lowering greenhouse gas emissions associated with electricity generation
- **Efficient Motor Operation:** Installed energy efficient and Variable-Frequency Drive (VFD)-grade motors for fermenter agitation, optimising energy usage and decreasing greenhouse gas emissions resulting from motor operation
- **Preventive Maintenance:** Incorporated preventive maintenance plans for critical and utility equipment (i.e. Diesel Generator set, Electrical Substation and Power Distribution network, Blowers, Insulation, etc.) ensures efficient performance, reducing energy consumption and greenhouse gas emissions associated with equipment operation

These projects collectively contribute to AETL's efforts to reduce greenhouse gas emissions and mitigate its environmental impact.

9. Provide details related to waste management by the entity, in the following format:

Parameter	FY 2024-25	FY 2023-24
Total waste generated (in metric tonnes)		
Plastic waste (A)	5.73	6.05
E-waste (B)	1.22	4.83
Bio-medical waste (C)	NIL	NIL
Construction and demolition waste (D)	NIL	NIL
Battery waste (E)	0.43	0.71
Radioactive waste (F)	NIL	NIL

Parameter	FY 2024-25	FY 2023-24
Other hazardous waste (G)		
Spent Oil	0.41	0.63
Processed Liquid	149.62	330.79
Semi-solid waste	268.40	326.50
Other non-hazardous waste generated (H)		
Corrugated Box & Packaging waste	22.54	23.61
Cotton waste	0.27	0.37
MS Scrap	14.01	21.65
Semi-solid waste	88.00	0.036
Total (A+B + C + D + E + F + G + H)	550.62	715.16
Waste intensity per rupee of turnover (Total waste generated/Revenue from operations)	1.57 * 10 ⁻⁷ MT/₹	1.96 * 10 ⁻⁷ MT/₹
Waste intensity per rupee of turnover adjusted for Purchasing Power Parity (PPP)* (Total waste generated/Revenue from operations adjusted for PPP)	3.24 * 10 ⁻⁶ MT/\$	4.38 * 10 ⁻⁶ MT/\$
Waste intensity in terms of physical output	1.21 * 10 ⁻⁴ MT/Kg	1.63 * 10 ⁻⁴ MT/Kg
Waste intensity (optional) – the relevant metric may be selected by the entity	-	-

For each category of waste generated, total waste recovered through recycling, re-using or other recovery operations (in metric tonnes)

Category of waste		
(i) Recycled	149.62	329.79
(ii) Re-used	356.04	326.50
(iii) Other recovery operations	NIL	NIL
Total	506.02	656.29

For each category of waste generated, total waste disposed by nature of disposal method (in metric tonnes)		
Category of waste		
(i) Incineration	NIL	NIL
(ii) Landfilling	NIL	NIL
(iii) Other disposal operations - By sale to authorized scrap dealers	43.95	50.92
Total	43.95	50.92

*PPP: INR Revenue X PPP Factor (US\$/INR) PPP Factor = 20.66; World Economic Outlook (April 2025) - Implied PPP conversion rate (imf.org). IMF PPP conversion rate (22.4), available for March 2024, was used for total income PPP adjusted value for FY 2023-24. Intensity calculation for FY 2023-24 has been changed as per the applicable SEBI circular.

Note: During FY 2024-25, 0.65MT waste remained unscrapped

Indicate if any independent assessment/evaluation/assurance has been carried out by an external agency? (Y/N)
If yes, the name of the external agency.:

No

10. Briefly describe the waste management practices adopted in your establishments. Describe the strategy adopted by your Company to reduce usage of hazardous and toxic chemicals in your products and processes and the practices adopted to manage such wastes:

AETL ensures waste management in its operations by ensuring the following:

- **Safety and Chemical Usage:** Prioritises safe handling and minimizes the usage of hazardous chemicals in products and processes. Implements best practices for managing the resulting waste
- **Environmental Compliance:** Adheres strictly to all relevant environmental regulations to ensure responsible operations
- **Resource Optimisation:** Optimises resource utilisation across all plants and laboratories to minimise waste and maximise efficiency
- **Energy Efficiency:** Commits to improving energy efficiency through innovative techniques and ideas to reduce waste and optimise consumption

11. If the entity has operations/offices in/around ecologically sensitive areas (such as national parks, wildlife sanctuaries, biosphere reserves, wetlands, biodiversity hotspots, forests, coastal regulation zones etc.) where environmental approvals/clearances are required, please specify details in the following format:

S. No.	Location of operations/ offices	Type of operations	Whether the conditions of environmental approval/clearance are being complied with? (Y/N) If no, the reasons thereof and corrective action taken, if any.
NIL			

12. Details of environmental impact assessments of projects undertaken by the entity based on applicable laws in the current financial year

Name and brief details of Project	EIA Notification No.	Date	Whether conducted by an independent external agency (Yes/No)	Results communicated in the public domain (Yes/No)	Relevant weblink
NA					

13. Is the entity compliant with the applicable environmental law/regulations/guidelines in India; such as the Water (Prevention and Control of Pollution) Act, Air (Prevention and Control of Pollution) Act, Environment protection act and rules thereunder (Y/N). If not, provide details of all such non-compliances, in the following format:

Yes, AETL adheres to all applicable environmental laws, regulations, and guidelines in India.

S. No.	Specify the law/regulation/ guidelines which were not complied with	Provide details of the non-compliance	Any fines/penalties/action taken by regulatory agencies such as Pollution Control Boards or by courts	Corrective action taken, if any
NA				

Leadership Indicators

1. Water withdrawal, consumption and discharge in areas of water stress (in kilolitres):

Not applicable, we are established away from water stress locations.

For each facility / plant located in areas of water stress, provide the following information: NA

(i) Name of the area

(ii) Nature of operations

(iii) Water withdrawal, consumption and discharge in the following format:

Parameter	FY 2024-25	FY 2023-24
Water withdrawal by source (in kilolitres)		
(i) Surface water	NA	NA
(ii) Groundwater		
(iii) Third-party water		
(iv) Seawater/desalinated water		
(v) Others		
Total volume of water withdrawal (in kilolitres)		
Total volume of water consumption (in kilolitres)		
Water intensity per rupee of turnover (water consumed/turnover)		
Water intensity (optional) – the entity may select the relevant metric		
Water discharge by destination and level of treatment (in kilolitres)		
(i) Into surface water	NA	NA
- No treatment		
- With treatment – please specify the level of treatment		
(ii) Into groundwater		
- No treatment		
- With treatment – please specify the level of treatment		
(iii) Into seawater		
- No treatment		
- With treatment – please specify the level of treatment		
(iv) Sent to third-parties		
- No treatment		
- With treatment – please specify the level of treatment		
(v) Others		
- No treatment		
- With treatment – please specify the level of treatment		
Total water discharged (in kilolitres)		

Note: Indicate if any independent assessment/evaluation/assurance carried out by an external agency? (Y/N)
If yes, the name of the external agency.:

NA

2. Please provide details of total Scope 3 emissions & their intensity in the following format:

Parameter	Unit	FY 2024-25	FY 2023-24
Total Scope 3 emissions (Break-up of the GHG into CO ₂ , CH ₄ , N ₂ O, HFCs, PFCs, SF ₆ , NF ₃ , CO ₂ equivalent if available)	Metric tonnes of CO ₂ equivalent	Not Applicable	Not Applicable
Total Scope 3 emissions per rupee of turnover			
Total Scope 3 emission intensity (optional) – the entity may select the relevant metric			

Note: Indicate if any independent assessment/evaluation/assurance has been carried out by an external agency? (Y/N)
If yes, the name of the external agency.

Not Applicable

3. With respect to the ecologically sensitive areas reported at Question 11 of Essential Indicators above, provide details of significant direct & indirect impact of the entity on biodiversity in such areas along-with prevention and remediation activities:

Not Applicable

4. If the entity has undertaken any specific initiatives or used innovative technology or solutions to improve resource efficiency, or reduce impact due to emissions/effluent discharge/waste generated, please provide details of the same as well as outcome of such initiatives, as per the following format:

S. No.	Initiative undertaken	Details of the initiative (web-link, if any, may be provided alongwith summary)	Outcome of the initiative
1.	Hot insulation of steam and utility systems	Installed hot insulation on steam and utility systems to minimise heat loss	Resulted in a reduction of steam consumption by 85 kg/hr
2.	Chilled water generation system heat recovery improvement	Implemented enhancements in the chilled water generation system to recover heat, reducing the steam requirement	Resulted in a reduction of 25 kg/hr in steam consumption
3.	Electrical current utilisation of blowers	Incorporated measures to optimise the electrical current utilisation of blowers	Reduced electrical current usage by 2-15 Amp/hr
4.	Preventive maintenance of all critical and utility equipment	Incorporated a preventive maintenance plan for critical and utility equipment	Enhanced energy efficiency and reduction in consumption of power and fuel
5.	Efficient performance of electrical equipment	Implemented measures to ensure the efficient performance of electrical equipment	Improved overall efficiency and reduced energy consumption
6.	Power bill incentive and other rebates	Received power bill incentives and rebates from MSEDCL	Received total incentives and rebates amounted to ₹ 16.31 lakhs
7.	Generator set KWH to fuel ratio improvement	Achieved a generator set KWH to fuel ratio of around 4%	Improved fuel efficiency, reducing fuel consumption and emissions
8.	Cold insulation of spray dryer plant	Installed cold insulation for the ducts of Air Handling (AHU) system to minimise heat transfer into cold air ducts	Improved energy efficiency, prevent heat gain, control condensation and noise reduction

5. Does the entity have a business continuity and disaster management plan? Give details in 100 words/weblink:

Yes, AETL has a comprehensive business continuity plan in place which encompasses the following:

- Multi-Location Production Facilities: AETL operates production facilities located in Sinnar, Pithampur, Vasind, and subsidiary plants
- Backup Locations: In the event of a disaster or cyberattack, work can commence from alternative sites like the New Thane Research Centre, Wagle Research Centre, and Thane Corporate Office
- Regular Data Backups: The Company follows a policy of regularly backing up systems to ensure swift restoration of data with minimal loss

6. Disclose any significant adverse impact to the environment, arising from the value chain of the entity. What mitigation or adaptation measures have been taken by the entity in this regard?

NA

7. Percentage of value chain partners (by value of business done with such partners) that were assessed for environmental impacts.

NIL

Principle 7: Businesses, when engaging in influencing public and regulatory policy, should do so in a manner that is responsible and transparent

Essential Indicators

1. a. Number of affiliations with trade and industry chambers/associations.

The Company is affiliated with the following 8 chambers/associations (refer point (b) below).

b. List the top 10 trade and industry chambers/associations (determined based on the total members of such body) the entity is a member of/affiliated to.

S. No.	Name of the trade and industry chambers/associations	Reach of trade and industry chambers/ associations (State/National)
1.	Confederation of Indian Industry	National
2.	Health Foods and Dietary Supplements Association	National
3.	The Council of EU Chambers of Commerce	International
4.	Bombay Chamber of Commerce and Industry	National
5.	Pharmaceuticals Export Promotion Council of India	National
6.	Confederation of Indian Industry	National
7.	Confederation of Indian Food Regulatory Cell	National
8.	Pithampur Audyogik Sangathan	State

2. Provide details of corrective action taken or underway on any issues related to anti-competitive conduct by the entity, based on adverse orders from regulatory authorities:

Name of authority	Brief of the case	Corrective action taken
NA		

Leadership Indicators

1. Details of public policy positions advocated by the entity:

S. No.	Public policy advocated	Method resorted for such advocacy	Whether information available in the public domain? (Yes/No)	Frequency of Review by Board (Annually/half yearly/Quarterly/ Others – please specify)	Weblink, if available
--------	-------------------------	-----------------------------------	--	--	-----------------------

Not Applicable, AETL stands firm in its commitment to supporting the growth of the supplement and nutrition industry, while persistently striving to enhance the health and well-being of people worldwide.

Principle 8: Businesses should promote inclusive growth and equitable development

Essential Indicators

1. Details of Social Impact Assessments (SIA) of projects undertaken by the entity based on applicable laws, in the current financial year:

Name and brief details of the project	SIA Notification No.	Date of Notification	Whether conducted by an independent external agency (Yes/No)	Results communicated in the public domain (Yes/No)	Relevant weblink
---------------------------------------	----------------------	----------------------	--	--	------------------

NIL

2. Provide information on project(s) for which ongoing Rehabilitation and Resettlement (R&R) is being undertaken by your entity, in the following format:

S. No.	Name of the project for which R&R is ongoing	State	District	No. of Project Affected Families (PAFs)	% of PAFs covered by R&R	Amounts paid to PAFs in the FY (in ₹)
--------	--	-------	----------	---	--------------------------	---------------------------------------

NIL

3. Describe the mechanisms to receive and redress grievances of the community:

AETL acknowledges the crucial importance of establishing an effective system to address community concerns. In pursuit of this objective, the Company has developed a well-defined process to promptly handle inquiries, grievances, comments, and suggestions from its external stakeholders, particularly members of the local community. Upon receiving any communication, the Company swiftly assign it to the relevant personnel within its organization to guarantee immediate and appropriate action. Additionally, AETL maintains a designated 'point of contact' available through various communication channels to streamline interactions. This structured approach empowers both its internal and external stakeholders, including the communities it serves, to utilise its reporting platform effectively. Through this platform, the Company addresses a wide array of issues, including ethics, fraud, financial matters, and human resources concerns, promptly underscoring AETL's indomitable commitment to community engagement and responsiveness.

4. Percentage of input material (inputs to total inputs by value) sourced from suppliers:

	FY 2024-25	FY 2023-24
Directly sourced from MSMEs/small producers	18%	19%
Directly from within India	72%	76%

5. Job creation in smaller towns – Disclose wages paid to persons employed (including employees or workers employed on a permanent or non-permanent/on contract basis) in the following locations, as % of total wage cost

Location	FY 2024-25	FY 2023-24
Rural	11.14%	16.38%
Semi-urban	18.22%	14.69%
Urban	28.98%	23.49%
Metropolitan	41.66%	45.44%

(Categorised as rural, semi-urban, urban, or metropolitan based on the RBI Classification System)

Leadership Indicators

1. Provide details of actions taken to mitigate any negative social impacts identified in the Social Impact Assessments (Reference: Question 1 of Essential Indicators above)

Details of negative social impact identified	Corrective action taken
NA	

2. Provide the following information on CSR projects undertaken by your entity in designated aspirational districts as identified by government bodies

S. No.	State	Aspirational district	Amount spent (in ₹)
NIL			

3. (a) Do you have a preferential procurement policy where you give preference to purchase from suppliers comprising marginalised/vulnerable groups? (Yes/No)

No, the Company does not have a preferential procurement policy for suppliers from marginalised/vulnerable groups.

- (b) From which marginalised/vulnerable groups do you procure? NA

- (c) What percentage of total procurement (by value) does it constitute? NA

4. Details of the benefits derived and shared from the intellectual properties owned or acquired by your entity (in the current financial year), based on traditional knowledge

S. No.	Intellectual property based on traditional knowledge	Owned/acquired (Yes/No)	Benefit shared (Yes/No)	Basis of calculating benefit share
NA				

5. Details of corrective actions taken or underway based on any adverse order in intellectual property related disputes wherein usage of traditional knowledge is involved.

Name of authority	Brief of the case	Corrective action taken
NA		

6. Details of beneficiaries of CSR Projects

S. No.	CSR project	No. of persons benefitted from CSR projects	% of beneficiaries from vulnerable and marginalised groups
1.	Contribution towards promotion of Health Care / Promotion of Education / Preventive Health Care including various activities for management of Thalassemia Patients	1,351	90%+

Principle 9: Businesses should engage with and provide value to their consumers in a responsible manner

Essential Indicators

1. Describe the mechanisms in place to receive and respond to consumer complaints and feedback:

AETL has established a structured mechanism to promptly address any customer complaints or feedback regarding its products and services. Customers are provided with multiple contact options, and the Company's representatives maintain regular communication to ensure swift resolution of any issues. Resolving customer feedback promptly and carefully is essential to prevent future dissatisfaction and enhance overall customer satisfaction.

2. Turnover of products and/services as a percentage of turnover from all products/services that carry information about:

	As a percentage to total turnover
Environmental and social parameters relevant to the product	100%
Safe and responsible usage	
Recycling and/or safe disposal	NA

3. Number of consumer complaints in respect of the following:

	FY 2024-25		Remarks	FY 2023-24		Remarks
	Received during the year	Pending resolution at the end of the year		Received during the year	Pending resolution at the end of the year	
Data privacy	NIL	NIL	NIL	NIL	NIL	NIL
Advertising						
Cybersecurity						
Delivery of essential services						
Restrictive trade practices						
Unfair trade practices						
Other						

4. Details of instances of product recalls on account of safety issues

	Number	Reasons for recall
Voluntary recalls	2	To check the transport worthiness trials
Forced recalls	0	NA

5. Does the entity have a framework/policy on cyber security and risks related to data privacy? (Yes/No) If available, provide a weblink to the policy.

Yes, AETL has implemented a system to identify potential cybersecurity risks. Considering the growing importance of data privacy, the Company has adopted a comprehensive and coordinated approach to information security and data privacy systems. The policy primarily concerns internal users and verified external entities, is selectively shared with relevant entities, and is not publicly available.

6. Provide details of any corrective actions taken or underway on issues relating to advertising, and delivery of essential services; cyber security and data privacy of customers; re-occurrence of instances of product recalls; penalty/action taken by regulatory authorities on the safety of products/services:

NA

7. Provide the following information relating to data breaches:

- a. Number of instances of data breaches - NIL
- b. Percentage of data breaches involving personally identifiable information of customers – Not Applicable
- c. Impact, if any, of the data breaches – Not Applicable

Leadership Indicators

1. Channels/platforms where information on products and services of the entity can be accessed (provide weblink, if available).

www.advancedenzymes.com

www.wellfa.com and

other leading platforms in the market

2. Steps taken to inform and educate consumers about safe and responsible usage of products and/or services.

The Company’s products include information on safe and responsible usage to educate customers accordingly.

3. Mechanisms in place to inform consumers of any risk of disruption/discontinuation of essential services:

The Company maintains continuous communication with its customers to address any potential issues that may impact customer relationships and business operations proactively. If there are any delays in customer delivery due to factors within or beyond the Company’s control, such as transportation disruptions or local disturbances, it promptly notifies its customers to prevent misunderstandings. Furthermore, AETL aims to minimise the occurrence of such incidents through diligent efforts.

4. Does the entity display product information on the product over and above what is mandated as per local laws? (Yes/No/Not Applicable) If yes, provide details in brief. Did your entity carry out any survey with regard to consumer satisfaction relating to the major products/services of the entity, significant locations of operation of the entity or the entity as a whole? (Yes/No)

No, the Company adheres to the applicable laws and regulations regarding displaying the product label and related information.

INDEPENDENT AUDITOR’S REPORT

To the Members of **Advanced Enzyme Technologies Limited**

Report on the Audit of the Standalone Financial Statements

Opinion

We have audited the accompanying standalone financial statements of Advanced Enzyme Technologies Limited (“the Company”), which comprise the Balance Sheet as at March 31, 2025, and the Statement of Profit and Loss, including Other Comprehensive Income, Statement of Changes in Equity and Statement of Cash Flows for the year then ended, and notes to the standalone financial statements, including material accounting policy information and other explanatory information (hereinafter referred to as the “standalone financial statements”).

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Companies Act, 2013 (“the Act”) in the manner so required and give a true and fair view in conformity with the Indian Accounting Standards prescribed under section 133 of the Act read with Companies (Indian Accounting Standards) Rules, 2015, as amended (“Ind AS”) and other accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2025, and profit (including other comprehensive income), changes in equity and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit of the standalone financial statements in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act. Our responsibilities under those Standards are further described in the ‘Auditor’s Responsibilities for the Audit of the Standalone Financial Statements’ section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (“ICAI”) together with the ethical requirements that are relevant to our audit of the standalone financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the standalone financial statements for the year ended March 31, 2025. These matters were addressed in the context of our audit of the standalone financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. We have determined the matters described below to be the key audit matters to be communicated in our report.

Investment in subsidiary

See Note 49 of Standalone Financial Statements

Sr. No	Key Audit Matters	How the Key Audit Matters was addressed in our audit
1	<p>During the year, the Company has made an additional investment of ₹ 478.18 million in its wholly owned subsidiary - Advanced Enzymes Europe B.V. (AEEBV), post which the carrying value of investment in AEEBV is ₹ 772.25 million (net of provision for impairment amounting to ₹ 189.48 million) as on March 31, 2025. AEEBV has further investment in Evoxx Technologies GmbH (Evoxx) (taken together as AEEBV group)</p> <p>AEEBV Group has been making operational losses and has cash outflows from its operating activities.</p> <p>Management of the Company has performed an impairment assessment in relation to such Investment as per the requirements of Ind AS 36 "Impairment of Assets" and has determined that no additional impairment provision is to be considered in the current year.</p> <p>In regard to the impairment testing on its investments, the determination of the fair value of the AEEBV group requires management of the Company to estimate significant assumptions including future revenue and terminal growth rates apart from margin assumptions and discount rates to estimate future cash flows. Given the past impairment, the history of losses, and the reliance on forward-looking estimates, we have identified the impairment assessment of the investment in the subsidiary as a key audit matter.</p>	<p>Our audit procedures to address the impairment of Investments included and were not limited to the following:</p> <ol style="list-style-type: none">Obtained an understanding from the Management of the Company with respect to policies and procedures followed by the Management with respect to measurement and testing of impairment on the Company’s Investment in AEEBV group.Reviewed valuation reports of AEEBV group issued by registered valuer and provided by the management of the Company.Assessed the reasonableness of inputs used in the valuation report provided by management for the future revenue and margin projections, the accuracy of the cash flow forecasts and analyzed the underlying key assumptions, including discounting rates and terminal growth rates.Compared the reasonableness of future operating cash flow forecasts with the business plan and tested the mathematical accuracy of management’s calculations.Involved our internal experts to assess the consistency and reasonableness of the Company’s valuation methodology and assumptions, applied in determining the fair value of the subsidiary, in order to assess related impairment on investment made in subsidiary.Compared the recoverable value and carrying value and concluded that recoverable value is in excess of carrying value and hence, impairment is not required.

Information Other than the Standalone Financial Statements and Auditor's Report Thereon

The Company's Board of Directors is responsible for the other information. The other information comprises the information included in the Company's annual report but does not include the standalone financial statements and our auditor's report thereon, which we obtained prior to the date of this auditor's report, and the Company's annual report, which is expected to be made available to us after that date.

Our opinion on the standalone financial statements does not cover the other information and we do not and will not express any form of assurance conclusion thereon.

In connection with our audit of the standalone financial statements, our responsibility is to read the other information identified above and, in doing so, consider whether the other information is materially inconsistent with the standalone financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated. If, based on the work we have performed on the other information that we obtained prior to the date of this auditor's report, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

When we read the Company's annual report, if we conclude that there is a material misstatement therein, we are required to communicate the matter to those charged with governance under SA 720 'The Auditor's responsibilities Relating to Other Information' and take necessary action under the relevant laws and regulations

Responsibilities of Management and Those Charged with Governance for the Standalone Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these standalone financial statements that give a true and fair view of the financial position, financial performance, changes in equity and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial statements, the Management and Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Statements

Our objectives are to obtain reasonable assurance about whether the standalone financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial statements.

We give in "Annexure A" a detailed description of Auditor's responsibilities for Audit of the Standalone Financial Statements.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2020 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act, we give in "Annexure B" a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.
2. As required by Section 143(3) of the Act, we report that:
 - (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
 - (b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
 - (c) The Balance Sheet, the Statement of Profit and Loss including other comprehensive income, the Statement of Changes in Equity and the Statement of Cash Flow dealt with by this Report are in agreement with the books of account.
 - (d) In our opinion, the aforesaid standalone financial statements comply with the Accounting Standards specified under Section 133 of the Act.
 - (e) On the basis of the written representations received from the directors as on March 31, 2025 taken on record by the Board of Directors, none of the directors are disqualified as on March 31, 2025 from being appointed as a director in terms of Section 164 (2) of the Act.
 - (f) With respect to the adequacy of the internal financial controls with reference to standalone financial statements of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure C".
 - (g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
 - i. The Company has disclosed the impact of pending litigations on its financial position in its standalone financial statements – Refer Note 53 to the standalone financial statements;

- ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
- iii. There has been no delay in transferring amounts, required to be transferred, to the Investor Education and Protection Fund by the Company.
- iv.
 - 1) The Management has represented that, to the best of its knowledge and belief, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other persons or entities, including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.
 - 2) The Management has represented, that, to the best of its knowledge and belief, no funds have been received by the Company from any persons or entities, including foreign entities (Funding Parties), with the understanding, whether recorded in writing or otherwise, as on the date of this audit report, that the Company shall, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.
 - 3) Based on the audit procedures performed that have been considered reasonable and appropriate in the circumstances, and according to the information and explanations provided to us by the Management in this regard nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) of Rule 11(e) as provided under (1) and (2) above, contain any material mis-statement.

- v.
 - 1) The interim dividend declared and paid by the Company during the year and until the date of this audit report is in accordance with section 123 of the Companies Act 2013.
 - 2) The final dividend paid by the Company during the year in respect of the same declared for the previous year is in accordance with section 123 of the Companies Act 2013 to the extent it applies to payment of dividend.
 - 3) The Board of Directors of the Company have proposed final dividend for the year which is subject to the approval of the members at the ensuing Annual General Meeting. The dividend declared is in accordance with section 123 of the Act to the extent it applies to declaration of dividend. (Refer Note 50 to the Standalone financial statements)
- vi. Based on our examination, the Company has used an accounting software for maintaining its books of account which has a feature of recording audit trail (edit log) facility. The audit trail feature has been operated throughout the year for all transactions recorded in the accounting software. Further, during the course of our audit, we did not come across any instance of the audit trail feature being tampered with.
3. In our opinion, according to information, explanations given to us, the remuneration paid by the Company to its directors is within the limits laid prescribed under Section 197 read with Schedule V of the Act and the rules thereunder.

For M S K A & Associates
Chartered Accountants
ICAI Firm Registration No. 105047W

Amrish Vaidya
Partner
Membership No. 101739
UDIN: 25101739BBIKFC2197

Place: Mumbai
Date: May 13, 2025

ANNEXURE A TO THE INDEPENDENT AUDITOR'S

REPORT OF EVEN DATE ON THE STANDALONE FINANCIAL STATEMENTS OF ADVANCED ENZYME TECHNOLOGIES LIMITED

Auditor's Responsibilities for the Audit of the Standalone Financial Statements

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to standalone financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management and Board of Directors.
- Conclude on the appropriateness of management and Board of Director's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the standalone financial statements, including the disclosures, and whether the standalone financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the standalone financial statements for the year ended March 31, 2025 and are therefore, the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

For M S K A & Associates

Chartered Accountants

ICAI Firm Registration No. 105047W

Amrish Vaidya

Partner

Membership No. 101739
UDIN: 25101739BMIKFC2197

Place: Mumbai
Date: May 13, 2025

ANNEXURE B TO INDEPENDENT AUDITORS'

REPORT OF EVEN DATE ON THE STANDALONE FINANCIAL STATEMENTS OF ADVANCED ENZYME TECHNOLOGIES LIMITED FOR THE YEAR ENDED MARCH 31, 2025

[Referred to in paragraph 1 under 'Report on Other Legal and Regulatory Requirements' in the Independent Auditors' Report]

- A The Company has maintained proper records showing full particulars including quantitative details and situation of property, plant and equipment, and relevant details of right-of-use assets.
 - B The Company has maintained proper records showing full particulars of intangible assets.
- Property, Plant and Equipment, and right of use assets were physically verified by the management according to a phased programme designed to cover all items over a period of 3 years which, in our opinion, is reasonable having regard to the size of the Company and the nature of its assets. Pursuant to the programme, a portion of Property, plant and equipment, and right of use assets have been physically verified by Management during the year. No material discrepancies were noticed on such verification.
 - According to the information and explanations given to us and on the basis of our examination of the records of the Company, the title deeds of immovable properties (other than properties where the Company is the lessee and the lease agreements are duly executed in favour of the lessee) as disclosed in the standalone financial statements, are held in the name of the Company.
 - According to the information and explanations given to us, the Company has not revalued its property, plant and Equipment (including Right of Use assets) and intangible assets during the year. Accordingly, the provisions stated under clause 3(i)(d) of the Order are not applicable to the Company.
 - According to the information and explanations given to us, no proceeding has been initiated or pending against the Company for holding benami property under the Benami Transactions (Prohibition) Act, 1988, as amended and rules made thereunder. Accordingly, the provisions stated under clause 3(i)(e) of the Order are not applicable to the Company.
- The inventory has been physically verified during the year by the management. In our opinion, the frequency of verification, coverage and procedure of such verification is reasonable and appropriate having regard to the size of the Company and the nature of its operations. The discrepancies noticed on physical verification of inventory as compared to book records were not 10% or more in aggregate for each class of inventory.

- During the year, the Company has been sanctioned working capital limits in excess of ₹ 5 crores rupees, in aggregate from Banks and financial institutions, on the basis of security of current assets. Based on the records examined by us in the normal course of audit of the standalone financial statements, quarterly returns / statements filed with such Banks/ financial institutions are in agreement with the books of accounts of the Company.
- During the year, the Company has made investment in a company. According to the information and explanations provided to us, the Company has not provided any guarantee or security, or granted any loans or advances in the nature of loans, secured or unsecured, to companies, firms, Limited Liability Partnerships or any other parties. Accordingly, the provisions stated under clause 3(iii)(c) to (f) of the Order are not applicable to the Company.
 - According to the information and explanations given to us and based on the audit procedures performed by us, we are of the opinion that the investments made are not prejudicial to the interest of the Company.
- According to the information and explanations given to us, the Company has complied with the provisions of Section 185 and 186 of the act, in respect of loans, investments, guarantees and security made.
- According to the information and explanations given to us, the Company has neither accepted any deposits from the public nor any amounts which are deemed to be deposits, within the meaning of the provisions of Sections 73 to 76 of the Act and the rules framed there under. Accordingly, the requirement to report under clause 3(v) of the Order is not applicable to the Company.
- Pursuant to the rules made by the Central Government of India, the Company is required to maintain cost records as specified under Section 148(1) of the Act in respect of its products. We have broadly reviewed the same, and are of the opinion that, *prima facie*, the prescribed accounts and records have been made and maintained. We have not, however, made a detailed examination of the records with a view to determine whether they are accurate or complete.
- According to the information and explanations given to us and the records examined by us, in our opinion, undisputed statutory dues including goods and services tax, provident fund, employees' state insurance, income-tax, sales-tax, service tax, duty of customs, duty of excise, value added tax, cess, and other statutory dues have been regularly deposited by the Company with appropriate authorities in all cases during the year. No undisputed amounts payable in respect of these statutory dues were outstanding as at March 31, 2025, for a period of more than six months from the date they became payable.

(b) According to the information and explanations given to us and the records examined by us, dues relating to which have not been deposited as on March 31, 2025, on account of any dispute, are as follows:

Name of the statute	Nature of dues	Amount Demanded ₹	Amount Paid ₹ (under protest)	Period to which the amount relates	Forum where dispute is pending	Remarks, if any
Income Tax Act, 1961	Income Tax	24.37	4.87	AY 2012-13	Commissioner Appeals	
Income Tax Act, 1961	Income Tax	0.18	-	AY 2013-14	Commissioner Appeals	
Income Tax Act, 1961	Income Tax	46.13	9.23	AY 2017-18	Commissioner Appeals	
Income Tax Act, 1961	Income Tax	38.63	7.73	AY 2018-19	Commissioner Appeals	
Income Tax Act, 1961	Income Tax	1.18	0.24	AY 2019-20	Commissioner Appeals	
Income Tax Act, 1961	Income Tax	49.77	-	AY 2020-21	Commissioner Appeals	
Income Tax Act, 1961	Income Tax	0.85	-	AY 2021-22	Commissioner Appeals	
Central Excise Act, 1944 read with Cenvat Credit Rules, 2004	Service Tax, Interest and Penalty	12.51	10.38	July 2010 to January 2015	Customs, Excise and Service Tax Appellate Tribunal, West Zone	
Central Excise Act, 1944 read with Cenvat Credit Rules, 2004	Excise Duty, Interest and Penalty	2.84	2.50	April 2012 to January 2015	Additional Commissioner of Central Excise, Customs and Service Tax	
Central Excise Act, 1944 read with Cenvat Credit Rules, 2004	Excise Duty	4.19	-	July 2010 to January 2015	Additional Commissioner of Central Excise, Customs and Service Tax	
Central Excise Act, 1944 read with Cenvat Credit Rules, 2004	Excise Duty, Interest and Penalty	2.79	2.79	July 2011 to January 2015	Commissioner of Central Excise, Customs and Service Tax	
Central Excise Act, 1944 read with Cenvat Credit Rules, 2004	Excise Duty, Interest and Penalty	0.53	0.53	March 2015 to October 2015	Customs, Excise and Service Tax Appellate Tribunal, West Zone	
Central Excise Act, 1944 read with Cenvat Credit Rules, 2004	Service Tax, Interest and Penalty	1.37	1.13	M a r c h 2015 to December 2015	Customs, Excise and Service Tax Appellate Tribunal, West Zone	
Central Excise Act, 1944 read with Cenvat Credit Rules, 2004	Excise Duty	0.60	-	M a r c h 2015 to December 2015	Commissioner of Central Excise, Customs and Service Tax	
Central Excise Act, 1944 read with Cenvat Credit Rules, 2004	Excise Duty	2.11	-	Jan 2016 to June 2017	Commissioner of Central Excise, Customs and Service Tax	
Central Excise Act, 1944 read with Cenvat Credit Rules, 2004	Excise Duty	0.64	0.13	Dec 2015 to January 2017	Customs, Excise and Service Tax Appellate Tribunal, West Zone	

- viii.

According to the information and explanations given to us, there are no transaction which are not recorded in the books of account which have been surrendered or disclosed as income during the year in Income-tax Assessment under the Income Tax Act, 1961. Accordingly, the requirement to report as stated under clause 3(viii) of the Order is not applicable to the Company.
- ix.

(a)

The Company does not have any loans or borrowings or interest thereon due to any lenders during the year. Accordingly, the requirement to report under clause 3(ix)(a) of the Order is not applicable to the Company.

(b)

According to the information and explanations given to us and on the basis of our audit procedures, we report that the Company has not been declared wilful defaulter by any bank or financial institution or government or any government authority.
- (c)

In our opinion and according to the information and explanations provided to us, no money was raised by way of term loans. Accordingly, the requirement to report under clause 3(ix)(c) of the Order is not applicable to the Company.
- (d)

According to the information and explanations provided to us, there are no funds raised during the year. Accordingly, the requirement to report under clause 3(ix)(d) of the Order is not applicable to the Company.
- (e)

According to the information and explanations given to us and on an overall examination of the standalone financial statements of the Company, we report that the Company has not taken any funds from an any entity or person on account of or to meet the obligations of its subsidiaries.

- (f)

According to the information and explanations given to us and procedures performed by us, we report that the Company has not raised any loans during the year. Accordingly, reporting under clause 3(ix)(f) of the order is not applicable to the Company.
- x.

(a)

In our opinion and according to the information and explanations given to us, the Company did not raise any money by way of initial public offer or further public offer (including debt instruments) during the year. Accordingly, the reporting requirement under clause 3(x)(a) of the Order is not applicable to the Company.

(b)

According to the information and explanations given to us and based on our examination of the records of the Company, the Company has not made any preferential allotment or private placement of shares or convertible debentures (fully, partly, or optionally convertible) during the year. Accordingly, the requirements to report under clause 3(x)(b) of the Order is not applicable to the Company.
- xi.

(a)

Based on our examination of the books and records of the Company and according to the information and explanations given to us, we report that no fraud by the Company or no fraud on the Company has been noticed or reported during the year in the course of our audit.

(b)

During the year no report under Section 143(12) of the Act, has been filed by us in Form ADT-4 as prescribed under Rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government.

(c)

As represented to us by the Management, there are no whistle-blower complaints received by the Company during the year.
- xii.

The Company is not a Nidhi Company. Accordingly, the provisions stated under clause 3(xii)(a) to (c) of the Order are not applicable to the Company.
- xiii.

According to the information and explanations given to us and based on our examination of the records of the Company, transactions with the related parties are in compliance with Sections 177 and 188 of the Act, where applicable and details of such transactions have been disclosed in the standalone financial statements as required by the applicable accounting standards.
- xiv.

(a)

In our opinion and based on our examination, the Company has an internal audit system commensurate with the size and nature of its business.

(b)

We have considered the internal audit reports of the Company issued till the date of our audit report, for the period under audit.
- xv.

According to the information and explanations given to us, and based on our examination of the records of the Company, in our opinion during the year the Company has not entered into any non-cash transactions with its directors or persons connected with its directors and accordingly, the requirement to report on clause 3(xv) of the Order is not applicable to the Company.

- xvi.

(a)

The Company is not required to be registered under Section 45 IA of the Reserve Bank of India Act, 1934 (2 of 1934) and accordingly, the requirements to report under clause 3(xvi)(a) of the Order is not applicable to the Company.

(b)

The Company is not engaged in any Non-Banking Financial or Housing Finance activities during the year and accordingly, the provisions stated under clause 3 (xvi)(b) of the Order are not applicable to the Company.

(c)

The Company is not a Core investment Company (CIC) as defined in the regulations made by Reserve Bank of India. Accordingly, the requirement to report under clause 3 (xvi)(c) of the Order is not applicable to the Company.

(d)

The Group (as defined in the Core Investment Companies (Reserve Bank) Directions, 2016) does not have any Core Investment Company (as part of its group. Accordingly, the requirement to report under clause 3(xvi)(d) of the Order is not applicable to the Company.
- xvii.

Based on the overall review of standalone financial statements, the Company has not incurred cash losses in the current financial year and in the immediately preceding financial year. Accordingly, the requirement to report under clause 3(xvii) of the Order is not applicable to the Company.
- xviii.

There has been no resignation of the statutory auditors during the year. Accordingly, reporting under clause 3(xviii) of the Order is not applicable to the Company.
- xix.

According to the information and explanations given to us and on the basis of the financial ratios (as disclosed in note 52 to the standalone financial statements), ageing and expected dates of realisation of financial assets and payment of financial liabilities, other information accompanying the standalone financial statements, our knowledge of the Board of Directors and management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report that Company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the Company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the Company as and when they fall due.
- xx

(a)

In respect of other than ongoing projects, there are no unspent amounts that are required to be transferred to a Fund as specified in Schedule VII of the Act as disclosed in note 47 to the standalone financial statements.

- (b) In respect of ongoing projects, the Company has transferred unspent amount to a special account within a period of thirty days from the end of the financial year in compliance with Section 135(6) of the Act as explained in Note 47 to the standalone financial statements.
- xxi. The reporting under clause 3(xxi) of the Order is not applicable in respect of audit of standalone financial statements. Accordingly, no comment in respect of the said Clause has been included in the report.

For M S K A & Associates

Chartered Accountants

ICAI Firm Registration No. 105047W

Amrish Vaidya

Partner

Membership No.101739

UDIN: 25101739BBIKFC2197

Place: Mumbai

Date: May 13, 2025

ANNEXURE C TO THE INDEPENDENT AUDITOR'S

REPORT OF EVEN DATE ON THE STANDALONE FINANCIAL STATEMENTS OF ADVANCED ENZYME TECHNOLOGIES LIMITED

[Referred to in paragraph (f) under 'Report on Other Legal and Regulatory Requirements' in the Independent Auditors' Report of even date to the Members of Advanced Enzyme Technologies Limited on the Financial Statements for the year ended March 31, 2025]

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

We have audited the internal financial controls with reference to standalone financial statements of Advanced Enzyme Technologies Limited ("the Company") as of March 31, 2025 in conjunction with our audit of the standalone financial statements of the Company for the year ended on that date.

Opinion

In our opinion, the Company has, in all material respects, an adequate internal financial controls with reference to standalone financial statements and such internal financial controls with reference to standalone financial statements were operating effectively as at March 31, 2025, based on the internal control with reference to standalone financial statements criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") issued by the Institute of Chartered Accountants of India ('ICAI').

Management's and Board of Director's Responsibility for Internal Financial Controls

The Company's Management and the Board of Directors are responsible for establishing and maintaining internal financial controls based on the internal control with reference to standalone financial statements criteria established by the Company considering the essential components of internal control stated in the Guidance Note issued by ICAI. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to Company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

Auditors' Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls with reference to standalone financial statements based on our audit. We conducted our audit in accordance with the Guidance Note and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Act, to the extent applicable to an audit of internal financial controls. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls with reference to standalone financial statements was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls with reference to standalone financial statements and their

operating effectiveness. Our audit of internal financial controls with reference to standalone financial statements included obtaining an understanding of internal financial controls with reference to standalone financial statements, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the standalone financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained, is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls with reference to standalone financial statements.

Meaning of Internal Financial Controls With reference to Standalone Financial Statements

A company's internal financial control with reference to standalone financial statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of standalone financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control with reference to standalone financial statements includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of standalone financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the standalone financial statements.

Inherent Limitations of Internal Financial Controls With reference to Standalone financial statements

Because of the inherent limitations of internal financial controls with reference to standalone financial statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls with reference to standalone financial statements to future periods are subject to the risk that the internal financial control with reference to standalone financial statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

For M S K A & Associates

Chartered Accountants

ICAI Firm Registration No. 105047W

Amrish Vaidya

Partner

Membership No.101739

UDIN: 25101739BBIKFC2197

Place: Mumbai

Date: May 13, 2025

Standalone Balance Sheet

As at 31 March 2025

(₹ in million)			
Particulars	Note	As at 31 March 2025	As at 31 March 2024
I. ASSETS			
1) Non-current assets			
(a) Property, plant and equipment	7	1,508.82	1,418.21
(b) Capital work-in-progress	7A	207.35	164.45
(c) Other intangible assets	8	56.18	3.10
(d) Intangible assets under development	8A	0.17	54.12
(e) Financial assets			
(i) Investments			
- investment in subsidiaries	9	2,536.50	2,054.26
- other investment	9	0.62	0.62
(ii) Loans	10	0.65	0.37
(iii) Other financial assets	11	79.26	22.45
(f) Income tax asset (net)		160.00	113.44
(g) Other non-current assets	12	14.77	14.91
Total non-current assets		4,564.32	3,845.93
2) Current assets			
(a) Inventories	13	1,014.50	968.84
(b) Financial assets			
(i) Investment	14	366.52	508.02
(ii) Trade receivables	15	781.69	751.72
(iii) Cash and cash equivalents	16	56.04	14.95
(iv) Bank balances other than (iii) above	16A	2.28	5.22
(v) Loans	17	0.26	0.42
(vi) Other financial assets	18	48.81	172.59
(c) Other current assets	19	51.89	61.64
Total current assets		2,321.99	2,483.40
Total assets		6,886.31	6,329.33
II. EQUITY AND LIABILITIES			
1) Equity			
(a) Equity share capital	20	223.76	223.65
(b) Other equity	21	6,069.65	5,581.06
Equity attributable to equity holders		6,293.41	5,804.71
2) Non-current liabilities			
(a) Financial liabilities			
(i) Lease liabilities	22	19.69	10.93
(b) Provisions	23	8.20	6.61
(c) Deferred tax liabilities (net)	24	118.00	106.94
Total non-current liabilities		145.89	124.48
3) Current liabilities			
(a) Financial liabilities			
(i) Lease liabilities	22	7.95	4.11
(ii) Trade payables	25		
a) total outstanding dues of micro enterprises and small enterprises		33.30	18.91
b) total outstanding dues other than micro enterprises and small enterprises		193.46	198.33
(iii) Other financial liabilities	26	134.89	120.08
(b) Other current liabilities	27	39.13	30.41
(c) Provisions	23	35.36	25.41
(d) Current tax liabilities (net)		2.92	2.89
Total current liabilities		447.01	400.14
Total equity and liabilities		6,886.31	6,329.33

The accompanying notes are an integral part of these standalone financial statements **36 - 59**

As per our report of even date attached
for **M S K A & Associates**
Chartered Accountants
Firm's Registration No: 105047W

for and on behalf of the Board

Amrish Vaidya
Partner
Membership No.: 101739

Mukund Kabra
Wholetime Director
DIN : 00148294
Place : Thane

Vinodkumar Jajoo
Director
DIN : 08224980
Place : Nashik

Place: Thane
Date: 13 May 2025

Sanjay Basantani
Company Secretary
Membership No: A19637
Place : Thane

Beni P. Rauka
Chief Financial Officer
Membership No: 039980
Place : Thane

Standalone Statement of Profit and Loss

For the year ended 31 March 2025

(₹ in million)			
Particulars	Note	For the year ended 31 March 2025	For the year ended 31 March 2024
Income			
Revenue from operations	28	3,514.11	3,654.69
Other income	29	614.90	588.09
Total income		4,129.01	4,242.78
Expenses			
Cost of materials consumed	30	1,488.00	1,395.61
Changes in inventories of finished goods, work-in-progress and stock-in-trade	31	(64.67)	(78.34)
Employee benefits expense	32	560.35	493.88
Finance costs	33	2.36	1.57
Depreciation and amortisation expense	34	114.05	108.98
Other expenses	35	823.64	791.68
Total expenses		2,923.73	2,713.38
Profit before tax		1,205.28	1,529.40
Exceptional items	51	-	189.48
Profit before tax after exceptional items		1,205.28	1,339.92
Tax expense	36		
Current tax		168.86	269.51
Deferred tax charge/(credit)		12.22	(10.82)
Total tax expense		181.08	258.69
Profit for the year		1,024.20	1,081.23
Other comprehensive income			
A (i) Items that will not be reclassified to profit or loss			
Remeasurements of defined benefit (charge)/credit		(4.60)	(1.38)
(ii) Income tax relating to items that will not be reclassified to profit or loss		1.16	0.35
B (i) Items that will be reclassified to profit or loss		-	-
(ii) Income tax relating to items that will be reclassified to profit or loss		-	-
		(3.44)	(1.03)
Total comprehensive income for the year		1,020.76	1,080.20
Earnings per equity share (face value ₹ 2 each fully paid up)	40		
Basic		9.16	9.67
Diluted		9.15	9.66

The accompanying notes are an integral part of these standalone financial statements 36 - 59

As per our report of even date attached
for **M S K A & Associates**
Chartered Accountants
Firm's Registration No: 105047W

for and on behalf of the Board

Amrish Vaidya
Partner
Membership No.: 101739

Mukund Kabra
Wholetime Director
DIN : 00148294
Place : Thane

Vinodkumar Jajoo
Director
DIN : 08224980
Place : Nashik

Place: Thane
Date: 13 May 2025

Sanjay Basantani
Company Secretary
Membership No: A19637
Place : Thane

Beni P. Rauka
Chief Financial Officer
Membership No: 039980
Place : Thane

Statement of Changes in Equity (SOCIE)

For the year ended 31 March 2025

(a) Equity share capital (refer note 20)	As at 31 March 2025		As at 31 March 2024	
	No. of Shares	Amount	No. of Shares	Amount
Balance at the beginning of the year	111,824,075	223.65	111,824,075	223.65
Changes in equity share capital due to prior period errors	-	-	-	-
Restated balance at the beginning of the current reporting year	111,824,075	223.65	111,824,075	223.65
Changes in equity share capital during the year	57,075	0.11	-	-
Balance at the end of the year	111,881,150	223.76	111,824,075	223.65

(b) Other equity (refer note 21)

Particulars	Reserves and Surplus					Total Equity
	Securities Premium	Capital Reserve	General reserve	Employee stock option reserve	Retained earnings	
Balance at 1 April 2023	819.13	3.00	32.53	-	4,175.01	5,029.67
Profit for the year	-	-	-	-	1,081.23	1,081.23
Other comprehensive income for the year	-	-	-	-	(1.03)	(1.03)
Total comprehensive income for the year	-	-	-	-	1,080.20	1,080.20
Add : Options granted during the year	-	-	-	30.31	-	30.31
Less: Dividend	-	-	-	-	(559.12)	(559.12)
Balance at 31 March 2024	819.13	3.00	32.53	30.31	4,696.09	5,581.06
Profit for the year	-	-	-	-	1,024.20	1,024.20
Other comprehensive income for the year	-	-	-	-	(3.44)	(3.44)
Total comprehensive income for the year	-	-	-	-	1,020.76	1,020.76
Add : Options granted during the year	-	-	-	36.80	-	36.80
Less: Options lapsed during the year	-	-	-	(2.34)	-	(2.34)
Add / (Less): Exercise of Share options	18.91	-	-	(15.24)	-	3.67
Less: Dividend	-	-	-	-	(570.30)	(570.30)
Balance at 31 March 2025	838.04	3.00	32.53	49.53	5,146.55	6,069.65

The accompanying notes are an integral part of these standalone financial statements 36 - 59

As per our report of even date attached for **M S K A & Associates**
Chartered Accountants
Firm's Registration No: 105047W

for and on behalf of the Board

Amrish Vaidya
Partner
Membership No.: 101739

Mukund Kabra
Wholetime Director
DIN : 00148294
Place : Thane

Place: Thane
Date: 13 May 2025

Sanjay Basantani
Company Secretary
Membership No: A19637
Place : Thane

Vinodkumar Jajoo
Director
DIN : 08224980
Place : Nashik

Beni P. Rauka
Chief Financial Officer
Membership No: 039980
Place : Thane

Standalone Cash Flow Statement

For the year ended 31 March 2025

	(₹ in million)	
	Year ended 31 March 2025	Year ended 31 March 2024
A. Cash flows from operating activities		
Profit before tax	1,205.28	1,339.92
	1,205.28	1,339.92
Adjustments for non-cash transactions		
Depreciation and amortization expense	114.04	108.98
Property, plant and equipment written off	-	0.68
(Profit) on sale of property, plant and equipment	(0.59)	(0.14)
Bad debts written off	4.91	4.32
Provision for doubtful trade receivables provided	6.27	(1.30)
Employee stock compensation expense	30.41	25.83
Excess provision written back	(1.98)	(7.14)
Sundry balances written off/ (back) (net)	(0.01)	0.56
Unrealized foreign exchange (gain)/loss	(0.84)	(0.77)
Fair value adjustment on investments	(19.20)	(20.08)
Provision for investments and loans given to subsidiary	-	189.48
	1,338.29	1,640.34
Items considered separately		
Interest income	(11.26)	(11.16)
Interest expenses	2.36	1.57
Dividend income	(561.06)	(526.71)
Operating profit before working capital changes	768.33	1,104.04
Adjustments for working capital changes.		
(Increase) / Decrease in Non-current loans	-	(0.19)
(Increase) / Decrease in Other non-current financial assets	(1.27)	(2.76)
(Increase) / Decrease in Other non-current assets	(0.33)	(1.64)
(Increase) / Decrease in Inventories	(45.66)	(200.96)
(Increase) / Decrease in Trade receivables	(40.62)	(87.24)
(Increase) / Decrease in Current loans	0.16	(0.01)
(Increase) / Decrease in Other current financial assets	120.83	(41.58)
(Increase) / Decrease in Other current assets	9.75	(15.45)
(Decrease) / Increase in Provisions	6.95	7.61
(Decrease) / Increase in Trade payables	11.82	42.47
(Decrease) / Increase in Other current financial liabilities	11.55	(10.11)
(Decrease) / Increase in Other current liabilities	8.73	(5.82)
Cash generated from operating activities	850.24	788.36
Income taxes paid (net)	(215.45)	(272.06)
Net cash generated from operating activities	634.79	516.30
B. Cash flows from investing activities		
Purchase of property, plant and equipment	(223.37)	(206.12)
Proceeds from sale of property, plant and equipment	1.21	1.30
Purchase of intangible assets (net of refunds)	(0.83)	(0.25)
Purchase of non-current investments	(478.18)	(56.07)
Proceeds / (Purchase) from sale of current investments (net)	160.71	(328.05)

Standalone Cash Flow Statement (Contd.)

For the year ended 31 March 2025

	(₹ in million)	
	Year ended 31 March 2025	Year ended 31 March 2024
Interest received	13.93	11.20
Dividend received	561.06	526.71
(Increase) / Decrease in bank deposits with maturity more than 3 months but less than 12 months	3.63	24.25
(Increase) / Decrease in bank deposits with maturity of more than 12 months #	(55.54)	(0.00)
Net cash (used in) investing activities	(17.38)	(27.03)
C. Cash flows from financing activities		
Proceeds from issue of share capital including securities premium	3.78	-
Repayment of short-term borrowings (net)	-	(0.07)
Interest paid	(0.02)	(1.57)
Payment of Lease liabilities	(9.78)	(8.05)
Dividends paid	(570.30)	(559.12)
Net cash (used in) financing activities	(576.32)	(568.81)
Net (decrease) / increase in cash and cash equivalents (A+B+C)	41.09	(79.54)
Cash and cash equivalents as at the beginning of the period	14.95	94.49
Cash and cash equivalents as at the end of the period*	56.04	14.95
* Composition of cash and cash equivalents (refer note 16)		
Cash in hand	0.40	0.31
Balance with banks :		
Current account	52.48	14.64
Fixed deposit account (with maturity less than 3 months)	3.16	-
	56.04	14.95

Figures are below ₹ 0.01 Million, hence disclosed as ₹ 0.00

Reconciliation between the opening and closing balances in the standalone balance sheet for liabilities arising from financing activities

Particulars	Notes	31 March 2024	Cashflows	Non cash changes				31 March 2025
				Acquisitions	Foreign exchange movement	Fair value change	Other adjustments	
Cash credit, packing credit, working capital demand loans and deferred sales tax liabilities	-	-	-	-	-	-	-	-
Total liabilities from financing		-	-	-	-	-	-	-

The accompanying notes are an integral part of these standalone financial statements 36 - 59

- 1) The cash flow statement has been prepared under indirect method as set out in Ind AS 7, 'Cash Flow Statement' as notified by the Central Government under the Companies Act, 2013.

As per our report of even date attached
for **M S K A & Associates**
Chartered Accountants
Firm's Registration No: 105047W

for and on behalf of the Board

Amrish Vaidya
Partner
Membership No.: 101739

Mukund Kabra
Wholetime Director
DIN : 00148294
Place : Thane

Vinodkumar Jajoo
Director
DIN : 08224980
Place : Nashik

Place: Thane
Date: 13 May 2025

Sanjay Basantani
Company Secretary
Membership No: A19637
Place : Thane

Beni P. Rauka
Chief Financial Officer
Membership No: 039980
Place : Thane

Notes to the Standalone Financial Statements for the year ended 31 March 2025

(₹ in million)

1 Corporate Information

Advanced Enzyme Technologies Limited ('the Company') (CIN: L24200MH1989PLC051018) is engaged in the business of manufacturing and sales of enzymes.

The Company is a public limited company and was incorporated on 15 March 1989 under the provisions of Companies Act, 1956 and is domiciled in India. The corporate office of the Company is situated at Sun Magnetica, A Wing, 5th floor, Near LIC Service Road, Louis Wadi, Thane (West) - 400 604.

The equity shares of the Company are listed on National Stock Exchange of India Limited (NSE) via id ADVENZYMES and on BSE Limited (BSE) via Id 540025.

The Board of Directors approved the standalone financial statements for the year ended 31 March 2025 and authorised for issue on 13 May 2025.

2 Statement of compliance

These standalone financial statements have been prepared in accordance with the Indian Accounting Standards (referred to as "Ind AS") as prescribed under section 133 of the Companies Act, 2013 read with the Companies (Indian Accounting Standards) Rules as amended from time to time

3 Basis of preparation

These Standalone financial statements have been prepared on a historical cost basis, except for certain financial instruments and defined benefit plans which are measured at fair value at the end of each reporting period. Historical cost is generally based on the fair value of the consideration given in exchange for goods and services. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

All the assets and liabilities have been classified as current or non current as per the Company's normal operating cycle and other criteria set out in Schedule III to the Act. Based on the nature of products and the time between the acquisition of assets for processing and their realization in cash and cash equivalent, the Company has ascertained the operating cycle to be 12 months.

The statement of cash flows has been prepared under indirect method, whereby profit or loss is adjusted for the effects of transactions of a non-cash nature, any deferrals or accruals of past or future operating cash receipts or payments and items of income or expense associated with investing or financing cash flows. The cash flows from operating, investing and financing activities of the Company are segregated. The Company considers all highly liquid investments that are readily convertible to known amounts of cash and are subject to an insignificant risk of changes in value to be cash equivalents

Functional and presentation currency:

These Standalone financial statements are presented in Indian rupees, which is the Company's functional currency. All amounts have been rounded off to two decimal places to the nearest million, unless otherwise indicated.

Going concern:

These standalone financial statements are prepared on going concern basis.

4 Use of estimates

The preparation of standalone financial statements in conformity with Ind AS requires the management to make use of judgements, estimates and assumptions, that affect the application of accounting policies and the reported amounts of assets and liabilities, revenue and expenses and disclosure of contingent liabilities. The estimates and assumptions used in accompanying financial statements are based upon management's evaluation of the relevant facts and circumstances as of the date of the financial statements. Actual results may differ from the estimates and assumptions used in preparing the accompanying standalone financial statements and reviewed on an ongoing basis. Any revision to accounting estimates is recognized prospectively in current and future periods.

Assumptions and estimation uncertainties that have a significant risk of resulting in a material adjustment in the year ended 31 March 2025 are as follows:

a. Depreciation and amortisation

Depreciation and amortisation is based on management estimates of the future useful lives of the property, plant and equipment and intangible assets. The management estimates the useful lives of tangible assets similar to the useful life prescribed in Schedule II of the Act. In cases, where the useful lives are different from that prescribed in Schedule II, they are based on technical advice, taking into account the nature of the asset, the estimated usage of the asset, the operating conditions of the asset, past history of replacement, anticipated technological changes, manufacturers' warranties and maintenance support.

Estimates may change due to technological developments, competition, changes in market conditions and other factors and may result in changes in the estimated useful life and in the depreciation and amortisation charges.

b. Defined benefit plans

The cost of the defined benefit gratuity plan and the present value of the gratuity obligation are determined using actuarial valuations. An actuarial valuation involves making various assumptions that may differ from actual developments in the future. These include the determination of the discount rate; future salary increases and mortality rates. Due to the complexities involved in the valuation and its long-term nature, a defined benefit obligation is highly sensitive to changes in these assumptions. In determining the appropriate discount rate for plans operated in India, the management considers the interest rates of government bonds where remaining maturity of such bond correspond to expected term of defined benefit obligation.

The mortality rate is based on publicly available mortality tables. Those mortality tables tend to change only at interval in response to demographic changes.

Notes to the Standalone Financial Statements
for the year ended 31 March 2025

(₹ in million)

Future salary increases and gratuity increases are based on expected future inflation rates.

All assumptions are reviewed at each reporting date.

c. Provision for income tax and deferred tax assets

The Company uses judgements based on the relevant rulings in the areas of allowances and disallowances which is exercised while determining the provision for income tax. A deferred tax asset is recognised to the extent that it is probable that future taxable profit will be available against which the deductible temporary differences, tax losses and unabsorbed depreciation can be utilised. Accordingly, the Company exercises its judgement to reassess the carrying amount of deferred tax assets at the end of each reporting period.

d. Recognition and measurement of other provisions

The recognition and measurement of other provisions are based on the assessment of the probability of an outflow of resources, and on past experience and circumstances known at the balance sheet date. The actual outflow of resources at a future date may therefore vary from the amount included in other provisions.

e. Provision for expected credit losses (ECL) of trade receivables

The Company uses a provision matrix to calculate ECLs for trade receivables. The provision rates are based on days past due for Groupings of various customer segments that have similar loss patterns (i.e., by aging of receivables after considering letters of credit and other forms of security).

The provision matrix is initially based on the Company's historical observed default rates. At every reporting date, the historical observed default rates are updated. The Company's historical credit loss experience and forecast of economic conditions may also not be representative of customer's actual default in the future.

f. Measurement of fair values

The Company's material accounting policies and disclosures require the measurement of fair values, for both financial and non-financial assets and liabilities.

The Company has an established control framework with respect to the measurement of fair values, which includes overseeing all significant fair value measurements, including Level 3 fair values by the management. The management regularly reviews significant unobservable inputs and valuation adjustments. If third party information, such as broker quotes or pricing services, is used to measure fair values, then the management assesses the evidence obtained from the third parties to support the conclusion that such valuations meet the requirements of Ind AS, including the level in the fair value hierarchy in which such valuations should be classified.

When measuring the fair value of a financial asset or a financial liability, the Company uses observable market data as far as possible. Fair values are categorised into different levels in a fair value hierarchy based on the inputs used in the valuation techniques as follows.

- Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities.
- Level 2: inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).
- Level 3: inputs for the asset or liability that are not based on observable market data (unobservable inputs).

If the inputs used to measure the fair value of an asset or a liability fall into different levels of the fair value hierarchy, then the fair value measurement is categorised in its entirety in the same level of the fair value hierarchy as the lowest level input that is significant to the entire measurement. The Company recognises transfers between levels of the fair value hierarchy at the end of the reporting period during which the change has occurred.

5 Standards issued but not yet effective

Ministry of Corporate Affairs ("MCA") notifies new standards or amendments to the existing standards under Companies (Indian Accounting Standards) Rules as issued from time to time. For the year ended March 31, 2025, MCA has notified a new Accounting Standard Ind AS 117 on Insurance Contracts and a amendment to Ind AS 116 on Leases to existing standards however these are not applicable to the Company.

6 Material accounting policies:

The accounting policies set out below have been applied consistently to the periods presented in the financial statements.

a. Revenue and other income

Revenue recognition

- i. The Company recognises revenue from sale of goods measured upon satisfaction of performance obligation which is at a point of time when the control of goods is transferred to the customer. Revenue is measured based on transaction price, which is the consideration, adjusted for estimated returns and allowances, discounts and volume rebates, if any, as specified in the contracts with the customers. Sales are exclusive of Goods and Service Tax (GST).
- ii. Export incentives received pursuant to the Duty Drawback Scheme and Remission of Duties and Taxes on Exported Products (RoDTEP) are accounted on an accrual basis, to the extent it is probable that realization is certain.

Notes to the Standalone Financial Statements
for the year ended 31 March 2025

(₹ in million)

Other income

- i Interest income is recognized on a time proportionate basis, taking into account the amount outstanding and the rates applicable.
- ii Dividend income is recognized when the Company's right to receive dividend is established by the reporting date.

b. Property, plant and equipment and depreciation

Recognition and measurement

- i. Items of property, plant and equipment are stated at cost less accumulated depreciation and amortisation and accumulated impairment losses, if any. Cost includes taxes, non refundable duties and taxes, freight and other incidental expenses directly related to acquisition/construction and installation of the assets. Any trade discounts and rebates are deducted in arriving the purchase price. Interest on borrowings to finance acquisition of property, plant and equipment during qualifying period is capitalized.
- ii. Leasehold improvements represent expenses incurred towards civil work and interior furnishings on the leased premises.
- iii. An asset is eliminated from the financial statements on disposal or when no further benefit is expected from its use and disposal. Gains / losses arising from disposal of property, plant and equipment carried at cost are recognised in the Statement of Profit and Loss.
- iv. Capital work-in-progress includes assets not ready for their intended use and related incidental expenses and attributable interest.
- v. The Company has elected to continue with the carrying value of all its property, plant and equipment as recognized in the standalone financial statements as at the date of transition to Ind AS, measured as per the previous GAAP and use that as the deemed cost as at the transition date pursuant to the exemption under Ind AS 101.

Subsequent expenditure

- vi. Subsequent expenditure is capitalised only if it is probable that the future economic benefits associated with the expenditure will flow to the Company.

Useful life

- vii. The Company has reviewed its policy for providing depreciation on its tangible assets and has also reassessed their useful lives as per Part C of Schedule II of the Act. The revised useful lives, as assessed by the management, match those specified in Part C of Schedule II of the Act, for all classes of tangible assets.

The estimated useful life of assets are as follows:

Particulars	Estimated useful life
Building including residential flats	30 - 60 years
Plant and equipment	10 - 25 years
Furniture and fixture	10 years
Vehicles	8 years
Office equipments	5 years
Computer and data processing equipment	3 - 6 years

Depreciation

- vii. Depreciation on tangible fixed assets other than plant and equipment and residential flat included under buildings has been provided on Written Down Value method and on plant and equipment and on residential flat included under buildings on Straight Line Method. Depreciation is provided on a pro-rata basis, i.e. from the date on which asset is ready for use.
- viii. Leasehold improvements and leasehold land are amortized on Straight Line Method over the unexpired primary period of lease.

c. Intangible assets

- i. Intangible assets are stated at cost of acquisition less accumulated amortisation and accumulated impairment losses, if any.
- ii. Costs relating to acquisition of technical know-how and software are capitalized as intangible assets. Further, the expenditure incurred towards product studies during the development of product dossiers are grouped under "Intangible assets under development" to the extent such expenditure meet the criteria of intangible asset.
- iii. Subsequent expenditure is capitalised only when it increases the future economic benefits embodied in the specific asset to which it relates.
- iv. An intangible asset is eliminated from the financial statements on disposal or when no further benefit is expected from its use and disposal. Gains / losses arising from disposal are recognised in the Statement of Profit and Loss.
- v. Any expected loss is recognized immediately in the Statement of Profit and Loss.
- vi. Intangible assets that are ready for use are amortized on a straight line basis as follows:

Particulars	Estimated useful life
Computer software	4 years
Product dossiers	10 years

Notes to the Standalone Financial Statements for the year ended 31 March 2025

(₹ in million)

d. Impairment of non-financial assets

The carrying values of assets at each balance sheet date are reviewed for impairment if any indication of impairment exists.

If the carrying amount of the assets exceed the estimated recoverable amount, an impairment is recognized for such excess amount. The impairment loss is recognized as an expense in the Statement of Profit and Loss, unless the asset is carried at revalued amount, in which case any impairment loss of the revalued asset is treated as a revaluation decrease to the extent a revaluation reserve is available for that asset.

The recoverable amount is the greater of the net selling price and their value in use. Value in use is arrived at by discounting the future cash flows to their present value based on an appropriate discount factor.

When there is indication that an impairment loss recognized for an asset (other than a revalued asset) in earlier accounting periods no longer exists or may have decreased, such reversal of impairment loss is recognized in the Statement of Profit and Loss, to the extent the amount was previously charged to the Statement of Profit and Loss. In case of revalued assets such reversal is not recognized.

e. Foreign currency transactions

- Functional and presentation currency - Items included in these standalone financial statements are measured using the currency of the primary economic environment in which the entity operates ('the functional currency'). These standalone financial statements are presented in Indian rupee (INR), which is the Company's functional and presentation currency.
- Initial recognition - Foreign currency transactions are recorded in the functional currency, by applying to the foreign currency amount the exchange rate between the functional currency and the foreign currency at the date of the transaction. All exchange differences arising on settlement/conversion on foreign currency transactions are included in the Statement of Profit and Loss in the period in which they arise.
- Subsequent measurement- Monetary assets and liabilities denominated in foreign currencies are translated into the functional currency at the exchange rate at the reporting date. Non-monetary assets and liabilities that are measured at fair value in a foreign currency are translated into the functional currency at the exchange rate when the fair value was determined. Foreign currency differences are generally recognised in the Statement of Profit and Loss. Non-monetary items that are measured based on historical cost in a foreign currency are not translated.

f. Share-based payments

Employees Stock Option Plans ("ESOPs"):

Equity-settled plans are accounted at fair value as at the grant date. The fair value of the share-based option is determined at the grant date using a market-based option valuation model (Black Scholes Option Valuation Model). The fair value of the option is recorded as compensation expense amortized over the vesting period of the options, with a corresponding increase in Reserves and Surplus under the head "Employee Stock Option Reserve". On exercise of the option, the proceeds are recorded as share capital.

The cumulative expense recognized for equity-settled transactions at each reporting date until the vesting date reflects the extent to which the vesting period has expired and the Company's best estimate of the number of equity instruments that will ultimately vest. The charge or credit to the Statement of Profit and Loss for a period represents the movement in cumulative expense recognized as at the beginning and end of that period and is recognized in employee benefits expense.

Service and non-market performance conditions are not taken into account when determining the grant date fair value of awards, but the likelihood of the conditions being met is assessed as part of the Company's best estimate of the number of equity instruments that will ultimately vest.

Employee stock options provided to the employees of subsidiary under a group plan is accounted as capital contribution to the subsidiary, if no payments for related costs from the subsidiary to the Company is agreed, and recorded as investments in the standalone financial statements.

g. Inventories

- Inventories of raw materials, packing materials, consumables, finished goods and work-in-process are valued at lower of cost or net realizable value on an item-by-item basis.
- Cost of raw materials, consumables and packing materials is determined on weighted average basis. Cost of finished goods and stock-in-process is determined by considering materials, labour costs, conversion costs, including an appropriate share of fixed production overheads based on normal operating capacity and other related costs incurred in bringing the inventories to their present condition and location.

Net realisable value is the estimated selling price in the ordinary course of business, less the estimated costs of completion and the estimated costs necessary to make the sale. Raw materials and other supplies held for use in the production of inventories are not written down below cost except in case where material prices have declined and it is estimated that the cost of the finished product will exceed its net realisable value.

Notes to the Standalone Financial Statements for the year ended 31 March 2025

(₹ in million)

h. Employee benefits

Employee benefits payable wholly within twelve months of receiving employees services are classified as short-term employee benefits. The short term employee benefits are accounted on undiscounted basis during the accounting period based on services rendered by employees.

i. Defined contribution plans

A defined contribution plan is a post-employment benefit plan under which an entity pays specified contributions to a separate entity and has no obligation to pay any further amounts. The Company contributes to statutory provident fund in accordance with Employees' Provident Fund and Miscellaneous Provisions Act, 1952 that is a defined contribution plan and contribution paid or payable is recognized as an expense in the period in which the employee renders services.

Superannuation benefits, a defined contribution plan, has been funded with Life Insurance Corporation of India and the contribution is charged to Statement of Profit and Loss, when the contribution to the Fund is due.

ii. Defined benefit plans

The Company provides for Gratuity benefit and Compensated Absences, which are defined benefit plans, covering all its eligible employees. Liability towards gratuity benefits and compensated absences expected to occur after twelve months, are determined using the Projected Unit Credit Method. Actuarial valuations are carried out at the balance sheet date. Remeasurements of the net defined benefit liability, which comprise actuarial gains and losses, the return on plan assets (excluding interest) and the effect of the asset ceiling (if any, excluding interest), are recognised in OCI. The retirement benefit obligation recognized in the balance sheet represents the present value of the defined benefit obligation as adjusted for unrecognized past service cost, and as reduced by the fair value of scheme assets. The gratuity benefit and compensated absences scheme is funded with the Life Insurance Corporation of India (LIC).

The short term provision for compensated absences has been calculated on undiscounted basis, based on the balance of leave available over and above the maximum accumulation allowed as per the Company policy.

i. Income taxes

Income tax expense comprises current tax (i.e. amount of tax for the period determined in accordance with the income tax law), deferred tax charge or credit (reflecting the tax effects of timing differences between accounting income and taxable income for the period) and Minimum Alternate Tax (MAT) credit entitlement.

Current tax

Current income tax relating to items recognised outside profit or loss is recognised outside profit or loss (either in other comprehensive income or in equity). Current tax items are recognised in correlation to the underlying transaction either in OCI or directly in equity. Management periodically evaluates positions taken in the tax returns with respect to situations in which applicable tax regulations are subject to interpretation and establishes provisions where appropriate.

Deferred tax

Deferred tax is recognised in respect of temporary difference between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the year when the asset is realised or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the reporting date.

Deferred tax assets are recognised for all deductible temporary differences, the carry forward of unused tax credits and any unused tax losses. Deferred tax assets are recognised to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, and the carry forward of unused tax credits and unused tax losses can be utilised.

The carrying amount of deferred tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilised. Unrecognised deferred tax assets are re-assessed at each reporting date and are recognised to the extent that it has become probable that future taxable profits will allow the deferred tax asset to be recovered.

Deferred tax relating to items recognised outside profit or loss is recognised outside profit or loss (either in other comprehensive income or in equity). Deferred tax items are recognised in correlation to the underlying transaction either in Other Comprehensive Income (OCI) or directly in equity.

Deferred tax assets and liabilities are offset only if:

- The entity has a legally enforceable right to set off current tax assets against current tax liabilities; and
- The deferred tax assets and the deferred tax liabilities relate to income taxes levied by the same taxation authority on the same taxable entity.

Deferred tax relating to items recognised outside profit or loss is recognised outside profit or loss (either in other comprehensive income or in equity). Deferred tax items are recognised in correlation to the underlying transaction either in OCI or directly in equity

j. Borrowing costs

Borrowing costs are interest and other costs that the Company incurs in connection with the borrowing of

Notes to the Standalone Financial Statements for the year ended 31 March 2025

(₹ in million)

funds and is measured with reference to the Effective Interest Rate (EIR) applicable to the respective borrowing. Borrowing cost include interest costs measured at EIR and exchange differences arising from foreign currency borrowings to the extent they are regarded as an adjustment to the interest cost.

Borrowing costs incurred on constructing or acquiring a qualifying asset are capitalized as cost of that asset until it is ready for its intended use. A qualifying asset is an asset that necessarily takes a substantial period of time to get ready for its intended use or sale. All other borrowing costs are charged to revenue and recognized as an expense in the Statement of Profit and Loss.

k. Research and development costs

Research and development costs incurred for development of products are expensed as incurred, except for development costs that relate to the design and testing of new or improved materials, products or processes, which are recognized as an intangible asset to the extent that it is technically feasible to complete the development of such asset and future economic benefits are expected to be generated from such assets. Capital expenditure on research and development is included as part of assets and depreciated on the same basis as other assets.

l. Provisions and contingencies

Provisions are determined by discounting the expected future cash flows specific to the liability. The unwinding of the discount is recognised as finance cost. A provision for onerous contracts is measured at the present value of the lower of the expected cost of terminating the contract and the expected net cost of continuing with the contract. Before a provision is established, the Company recognises any impairment loss on the assets associated with that contract.

A disclosure for a contingent liability is made when there is a possible obligation or a present obligation that may, but will probably not, require an outflow of resources. When there is a possible obligation or a present obligation in respect of which the likelihood of outflow of resources is remote, no provision or disclosure is made.

A contingent asset is not recognised but disclosed in the financial statements where an inflow of economic benefit is probable.

m. Leases

The Company assesses whether a contract contains a lease, at inception of a contract. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. To assess whether a contract conveys the right to control the use of an identified assets, the Company assesses whether:

- the contact involves the use of an identified asset
- the Company has substantially all of the economic benefits from use of the asset through the period of the lease and

- the Company has the right to direct the use of the asset.

As a lessee, the Company recognises a right-of-use asset and a lease liability at the lease commencement date. The right of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset or to restore the underlying asset or the site on which it is located, less any lease incentives received.

The right-of-use asset is subsequently depreciated using the straight-line method from the commencement date to the earlier of the end of the useful life of the right of-use asset or the end of the lease term. The estimated useful lives of right-of-use assets are determined on the same basis as those of property and equipment. In addition, the right-of-use asset is periodically reduced by impairment losses, if any, and adjusted for certain remeasurements of the lease liability.

The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company's incremental borrowing rate.

Generally, the Company uses its incremental borrowing rate as the discount rate. Lease payments included in the measurement of the lease liability comprise the fixed payments, including in substance fixed payments;

The lease liability is measured at amortised cost using the effective interest method.

The Company has elected not to recognise right-of-use assets and lease liabilities for short-term leases that have a lease term of 12 months or less and leases of low-value assets.

The Company's leases mainly comprise of office premises and land and buildings for warehouse facilities.

n. Cash and cash equivalents

Cash comprises of cash at bank and in hand and cash equivalents comprise of short-term bank deposits with an original maturity of three months or less.

For the purpose of the statement of cash flows, cash and cash equivalents consist of cash and short term deposits, as defined above, net of outstanding bank overdrafts as they are considered an integral part of the Company's cash management.

o. Financial Instruments

a. Financial assets

i. Recognition and initial measurement

Trade receivables and debt instruments issued are initially recognised when they are originated. All other financial assets

Notes to the Standalone Financial Statements for the year ended 31 March 2025

(₹ in million)

are initially recognised when the Company becomes a party to the contractual provisions of the instrument.

A financial asset is initially measured at fair value. In the case of financial assets which are recognised at fair value through profit and loss (FVTPL), the transaction costs are recognised in the Statement of Profit and Loss. In other cases, the transaction costs are attributed to the acquisition value of the financial asset.

ii. Classification

On initial recognition, a financial asset is classified as measured at

- amortised cost; or
- fair value through profit and loss (FVTPL); or
- fair value through other comprehensive income (FVOCI) - debt investment or equity investment

Financial assets are not reclassified subsequent to their initial recognition, except if and in the period the Company changes its business model for managing financial assets.

A financial asset is measured at amortised cost if it meets both of the following conditions and is not designated as at FVTPL:

- the asset is held within a business model whose objective is to hold assets to collect contractual cash flows; and
- the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

iii. Recognition and initial measurement

A debt investment is measured at FVOCI if it meets both of the following conditions and is not designated as at FVTPL:

- the asset is held within a business model whose objective is achieved by both collecting contractual cash flows and selling financial assets; and
- the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

On initial recognition of an equity investment that is not held for trading, the Company may irrevocably elect to present subsequent changes in the investment's fair value in OCI (designated as FVOCI –

equity investment). This election is made on an investment- by- investment basis.

All financial assets not classified as measured at amortised cost or FVOCI as described above are measured at FVTPL. This includes all derivative financial assets. On initial recognition, the Company may irrevocably designate a financial asset that otherwise meets the requirements to be measured at amortised cost or at FVOCI as at FVTPL if doing so eliminates or significantly reduces an accounting mismatch that would otherwise arise.

Financial assets that are held for trading or are managed and whose performance is evaluated on a fair value basis are measured at FVTPL.

iv. Subsequent measurement and gains and losses

Financial assets at FVTPL

These assets are subsequently measured at fair value. Net gains and losses, including any interest or dividend income, are recognised in Statement of Profit and Loss.

Financial assets at amortised cost

These assets are subsequently measured at amortised cost using the effective interest method. The amortised cost is reduced by impairment losses. Interest income, foreign exchange gains and losses and impairment are recognised in Statement of Profit and Loss. Any gain or loss on derecognition is recognised in Statement of Profit and Loss.

Debt investments at FVOCI

These assets are subsequently measured at fair value. Interest income under the effective interest method, foreign exchange gains and losses and impairment are recognised in Statement of Profit and Loss. Other net gains and losses are recognised in OCI. On derecognition, gains and losses accumulated in OCI are reclassified to Statement of Profit and Loss.

Equity investments at FVOCI

These assets are subsequently measured at fair value. Dividends are recognised as income in Statement of Profit and Loss unless the dividend clearly represents a recovery of part of the cost of the investment. Other net gains and losses are recognised in OCI and are not reclassified to Statement of Profit and Loss.

v. Derecognition

The Company derecognises a financial asset when the contractual rights to the

Notes to the Standalone Financial Statements
for the year ended 31 March 2025

(₹ in million)

cash flows from the financial asset expire, or it transfers the rights to receive the contractual cash flows in a transaction in which substantially all of the risks and rewards of ownership of the financial asset are transferred or in which the Company neither transfers nor retains substantially all of the risks and rewards of ownership and does not retain control of the financial asset.

If the Company enters into transactions whereby it transfers assets recognised on its balance sheet, but retains either all or substantially all of the risks and rewards of the transferred assets, the transferred assets are not derecognised.

vi. Impairment of financial assets

In accordance with Ind AS 109, the company applies Expected Credit Loss (ECL) model for measurement and recognition of impairment loss on the following financial assets and credit risk exposure:

- i. Financial assets that are debt instruments, and are measured at amortised cost e.g., loans, debt securities, deposits, and bank balance.
- ii. Trade receivables.

The application of simplified approach does not require the company to track changes in credit risk. Rather, it recognises impairment loss allowance based on lifetime ECLs at each reporting date, right from its initial recognition.

vii. Investment in subsidiaries

Investment in subsidiaries is carried at cost in the standalone financial statements.

b. Financial liabilities

i. Recognition and initial measurement

All financial liabilities are initially recognised when the Company becomes a party to the contractual provisions of the instrument.

A financial liability is initially measured at fair value. In the case of financial liabilities which are recognised at fair value through profit and loss (FVTPL), the transaction costs are recognised in the Statement of Profit and Loss. In other cases, the transaction costs are attributed to the acquisition or issue of financial liability.

ii. Classification, subsequent measurement and gains and losses

Financial liabilities are classified as measured at amortised cost or FVTPL. A

financial liability is classified as at FVTPL if it is classified as held- for- trading, or it is a derivative or it is designated as such on initial recognition. Financial liabilities at FVTPL are measured at fair value and net gains and losses, including any interest expense, are recognised in Statement of Profit and Loss. Other financial liabilities are subsequently measured at amortised cost using the effective interest method. Interest expense and foreign exchange gains and losses are recognised in Statement of Profit and Loss. Any gain or loss on derecognition is also recognised in Statement of Profit and Loss.

iii. Derecognition

The Company derecognises a financial liability when its contractual obligations are discharged or cancelled, or expire.

The Company also derecognises a financial liability when its terms are modified and the cash flows under the modified terms are substantially different. In this case, a new financial liability based on the modified terms is recognised at fair value. The difference between the carrying amount of the financial liability extinguished and the new financial liability with modified terms is recognised in Statement of Profit and Loss.

iv. Offsetting

Financial assets and financial liabilities are offset and the net amount presented in the balance sheet when, and only when, the Company currently has a legally enforceable right to set off the amounts and it intends either to settle them on a net basis or to realise the asset and settle the liability simultaneously.

v. Financial guarantee contract

Financial guarantee contracts issued on behalf of a subsidiary is accounted as capital contribution to the subsidiary, if no payments from the subsidiary to the Company is agreed, and recorded as investments in the standalone financial statement.

p. Earnings Per Share:

Basic earnings per share are calculated by dividing the net profit or loss for the period attributable to equity shareholders by the weighted average number of equity shares outstanding during the period.

For the purpose of calculating diluted earnings per share, the net profit or loss for the period attributable to equity shareholders and the weighted average number of shares outstanding during the period are adjusted for the effects of all dilutive potential equity shares.

Notes to the Standalone Financial Statements
for the year ended 31 March 2025

(₹ in million)

7 Property, plant and equipment

Gross block	Land Freehold	Land Leasehold	Buildings	Plant and equipment	Furniture and fixtures	Vehicles	Office equipments	Leasehold improvements	Computer and data processing equipments	Right to use asset (Refer note b)	Total
Balance as at 1 April 2023	368.05	5.22	314.79	1,148.44	32.57	33.24	19.72	3.60	27.44	48.28	2,001.35
Additions	-	-	5.00	73.08	2.12	1.85	7.95	-	12.59	0.65	103.24
Disposals	-	-	-	1.95	0.14	1.33	0.09	-	0.22	-	3.73
Other adjustments	-	-	-	-	-	-	-	-	-	-	-
Reversal on account of assets written off	-	-	-	-	-	-	0.68	-	6.55	-	7.23
Balance as at 31 March 2024	368.05	5.22	319.79	1,219.57	34.55	33.76	26.90	3.60	33.26	48.93	2,093.63
Additions	-	-	15.05	150.31	1.30	9.69	4.28	0.15	2.74	20.05	203.57
Disposals	-	-	0.03	5.68	0.37	2.23	0.26	-	-	-	8.57
Balance as at 31 March 2025	368.05	5.22	334.81	1,364.20	35.48	41.22	30.92	3.75	36.00	68.98	2,288.63
Accumulated depreciation and amortization											
Balance as at 1 April 2023	-	0.49	109.27	376.46	17.67	17.32	11.92	2.24	21.71	19.82	576.90
Depreciation and amortization	-	0.07	17.83	61.26	3.68	5.05	4.84	0.44	5.80	8.67	107.64
Reversal on disposal of assets	-	-	-	0.96	0.11	1.24	0.07	-	0.19	-	2.57
Other adjustments	-	-	-	-	-	-	-	-	-	-	-
Reversal on account of assets written off	-	-	-	-	-	-	0.62	-	5.93	-	6.55
Balance as at 31 March 2024	-	0.56	127.10	436.76	21.24	21.13	16.07	2.68	21.39	28.49	675.42
Depreciation and amortization	-	0.07	16.79	65.61	3.22	6.19	5.43	0.26	5.86	8.92	112.35
Reversal on disposal of assets	-	-	0.03	5.32	0.34	2.07	0.20	-	-	-	7.96
Balance as at 31 March 2025	-	0.63	143.86	497.05	24.12	25.25	21.30	2.94	27.25	37.41	779.81
Net block											
Balance as at 31 March 2024	368.05	4.66	192.69	782.81	13.31	12.63	10.83	0.92	11.87	20.44	1,418.21
Balance as at 31 March 2025	368.05	4.59	190.95	867.15	11.36	15.97	9.62	0.81	8.75	31.57	1,508.82

Notes to the Standalone Financial Statements

for the year ended 31 March 2025

(₹ in million)

7A Capital work-in-progress (CWIP)

	Amount
CWIP as at 1 April 2023	56.06
Additions during the year	210.98
Capitalised during the year	102.59
CWIP as at 31 March 2024	164.45
Additions during the year	226.41
Capitalised during the year	183.51
CWIP as at 31 March 2025	207.35

(a) For Capital-work-in progress ageing schedule

CWIP as at 31 March 2025	Amount in CWIP for a period of				Total
	Less than 1 year	1 - 2 years	2 - 3 years	More than 3 years	
Projects in progress	125.72	38.82	39.59	3.22	207.35
Projects temporarily suspended	-	-	-	-	-

CWIP as at 31 March 2024	Amount in CWIP for a period of				Total
	Less than 1 year	1 - 2 years	2 - 3 years	More than 3 years	
Projects in progress	121.64	39.59	0.36	2.86	164.45
Projects temporarily suspended	-	-	-	-	-

(b) For Right to use asset (refer note 38)

Gross block	Buildings	Land Leasehold	Total
Balance as at 1 April 2023	35.66	12.62	48.28
Additions	0.65	-	0.65
Disposals	-	-	-
Balance as at 31 March 2024	36.31	12.62	48.93
Additions	20.05	-	20.05
Disposals	-	-	-
Balance as at 31 March 2025	56.36	12.62	68.98
Accumulated depreciation and amortization			
Balance as at 1 April 2023	17.60	2.22	19.82
Depreciation and amortization	7.93	0.74	8.67
Reversal on disposal of assets	-	-	-
Balance as at 31 March 2024	25.53	2.96	28.49
Depreciation and amortization	8.18	0.74	8.92
Reversal on disposal of assets	-	-	-
Balance as at 31 March 2025	33.71	3.70	37.41
Net block			
Balance as at 31 March 2024	10.78	9.66	20.44
Balance as at 31 March 2025	22.65	8.92	31.57

Notes to the Standalone Financial Statements

for the year ended 31 March 2025

(₹ in million)

8 Intangible assets

Gross block	Computer Software	Product Dossiers	Total
Balance as at 1 April 2023	30.97	3.83	34.80
Additions	0.31	-	0.31
Disposals	-	-	-
Balance as at 31 March 2024	31.28	3.83	35.11
Additions	1.09	53.69	54.78
Disposals	-	-	-
Balance as at 31 March 2025	32.37	57.52	89.89
Accumulated amortisation			
Balance as at 1 April 2023	29.04	1.63	30.67
Amortisation	0.96	0.38	1.34
Balance as at 31 March 2024	30.00	2.01	32.01
Amortisation	0.55	1.15	1.70
Balance as at 31 March 2025	30.55	3.16	33.71
Net block			
Balance as at 31 March 2024	1.28	1.82	3.10
Balance as at 31 March 2025	1.82	54.36	56.18

8A Intangible assets under development

	Amount
Balance as at 1 April 2023	54.19
Additions during the year	0.24
Capitalised during the year	0.31
Balance as at 31 March 2024	54.12
Additions during the year	0.82
Capitalised during the year	54.77
Balance as at 31 March 2025	0.17

(a) Intangible assets under development ageing schedule

Intangible assets under development as at 31 March 2025	Projects in progress	Projects temporarily suspended
Less than 1 year	0.05	-
1 - 2 years	0.09	-
2 - 3 years	0.03	-
More than 3 years	-	-
Total	0.17	-

Intangible assets under development as at 31 March 2024	Projects in progress	Projects temporarily suspended
Less than 1 year	0.09	-
1 - 2 years	0.04	-
2 - 3 years	0.30	-
More than 3 years	53.69	-
Total	54.12	-

Notes to the Standalone Financial Statements

for the year ended 31 March 2025

(₹ in million)

9 Non-current investments

	As at 31 March 2025	As at 31 March 2024
Investment in Equity Instruments (Unquoted)		
Investment in subsidiaries (Valued at cost unless stated otherwise)		
60,000 Equity shares (31 March 2024 - 60,000) of ₹ 10 each fully paid up of Advanced Bio-Agro Tech Limited ^	0.60	0.60
70,000 Equity shares (31 March 2024 - 70,000) of ₹ 10 each fully paid up of Advanced Enzytech Solutions Limited ^	1.57	1.57
5,839 Equity shares (31 March 2024 - 5,839) of USD 1,000 each fully paid up of Advanced Enzymes USA, Inc. * ^	533.83	532.77
19,824,656 Equity shares (31 March 2024 - 19,824,656) of ₹ 10 each fully paid up of JC Biotech Private Limited (refer note 48) *#^	852.00	851.34
7,900,000 Equity shares (31 March 2024 - 4,276,837) of Euro 1 each fully paid up of Advanced Enzymes Europe B.V. * ^ (refer note 49, 51 and 56)	961.74	481.22
520,408 Equity shares (31 March 2024 - 520,408) of ₹ 10 each fully paid up of Scitech Specialities Pvt. Ltd. ^	316.26	316.26
19,991,663 Equity shares (31 March 2024 - 19,991,663) of Re 1 each fully paid up of Saiganesh Enzytech Solutions Private Limited ^	59.98	59.98
Less: Provision for diminution in the value of investment (refer note 51)	(189.48)	(189.48)
	2,536.50	2,054.26
Other investments (unquoted)		
Equity shares at fair value through profit and loss		
19,100 Equity shares (31 March 2024 - 19,100) of ₹ 10 each fully paid up of Advenza Global Limited (Formerly known as Advanced Vital Enzymes Pvt Ltd) ^	0.57	0.57
1,666 Equity shares (31 March 2024 - 1,666) of ₹ 30 each fully paid up of Bombay Mercantile Co-op. Bank Limited	0.05	0.05
	0.62	0.62
	2,537.12	2,054.88
Aggregate value of unquoted investments	2,537.12	2,054.88
Provision for diminution in value of investments	189.48	189.48

^ Refer Note 42

* Includes cost of shares options issued to employees of subsidiary under the group plan as per Ind AS 102.

Includes Guarantee commission income recorded for accounting of fair value for financial guarantee contract as per Ind AS 109

10 Long-term loans

(Unsecured considered good unless otherwise stated)

	As at 31 March 2025	As at 31 March 2024
Loans	0.02	0.02
Interest receivable	0.63	0.35
	0.65	0.37

Notes to the Standalone Financial Statements

for the year ended 31 March 2025

(₹ in million)

11 Other non-current financial assets

(unsecured considered good unless otherwise stated)

	As at 31 March 2025	As at 31 March 2024
Non-current bank balances having maturity of more than 12 months	55.60	0.06
Security deposits	23.66	22.39
	79.26	22.45

12 Other non-current assets

(unsecured considered good unless otherwise stated)

	As at 31 March 2025	As at 31 March 2024
Prepaid expenses	3.83	3.50
Capital advances	10.94	11.41
	14.77	14.91

13 Inventories

(valued at lower of cost and net realizable value)

	As at 31 March 2025	As at 31 March 2024
Raw materials and packing materials [including goods-in-transit of ₹ 2.84 million (31 March 2024: ₹ 37.77 million)]	363.57	388.56
Work-in-progress	422.79	354.56
Finished goods [including goods-in-transit of ₹ 67.54 million (31 March 2024 ₹ 36.64 million)]	154.33	157.90
Consumables and fuel [including goods-in-transit of ₹ Nil (31 March 2024 ₹ 2.50 million)]	73.81	67.82
	1,014.50	968.84

As at 31 March 2025, the Company has written down the value for slow moving inventory including net realisable value aggregating ₹ 49.59 million (31 March 2024: ₹ 69.60 million). Charge reversal during the year ended 31 March 2025 is ₹ 20.01 million (31 March 2024: charge of ₹ 17.52 million) is included in cost of materials consumed and changes in inventories.

14 Current investments

Mutual funds (Quoted)

(carried at fair value through profit and loss)

	As at 31 March 2025	As at 31 March 2024
Aditya Birla Sunlife Limited Money Manager Fund - Growth - Direct (No. of units 31 March 2025: Nil, 31 March 2024: 212,983.146) (Market value 31 March 2024: 340.7909/unit)	-	72.58
UTI Money Market Fund - Direct - Growth (No. of units 31 March 2025: 24,874.866, 31 March 2024: 67,752.111) (Market value 31 March 2025: 3,060.6445/unit; 31 March 2024: 2,837.2161/unit)	76.13	192.23

Notes to the Standalone Financial Statements

for the year ended 31 March 2025

(₹ in million)

	As at 31 March 2025	As at 31 March 2024
UTI Overnight Fund -Direct - Growth	-	14.43
(No. of units 31 March 2025: Nil, 31 March 2024: 4,404.003)		
(Market value 31 March 2024: 3,277.4011/unit)		
Tata Overnight Fund - Direct - Growth	20.29	18.29
(No. of units 31 March 2025: 15,057.214, 31 March 2024: 14,478.958)		
(Market value 31 March 2025: 1,347.4855/unit; 31 March 2024: 1,263.236/unit)		
Tata Money Market Fund - Direct - Growth	180.18	139.20
(No. of units 31 March 2025: 38,203.968, 31 March 2024: 31,872.195)		
(Market value 31 March 2025: 4,716.3196/unit; 31 March 2024: 4,367.520/unit)		
HDFC Overnight Fund - Direct Plan Growth	-	2.77
(No. of units 31 March 2025: Nil, 31 March 2024: 779.253)		
(Market value 31 March 2024: 3,553.188/unit)		
HDFC Money Market Fund - Direct Plan Growth	89.92	68.52
(No. of units 31 March 2025: 15,728.622, 31 March 2024: 12,929.034)		
(Market value 31 March 2025: 5,716.824/unit; 31 March 2024: 5,300.037/unit)		
	366.52	508.02

15 Trade receivables

	As at 31 March 2025	As at 31 March 2024
Secured, considered good	0.08	0.08
Unsecured, considered good	781.61	751.64
Unsecured, credit impaired	11.87	5.60
Less : Impairment loss allowance	(11.87)	(5.60)
	781.69	751.72
(Refer note 41 for information about credit risk and market risk of trade receivables)		
The above balance includes amounts due by private companies in which directors are interested (Refer note 42)	152.42	207.60

Notes to the Standalone Financial Statements

for the year ended 31 March 2025

(₹ in million)

Outstanding as on 31 March 2025							
Particulars	Not due	Less than 6 months	6 months - 1 year	1 - 2 years	2 - 3 years	More than 3 years	Total
i) Undisputed Trade Receivables – considered good	374.65	396.11	4.82	5.21	0.59	0.31	781.69
ii) Undisputed Trade Receivables – which have significant increase in credit risk	-	-	-	-	-	-	-
iii) Undisputed Trade Receivables – credit impaired	0.99	2.55	0.93	3.33	2.65	1.42	11.87
iv) Disputed Trade Receivables – considered good	-	-	-	-	-	-	-
v) Disputed Trade Receivables – which have significant increase in credit risk	-	-	-	-	-	-	-
vi) Disputed Trade Receivables – credit impaired	-	-	-	-	-	-	-
Total trade receivables	375.64	398.66	5.75	8.54	3.24	1.73	793.56
Provision for doubtful trade receivables	(0.99)	(2.55)	(0.93)	(3.33)	(2.65)	(1.42)	(11.87)
Net receivable	374.65	396.11	4.82	5.21	0.59	0.31	781.69

Outstanding as on 31 March 2024							
Particulars	Not due	Less than 6 months	6 months - 1 year	1 - 2 years	2 - 3 years	More than 3 years	Total
i) Undisputed Trade Receivables – considered good	463.04	282.08	1.28	4.99	0.33	-	751.72
ii) Undisputed Trade Receivables – which have significant increase in credit risk	-	-	-	-	-	-	-
iii) Undisputed Trade Receivables – credit impaired	0.84	0.96	0.36	1.88	1.33	0.23	5.60
iv) Disputed Trade Receivables – considered good	-	-	-	-	-	-	-
v) Disputed Trade Receivables – which have significant increase in credit risk	-	-	-	-	-	-	-
vi) Disputed Trade Receivables – credit impaired	-	-	-	-	-	-	-
Total trade receivables	463.88	283.04	1.64	6.87	1.66	0.23	757.32
Provision for doubtful trade receivables	(0.84)	(0.96)	(0.36)	(1.88)	(1.33)	(0.23)	(5.60)
Net receivable	463.04	282.08	1.28	4.99	0.33	-	751.72

16 Cash and cash equivalents

	As at 31 March 2025	As at 31 March 2024
Cash on hand	0.40	0.31
Balances with banks		
- in current accounts	52.48	14.64
- in deposit account with original maturity upto three months	3.16	-
	56.04	14.95

16A Other bank balances

	As at 31 March 2025	As at 31 March 2024
Unpaid dividend accounts	2.28	1.59
Bank deposits with original maturity more than three months but less than twelve months	-	3.04
Earmarked bank balances *	-	0.59
	2.28	5.22

* These balances represent unspent Corporate Social Responsibility (CSR) amount of prior years and are transferred to separate bank account as per Section 135(6) of the Companies Act, 2013.

Notes to the Standalone Financial Statements

for the year ended 31 March 2025

(₹ in million)

17 Loans

(unsecured considered good unless otherwise stated)

	As at 31 March 2025	As at 31 March 2024
Loan to employees	0.26	0.42
	0.26	0.42

18 Other current financial assets

(unsecured considered good unless otherwise stated)

	As at 31 March 2025	As at 31 March 2024
Interest receivable	1.26	4.21
Export incentives receivable	1.78	2.87
Bank deposits having original maturity of more than 12 months but remaining maturity is less than 12 months	45.66	165.50
Others	0.11	0.01
	48.81	172.59

19 Other current assets

(unsecured considered good unless otherwise stated)

	As at 31 March 2025	As at 31 March 2024
Prepaid expenses	12.51	13.06
Advance to suppliers	6.62	21.05
Balance with Government authorities	27.75	17.29
Others	5.01	10.24
	51.89	61.64

20 Equity share capital

	As at 31 March 2025		As at 31 March 2024	
	Number of shares	Amount	Number of shares	Amount
Authorised				
Equity shares of Face Value ₹ 2 each	175,000,000	350.00	175,000,000	350.00
	175,000,000	350.00	175,000,000	350.00
Issued, subscribed and fully paid up				
Equity shares of Face Value ₹ 2 each	111,881,150	223.76	111,824,075	223.65
Total	111,881,150	223.76	111,824,075	223.65

a) Reconciliation of equity share capital

	As at 31 March 2025		As at 31 March 2024	
	Number of shares	Amount	Number of shares	Amount
Balance at the beginning of the year	111,824,075	223.65	111,824,075	223.65
Add : Issued during the year (Refer note 20d below)	57,075	0.11	-	-
Balance at the end of the year	111,881,150	223.76	111,824,075	223.65

Notes to the Standalone Financial Statements

for the year ended 31 March 2025

(₹ in million)

b) Shareholders holding more than 5% of equity shares

	As at 31 March 2025		As at 31 March 2024	
	Number of shares	% of holding	Number of shares	% of holding
Equity shares of Face Value ₹ 2 each				
Mr. Vasant L. Rathī *	37,123,702	33.18%	37,053,702	33.14%
Nalanda India Equity Fund Limited	9,465,501	8.46%	9,963,685	8.91%
Orbimed Asia III Mauritius Limited	13,509,522	12.07%	11,053,245	9.88%
	60,098,725	53.71%	58,070,632	51.93%

*includes shares held by Vasant and Prabha Rathī Generation Trust – 31 March 2025: 7,500,000 shares (6.70%) [31 March 2024: 7,500,000 shares (6.71%)]

c) Rights, preferences and restrictions attached to equity shares

The Company has only one class of equity share having a par value of ₹ 2 per share. Each holder of equity share is entitled to one vote per share. All shares rank pari passu on repayment of capital and surplus assets in the event of liquidation. Dividend proposed by the Board of Directors is subject to the approval of shareholders in the ensuing Annual General Meeting except interim dividend.

d) Shares reserved for issue under “Employees Stock Option Scheme 2022 (ESOS 2022)”

The Company had reserved issuance of 1,088,500 Equity shares having face value of ₹ 2 each for offering to eligible employees of the Company under AETL Employees Stock Option Scheme 2022 (ESOS 2022) . The option would vest on graded basis over a maximum period of 5 years or such other period as may be decided by the Nomination and Remuneration Committee from the date of grant based on specific criteria. (refer note 43 & note 43A)

20A Equity share capital

Details of Shares held by Promoters and Promoter Group Members at the end of the year

No.	Promoter and Promoter Group Members name	As at 31 March 2025		As at 31 March 2024		% change between 31 Mar 25 vs 31 Mar 24	As at 31 March 2023		% change between 31 Mar 24 vs 31 Mar 23
		No. of shares	% of total shares	No. of shares	% of total shares		No. of shares	% of total shares	
1	Vasant Rathī *	37,123,702	33.18%	37,053,702	33.14%	0.05%	36,503,702	32.64%	0.50%
2	Chandrakumar Laxminarayan Rathī	-	0.00%	46,500	0.04%	-0.04%	46,500	0.04%	0.00%
3	Reshma Namita Rathī	2,646,858	2.37%	2,646,858	2.37%	0.00%	2,646,858	2.37%	0.00%
4	Rachana Vasant Rathī	2,641,500	2.36%	2,641,500	2.36%	0.00%	2,641,500	2.36%	0.00%
5	Rasika Vasant Rathī	2,665,825	2.38%	2,665,825	2.38%	0.00%	2,636,700	2.36%	0.02%
6	Prabhavati Vasant Rathī	913,000	0.82%	913,000	0.82%	0.00%	913,000	0.82%	0.00%
7	Kishor Laxminarayan Rathī	406,000	0.36%	1,466,000	1.31%	-0.95%	1,466,000	1.31%	0.00%
8	Kishor Laxminarayan Rathī HUF	1,100,000	0.98%	-	0.00%	0.98%	-	0.00%	0.00%
9	Madhusudan Kabra	615,600	0.55%	715,600	0.64%	-0.09%	715,600	0.64%	0.00%
10	Savita Chandrakumar Rathī	-	0.00%	-	0.00%	0.00%	-	0.00%	0.00%
11	Radhika Ashish Pujara	-	0.00%	-	0.00%	0.00%	-	0.00%	0.00%
12	Piyush Chandrakumar Rathī	-	0.00%	-	0.00%	0.00%	-	0.00%	0.00%
13	Jayesh Madhusudan Soni #	35,000	0.03%	-	0.00%	0.03%	10,000	0.01%	-0.01%
14	Sanju Madhusudan Soni #	-	0.00%	-	0.00%	0.00%	10,000	0.01%	-0.01%
15	Tejasvi Madhusudan Soni #	-	0.00%	-	0.00%	0.00%	10,000	0.01%	-0.01%
16	Abhijit Kishor Rathī #	-	0.00%	-	0.00%	0.00%	82,835	0.07%	-0.07%
17	Ankit Kishor Rathī #	-	0.00%	-	0.00%	0.00%	100,000	0.09%	-0.09%
18	Amit Kishor Rathī #	-	0.00%	-	0.00%	0.00%	75,001	0.07%	-0.07%
19	Sunita Sunil Attal #	-	0.00%	-	0.00%	0.00%	11,760	0.01%	-0.01%
20	Sunil Ramdayal Attal	5,000	0.00%	-	0.00%	0.00%	-	0.00%	0.00%
21	Anisha Sunil Attal #	-	0.00%	-	0.00%	0.00%	9,421	0.01%	-0.01%
22	Megha Jhawar #	20,000	0.02%	-	0.00%	0.02%	10,000	0.01%	-0.01%
23	Nikita Madhusudan Soni #	-	0.00%	-	0.00%	0.00%	10,000	0.01%	-0.01%

Notes to the Standalone Financial Statements

for the year ended 31 March 2025

(₹ in million)

No.	Promoter and Promoter Group Members name	As at 31 March 2025		As at 31 March 2024		% change between 31 Mar 25 vs 31 Mar 24	As at 31 March 2023		% change between 31 Mar 24 vs 31 Mar 23
		No. of shares	% of total shares	No. of shares	% of total shares		No. of shares	% of total shares	
24	Payal Akshay Kulkarni #	7,500	0.01%	-	0.00%	0.01%	5,000	0.00%	0.00%
25	Pramila Shamsunder Soni .	5,000	0.00%	-	0.00%	0.00%	-	0.00%	0.00%
26	Snehal Shamsunder Soni #	15,000	0.01%	-	0.00%	0.01%	4,400	0.00%	0.00%
27	Advenza Global Limited (Formerly known as Advanced Vital Enzymes Pvt Ltd)	-	0.00%	487,609	0.44%	-0.44%	7,232,844	6.47%	-6.03%
28	Atharva Green Ecotech LLP	-	0.00%	-	0.00%	0.00%	6,29,000	0.56%	-0.56%
Total		48,199,985	43.08%	48,636,594	43.49%	-0.41%	55,770,121	49.87%	-6.38%

*includes shares held by Vasant and Prabha Rathii Generation Trust – 31 March 2025: 7,500,000 shares (6.70%) [31 March 2024: 7,500,000 shares (6.71%)]

Reclassified from Promoter Group category to public category with effect from 17 April 2023

Snehal Shamsunder Soni, Pramila Shamsunder Soni, Sunil Ramdayal Attal, Megha Jhavar, Payal Akshay Kulkarni and Kishor Laxminarayan Rathii HUF are classified as promoter group members pursuant to gift of shares by promoter and promoter group members during the year.

21 Other equity

	As at 31 March 2025	As at 31 March 2024
Capital reserve		
Balance at the beginning of the year	3.00	3.00
Add : Additions made during the year	-	-
Less : Deletions made during the year	-	-
Balance at the end of the year	3.00	3.00
Securities premium		
Balance at the beginning of the year	819.13	819.13
Add: Premium on issue of equity shares under ESOP scheme	18.91	-
Balance at the end of the year	838.04	819.13
Employee stock option reserve		
Balance at the beginning of the year	30.31	-
Add: Options granted during the year (refer note 43 and 43A)	36.80	30.31
Less: Exercised during the year	(15.24)	-
Less: Lapsed during the year	(2.34)	-
Balance at the end of the year	49.53	30.31
General reserve		
Balance at the beginning of the year	32.53	32.53
Add : Additions made during the year	-	-
Less : Deletions made during the year	-	-
Balance at the end of the year	32.53	32.53
Retained earnings		
Balance at the beginning of the year	4,696.09	4,175.01
Add: Transferred from Statement of Profit and Loss	1,024.20	1,081.23
Add: Transferred from Other comprehensive income	(3.44)	(1.03)
Less: Dividend	(570.30)	(559.12)
Balance at the end of the year	5,146.55	4,696.09
	6,069.65	5,581.06

Notes to the Standalone Financial Statements

for the year ended 31 March 2025

(₹ in million)

Nature and purpose of reserves

Capital reserve

The reserve comprises of profits/gains of capital nature earned by the Company and credited directly to such reserve.

Securities premium

Securities premium is used to record the premium received on issue of shares. It is utilised in accordance with the provisions of the Companies Act, 2013.

Employee stock option reserve

This represents the fair value of options granted to eligible employees of the Company under the ESOS 2022 Scheme over the vesting period. This reserve will be utilised on exercise of options by the employees.

General reserve

General reserve is created out of the profits earned by the Company by way of transfer from surplus in the Statement of Profit and Loss. The Company can use this reserve for payment of dividend and issue of fully paid up and not paid up bonus shares.

Retained earnings

This reserve represents surplus of profit and loss account.

22 Lease liabilities

	As at 31 March 2025		As at 31 March 2024	
	Non-current	Current	Non-current	Current
Lease liability (refer note 38)	19.69	7.95	10.93	4.11
	19.69	7.95	10.93	4.11

23 Provisions

	As at 31 March 2025		As at 31 March 2024	
	Non-current	Current	Non-current	Current
Provision for employee benefits				
Compensated absences	-	9.68	0.58	8.33
Gratuity (Refer note 37)	8.20	13.28	6.03	6.82
Provision for sales return (Also, refer note below)	-	12.40	-	10.26
	8.20	35.36	6.61	25.41

Note:

As per best estimate of the management, provision has been made towards probable return of goods from customers, as per Indian Accounting Standard (Ind AS) 37

	As at 31 March 2025	As at 31 March 2024
Movement in provision for sales return		
Provision at the beginning of the year	10.26	5.90
Provision created during the year	12.40	10.26
Provision reversed/utilised during the year	(10.26)	(5.90)
Provision at the end of the year	12.40	10.26

Notes to the Standalone Financial Statements

for the year ended 31 March 2025

(₹ in million)

24 Deferred tax liabilities (net)

	As at 31 March 2025	As at 31 March 2024
Deferred tax liabilities		
Excess of depreciation/amortisation on Property, plant and equipment under income-tax law over depreciation/amortisation provided in standalone financial statements	135.43	120.55
	135.43	120.55
Deferred tax assets		
Provision for employee benefits	11.32	9.62
Others	6.11	3.99
	17.43	13.61
	118.00	106.94

Movement in deferred tax balances

Particulars	31 March 2025					
	Net balance 1 April 2024	Recognised in Statement of Profit and Loss	Recognised in OCI	Net deferred tax asset/ (liability)	Deferred tax asset	Deferred tax liability
Deferred tax asset/(liabilities)						
Property, plant and equipment	(120.55)	(14.88)	-	(135.43)	-	(135.43)
Provision for employee benefits	9.62	0.54	1.16	11.32	11.32	-
Other items	3.99	2.12	-	6.11	6.11	-
Tax assets/(liabilities)	(106.94)	(12.22)	1.16	(118.00)	17.43	(135.43)
Offsetting of deferred tax assets and liabilities					(17.43)	17.43
Net deferred tax assets/(liabilities)	(106.94)	(12.22)	1.16	(118.00)	-	(118.00)

Particulars	31 March 2024					
	Net balance 1 April 2023	Recognised in Statement of Profit and Loss	Recognised in OCI	Net deferred tax asset/ (liability)	Deferred tax asset	Deferred tax liability
Deferred tax asset/(liabilities)						
Property, plant and equipment	(129.32)	8.77	-	(120.55)	-	(120.55)
Provision for employee benefits	8.00	1.28	0.34	9.62	9.62	-
Other items	3.22	0.77	-	3.99	3.99	-
Tax assets/(liabilities)	(118.10)	10.82	0.34	(106.94)	13.61	(120.55)
Offsetting of deferred tax assets and liabilities					(13.61)	13.61
Net deferred tax assets/(liabilities)	(118.10)	10.82	0.34	(106.94)	-	(106.94)

The Company offsets tax assets and liabilities if and only if it has a legally enforceable right to set off current tax assets and current tax liabilities and the deferred tax assets and deferred tax liabilities relate to income taxes levied by the same tax authority.

Significant management judgement is required in determining provision for income tax, deferred income tax assets and liabilities and recoverability of deferred income tax assets. The recoverability of deferred income tax assets is based on estimates of taxable income and the period over which deferred income tax assets will be recovered. Any changes in future taxable income would impact the recoverability of deferred tax assets.

Given that the Company does not have any intention to dispose investments in subsidiaries in the foreseeable future, deferred tax asset on indexation benefit in relation to such investments has not been recognised.

Notes to the Standalone Financial Statements

for the year ended 31 March 2025

(₹ in million)

25 Trade payables

	As at 31 March 2025	As at 31 March 2024
Total outstanding dues to micro and small enterprises (refer note below)	33.30	18.91
Total outstanding dues to others	193.46	198.33
	226.76	217.24
Amount due to related parties (refer note 42)	116.08	137.61

Note:

Dues to micro, small and medium enterprises pursuant to section 22 of the Micro, Small and Medium Enterprises Development Act (MSMED), 2006

Principal amount remaining unpaid	33.30	18.91
Interest due thereon	-	-
Interest paid by the Company in terms of Section 16 of MSMED Act, 2006, along with the amount of the payment made to the suppliers and service providers beyond the appointed day during the year.	-	-
Interest due and payable for the period of delay in making payment (which has been paid but beyond the appointed day during the year) but without adding the interest specified under MSMED Act, 2006	-	-
Interest accrued and remaining unpaid as at balance sheet date	0.05	0.05
Further interest remaining due and payable even in the succeeding years, until such date when the interest dues as above are actually paid to the small enterprise for the purpose of disallowance as a deductible expenditure under section 23 of the MSMED Act, 2006.	0.05	0.05

The Management has identified enterprises which have provided goods and services to the Company and which qualify under the definition of micro and small enterprises, as defined under Micro, Small and Medium Enterprises Development Act, 2006. Accordingly, the disclosure in respect of the amounts payable to such enterprises as at 31 March 2025 has been made in the standalone financial statements based on information received and available with the Company.

Outstanding as at 31 March 2025

Particulars	Not due	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
MSME	31.37	1.93	-	-	-	33.30
Others	73.21	120.13	-	-	0.12	193.46
Disputed dues (MSMEs) and	-	-	-	-	-	-
Disputed dues (Others)	-	-	-	-	-	-
Total	104.58	122.06	-	-	0.12	226.76

Outstanding as at 31 March 2024

Particulars	Not due	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
MSME	18.70	0.21	-	-	-	18.91
Others	134.78	63.43	-	-	0.12	198.33
Disputed dues (MSMEs) and	-	-	-	-	-	-
Disputed dues (Others)	-	-	-	-	-	-
Total	153.48	63.64	-	-	0.12	217.24

Notes to the Standalone Financial Statements

for the year ended 31 March 2025

(₹ in million)

26 Other current financial liabilities

	As at 31 March 2025	As at 31 March 2024
Unpaid dividends (refer note below)	2.28	1.59
Security deposits from customers	0.17	0.17
Payable for purchase of property, plant and equipment	20.01	17.43
Employee benefits payable	71.92	73.66
Other payables	40.51	27.23
	134.89	120.08

Note:

The amount due and paid during the year to “Investor Education and Protection Fund” is ₹ 0.18 million (31 March 2024: 0.11 million).

27 Other current liabilities

	As at 31 March 2025	As at 31 March 2024
Statutory dues:		
Provident fund payable	3.34	2.95
Employees' State Insurance Scheme contribution payable	0.03	0.03
Other dues payable	5.81	5.93
Advance from customers	28.15	17.26
Others	1.80	4.24
	39.13	30.41

28 Revenue from operations

	Year ended 31 March 2025	Year ended 31 March 2024
Revenue from operations		
Sale of goods (refer note 39)		
Export	1,269.62	1,134.38
Domestic	2,240.58	2,516.52
	3,510.20	3,650.90
Other operating revenues		
Export incentives	3.91	3.79
	3,514.11	3,654.69

Disaggregation of revenue

Following table provides disaggregation of revenue and a reconciliation of product category wise revenue and revenue recognised in Statement of Profit and Loss as revenue from contracts with customers:

Particulars	Year Ended 31 March 2025	Year ended 31 March 2024
Human nutrition	2,032.43	2,448.39
Animal nutrition	657.59	562.58
Bio-process	821.47	652.40
	3,511.49	3,663.37
Adjustments		
Reversal/(Provision) for sales return	(2.15)	(4.37)
Discount (given) / reversal	0.86	(8.10)
	(1.29)	(12.47)
Total revenue from contract with customers	3,510.20	3,650.90

Notes to the Standalone Financial Statements

for the year ended 31 March 2025

(₹ in million)

29 Other income

	Year ended 31 March 2025	Year ended 31 March 2024
Interest income		
- on others	11.26	11.16
Liabilities no longer required written back	1.98	7.14
Profit on sale of property, plant and equipment (net)	0.59	0.14
Net gain on foreign currency transactions and translations	7.00	3.51
Dividend income (refer note 42)	561.06	526.71
Miscellaneous income	33.01	39.43
	614.90	588.09

30 Cost of materials consumed

	Year ended 31 March 2025	Year ended 31 March 2024
Opening stock	388.56	270.93
Add: Purchases during the year	1,463.01	1,513.24
Less: Closing stock	363.57	388.56
	1,488.00	1,395.61

31 Changes in inventories of finished goods, work-in-progress and stock-in-trade

	Year ended 31 March 2025	Year ended 31 March 2024
Opening stock		
- Finished goods	157.89	118.24
- Work-in-progress	354.56	315.86
	512.45	434.10
Closing stock		
- Finished goods	154.33	157.89
- Work-in-progress	422.79	354.56
	577.12	512.45
	(64.67)	(78.34)

32 Employee benefits expense

	Year ended 31 March 2025	Year ended 31 March 2024
Salaries, wages and bonus	474.58	417.73
Contribution to provident and other funds (refer note 37)	20.95	17.44
Retirement benefits expense (refer note 37)	13.97	10.83
Staff welfare expenses	20.44	22.05
Employee stock compensation expense (refer note 43)	30.41	25.83
	560.35	493.88

33 Finance costs

	Year ended 31 March 2025	Year ended 31 March 2024
Interest expenses on financial liabilities - borrowings carried at amortised cost	0.02	0.17
Interest expenses on lease liabilities (refer note 38)	2.34	1.40
	2.36	1.57

Notes to the Standalone Financial Statements

for the year ended 31 March 2025

(₹ in million)

34 Depreciation and amortisation expense

	Year ended 31 March 2025	Year ended 31 March 2024
Depreciation on property, plant and equipment (refer note 7)	103.43	98.97
Amortisation of intangible assets (refer note 8)	1.70	1.34
Amortisation of right to use assets (refer note 7)	8.92	8.67
	114.05	108.98

35 Other expenses

	Year ended 31 March 2025	Year ended 31 March 2024
Consumption of stores and spare parts	86.32	92.74
Power and fuel	185.24	227.29
Water charges	5.20	5.56
Laboratory expenses	36.96	25.93
Repairs and maintenance		
- Buildings	11.06	20.79
- Plant and equipment	50.10	33.38
- Others	9.75	7.29
Travel, conveyance and car hire	25.77	23.95
Commission	9.33	8.97
Sales promotion and advertisement	6.28	7.17
Freight outward and forwarding	72.50	41.58
Selling and distribution expenses	24.24	17.59
Rent (refer note 38)	2.17	2.00
Rates and taxes	53.63	49.27
Insurance	9.82	8.67
Printing and stationery	2.48	2.28
Communication expenses	5.89	4.89
Directors' sitting fees (refer note 42)	0.87	1.51
Commission to Non Executive Directors	4.97	5.83
Legal and professional charges	46.11	50.94
Technical services	115.31	107.94
Payment to Auditors (refer note 45)	4.49	3.77
Bad debts (refer note 41)	4.91	4.32
Provisions of doubtful accounts receivable (net) (refer note 41)	6.27	(1.30)
Donations	0.99	0.64
Property, plant and equipment written off	-	0.68
Bank charges	2.70	2.30
Corporate Social Responsibility expenditure (refer note 47)	19.24	15.59
Miscellaneous expenses	21.04	20.11
	823.64	791.68

Notes to the Standalone Financial Statements

for the year ended 31 March 2025

(₹ in million)

36 Income taxes

Tax expense

(a) Income tax recognised in Statement of Profit and Loss

	Year ended 31 March 2025	Year ended 31 March 2024
Current income tax	168.86	269.51
Deferred income tax liability / (asset), net		
Origination and reversal of temporary differences	12.22	(10.82)
Tax expense for the year	181.08	258.69

(b) Income tax recognised in Other Comprehensive Income

	Year ended 31 March 2025			Year ended 31 March 2024		
	Before tax	Tax (expense) / benefit	Net of tax	Before tax	Tax (expense) / benefit	Net of tax
Items that will not be reclassified to profit and loss						
Remeasurements of the defined benefit plans	(4.60)	1.16	(3.44)	(1.38)	0.35	(1.03)
	(4.60)	1.16	(3.44)	(1.38)	0.35	(1.03)

(c) Reconciliation of effective tax rate

	Year ended 31 March 2025	Year ended 31 March 2024
Profit before tax after exceptional item	1,205.28	1,339.92
Tax using the Company's domestic tax rate (31 March 2025: 25.168% and 31 March 2024: ₹ 25.168%)	303.35	337.23
Tax effect of:		
Tax-exempt income	(141.21)	(132.56)
Non tax deductible items	4.94	51.91
Ind AS impacts	2.35	1.97
Investment allowance deduction	-	-
Others	11.65	0.14
Tax expense as per profit and loss	181.08	258.69

37 Employee benefits

The Company contributes to the following post-employment plans in India.

(A) Defined Contribution Plans:

The Company makes contributions towards provident fund and superannuation fund which are in the nature of defined contribution post employment benefit plans. Under the plan, the Company is required to contribute a specified percentage of payroll cost to fund the benefits.

The Company recognised ₹ 18.89 million for the year ended 31 March 2025 (31 March 2024: ₹ 16.62 million) towards provident fund and employee deposit linked insurance contribution and ₹ 3.38 million for the year ended 31 March 2025 (31 March 2024: ₹ 3.49 million) towards superannuation fund contribution in the Statement of Profit and Loss.

The contributions payable to these plans by the Company are at rates specified in the rules of the schemes.

(B) Defined Benefit Plan:

The Company provides for gratuity benefit, which is defined benefit plans, covering all its eligible employees. The Company has taken a Group Gratuity for its employees with the Life Insurance Corporation of India (LIC). Under gratuity policy, the eligible employees are entitled to receive gratuity payments upon their resignation or death (subject to completion of 4.5 years of employment) in lumpsum after deduction of necessary taxes.

The most recent actuarial valuation of the defined benefit obligation along with the fair valuation of the plan assets in relation to the gratuity scheme was carried out as at 31 March 2025. The present value of the defined benefit obligations and the related current service cost and past service cost, were measured using the Projected Unit Credit Method.

Notes to the Standalone Financial Statements
for the year ended 31 March 2025

(₹ in million)

Based on the actuarial valuation obtained in this respect, the following table sets out the details of the employee benefit obligation and the plan assets as at balance sheet date:

	As at 31 March 2025 Gratuity	As at 31 March 2024 Gratuity
Defined benefit obligation	102.29	82.79
Fair value of plan assets	80.81	69.94
Net defined benefit obligation/(assets)	21.48	12.85

i) Reconciliation in present value of obligations ('PVO') – defined benefit obligation:

	Defined benefit obligation	
	As at 31 March 2025 Gratuity	As at 31 March 2024 Gratuity
Opening balance	82.79	71.29
Included in profit and loss		
Current service cost	7.85	6.94
Past service cost	1.98	-
Interest cost	5.65	5.00
	98.27	83.23
Included in OCI		
Remeasurement loss/(gain):		
Actuarial loss/(gain) arising from:		
Financial assumptions	3.89	1.07
Experience adjustment	1.55	0.73
	103.71	85.03
Benefits paid	(1.42)	(2.24)
Closing balance	102.29	82.79

ii) Change in fair value of plan assets

	Fair value of plan assets	
	As at 31 March 2025 Gratuity	As at 31 March 2024 Gratuity
Opening balance	69.94	63.07
Included in profit and loss		
Expected return on plan assets	4.97	4.62
	74.91	67.69
Included in OCI		
Remeasurement (loss)/gain:		
Actuarial (loss)/gain arising from:		
Expected return on plan assets	0.84	0.43
	75.75	68.12
Other		
Contributions paid by the employer	6.48	3.80
Benefits paid	(1.42)	(1.98)
Closing balance	80.81	69.94

Notes to the Standalone Financial Statements
for the year ended 31 March 2025

(₹ in million)

Impact on Standalone Statement of Profit and Loss for the current year

	31 March 2025 Gratuity	31 March 2024 Gratuity
Service cost:		
Current service cost	7.85	6.94
Past service cost and loss/(gain) on curtailments and settlement	1.98	-
Net interest cost	0.68	0.38
Total included in Employee Benefit expenses	10.51	7.32
Expenses deducted from the fund	-	-
Total Charge to Standalone Statement of Profit and Loss	10.51	7.32

Impact on Other comprehensive income for the current year

	31 March 2025 Gratuity	31 March 2024 Gratuity
Components of actuarial gain/losses on obligations:		
Due to Change in financial assumptions	3.89	1.07
Due to experience adjustments	1.55	0.73
Return on plan assets excluding amounts included in interest income	(0.84)	(0.43)
Amounts recognized in Other Comprehensive Income	4.60	1.37

Plan assets

Plan assets comprise the following

Gratuity	31 March 2025	31 March 2024
Policy of insurance	100%	100%
	100%	100%

iii. Actuarial assumptions

The following were the principal actuarial assumptions at the reporting date (expressed as weighted averages).

	31 March 2025 Gratuity	31 March 2024 Gratuity
Discount rate	6.60%	7.20%
Rate of return on plan assets	6.60%	7.20%
Salary Escalation	8.50%	8.50%
Withdrawal rates	12% at younger ages reducing to 2% at older ages	12% at younger ages reducing to 2% at older ages
Retirement age	58 years	58 years
Mortality rates	As published under the Indian assured lives mortality (2012-14) table	As published under the Indian assured lives mortality (2012-14) table

Assumptions regarding future mortality have been based on published statistics and mortality tables.

Notes to the Standalone Financial Statements

for the year ended 31 March 2025

(₹ in million)

iv. Sensitivity analysis

Reasonably possible changes at the reporting date to one of the relevant actuarial assumptions, holding other assumptions constant, would have affected the defined benefit obligation as shown below.

	31 March 2025 Gratuity	31 March 2024 Gratuity
Increase in	₹ in million	₹ in million
Discount rate (0.5% movement)	98.99	80.15
Future salary growth (0.5% movement)	105.38	85.50
Withdrawal rates (10% movement)	101.94	82.58
	31 March 2025 Gratuity	31 March 2024 Gratuity
Decrease in	₹ in million	₹ in million
Discount rate (0.5% movement)	105.73	85.56
Future salary growth (0.5% movement)	99.29	80.18
Withdrawal rates (10% movement)	102.64	82.96

The sensitivity analysis above have been determined based on a method that extrapolates the impact on defined benefit obligation as a result of reasonable changes in key assumptions occurring at the end of the reporting period.

v. Expected future cash flows

Expected contribution

The expected contributions for the defined benefit plan for the next financial year is ₹ 8.20 million

Expected future benefit payments	₹ in million
31 March 2026	6.67
31 March 2027	16.93
31 March 2028	10.02
31 March 2029	11.07
31 March 2030	6.03
Thereafter	53.00

The trustees of the plan have outsourced the investment management of the fund to an insurance company. The insurance company in turn manages these funds as per the mandate provided to them by the trustees and the asset allocation which is within the permissible limits prescribed in the insurance regulations. Due to the restrictions in the type of investments that can be held by the fund, it may not be possible to explicitly follow an asset-liability matching strategy to manage risk actively in a conventional fund.

Compensated absences

The Company recognised ₹ 11.86 million for the year ended 31 March 2025 (31 March 2024: ₹ 8.18 million) towards compensated absences.

38 Leases

(a) Maturity analysis of lease liabilities– contractual undiscounted cash flows:

Particulars	Year Ended 31 March 2025	Year Ended 31 March 2024
Less than one year	10.22	5.21
One to five years	20.33	10.01
More than five years	2.20	2.59
Total undiscounted lease liabilities at 31 March	32.75	17.81
Discounted Lease liabilities included in the statement of financial position at 31 March		
Current lease liability	7.95	4.11
Non-current lease liability	19.69	10.93

Notes to the Standalone Financial Statements

for the year ended 31 March 2025

(₹ in million)

- (b) The Weighted average incremental borrowing rate of 9.50% p.a. for local currency borrowings has been applied for measuring the lease liability at the date of initial application.
- (c) The Company incurred ₹ 13.42 million for the year ended 31 March 2025 (31 March 2024: ₹ 12.07 million) towards expenses relating to leases in statement of profit and loss. Lease rent incurred not falling under the scope of Ind AS 116 amounted to ₹ 2.17 million for the year ended 31 March 2025 (31 March 2024: ₹ 2.00 million). (refer Note 35).
- (d) Total cash outflow for leases for year ended 31 March 2025 is ₹ 9.80 million (31 March 24: ₹ 9.44 million).
- (e) General Description of leasing agreements:
- Leased Assets: Office premises and leasehold land
 - Future Lease rentals are determined on the basis of agreed terms.
 - At the expiry of lease terms, the Company has an option to return the assets or extend the term by giving notice in writing.
 - Lease agreements are generally cancellable and are renewable by mutual consent on mutually agreed terms.
- (f) Please refer note 7 for carrying value of Right of Use Assets for the year ended 31 March 2025

(g) Changes in the lease liabilities

Particulars	Building	Leasehold land
Opening balance as at 1 April 2023	19.15	3.26
Add: Interest for the year	1.19	0.21
Less: Lease payments during the year	9.06	0.38
Add: Other adjustments	0.67	-
Closing balance as at 31 March 2024	11.95	3.09
Add: Additions during the year	20.05	-
Add: Interest for the year	2.14	0.20
Less: Lease payments during the year	9.41	0.38
Closing balance as at 31 March 2025	24.73	2.91

39 Segment reporting

Basis of segmentation

Segments are identified based on the manner in which the Company's Chief Operating Decision Maker ('CODM') decides about resource allocation and reviews performance.

The Company has identified that it operates only in one business segment viz. 'manufacturing and sales of enzymes' and hence no separate information for primary segment wise disclosure is required.

Geographic information

The geographic information analyses the Company's revenues and non-current assets by the Company's country of domicile and other countries. In presenting geographic information, segment revenue has been based on the selling location in relation to sales to customers and segment assets are based on geographical location of assets.

	Year ended 31 March 2025	Year ended 31 March 2024
Segment revenue (based upon location of customers)		
India	2,240.58	2,516.52
Europe	179.76	230.31
USA	531.48	479.18
Asia	449.95	332.74
Others	108.43	92.15
	3,510.20	3,650.90

Notes to the Standalone Financial Statements

for the year ended 31 March 2025

(₹ in million)

	31 March 2025	31 March 2024
Segment assets (based upon location of assets)		
India	1,892.95	1,712.73
Europe	52.92	53.69
USA	1.42	1.81
	1,947.29	1,768.23

Major customer

Revenue from a customer i.e. a subsidiary based in U.S.A. is ₹ 473.13 million is in excess of 10% of the Company's revenue for the year (31 March 2024: ₹ 456.40 million from a subsidiary based in U.S.A) (Refer note 42 for related party disclosures).

40 Earnings per share (EPS)

Basic EPS amounts are calculated by dividing the profit for the year attributable to equity holders by the weighted average number of Equity shares outstanding during the year.
Diluted EPS amounts are calculated by dividing the profit attributable to equity holders by the weighted average number of Equity shares outstanding during the year plus the weighted average number of Equity shares that would be issued on conversion of all the dilutive potential Equity shares into Equity shares.

i. Profit attributable to Equity holders

	31 March 2025	31 March 2024
Profit attributable to equity holders	1,024.20	1,081.23

ii. Weighted average number of equity shares

	31 March 2025	31 March 2024
Issued equity shares at 1 April	111,824,075	111,824,075
Effect of fresh issue of shares for cash under ESOP scheme	28,071	-
Weighted average number of shares at 31 March for basic EPS	111,852,146	111,824,075
Effect of exercise of share options	138,199	55,236
Weighted average number of shares at 31 March for diluted EPS	111,990,345	111,879,311

	31 March 2025	31 March 2024
Basic earnings per share	9.16	9.67
Diluted earnings per share	9.15	9.66

41 Financial instruments

i. Financial instruments – Fair values and risk management

A. Accounting classification and fair values

The following table shows the carrying amounts and fair values of financial assets and financial liabilities, including their levels are presented below. It does not include the fair value information for financial assets and financial liabilities not measured at fair value if their carrying amount is a reasonable approximation of fair value.

Notes to the Standalone Financial Statements

for the year ended 31 March 2025

(₹ in million)

31 March 2025	Note No.	Carrying amount				Fair value			
		FVTPL	FVTOCI	Amortised Cost	Total	Quoted prices in active markets (Level 1)	Significant observable inputs (Level 2)	Significant unobservable inputs (Level 3)	Total
Financial assets									
Investments - Non-current	9	-	-	2,537.12	2,537.12	-	-	-	-
Loans - Non-current	10	-	-	0.65	0.65	-	-	-	-
Others - Non-current	11	-	-	79.26	79.26	-	-	-	-
Investments	14	366.52	-	-	366.52	366.52	-	-	366.52
Trade receivables	15	-	-	781.69	781.69	-	-	-	-
Cash and cash equivalents	16	-	-	56.04	56.04	-	-	-	-
Bank balances	16A	-	-	2.28	2.28	-	-	-	-
Loans - Current	17	-	-	0.26	0.26	-	-	-	-
Others - Current	18	-	-	48.81	48.81	-	-	-	-
		366.52	-	3,506.11	3,872.63	366.52	-	-	366.52
Financial liabilities									
Leases - Non current	22	-	-	19.69	19.69	-	-	-	-
Leases - Current	22	-	-	7.95	7.95	-	-	-	-
Trade payables	25	-	-	226.76	226.76	-	-	-	-
Other financial Liabilities	26	-	-	134.89	134.89	-	-	-	-
		-	-	389.29	389.29	-	-	-	-

Note: There have been no transfers among Level 1, Level 2 and Level 3 during the year.

31 March 2024	Note No.	Carrying amount				Fair value			
		FVTPL	FVTOCI	Amortised Cost	Total	Quoted prices in active markets (Level 1)	Significant observable inputs (Level 2)	Significant unobservable inputs (Level 3)	Total
Financial assets									
Investments - Non-current	9	-	-	2,054.88	2,054.88	-	-	-	-
Loans - Non-current	10	-	-	0.37	0.37	-	-	-	-
Others - Non-current	11	-	-	22.45	22.45	-	-	-	-
Investments	14	508.02	-	-	508.02	508.02	-	-	508.02
Trade receivables	15	-	-	751.72	751.72	-	-	-	-
Cash and cash equivalents	16	-	-	14.95	14.95	-	-	-	-
Bank balances	16A	-	-	5.22	5.22	-	-	-	-
Loans - Current	17	-	-	0.42	0.42	-	-	-	-
Others - Current	18	-	-	172.59	172.59	-	-	-	-
		508.02	-	3,022.60	3,530.62	508.02	-	-	508.02
Financial liabilities									
Leases - Non current	22	-	-	10.93	10.93	-	-	-	-
Leases - Current	22	-	-	4.11	4.11	-	-	-	-
Trade payables	25	-	-	217.23	217.23	-	-	-	-
Other financial Liabilities	26	-	-	120.08	120.08	-	-	-	-
		-	-	352.35	352.35	-	-	-	-

Note: There have been no transfers among Level 1, Level 2 and Level 3 during the year.

Notes to the Standalone Financial Statements for the year ended 31 March 2025

(₹ in million)

B. Measurement of fair values

The fair value hierarchy is based on inputs to valuation techniques that are used to measure fair value that are either observable or unobservable and consists of the following three levels:

- Level 1 – Inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities.
- Level 2 – Inputs are other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).
- Level 3 – Inputs are not based on observable market data (unobservable inputs). Fair values are determined in whole or in part using a valuation model based on assumptions that are neither supported by prices from observable current market transactions in the same instrument nor are they based on available market data.

The cost of unquoted investments included in Level 3 of fair value hierarchy approximate their fair value because there is a wide range of possible fair value measurements and the cost represents estimate of fair value within that range.

C. Financial risk management

The Company has exposure to the following risks arising from financial instruments:

- Credit risk;
- Liquidity risk; and
- Market risk

i. Risk management framework

The Company's board of directors has overall responsibility for the establishment and oversight of the Company's risk management framework. The board of directors has established the Risk Management Committee, which is responsible for developing and monitoring the Company's risk management policies. The committee reports regularly to the board of directors on its activities

The Company's risk management policies are established to identify and analyse the risks faced by the Company, to set appropriate risk limits and controls and to monitor risks and adherence to limits. Risk management policies and systems are reviewed regularly to reflect changes in market conditions and the Company's activities. The Company, through its training and management standards and procedures, aims to maintain a disciplined and constructive control environment in which all employees understand their roles and obligations.

The audit committee oversees how management monitors compliance with the company's risk management policies and procedures, and reviews the adequacy of the risk management framework in relation to the risks faced by the Company. The audit committee is assisted in its oversight role by internal audit. Internal auditor undertakes both regular and ad hoc reviews of risk management controls and procedures, the results of which are reported to the audit committee.

ii. Credit risk

Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations, and arises principally from the Company's receivables from customers and investment securities. Credit risk is managed through credit approvals, establishing credit limits and continuously monitoring the creditworthiness of customers to which the Company grants credit terms in the normal course of business. The Company establishes an allowance for doubtful debts and impairment that represents its estimate of incurred losses in respect of trade and other receivables and investments.

Trade and other receivables

The Company's exposure to credit risk is influenced mainly by the individual characteristics of each customer. The demographics of the customer, including the default risk of the industry and country in which the customer operates, also has an influence on credit risk assessment.

At 31 March 2025, the carrying amount of the Company's most significant customer accounted for ₹ 118.22 million (31 March 2024 - ₹ 167.44 million)

Notes to the Standalone Financial Statements for the year ended 31 March 2025

(₹ in million)

Summary of the Company's exposure to credit risk by age of the outstanding from various customers is as follows:

	31 March 2025		
	Carrying Amount	Weighted Average Loss Rate	Loss Allowance
Not due	375.64	0.26%	0.99
0-90 days	384.64	0.36%	1.39
91-180 days	11.43	7.09%	0.81
181-270 days	5.74	13.38%	0.77
271-360 days	2.60	19.43%	0.51
More than 360 days	13.51	54.76%	7.40
	793.56		11.87

	31 March 2024		
	Carrying Amount	Weighted Average Loss Rate	Loss Allowance
Not due	463.88	0.18%	0.84
0-90 days	272.06	0.30%	0.82
91-180 days	10.98	1.25%	0.14
181-270 days	0.70	0.00%	0.13
271-360 days	0.94	24.91%	0.23
More than 360 days	8.76	39.30%	3.44
	757.32		5.60

Expected credit loss assessment for customers as at 31 March 2025 and 31 March 2024

The Company allocates each exposure to a credit risk grade based on a variety of data that is determined to be predictive of the risk of loss (e.g. timeliness of payments, available press information etc.) and applying experienced credit judgement.

Exposures to customers outstanding at the end of each reporting period are reviewed by the Company to determine incurred and expected credit losses. Historical trends of impairment of trade receivables do not reflect any significant credit losses. Given that the macro economic indicators affecting customers of the Company have not undergone any substantial change, the Company expects the historical trend of minimal credit losses to continue.

The movement in the allowance for impairment in respect of trade and other receivables during the year was as follows:

Particulars	Amount
Balance as at 1 April 2023	6.90
Add: Impairment loss recognised	3.02
Less: Amounts written back	4.32
Balance as at 31 March 2024	5.60
Add: Impairment loss recognised	11.18
Less: Amounts written back	4.91
Balance as at 31 March 2025	11.87

The impairment loss at 31 March 2025 and 31 March 2024 related to certain customers that have defaulted on their payments to the Company and are not expected to be able to pay their outstanding balances, mainly due to economic circumstances.

Cash and cash equivalents

The Company held cash and cash equivalents of ₹ 56.04 million at 31 March 2025 (31 March 2024: ₹ 14.95 million). The cash and cash equivalents are held with bank and financial institution counterparties with good credit ratings.

Derivatives

There are no derivatives contracts outstanding as on 31 March 2025.

Notes to the Standalone Financial Statements

for the year ended 31 March 2025

(₹ in million)

Investments

The Company limits its exposure to credit risk by generally investing in liquid securities and only with counterparties that have a good credit rating. The Company does not expect any losses from non-performance by these counter-parties, and does not have any significant concentration of exposures to specific industry sectors or specific country risks.

Other than trade and other receivables, the Company has no other financial assets that are past due but not impaired.

iii. Liquidity risk

Liquidity risk is the risk that the Company will encounter difficulty in meeting the obligations associated with its financial liabilities that are settled by delivering cash or another financial asset. The Company’s approach to managing liquidity is to ensure, as far as possible, that it will have sufficient liquidity to meet its liabilities when they are due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the Company’s reputation.

The Company has obtained fund and non-fund based working capital lines from various banks. The Company invests its surplus funds in bank fixed deposit and mutual funds which carry no/low mark-to-market risks. The Company monitors funding options available in the debt and capital markets with a view to maintaining financial flexibility.

Exposure to liquidity risk:

The following are the remaining contractual maturities of financial liabilities at the reporting date. The amounts are gross and undiscounted except in case of lease liabilities where the amounts are mentioned on discounted basis, and include estimated interest payments:

31 March 2025	Carrying amount	Contractual cash flows				
		Total	Upto 1 year	1-3 years	3-5 years	More than 5 years
Lease liabilities - Non-current	19.69	19.69	-	13.11	4.79	1.79
Lease liabilities - Current	7.95	7.95	7.95	-	-	-
Trade payables	226.76	226.76	226.76	-	-	-
Other financial liabilities	134.89	134.89	134.89	-	-	-

31 March 2024	Carrying amount	Contractual cash flows				
		Total	Upto 1 year	1-3 years	3-5 years	More than 5 years
Lease liabilities - Non-current	10.93	10.93	-	8.26	0.62	2.04
Lease liabilities - Current	4.11	4.11	4.11	-	-	-
Trade payables	217.24	217.24	217.24	-	-	-
Other financial liabilities	120.08	120.08	120.08	-	-	-

iv. Market risk

Market risk is the risk that changes in market prices – such as foreign exchange rates, interest rates and equity prices – will affect the Company’s income or the value of its holdings of financial instruments. Market risk is attributable to all market risk sensitive financial instruments including foreign currency receivables and payables and long term debt. We are exposed to market risk primarily related to foreign exchange rate risk. Thus, our exposure to market risk is a function of revenue generating and operating activities in foreign currency. The objective of market risk management is to avoid excessive exposure in our foreign currency revenues and costs.

Currency risk

The Company is exposed to currency risk on account of its operations in other countries. The functional currency of the Company is Indian Rupee. The exchange rate between the Indian rupee and foreign currencies has changed substantially in recent periods and may continue to fluctuate substantially in the future. Consequently, the Company uses derivative instruments, i.e. foreign exchange forward contracts to mitigate the risk of changes in foreign currency exchange rates in respect of its highly probable forecasted transactions and recognized assets and liabilities.

Notes to the Standalone Financial Statements

for the year ended 31 March 2025

(₹ in million)

Exposure to currency risk

The currency profile of financial assets and financial liabilities as at 31 March 2025 and 31 March 2024 are as below:

	₹ in million		
	31 March 2025 USD	31 March 2025 EURO	31 March 2025 Others
Financial assets			
Cash and cash equivalents	0.03	0.06	0.03
Trade and other receivables	172.12	68.06	-
	172.15	68.12	0.03
Financial liabilities			
Trade and other payables	23.58	1.96	-
	23.58	1.96	-
Net exposure	148.57	66.16	0.03

	31 March 2024 USD	31 March 2024 EURO	31 March 2024 Others
Financial assets			
Cash and cash equivalents	0.02	0.08	0.03
Trade and other receivables	181.03	36.18	3.62
	181.05	36.26	3.65
Financial liabilities			
Trade payables	14.38	7.55	-
	14.38	7.55	-
Net exposure	166.67	28.71	3.65

Sensitivity analysis

A reasonably possible strengthening / (weakening) of the Indian Rupee against US dollars and Euros at 31 March would have affected the measurement of financial instruments denominated in US dollars and Euros and affected equity and profit or loss by the amounts shown below. This analysis assumes that all other variables, in particular interest rates, remain constant and ignores any impact of forecast sales and purchases.

Effect in ₹	Profit or loss	
	Strengthening	Weakening
31 March 2025		
1% movement		
USD	(1.49)	1.49
EUR	(0.66)	0.66
Others #	(0.00)	0.00
	(2.15)	2.15

Effect in ₹	Profit or loss	
	Strengthening	Weakening
31 March 2024		
1% movement		
USD	(1.67)	1.67
EUR	(0.29)	0.29
Others #	(0.04)	0.04
	(2.00)	2.00

Figures are below ₹ 0.01 Million, hence disclosed as ₹ 0.00

Notes to the Standalone Financial Statements

for the year ended 31 March 2025

(₹ in million)

42 Related party relationships, transactions and balances

The table provides the information about the Group's structure including the details of the subsidiaries and the holding company. The following table provides the total amount of transactions that have been entered into with related parties for the relevant financial year:

a Name of Related Parties where control exists irrespective of whether transactions have occurred or not

I Subsidiaries including step-down subsidiaries

Advanced Bio-Agro Tech Limited
Advanced Enzytech Solutions Limited
Advanced Enzymes Europe B.V.
JC Biotech Private Limited
Advanced Enzymes USA, Inc.
Evovx Technologies GmbH (Wholly owned subsidiary of Advanced Enzymes Europe B. V.)
Advanced Enzymes (Malaysia) Sdn. Bhd. (Voluntary strike off with effect from 8 November 2023)
Cal India Foods International (Wholly owned subsidiary of Advanced Enzymes USA, Inc.)
Advanced Supplementary Technologies Corporation (Wholly owned subsidiary of Advanced Enzymes USA, Inc.)
Enzyme Innovation, Inc. (Wholly owned subsidiary of Advanced Supplementary Technologies Corporation)
Dynamic Enzymes, Inc. (Merged with Advanced Supplementary Technologies Corporation w.e.f 1 April 2023)
Scitech Specialities Private Limited
Saiganesh Enzytech Solutions Private Limited
Starya Labs Inc. (Wholly owned subsidiary of Advanced Enzymes USA, Inc. w.e.f. 9 December 2024)

b Name of other related parties

II Key Management Personnel (KMP)

Mr. Vasant L Rathī	Chairman and Non-executive Director
Mr. Mukund M. Kabra	Whole-time Director
Mr. Beni P. Rauka	Chief Financial Officer
Mr. Sanjay Basantani	Company Secretary
Mr. Kedar Desai (up to 31 March 2024)	Independent Director
Mr. Pramod Kasat	Independent Director
Mr. Rajesh Sharma (up to 10 August 2023)	Independent Director
Ms. Rasika Rathī	Non-executive director and daughter of Chairman
Mr. Vinodkumar Jajoo	Independent Director
Dr. Sunny Sharma	Non-executive director
Mrs. Rajshree Patel	Independent Director
Mr. Nitin Jagannath Deshmukh	Independent Director
Mrs. Vandana Tilak (w.e.f. 1 July 2023)	Independent Director

Relatives of KMP :

Mrs. Prabha V. Rathī	Wife of chairman
Mr. Kishor L. Rathī	Brother of Chairman

III Other related parties (entities in which either of the KMP's have significant influence) and with whom transactions have taken place during the year

Advenza Global Limited (Formerly known as Advanced Vital Enzymes Pvt Ltd)

Notes to the Standalone Financial Statements

for the year ended 31 March 2025

(₹ in million)

c) Transactions with related parties

Transactions during the year	Subsidiaries		KMP and relatives		Other related parties	
	Year ended 31 March 2025	Year ended 31 March 2024	Year ended 31 March 2025	Year ended 31 March 2024	Year ended 31 March 2025	Year ended 31 March 2024
1 Purchases of materials						
JC Biotech Private Limited	587.74	618.95	-	-	-	-
Cal India Foods International	0.03	-	-	-	-	-
Evovx Technologies GmbH	0.62	2.21	-	-	-	-
Scitech Specialities Private Limited	3.04	3.15	-	-	-	-
Saiganesh Enzytech Solutions Private Limited	67.56	66.93	-	-	-	-
	658.99	691.24	-	-	-	-
2 Sale of goods and materials						
Advanced EnzyTech Solutions Limited	141.58	113.51	-	-	-	-
Advanced Bio-Agro Tech Limited	305.44	281.10	-	-	-	-
Advenza Global Limited (Formerly known as Advanced Vital Enzymes Pvt Ltd)	-	-	-	-	2.06	3.44
Cal India Foods International	473.13	456.40	-	-	-	-
JC Biotech Private Limited	5.02	13.00	-	-	-	-
Evovx Technologies GmbH	21.55	36.72	-	-	-	-
Scitech Specialities Private Limited	22.48	4.72	-	-	-	-
	969.20	905.45	-	-	2.06	3.44
3 Remuneration * ^						
Mr. Mukund Kabra	-	-	27.14	25.00	-	-
Mr. Kishor L. Rathī	-	-	3.90	3.71	-	-
Mr. Beni P. Rauka	-	-	15.94	14.56	-	-
Mr. Sanjay Basantani	-	-	5.50	4.79	-	-
	-	-	52.48	48.06	-	-
4 Commission to directors						
Mr. Vasant L. Rathī	-	-	0.99	1.13	-	-
Mr. Mukund Kabra	-	-	5.11	5.37	-	-
Ms. Rasika Rathī	-	-	0.59	0.26	-	-
Mr. Kedar Desai	-	-	-	1.22	-	-
Mr. Pramod Kasat	-	-	0.89	0.87	-	-
Mr. Vinodkumar Jajoo	-	-	1.09	0.87	-	-
Dr. Sunny Sharma	-	-	0.30	0.35	-	-
Mrs. Rajshree Patel	-	-	0.30	0.52	-	-
Mr. Nitin Jagannath Deshmukh	-	-	0.59	0.44	-	-
Mrs. Vandana Tilak	-	-	-	0.17	-	-
	-	-	9.86	11.20	-	-
5 Sitting fees to Independent directors						
Mr. Kedar Desai	-	-	-	0.42	-	-
Mr. Pramod Kasat	-	-	0.29	0.31	-	-
Mr. Vinodkumar Jajoo	-	-	0.34	0.32	-	-
Mrs. Rajshree Patel	-	-	0.10	0.20	-	-
Mr. Nitin Jagannath Deshmukh	-	-	0.22	0.18	-	-
Ms. Vandana Tilak	-	-	(0.08)	0.10	-	-
	-	-	0.87	1.51	-	-

Notes to the Standalone Financial Statements

for the year ended 31 March 2025

(₹ in million)

Transactions during the year	Subsidiaries		KMP and relatives		Other related parties	
	Year ended 31 March 2025	Year ended 31 March 2024	Year ended 31 March 2025	Year ended 31 March 2024	Year ended 31 March 2025	Year ended 31 March 2024
6 Conversion of loan into investment						
Advanced Enzymes Europe B.V.	-	329.00	-	-	-	-
	-	329.00	-	-	-	-
7 Investment in subsidiaries						
JC Biotech Private Limited	-	56.07	-	-	-	-
Advanced Enzymes Europe B.V.	478.18	-	-	-	-	-
	478.18	56.07	-	-	-	-
8 Dividend income						
Advanced Enzytech Solutions Limited	21.00	14.00	-	-	-	-
Advanced Bio-Agro Tech Limited	24.00	12.00	-	-	-	-
Advanced Enzymes USA, Inc.	512.06	500.71	-	-	-	-
Saiganesh Enzytech Solutions Private Limited	4.00	-	-	-	-	-
	561.06	526.71	-	-	-	-
9 Reimbursement of expenses						
Advanced Enzymes USA, Inc.	1.07	1.58	-	-	-	-
JC Biotech Private Limited	0.65	0.53	-	-	-	-
Advanced Enzymes Europe B.V.	2.33	2.37	-	-	-	-
	4.05	4.48	-	-	-	-
10 Technical services procured						
Evoxx Technologies GmbH	89.28	90.85	-	-	-	-
	89.28	90.85	-	-	-	-

* included in Employee benefit expense

^ The amount does not include gratuity and compensated absences which are actuarially determined on an overall basis for the Company and individual information in respect of the Key Management Personnel is not available.

d) Balances at the year end

	Subsidiaries		KMP and relatives		Other related parties	
	As on 31 March 2025	As on 31 March 2024	As on 31 March 2025	As on 31 March 2024	As on 31 March 2025	As on 31 March 2024
Outstanding balances						
1 Investments						
Advanced Bio-Agro Tech Limited	0.60	0.60	-	-	-	-
Advanced EnzyTech Solutions Limited	1.57	1.57	-	-	-	-
Advanced Enzymes USA, Inc.	533.83	532.77	-	-	-	-
JC Biotech Private Limited	852.00	851.34	-	-	-	-
Advanced Enzymes Europe B.V.	961.74	481.22	-	-	-	-
Advenza Global Limited (Formerly known as Advanced Vital Enzymes Pvt Ltd)	-	-	-	-	0.57	0.57
Scitech Specialities Private Limited	316.26	316.26	-	-	-	-
Saiganesh Enzytech Solutions Private Limited	59.98	59.98	-	-	-	-
	2,725.98	2,243.74	-	-	0.57	0.57

Notes to the Standalone Financial Statements

for the year ended 31 March 2025

(₹ in million)

	Subsidiaries		KMP and relatives		Other related parties	
	As on 31 March 2025	As on 31 March 2024	As on 31 March 2025	As on 31 March 2024	As on 31 March 2025	As on 31 March 2024
2 Trade receivables						
Advanced EnzyTech Solutions Limited	7.72	4.16	-	-	-	-
Advanced Bio-Agro Tech Limited	10.30	19.60	-	-	-	-
Cal India Foods International	118.22	167.44	-	-	-	-
Evoxx Technologies GmbH	12.19	14.62	-	-	-	-
Scitech Specialities Private Limited	3.99	1.78	-	-	-	-
	152.42	207.60	-	-	-	-
3 Trade payables						
Evoxx Technologies GmbH	1.96	5.82	-	-	-	-
JC Biotech Private Limited	104.54	117.93	-	-	-	-
Scitech Specialities Private Limited	1.03	3.51	-	-	-	-
Saiganesh Enzytech Solutions Private Limited	8.55	10.35	-	-	-	-
	116.08	137.61	-	-	-	-
4 Remuneration payable						
Mr. Mukund M. Kabra	-	-	1.27	1.14	-	-
Mr. Kishor L. Rathi	-	-	0.22	0.21	-	-
Mr. Beni P. Rauka	-	-	0.52	0.51	-	-
Mr. Sanjay Basantani	-	-	0.21	0.22	-	-
	-	-	2.22	2.08	-	-
5 Commission payable						
Mr. Vasant L. Rathi	-	-	0.99	1.13	-	-
Mr. Mukund Kabra	-	-	5.11	5.37	-	-
Ms. Rasika Rathi	-	-	0.59	0.26	-	-
Mr. Kedar Desai	-	-	-	1.22	-	-
Mr. Pramod Kasat	-	-	0.89	0.87	-	-
Mr. Vinodkumar Jajoo	-	-	1.09	0.87	-	-
Dr. Sunny Sharma	-	-	0.30	0.35	-	-
Mrs. Rajshree Patel	-	-	0.30	0.52	-	-
Mr. Nitin Jagannath Deshmukh	-	-	0.59	0.44	-	-
Mrs. Vandana Tilak	-	-	-	0.17	-	-
	-	-	9.86	11.20	-	-
6 Directors' sitting fees payable						
Mr. Kedar Desai	-	-	-	0.02	-	-
Mr. Pramod Kasat	-	-	0.02	0.02	-	-
Mr. Vinodkumar Jajoo	-	-	0.02	0.02	-	-
Mrs. Rajshree Patel	-	-	0.05	0.09	-	-
Mr. Nitin Jagannath Deshmukh	-	-	0.02	0.02	-	-
	-	-	0.11	0.17	-	-

Notes:

The Company's international transactions with related parties are at arm's length as per the independent accountants report for the year ended 31 March 2024. Management believes that the Company's international transactions and domestic transactions with related parties post 31 March 2024 continue to be at arm's length and that the transfer pricing legislation will not have any material impact on these financial statements, particularly on amount of tax expense and that of provision for taxation.

Notes to the Standalone Financial Statements

for the year ended 31 March 2025

(₹ in million)

In compliance with Ind AS – 27 ‘Separate Financial Statements’, the required information is as under:

Subsidiaries	Country of incorporation	Ownership interest	
		31 March 2025	31 March 2024
i. Advanced Bio-Agro Tech Limited	India	60.00%	60.00%
ii. JC Biotech Private Limited	India	95.72%	95.72%
iii. Advanced Enzytech Solutions Limited	India	100.00%	100.00%
iv. Advanced Enzymes USA, Inc.	USA	100.00%	100.00%
v. Advanced Enzymes Europe B.V.	Netherlands	100.00%	100.00%
vi. Evoxx Technologies GmbH (Wholly owned subsidiary of Advanced Enzymes Europe B. V.)	Germany	100.00%	100.00%
vii. Cal India Foods International (Wholly owned subsidiary of Advanced Enzymes USA, Inc.)	USA	100.00%	100.00%
viii. Advanced Supplementary Technologies Corporation (Wholly owned subsidiary of Advanced Enzymes USA, Inc.)	USA	100.00%	100.00%
ix. Enzyme Innovation, Inc. (Wholly owned subsidiary of Cal India Foods International)	USA	100.00%	100.00%
x. Advanced Enzymes (Malaysia) Sdn. Bhd. (Voluntary strike off with effect from 8 November 2023)	Malaysia	0.00%	0.00%
xi. Scitech Specialities Private Limited	India	51.00%	51.00%
xii. Saiganesh Enzytech Solutions Private Limited	India	50.00%	50.00%
xiii. Starya Labs Inc. (Wholly owned subsidiary of Advanced Enzymes USA, Inc. w.e.f. 9 December 2024)	USA	100.00%	0.00%

43 Employee share-based payment plans

a) Description of share-based payment arrangements:

As at 31 March 2025, the Company has the following share-based payment arrangements for employees.

‘AETL Employee Stock Option Scheme 2022’- (“AETL ESOS 2022”) AETL ESOS 2022, 1st grant provides for the grant of 576,000 stock options to specified employees on 12 August 2023. The AETL ESOS 2022 had been formulated by Board of Directors which was further adopted by Nomination and Remuneration committee. The Shareholders approved scheme on 12 August 2023. The plan entitles specified employees to purchase shares in the Company at the stipulated exercise price, subject to compliance with vesting conditions. As per the plan, holders of vested options are entitled to purchase one equity share of face value of ₹ 2 each for every option as per the scheme.

576,000 Equity Shares of Face Value of ₹ 2 each are reserved for issue under AETL Employee Stock Option Scheme 2022 (AETL ESOS 2022)

The terms and conditions related to the grant of the share options are as follows:

Employees entitled	Specified employees
Number of options	5,76,000
Scheme formulation	
Category I	First 500 Options at the Exercise Price of ₹ 2 /- each
Category II	Employees who have been granted Options upto 5,000; First 500 Options at ₹ 2 /- each and remaining Options at ₹ 141 /-
Category III	Employees who have been granted Options more than 5,000; First 500 Options at ₹ 2 /- each, Next 4,500 Option at ₹ 141 /- and remaining Options at ₹ 188 /-
Vesting conditions	
Category I	After 1 year of the date of grant
Category II	First 500 option after 1 year of the date of grant and for balance options
	After 1 year of the date of grant 5% vesting
	After 2 year of the date of grant 10% vesting

Notes to the Standalone Financial Statements

for the year ended 31 March 2025

(₹ in million)

	After 3 year of the date of grant 20% vesting
	After 4 year of the date of grant 30% vesting
	After 5 year of the date of grant 35% vesting
Category III	After 1 year of the date of grant 5% vesting
	After 2 year of the date of grant 10% vesting
	After 3 year of the date of grant 20% vesting
	After 4 year of the date of grant 30% vesting
	After 5 year of the date of grant 35% vesting
Contractual life of options	Graded vesting over 5 years

b) Measurement of fair value :

The fair values are measured based on the Black-Scholes-option valuation model. Service and non-market performance conditions attached to the arrangements were not taken into account in measuring fair value.

The inputs used in the measurement of the fair values at grant date and measurement date of the stock options were as follows.

Particulars					
Vesting	1 Year	2 Year	3 Years	4 Years	5 Years
Share price at grant date (Face value - ₹ 2 per share)	₹ 329	₹ 329	₹ 329	₹ 329	₹ 329
Exercise price (Face value - ₹ 2 per share)					
Expected volatility (weighted average)	31.41%	33.82%	40.78%	43.12%	42.13%
Expected life (weighted average)	1.25 years	2.25 years	3.25 years	4.25 years	5.25 years
Expected dividend	0.30%	0.30%	0.30%	0.30%	0.30%
Risk-free interest rate (based on government bond)	6.69% p.a.	6.77% p.a.	6.80% p.a.	6.81% p.a.	6.82% p.a.

Weighted-average exercise prices and weighted-average fair values of options

Date of Vesting	1 Year	2 Year	3 Years	4 Years	5 Years
Weighted-average exercise prices	64	156	156	156	156
Weighted-average fair value of options	269	195	208	219	227

c) Reconciliation of outstanding stock options :

Particular	31 March 2025 No. of options	31 March 2024 No. of options
Outstanding at 1 April	5,70,000	-
Granted	-	5,76,000
Vested	-	-
Forfeited	-	-
Expired	14,175	6,000
Exercised	57,075	-
Outstanding at 31 March	4,98,750	5,70,000
Exercisable at 31 March	-	-

d) Expense recognized in the Standalone Statement of Profit and Loss :

	31 March 2025	31 March 2024
AETL ESOS 2022	30.13	25.83
Total expense recognized in ‘employee benefits’	30.13	25.83

Notes to the Standalone Financial Statements

for the year ended 31 March 2025

(₹ in million)

43A a) Description of share-based payment arrangements:

As at 31 March 2025, the Company has the following share-based payment arrangements for employees.

'AETL Employee Stock Option Scheme 2022'- ("AETL ESOS 2022")

AETL ESOS 2022, 2nd grant provides for the grant of 512,500 stock options to specified employees on 27 March 2025. The AETL ESOS 2022 had been formulated by Board of Directors which was further adopted by Nomination and Remuneration committee. The Shareholders approved scheme on 12 August 2023. The plan entitles specified employees to purchase shares in the Company at the stipulated exercise price, subject to compliance with vesting conditions. As per the plan, holders of vested options are entitled to purchase one equity share of face value of ₹ 2 each for every option as per the scheme.

512,500 Equity Shares of Face Value of ₹ 2 each are reserved for issue under AETL Employee Stock Option Scheme 2022 (AETL ESOS 2022)

The terms and conditions related to the grant of the share options are as follows:

Employees entitled	Specified employees
Number of options	5,12,500
Scheme formulation	
Category I	First 500 Options at the Exercise Price of ₹ 2 /- each
Category II	Employees who have been granted Options upto 5,000; First 500 Options at ₹ 2 /- each and remaining Options at ₹ 166 /-
Category III	Employees who have been granted Options more than 5,000; First 500 Options at ₹ 2 /- each, Next 4,500 Option at ₹ 166 /- and remaining Options at ₹ 221 /-
Vesting conditions	
Category I	After 1 year of the date of grant
Category II	First 500 option after 1 year of the date of grant and
	for balance options
	After 1 year of the date of grant 5% vesting
	After 2 year of the date of grant 10% vesting
	After 3 year of the date of grant 20% vesting
	After 4 year of the date of grant 30% vesting
	After 5 year of the date of grant 35% vesting
Category III	After 1 year of the date of grant 5% vesting
	After 2 year of the date of grant 10% vesting
	After 3 year of the date of grant 20% vesting
	After 4 year of the date of grant 30% vesting
	After 5 year of the date of grant 35% vesting
Contractual life of options	Graded vesting over 5 years

b) Measurement of fair value :

The fair values are measured based on the Black-Scholes-option valuation model. Service and non-market performance conditions attached to the arrangements were not taken into account in measuring fair value.

The inputs used in the measurement of the fair values at grant date and measurement date of the stock options were as follows.

Particulars					
Vesting	1 Year	2 Year	3 Years	4 Years	5 Years
Share price at grant date (Face value - ₹ 2 per share)	₹ 278.90	₹ 278.90	₹ 278.90	₹ 278.90	₹ 278.90
Exercise price (Face value - ₹ 2 per share)					
Expected volatility (weighted average)	38.44%	35.06%	35.64%	35.76%	41.78%
Expected life (weighted average)	1.25 years	2.25 years	3.25 years	4.25 years	5.25 years
Expected dividend	0.68%	0.78%	0.70%	0.62%	0.58%
Risk-free interest rate (based on government bond)	6.24% p.a.	6.21% p.a.	6.20% p.a.	6.21% p.a.	6.22% p.a.

Notes to the Standalone Financial Statements

for the year ended 31 March 2025

(₹ in million)

Weighted-average exercise prices and weighted-average fair values of options

Date of Vesting	1 Year	2 Year	3 Years	4 Years	5 Years
Weighted-average exercise prices	81	184	184	184	184
Weighted-average fair value of options	205	125	136	146	162

c) Reconciliation of outstanding stock options :

Particular	31 March 2025 No. of options	31 March 2024 No. of options
Granted	5,12,500	
Vested	-	-
Forfeited	-	-
Expired	-	-
Exercised	-	-
Outstanding at 31 March	5,12,500	-
Exercisable at 31 March	-	-

d) Expense recognized in the Standalone Statement of Profit and Loss :

	31 March 2025	31 March 2024
AETL ESOS 2022	0.28	-
Total expense recognized in 'employee benefits'	0.28	-

44 Capital Management

For the purpose of the Company's capital management, capital includes issued capital and other equity reserves. The primary objective of the Company's Capital Management is to maximise shareholders value. The Company manages its capital structure and makes adjustments in the light of changes in economic environment and the requirements of the financial covenants.

The Company monitors capital using adjusted net debt to equity ratio. For this purpose, adjusted net debt is defined as total debt less cash and bank balances.

	31 March 2025	31 March 2024
Non-current borrowings	-	-
Current borrowings	-	-
Gross debt	-	-
Less - Cash and cash equivalents	56.04	14.95
Less - Other bank deposits	2.28	5.22
Adjusted net debt	(58.32)	(20.17)
Total equity	6,293.41	5,804.71
Adjusted net debt to equity ratio	-0.93%	-0.35%

45 Payments to auditors (excluding GST)

	Year ended 31 March 2025	Year ended 31 March 2024
Statutory audit	2.26	2.15
Limited review	1.49	1.38
Certification work	0.10	0.07
Reimbursement of expenses	0.64	0.17
	4.49	3.77

Notes to the Standalone Financial Statements

for the year ended 31 March 2025

(₹ in million)

46 Research and development

The Company has incurred the following expenditure on research and development activities:

	Year ended 31 March 2025	Year ended 31 March 2024
Revenue expenditure		
Laboratory expenses and consumables	31.93	21.16
Employee benefit expenses	105.55	92.48
Legal and professional charges	9.86	4.49
Technical services	113.92	107.95
Electricity	15.20	9.62
Rent, rates and taxes	2.34	2.22
Repairs and maintenance	11.51	11.38
Travelling and conveyance expenses	2.47	2.59
Other expenses	3.74	3.31
	296.52	255.20
Capital expenditure		
Plant and equipment	24.69	15.35
Furniture and fixtures	0.39	0.49
Office equipment	2.82	1.87
Computer and data processing equipment	1.14	1.14
Vehicles	2.68	-
Building	0.15	-
	31.87	18.85

47 Corporate Social Responsibility

Particulars	For the year ended 31 March 2025	For the year ended 31 March 2024
1) amount required to be spent by the company during the year	19.24	15.59
2) amount of expenditure incurred *	19.24	15.59
3) shortfall at the end of the year	-	-
4) total of previous years shortfall	-	-
5) reason for shortfall	Not applicable	Not applicable
6) nature of CSR activities	Promotion of education, Healthcare and skill development	
7) details of related party transactions, e.g., contribution to a trust controlled by the company in relation to CSR expenditure as per relevant Accounting Standard	-	-
8) where a provision is made with respect to a liability incurred by entering into a contractual obligation, the movements in the provision during the year should be shown separately.	10.77	4.31

*The Committee of Corporate Social Responsibility had approved the budget of ₹ 19.24 million (31 March 2024: 15.59 million), the Company contributes to the various projects undertaken by various organisations. During the year the amount spent is ₹ 7.97 million (31 March 2024: ₹ 11.28 million) on the ongoing projects and ₹ 0.5 million towards current year project (31 March 2024: ₹ Nil). The Company has deposited the balance unspent amount of ₹ 10.77 million (31 March 2024: ₹ 4.31 million) in a separate bank account.

48 Acquisition of additional stake in JC Biotech Private Limited

On 5 March 2024, the Company has acquired additional stake of 5.89% in its subsidiary JC Biotech Private Limited for a consideration of ₹ 56.07 million. Post this additional acquisition the Company holds 95.72% stake in the subsidiary.

Notes to the Standalone Financial Statements

for the year ended 31 March 2025

(₹ in million)

49 Investment in Advanced Enzymes Europe B.V.

On 19 December 2024, the Company invested ₹ 478.18 million in Advanced Enzymes Europe B.V. ('AEEBV') (wholly owned subsidiary) by way of subscription to 3,623,163 equity shares. The value per equity share is EUR 1.48 and the face value of EUR 1 per share. Pursuant to this the Company now holds 7,900,000 equity share of AEEBV and the Company continues to be 100% shareholder of AEEBV.

50 Proposed Dividend

The Board of Directors recommended a final dividend for the financial year 2024-25 of ₹ 1.20/- (31 March 2024: ₹ 1.10) per equity share of the face value of ₹ 2/- each, and the same will be paid after approval of shareholders in the Annual General Meeting of the Company.

51 Impairment of investment in Advanced Enzymes Europe B.V.

During the year ended 31 March 2024, the Company has carried out fair value assessment of its investment in Advanced Enzymes Europe B.V. (AEEBV) after considering past business performance, prevailing business conditions and revised expectations of its future performance and this assessment has resulted in impairment loss of ₹ 189.48 million of investment in the subsidiary.

52 Ratios

Sr. No.	Ratio	Particulars		Ratio as on		Variation	Reason (If variation is more than 25%)
		Numerator	Denominator	31-March 25	31-March 24		
1	Current Ratio	Total current assets	Total current liabilities	5.19	6.21	-16.30%	NA
2	Debt-Equity Ratio #	Long term and short term borrowings	Total equity	-	-	0.00%	NA
3	Debt Service Coverage Ratio	Net Operating Income	Debt Service	118.22	123.27	-4.10%	NA
4	Return on Equity Ratio	Profit after tax	Shareholder's Equity	16.27%	18.63%	-12.63%	NA
5	Inventory Turnover Ratio	Cost of Goods Sold ('COGS')	Average Inventory	1.55	1.64	-5.78%	NA
6	Trade Receivables Turnover Ratio	Revenue from operations	Average Trade Receivables	4.58	5.15	-11.06%	NA
7	Trade Payables Turnover Ratio	COGS + Other expenses	Average Trade Payables	10.12	10.55	-4.09%	NA
8	Net Capital Turnover Ratio	Revenue from operations	Average Working Capital	1.87	1.75	6.83%	NA
9	Net Profit Ratio	Net Profit	Net Sales	29%	30%	-1.49%	NA
10	Return on Capital Employed	EBIT	Capital Employed	19%	26%	-27.40%	Decrease is on account of lower EBIT during current year.
11	Return on Investment	Net Profit	Net Investment	17%	20%	-13.42%	NA

Figures are below 0.01, hence disclosed as ₹ 0.00

53 Contingent liabilities and commitments (to the extent not provided for)

	31 March 2025	31 March 2024
Contingent liabilities		
Pertains to income tax demand/ matters on account of deductions/ disallowances for earlier years, pending for appeals consequent to order passed against the Company/ demands raised by the Department under Income Tax Act, 1961. Amount paid and adjusted there against and included under Income tax asset ₹ 144.20 million (31 March 2024: ₹ 129.52 million).	49.64	25.92
Pertains to Excise Duty and Service Tax demand raised by Commissioner of Central Excise, Customs and Service tax on account of inadmissible CENVAT credit, incorrect product classification and service tax levy on directors' remuneration for various periods. Amount paid there against and included under note 19 'Other current assets'.	27.58	27.58

Notes to the Standalone Financial Statements

for the year ended 31 March 2025

(₹ in million)

	31 March 2025	31 March 2024
The Hon'ble Supreme Court of India ("SC") by their order dated February 28, 2019, in the case of Surya Roshni Limited & others v/s EPFO, set out the principles based on which allowances paid to the employees should be identified for inclusion in basic wages for the purposes of computation of Provident Fund contribution. Subsequently, a review petition against this decision has been filed and is pending before the SC for disposal. In view of the management, the liability for the period from date of the SC order to 31 March 2019 is not significant. Further, pending decision on the subject review petition and directions from the EPFO, the impact for the past period, if any, is not ascertainable and consequently no effect has been given in the accounts. Accordingly, this has been disclosed as a Contingent liability in the financial statements.	-	-
	77.22	53.50

The Company has reviewed all its pending litigations and proceedings and has adequately provided for where provisions are required and disclosed as contingent liability, where applicable in its standalone financial statements. The Company's management does not reasonably expect that these legal actions, when ultimately concluded and determined, will have a material and adverse effect of the Company's results of operations or financial condition.

	31 March 2025	31 March 2024
Commitments		
Estimated amount of commitments remaining to be executed		
- Capital (net of advances)	122.62	123.81
	122.62	123.81

54 The Code on Social Security 2020

The Code on Social Security 2020 ('the Code') relating to employee benefits, during the employment and post-employment, has received Presidential assent on September 28, 2020. The Code has been published in the Gazette of India. Further, the Ministry of Labour and Employment has released draft rules for the Code on November 13, 2020. However, the effective date from which the changes are applicable is yet to be notified and rules for quantifying the financial impact are also not yet issued.

The Company will assess the impact of the Code and will give appropriate impact in the financial statements in the period in which, the Code becomes effective and the related rules to determine the financial impact are published. Based on a preliminary assessment, the Company believes the impact of the change will not be significant.

55 Disclosure under Section 186 of the Companies Act, 2013

- a) The details of investment and loan under Section 186 of the Act read with the Companies (Meetings of the board and its Powers) Rules, 2014 are as follows:

Name of entity	As at 31 March 2023	Loan given during the year	Repaid/written/ Conversion off during the year	As at 31 March 2024
Advanced Enzymes Europe B.V.	245.95	-	245.95	-

	As at 31 March 2023	Investment during the year	Investment reversed during the year	As at 31 March 2024
Advanced Bio-Agro Tech Limited	0.60	-	-	0.60
Advanced Enzytech Solutions Limited	1.57	-	-	1.57
Advanced Enzymes USA, Inc.	531.19	1.58	-	532.77
JC Biotech Private Limited	794.75	56.60	-	851.35
Advanced Enzymes Europe B.V.	149.85	331.37	-	481.22
Saiganesh Enzytech Solutions Private Limited	59.98	-	-	59.98
Scitech Specialities Private Limited	316.26	-	-	316.26

Notes to the Standalone Financial Statements

for the year ended 31 March 2025

(₹ in million)

Name of entity	As at 31 March 2024	Loan given during the year	Repaid / written off/ Conversion during the year	As at 31 March 2025
Advanced Enzymes Europe B.V.	-	-	-	-

	As at 31 March 2024	Investment during the year	Investment reversed during the year	As at 31 March 2025
Advanced Bio-Agro Tech Limited	0.60	-	-	0.60
Advanced Enzytech Solutions Limited	1.57	-	-	1.57
Advanced Enzymes USA, Inc.	532.77	1.07	-	533.84
JC Biotech Private Limited	851.35	0.65	-	852.00
Advanced Enzymes Europe B.V.	481.22	480.52	-	961.74
Saiganesh Enzytech Solutions Private Limited	59.98	-	-	59.98
Scitech Specialities Private Limited	316.26	-	-	316.26

Note 1:

Purpose of utilisation of above loans 1) **Advanced Enzymes Europe B.V.:** For acquisition of Evoxx Technologies GmbH and working capital requirements.

Loan repayment terms 1) **Advanced Enzymes Europe B.V.:** 20 quarterly instalments including interest starting from September 2023.

Rate of Interest 1) **Advanced Enzymes Europe B.V.: 9.00%**

Maximum amount outstanding including interest during the year is Nil (31 March 2024: ₹ 329.00 million) as per additional disclosures pursuant to Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

56 Conversion of loan to Advanced Enzymes Europe B.V. ('AEEBV') into equity

Effective date 7 April 2023, loan given by the Company to Advanced Enzymes Europe B.V. (AEEBV) including the outstanding interest aggregating to ₹ 329 million got converted into 2,276,837 fully paid up equity shares. The value per equity share is EUR 1.63 and the face value of EUR 1 per share. Pursuant to this conversion, the Company now holds 4,276,837 equity share of AEEBV and the Company continues to be 100% shareholder of AEEBV.

57 Voluntary strike off of Advanced Enzymes Malaysia Sdn. Bhd. ('AEM')

Effective 8 November 2023, the wholly owned subsidiary AEM was struck off on 8 November 2023 after approval from Registrar of Companies, Malaysia , and status of AEM is now appearing as 'Dissolved'. Consequently, AEM ceases to be the subsidiary of the Company. The Company has written off its investment in equity share capital and loan given by the Company to AEM along with interest receivable and corresponding provision created against investment, loan and interest receivable is also released. There is no impact on the profitability of the Company in the current year.

58 Other Statutory Information

- (i) The Company does not have any Benami property, where any proceeding has been initiated or pending against the Company for holding any Benami property.
- (ii) The Company does not have any transactions with companies struck off.
- (iii) The Company has complied with the requirement with respect to number of layers as prescribed under section 2(87) of the Companies Act, 2013 read with the Companies (Restriction on number of layers) Rules, 2017.
- (iv) The Company does not have any charges or satisfaction which is yet to be registered with ROC beyond the statutory period.
- (v) The Company has not traded or invested in Crypto currency or Virtual Currency during the financial year.
- (vi) The Company has not advanced or loaned or invested funds to any other person(s) or entity(ies), including foreign entities (Intermediaries)with the understanding that the Intermediary shall:
 - a. directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company (Ultimate Beneficiaries) or

Notes to the Standalone Financial Statements
for the year ended 31 March 2025

(₹ in million)

- b.

provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries
- (vii)

The Company has not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Company shall:

a.

directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or

b.

provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

(viii)

The Company does not have any such transaction which is not recorded in the books of accounts that has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961.
- 59 Previous year amounts have been regrouped / reclassified wherever necessary.
- for **M S K A & Associates**
Chartered Accountants
Firm's Registration No: 105047W
- Amrish Vaidya**
Partner
Membership No.: 101739
- Place: Thane
Date: 13 May 2025
- for and on behalf of the Board
- Mukund Kabra**
Wholetime Director
DIN : 00148294
Place : Thane
- Sanjay Basantani**
Company Secretary
Membership No: A19637
Place : Thane
- Vinodkumar Jajoo**
Director
DIN : 08224980
Place : Nashik
- Beni P. Rauka**
Chief Financial Officer
Membership No: 039980
Place : Thane
- INDEPENDENT AUDITOR’S REPORT
- To the Members of Advanced Enzyme Technologies Limited
- Report on the Audit of the Consolidated Financial Statements
- Opinion
- We have audited the accompanying consolidated financial statements of Advanced Enzyme Technologies Limited (hereinafter referred to as the “Holding Company”) and its subsidiaries (Holding Company, and its subsidiaries together referred to as “the Group”), which comprise the Consolidated Balance Sheet as at March 31, 2025, and the Consolidated Statement of Profit and Loss including Other Comprehensive Income, the Consolidated Statement of Changes in Equity and the Consolidated Statement of Cash Flows for the year then ended, and notes to the Consolidated Financial Statements, including material accounting policy information and other explanatory information (hereinafter referred to as the “consolidated financial statements”).
- In our opinion and to the best of our information and according to the explanations given to us, and based on consideration of reports of other auditors on separate & consolidated financial statements of subsidiaries, the aforesaid consolidated financial statements give the information required by the Companies Act, 2013 (“the Act”) in the manner so required and give a true and fair view in conformity with the Indian Accounting Standards prescribed under section 133 of the Act read with Companies (Indian Accounting Standards) Rules, 2015, as amended (“Ind AS”) and other accounting principles generally accepted in India, of their consolidated state of affairs of the Group as at March 31, 2025, and of consolidated profit (including other
- comprehensive income),consolidated changes in equity and its consolidated cash flows for the year then ended.
- Basis for Opinion
- We conducted our audit of the consolidated financial statements in accordance with the Standards on Auditing (SAs), as specified under section 143(10) of the Act. Our responsibilities under those SAs are further described in the Auditor’s Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are independent of the Group, in accordance with the ethical requirements that are relevant to our audit of the consolidated financial statements in terms of the Code of Ethics issued by Institute of Chartered Accountant of India (“ICAI”), and the relevant provisions of the Act and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained and on consideration of audit reports of other auditors referred to in paragraph (a) of the “Other Matters” section below, is sufficient and appropriate to provide a basis for our opinion.
- Key Audit Matters
- Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the consolidated financial statements for the year ended March 31, 2025. These matters were addressed in the context of our audit of the consolidated financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. We have determined the matters described below to be the key audit matters to be communicated in our report:
- Impairment of Goodwill recognized in Consolidated Financial Statements
- See Note 5(d) and 53 of the Consolidated Financial Statements
- | Key Audit Matters | How the Key Audit Matters was addressed in our audit |
|---|--|
| Advanced Enzyme Technologies Limited’s (AETL) subsidiary Advanced Enzymes Europe B.V. (AEEBV) had acquired 100% stake in Evoxx Technologies GmbH (Evoxx) in earlier years. The Group in the consolidated financial statements has recognised goodwill in relation to such acquisition.

On March 31, 2025, the carrying amount of Goodwill reflected in AEEBV consolidated financial statements and consequently in AETL’s consolidated financial statements is ₹ 292.68 millions.

AEEBV Group has been making operational losses and has cash outflows from operating activities.

Management of AETL has performed an impairment assessment in relation to such Investment as per the requirements of Ind AS 36 "Impairment of Assets" and has determined that no impairment provision is to be considered in the current year.

In regard to the impairment testing on its investments, the determination of the fair value of the AEEBV group requires management of the Company to estimate significant assumptions including future revenue and terminal growth rates apart from margin assumptions and discount rates to estimate future cash flows. Given the past impairment, the history of losses, and the reliance on forward-looking estimates, We have identified the impairment assessment of the investment in the subsidiary as a key audit matter. | Our audit procedures to address the impairment of Goodwill included and were not limited to the following:

1. Obtained an understanding from the Management of the Company with respect to policies and procedures followed by the Management with respect to measurement and testing of impairment of Goodwill appearing in the books relating to Acquisition of Evoxx Technologies GmbH

2. Reviewed valuation reports provided by the management of the Company.

3. Assessed the reasonableness of inputs used in valuation report provided by management for the future revenue and margin projections, the accuracy of the cash flow forecasts and analyzed the underlying key assumptions, including discounting rates and terminal growth rates.

4. Involved our internal experts to assess the consistency and reasonableness of Company’s valuation methodology and assumptions, applied, in order to assess related impairment on Goodwill.

5. Assessed the adequacy and appropriateness of the disclosures made in the Consolidated Financial Statements in compliance with the requirements of applicable Indian Accounting Standards and applicable financial reporting framework |
- 222 INTEGRATED ANNUAL REPORT 2024-25
- INTEGRATED ANNUAL REPORT 2024-25 223
- CORPORATE OVERVIEW—006-063
- STATUTORY REPORTS — 064-160
- FINANCIAL STATEMENTS —
- 161-292

Information Other than the Consolidated Financial Statements and Auditor's Report Thereon

The Holding Company's Board of Directors is responsible for the other information. The other information comprises of the information included in Holding Company's Annual Report but does not include the consolidated financial statements and our auditor's report thereon. The Holding Company's Annual Report is expected to be made available to us after the date of this auditor's report.

Our opinion on the consolidated financial statements does not cover the other information and we will not express any form of assurance conclusion thereon.

In connection with our audit of the consolidated financial statements, our responsibility is to read the other information identified above when it becomes available and, in doing so, consider whether the other information is materially inconsistent with the consolidated financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated.

When we read the Holding Company's Annual Report, if we conclude that there is a material misstatement therein, we are required to communicate the matter to those charged with governance under SA 720 'The Auditor's responsibilities Relating to Other Information' and take necessary action under the relevant laws and regulations.

Responsibilities of Management and Those Charged with Governance for the Consolidated Financial Statements

The Holding Company's Board of Directors is responsible for the preparation and presentation of these consolidated financial statements in term of the requirements of the Act that give a true and fair view of the consolidated financial position, consolidated financial performance, consolidated changes in equity and consolidated cash flows of the Group in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under section 133 of the Act. The respective Management and Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Group for preventing and detecting frauds and other irregularities; the selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated financial statements by the Management and Board of Directors of the Holding Company, as aforesaid.

In preparing the consolidated financial statements, the respective Management and Board of Directors of the companies included in the Group are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group are responsible for overseeing the financial reporting process of each company.

Auditors' Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with Standards on Auditing ("SAs") will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

We give in "Annexure A" a detailed description of Auditor's responsibilities for Audit of the Consolidated Financial Statements.

Other Matters:

- We did not audit the financial statements of twelve subsidiaries, whose financial statements before consolidation adjustments reflect total assets of ₹11,994.86 Mn as at March 31, 2025, total revenues of ₹4,586.23 Mn and net cash outflows amounting to ₹(236.25) Mn for the year ended on that date, as considered in the consolidated financial statements. These financial statements have been audited by other auditors whose reports have been furnished to us by the Management and our opinion on the consolidated financial statements, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and our report in terms of sub-section (3) of Section 143 of the Act, in so far as it relates to the aforesaid subsidiaries, is based solely on the reports of the other auditors.

Certain of these subsidiaries, are located outside India whose financial statements have been prepared in accordance with accounting principles generally accepted in their respective countries and which have been audited by other auditors under generally accepted auditing standards applicable in their respective countries. The Holding Company's management has converted the financial statements of such subsidiaries located outside India from accounting principles generally accepted in their respective countries to accounting principles generally accepted in India.

These conversion adjustments have been audited by another auditor. Our opinion in so far as it relates to the balances and affairs of such subsidiaries located outside India is based on the report of other auditors and the conversion adjustments prepared by the management of the Holding Company and audited by another auditor.

Our opinion on the consolidated financial statements is not modified in respect of the above matters.

Report on Other Legal and Regulatory Requirements

- As required by Section 143(3) of the Act, based on our audit and on the consideration of the reports of the other auditors on the Separate and Consolidated Financial Statements of the subsidiaries referred to in the Other Matters section above we report, to the extent applicable, that:

- We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit of the aforesaid consolidated financial statements.
- In our opinion, proper books of account as required by law relating to preparation of the aforesaid consolidated financial statements have been kept so far as it appears from our examination of those books and the reports of the other auditors
- The Consolidated Balance Sheet, the Consolidated Statement of Profit and Loss including other comprehensive income, the Consolidated Statement of Changes in Equity and the Consolidated Statement of Cash Flow dealt with by this Report are in agreement with the relevant books of account maintained for the purpose of preparation of the consolidated financial statements.
- In our opinion, the aforesaid consolidated financial statements comply with the Accounting Standards specified under Section 133 of the Act.
- On the basis of the written representations received from the directors of the Holding Company as on March 31, 2025 taken on record by the Board of Directors of the Holding Company and the reports of the statutory auditors of its subsidiary companies incorporated in India, none of the directors of the Group companies are disqualified as on March 31, 2025 from being appointed as a director in terms of Section 164 (2) of the Act.
- With respect to the adequacy of internal financial controls with reference to consolidated financial statements of the Group and the operating effectiveness of such controls, refer to our separate report in "Annexure B".
- With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditor's) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
 - The consolidated financial statements disclose the impact of pending litigations on the consolidated financial position of the Group—Refer Note 56 to the consolidated financial statements.
 - The Group did not have any material foreseeable losses on long-term contracts including derivative contracts.
 - There has been no delay in transferring amounts, required to be transferred, to the Investor Education and Protection Fund by the Holding Company and its subsidiary companies incorporated in India.
 - The respective Managements of the Holding Company and its subsidiaries, which are companies incorporated in India whose financial statements have been audited under the Act have represented to us and the other auditors of such subsidiaries that,

to the best of their knowledge and belief, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Holding Company or any of such subsidiaries, to or in any other person(s) or entity(ies), including foreign entities with the understanding, whether recorded in writing or otherwise, as on the date of this audit report, that such parties shall, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Holding Company or any of such subsidiaries ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

- The respective Managements of the Holding Company and its subsidiaries which are companies incorporated in India whose financial statements have been audited under the Act have represented to us and the other auditors of such subsidiaries that, to the best of their knowledge and belief, no funds have been received by the Holding Company or any of such subsidiaries from any person(s) or entity(ies), including foreign entities with the understanding, whether recorded in writing or otherwise, as on the date of this audit report, that the Holding Company or any of such subsidiaries shall, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.
- Based on the audit procedures that have been considered reasonable and appropriate in the circumstances performed by us and that performed by the auditors of the subsidiaries which are companies incorporated in India whose financial statements have been audited under the Act, and according to the information and explanations provided to us by the Management of the Holding company in this regard nothing has come to our or other auditors' notice that has caused us or the other auditors to believe that the representations under sub-clause (i) and (ii) of Rule 11(e) as provided under (1) and (2) above, contain any material mis-statement.
- On the basis of our verification and on consideration of the reports of the statutory auditors of subsidiaries that are Indian companies under the Act, interim dividend declared and paid by the Holding Company and its subsidiaries, during the year and until the date of this audit report is in accordance with section 123 of the Companies Act 2013.

2.

The final dividend paid by the Holding Company during the year in respect of the same declared for the previous year is in accordance with section 123 of the Companies Act 2013 to the extent it applies to payment of dividend.
3.

The Board of Directors of the Holding Company have proposed final dividend for the year which is subject to the approval of their respective members at the ensuing Annual General Meeting. The dividend declared is in accordance with section 123 of the Act to the extent it applies to declaration of dividend. (Refer Note 61 to the consolidated financial statements)
2.

In our opinion, according to information, explanations given to us, the remuneration paid by the Group to its directors is within the limits laid prescribed under Section 197 read with Schedule V of the Act and the rules thereunder.
3.

According to the information and explanations given to us, the details of Qualifications/adverse remarks made by the respective auditors of the subsidiaries in the Companies (Auditor's Report) Order 2020 (CARO) Reports issued till the date of our audit report for the companies included in the consolidated financial statements are as follows:

Sr. No	Name of the Company	CIN	Type of Company (Holding /Subsidiary/ Associate)	Clause number of the CARO Report which is qualified or Adverse
1	Advanced Bio Agro Tech Limited	U24100MH2004PLC149464	Subsidiary	(vii)(a)
2	Scitech Specialities Private Limited	U85190MH2007PTC175484	Subsidiary	(ii)(b)

For M S K A & Associates

Chartered Accountants

ICAI Firm Registration No. 105047W

Amrish Vaidya

Partner

Membership No. 101739

UDIN: 25101739BBIKFD2969

Place: Mumbai

Date: May 13, 2025

- vi.

Based on our examination which included test checks and that performed by the respective auditors of the subsidiaries which are companies incorporated in India whose financial statements have been audited under the Act, the company and subsidiaries have used an accounting software for maintaining its books of account which has a feature of recording audit trail (edit log) facility and the same has operated throughout the year for all relevant transactions recorded in the software. Further, during the course of our audit, we and respective auditors of the above referred subsidiaries did not come across any instance of audit trail feature being tampered with.

ANNEXURE A TO THE INDEPENDENT AUDITOR'S

REPORT OF EVEN DATE ON THE CONSOLIDATED FINANCIAL STATEMENTS OF ADVANCED ENZYME TECHNOLOGIES LIMITED

Auditor's Responsibilities for the Audit of the Consolidated Financial Statements

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Holding Company has adequate internal financial controls with reference to consolidated financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the management and Board of Directors.
- Conclude on the appropriateness of the management and Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities

within the Group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the audit of the financial statements of such entities included in the consolidated financial statements of which we are the independent auditors. For the other entities included in the consolidated financial statements, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

We communicate with those charged with governance of the Holding Company and such other entities included in the consolidated financial statements of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the consolidated financial statements for the year ended March 31, 2025 and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

For M S K A & Associates

Chartered Accountants

ICAI Firm Registration No. 105047W

Amrish Vaidya

Partner

Membership No. 101739

UDIN: 25101739BBIKFD2969

Place: Mumbai

Date: May 13, 2025

ANNEXURE B TO THE INDEPENDENT AUDITOR’S

REPORT OF EVEN DATE ON THE CONSOLIDATED FINANCIAL STATEMENTS OF ADVANCED ENZYME TECHNOLOGIES LIMITED

[Referred to in paragraph f under ‘Report on Other Legal and Regulatory Requirements’ in the Independent Auditors’ Report of even date to the Members of Advanced Enzyme Technologies Limited on the consolidated Financial Statements for the year ended March 31, 2025]

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 (“the Act”)

Opinion

In conjunction with our audit of the consolidated financial statements of the Advanced Enzymes Technologies Limited (hereinafter referred to as “the Holding Company”) as of and for the year ended March 31, 2025, we have audited the internal financial controls with reference to consolidated financial statements of Holding Company which includes the internal financial controls over financial reporting of the Holding Company and its subsidiary companies which are companies incorporated in India as of that date.

In our opinion, the Holding Company and its subsidiary companies which are companies incorporated in India, to the best of our information and according to the explanations given to us, have in all material respects, an adequate internal financial controls with reference to consolidated financial statements and such internal financial controls with reference to consolidated financial statements were operating effectively as at March 31, 2025, based on the internal financial controls with reference to consolidated financial statements criteria established by the respective companies considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the “Guidance Note”) issued by the Institute of Chartered Accountants of India (“ICAI”).

Management's and Board of Director's Responsibility for Internal Financial Controls

The respective Company's Management and the Board of Directors are responsible for establishing and maintaining internal financial controls based on the internal control with reference to consolidated financial statements criteria established by the respective companies considering the essential components of internal control stated in the Guidance Note issued by ICAI. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to the respective company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

Auditors' Responsibility

Our responsibility is to express an opinion on the internal financial controls with reference to consolidated financial statements based on our audit. We conducted our audit in accordance with the Guidance Note issued by the ICAI and the Standards on Auditing prescribed under section 143(10) of the Act, to the extent applicable to an audit of internal financial

controls. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls with reference to consolidated financial statements was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls with reference to consolidated financial statements and their operating effectiveness. Our audit of internal financial controls with reference to consolidated financial statements included obtaining an understanding of internal financial controls with reference to consolidated financial statements, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained and the audit evidence obtained by the other auditors in terms of their reports referred to in the Other Matter paragraph below, is sufficient and appropriate to provide a basis for our audit opinion on the internal financial controls with reference to consolidated financial statements.

Meaning of Internal Financial Controls with Reference to Consolidated Financial Statements

A Company's internal financial control with reference to consolidated financial statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control with reference to consolidated financial statements includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of consolidated financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the consolidated financial statements.

Inherent Limitations of Internal Financial Controls with Reference to Consolidated Financial Statements

Because of the inherent limitations of internal financial controls with reference to consolidated financial statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls with reference to consolidated financial statements to future periods are subject to the risk that the internal financial control with reference to consolidated financial statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Other Matter

Our aforesaid report under Section 143(3)(i) of the Act on the adequacy and operating effectiveness of the internal financial controls with reference to consolidated financial statements in so far as it relates to five subsidiary companies, which are companies incorporated in India, is based on the corresponding reports of the auditors of such companies incorporated in India. Our opinion is not modified in respect of this matter.

For M S K A & Associates

Chartered Accountants

ICAI Firm Registration No. 105047W

Amrish Vaidya

Partner

Membership No. 101739

UDIN: 25101739BBIKFD2969

Place: Mumbai

Date: May 13, 2025

Consolidated Balance Sheet

As at 31 March 2025

Particulars	Note	(₹ in million)	
		As at 31 March 2025	As at 31 March 2024
I. ASSETS			
1) Non-current assets			
(a) Property, plant and equipment	6A	2,929.41	2,765.28
(b) Capital work-in-progress	6B	216.91	307.37
(c) Goodwill	6C	3,334.40	3,252.95
(d) Other intangible assets	6D	522.91	479.24
(e) Intangible assets under development	6E	0.17	103.62
(f) Financial assets			
(i) Investments	7	0.65	1.65
(ii) Loans	8	0.65	0.38
(iii) Other financial assets	9	99.19	41.93
(g) Deferred tax assets (net)	40	101.92	142.82
(h) Income tax asset (net)		177.69	123.31
(i) Other non-current assets	10	30.88	38.66
Total non-current assets		7,414.78	7,257.21
2) Current assets			
(a) Inventories	11	1,573.05	1,484.55
(b) Financial assets			
(i) Investments	12	4,802.58	4,028.50
(ii) Trade receivables	13	1,153.99	985.68
(iii) Cash and cash equivalents	14	942.25	1,137.51
(iv) Bank balances other than (iii) above	15	134.60	131.96
(v) Loans	16	1.03	1.01
(vi) Other financial assets	17	80.48	197.20
(c) Income tax asset (net)		-	2.71
(d) Other current assets	18	110.71	128.30
Total current assets		8,798.69	8,097.42
Total assets		16,213.47	15,354.63
II. EQUITY AND LIABILITIES			
1) Equity			
(a) Equity share capital	19	223.76	223.65
(b) Other equity	20	13,984.87	13,017.63
Equity attributable to the owners of the parent		14,208.63	13,241.28
Non-controlling interest	52	478.07	469.52
Total equity		14,686.70	13,710.80
2) Non-current liabilities			
(a) Financial liabilities			
(i) Borrowings	21	91.83	69.60
(ii) Lease liability	22	117.34	158.56
(b) Provisions	23	13.71	8.86
(c) Deferred tax liabilities (net)	40	336.34	343.24
Total non-current liabilities		559.22	580.26
3) Current liabilities			
(a) Financial liabilities			
(i) Borrowings	24	123.53	181.52
(ii) Lease liability	25	60.80	63.40
(iii) Trade payables	26		
a) total outstanding dues of micro enterprises and small enterprises		42.93	32.69
b) total outstanding dues other than micro enterprises and small enterprises		129.08	124.90
(iv) Other financial liabilities	27	266.33	236.99
(b) Other current liabilities	28	85.28	135.91
(c) Provisions	29	213.68	196.75
(d) Current tax liabilities (net)		45.92	91.41
Total current liabilities		967.55	1,063.57
Total equity and liabilities		16,213.47	15,354.63

The accompanying notes form an integral part of these consolidated financial statements

As per our report of even date attached

for **M S K A & Associates**

Chartered Accountants

Firm's Registration No: 105047W

for and on behalf of the Board

Amrish Vaidya
Partner
Membership No.: 101739

Mukund Kabra
Wholetime Director
DIN : 00148294
Place: Thane

Place: Thane
Date: 13 May 2025

Sanjay Basantani
Company Secretary
Membership No: A19637
Place: Thane

Vinodkumar Jajoo
Director
DIN : 08224980
Place: Nashik

Beni P. Rauka
Chief Financial Officer
Membership No: 039980
Place: Thane

Consolidated Statement of Profit and Loss

For the year ended 31 March 2025

Particulars	Note	(₹ in million)	
		For the year ended 31 March 2025	For the year ended 31 March 2024
Income			
Revenue from operations	30	6,369.10	6,238.68
Other income	31	330.41	366.64
Total income		6,699.51	6,605.32
Expenses			
Cost of materials consumed	32	1,619.56	1,554.50
Purchases of stock-in-trade	33	-	0.20
Changes in inventories of finished goods, work-in-progress and stock-in-trade	34	(100.95)	(108.91)
Employee benefits expense	35	1,415.42	1,277.84
Finance costs	36	35.57	29.28
Depreciation and amortisation expense	37	365.56	352.42
Other expenses	38	1,490.71	1,470.46
Total expenses		4,825.87	4,575.79
Profit before exceptional items and tax		1,873.64	2,029.53
Exceptional items	39	-	151.32
Profit before tax		1,873.64	1,878.21
Tax expense	40		
Current tax		495.59	565.52
Minimum Alternate Tax (MAT) credit entitlement		(2.44)	(4.21)
Deferred tax (credit)/ charge		38.57	(53.30)
Tax adjustment for earlier years		2.18	0.69
Total tax expense		533.90	508.70
Profit for the year		1,339.74	1,369.51
Other comprehensive income			
A (i) Items that will not be reclassified to profit or loss			
Remeasurements of defined benefit (charge)/credit		(6.78)	(2.40)
(ii) Income tax related to items that will not be reclassified to profit or loss		1.77	0.58
B (i) Items that will be reclassified to profit or loss			
Exchange differences in translating financial statements of foreign operations		193.23	94.31
(ii) Income tax related to items that will be reclassified to profit or loss		-	-
Other comprehensive income for the year, net of tax		188.22	92.49
Net profit attributable to:			
Owners of the parent		1,311.15	1,333.05
Non-Controlling Interest		28.59	36.46
		1,339.74	1,369.51
Other comprehensive income attributable to:			
Owners of the parent		188.26	92.53
Non-Controlling Interest		(0.04)	(0.04)
		188.22	92.49
Total Comprehensive Income attributable to:			
Owners of the parent		1,499.41	1,425.58
Non-Controlling Interest		28.55	36.42
		1,527.96	1,462.00
Earnings per equity share (face value ₹ 2 each fully paid up)	47		
Basic		11.72	11.92
Diluted		11.71	11.92

The accompanying notes are an integral part of these consolidated

financial statements

As per our report of even date attached

for **M S K A & Associates**

Chartered Accountants

Firm's Registration No: 105047W

for and on behalf of the Board

Amrish Vaidya
Partner
Membership No.: 101739

Place: Thane
Date: 13 May 2025

Mukund Kabra
Wholetime Director
DIN : 00148294
Place: Thane

Sanjay Basantani
Company Secretary
Membership No: A19637
Place: Thane

Vinodkumar Jajoo
Director
DIN : 08224980
Place: Nashik

Beni P. Rauka
Chief Financial Officer
Membership No: 039980
Place: Thane

Consolidated Statement of Changes in Equity

For the year ended 31 March 2025

₹ in million

(a) Equity share capital (refer note 19)	As at 31 March 2025		As at 31 March 2024	
	No. of Shares	Amount	No. of Shares	Amount
Balance at the beginning of the year	111,824,075	223.65	111,824,075	223.65
Changes in equity share capital due to prior period errors	-	-	-	-
Restated balance at the beginning of the current reporting year	111,824,075	223.65	111,824,075	223.65
Changes in equity share capital during the year	57,075	0.11	-	-
Balance at the end of the year	111,881,150	223.76	111,824,075	223.65

(b) Other equity (refer note 20)

Particulars	Attributable to owners of the parent							Total attributable to owners of the parent	Attributable to Non- Controlling Interest	Total Equity
	Reserves and Surplus									
	Securities Premium account	Capital Reserve	General reserve	Retained earnings	Non controlling interest reserve	Employee stock option reserve	Foreign currency translation reserve			
Balance at 1 April 2023	821.31	6.74	38.77	10,022.77	(116.22)	-	1,353.67	12,127.04	491.02	12,618.06
Profit for the year	-	-	-	1,333.04	-	-	-	1,333.04	36.46	1,369.50
Other comprehensive income for the year	-	-	-	(1.78)	-	-	94.31	92.53	(0.04)	92.49
Total comprehensive income for the year	-	-	-	1,331.26	-	-	94.31	1,425.57	36.42	1,461.99
Less: Dividends paid	-	-	-	(559.12)	-	-	-	(559.12)	(8.00)	(567.12)
Less: Acquisition of non-controlling interests (refer note 49)	-	-	-	-	(6.17)	-	-	(6.17)	-	(6.17)
Add : Options granted during the year (refer note 46 & 46A)	-	-	-	-	-	30.31	-	30.31	-	30.31
Less: Movement in non-controlling interest (refer note 49)	-	-	-	-	-	-	-	-	(49.92)	(49.92)
Balance at 31 March 2024	821.31	6.74	38.77	10,794.91	(122.39)	30.31	1,447.98	13,017.63	469.52	13,487.15
Profit for the year	-	-	-	1,311.15	-	-	-	1,311.15	28.59	1,339.74
Other comprehensive income for the year	-	-	-	(4.97)	-	-	193.23	188.26	(0.04)	188.22
Total comprehensive income for the year	-	-	-	1,306.18	-	-	193.23	1,499.41	28.55	1,527.96
Add / (Less): Exercise of Share options	18.91	-	-	-	-	(15.24)	-	3.67	-	3.67
Options lapsed during the year	-	-	-	-	-	(2.34)	-	(2.34)	-	(2.34)
Less: Dividends paid	-	-	-	(570.30)	-	-	-	(570.30)	(20.00)	(590.30)
Add : Options granted during the year (refer note 46 & 46A)	-	-	-	-	-	36.80	-	36.80	-	36.80
Balance at 31 March 2025	840.22	6.74	38.77	11,530.79	(122.39)	49.53	1,641.21	13,984.87	478.07	14,462.94

The accompanying notes are an integral part of these consolidated financial statements 1 - 62

As per our report of even date attached for **M S K A & Associates** Chartered Accountants Firm's Registration No: 105047W

Amrish Vaidya
Partner
Membership No.: 101739

Place: Thane
Date: 13 May 2025

for and on behalf of the Board

Mukund Kabra
Wholetime Director
DIN : 00148294
Place: Thane

Sanjay Basantani
Company Secretary
Membership No: A19637
Place: Thane

Vinodkumar Jajoo
Director
DIN : 08224980
Place: Nashik

Beni P. Rauka
Chief Financial Officer
Membership No: 039980
Place: Thane

Consolidated Cash Flow Statement

For the year ended 31 March 2025

	(₹ in million)	
	Year ended 31 March 2025	Year ended 31 March 2024
A. Cash flows from operating activities		
Profit before tax	1,873.64	1,878.21
	1,873.64	1,878.21
Adjustments for non-cash transactions		
Depreciation and amortization expense	365.56	352.42
Prepaid lease amortisation	0.18	0.18
Property, plant and equipments written off	-	0.68
(Profit)/ Loss on sale of Property, plant and equipments	(2.17)	2.30
Allowances for bad and doubtful trade receivables	9.25	2.05
Bad and doubtful trade receivables written off	6.43	9.76
Provision for doubtful trade receivables written back	(0.38)	-
Employee stock compensation expense	34.46	30.31
Excess provision written back	(1.98)	(47.67)
Sundry balances written back	(0.01)	(1.26)
Fair valuation of investments in marketable securities	(82.25)	(108.48)
Provision for inventory	2.08	-
Provision for investments	1.01	-
Provision for claims and litigations	-	151.32
Unrealized foreign exchange gain	(0.84)	(0.82)
	2,204.98	2,269.00
Items considered separately		
Interest income	(96.72)	(129.72)
Interest expenses	35.75	29.28
	2,144.01	2,168.56
Operating profit before working capital changes		
(Increase) / Decrease in Non-current loans	(0.44)	(1.53)
(Increase) / Decrease in Other non-current financial assets	(1.27)	(2.76)
(Increase) / Decrease in Other non-current assets	3.02	(10.58)
(Increase) / Decrease in Inventories	(77.97)	(238.34)
(Increase) / Decrease in Trade receivables	(177.29)	9.12
(Increase) / Decrease in Current loans	(0.02)	0.14
(Increase) / Decrease in Other current financial assets	113.73	2.12
(Increase) / Decrease in Other current assets	18.20	(20.22)
(Decrease) / Increase in Provisions	10.48	40.21
(Decrease) / Increase in Trade payables	12.06	(39.41)
(Decrease) / Increase in Current financial liabilities- others	9.66	(3.39)
(Decrease) / Increase in Other current liabilities	(32.46)	2.11
Cash generated from operating activities	2,021.71	1,906.03
Income taxes paid (net of refund)	(596.74)	(492.34)
Net cash generated from operating activities	1,424.97	1,413.69
B. Cash flows from investing activities		
Purchase of property, plant and equipment	(338.08)	(423.13)
Proceeds from sale of property, plant and equipment	5.27	1.55
Capital expenditure on intangible assets under development	-	(49.50)
Purchase of intangible assets (net of refund)	(9.73)	(0.50)
(Purchase) / Proceeds from sale of current investments (net)	(590.42)	(276.55)

Consolidated Cash Flow Statement (Contd.)

For the year ended 31 March 2025

	(₹ in million)	
	Year ended 31 March 2025	Year ended 31 March 2024
Interest received	99.43	129.39
(Increase) in bank deposits with maturity more than 3 months but less than 12 months	(1.94)	(27.75)
(Increase) / Decrease in bank deposits with maturity of more than 12 months #	(55.54)	0.00
Net cash (used in) investing activities	(891.01)	(646.49)
C. Cash flows from financing activities		
Proceeds from issue of share capital including securities premium	3.78	-
Repayment of long-term borrowings	22.30	(6.48)
Proceeds from short-term borrowings (net)	(58.08)	127.03
Transactions with non-controlling interests	-	(56.07)
Interest paid	(33.42)	(29.25)
Lease liability paid	(69.72)	(60.49)
Dividends paid	(590.30)	(567.12)
Net cash (used in) financing activities	(725.44)	(592.38)
Net (decrease) / increase in cash and cash equivalents (A+B+C)	(191.48)	174.82
Cash and cash equivalents as at the beginning of the period	1137.51	964.20
Effect of exchange rate changes on cash and cash equivalents held	(3.78)	(1.51)
Cash and cash equivalents as at the end of the period*	942.25	1137.51
* Composition of cash and cash equivalents (refer note 14)		
Cash in hand	0.96	0.52
Cheques in hand	-	5.40
Balance with banks :		
Current account	266.14	414.11
Fixed deposit account (with maturity less than 3 months)	7.65	54.90
Money market deposits	667.50	662.58
	942.25	1137.51

Figures are below ₹ 0.01 Million, hence disclosed as ₹ 0.00

Reconciliation between the opening and closing balances in the balance sheet for liabilities arising from financing activities

Particulars	Notes	31 March 2024	Cashflows	Non cash changes				31 March 2025
				Acquisitions	Foreign exchange movement	Fair value change	Other adjustments	
Non-current borrowings	21	69.60	22.30	-	(0.07)	-	-	91.83
Cash credit, packing credit and working capital demand loans and vehicle loans	24	181.52	(58.08)	-	0.09	-	-	123.53
Total liabilities from financing		251.12	(35.78)	-	0.02	-	-	215.36

The accompanying notes are an integral part of these consolidated financial statements 1 - 62

1) The cash flow statement has been prepared under indirect method as set out in Ind AS 7, 'Statement of cashflows'.

As per our report of even date attached for **M S K A & Associates** Chartered Accountants Firm's Registration No: 105047W

for and on behalf of the Board

Amrish Vaidya
Partner
Membership No.: 101739

Mukund Kabra
Wholetime Director
DIN : 00148294
Place : Thane

Vinodkumar Jajoo
Director
DIN : 08224980
Place : Nashik

Place: Thane
Date: 13 May 2025

Sanjay Basantani
Company Secretary
Membership No: A19637
Place : Thane

Beni P. Rauka
Chief Financial Officer
Membership No: 039980
Place : Thane

Notes to the Consolidated Financial Statements for the year ended 31 March 2025

(₹ in million)

1 Overview of the Company

Advanced Enzyme Technologies Limited (herein referred to as 'the Parent Company' or the 'the Company') together with its subsidiaries (together referred to as 'the Group') carries on the business of manufacturing and sales of enzymes. The equity shares of the Company were listed on National Stock Exchange of India Limited (NSE) via id ADVENZYMES and on BSE Limited (BSE) via Id 540025 on 1 August 2016. The registered office of the Company is Sun Magnetica, A wing, 5th Floor, Near LIC Service Road, Louiswadi, Thane (W), Maharashtra - 400604

2 Basis of preparation

a Statement of compliance

These consolidated Ind AS financial statements have been prepared in accordance with Indian Accounting Standards (Ind AS) as per the Companies (Indian Accounting Standards) Rules, 2015 notified under Section 133 of the Companies Act, 2013 ('the Act') and other relevant provisions and amendments as applicable.

These consolidated Ind AS financial statements were authorised for issue by the Group's Board of Directors on 13 May 2025.

All the assets and liabilities have been classified as current or non current as per the Group's normal operating cycle and other criteria set out in Schedule III to the Act. Based on the nature of products and the time between the acquisition of assets for processing and their realization in cash and cash equivalent, the Group has ascertained the operating cycle to be 12 months.

b Functional and presentation currency

These consolidated financial statements are presented in Indian Rupees (INR), which is also the Company's functional currency. All amounts have been rounded-off to the nearest millions, unless otherwise indicated.

c Historical cost convention:

The Consolidated financial statements have been prepared on a historical cost basis, except for the following:

- certain financial assets and liabilities (including derivative instrument) that are measured at fair value;
- defined benefit plans – plan assets measured at fair value

3 Use of estimates

The preparation of Consolidated Financial Statements in conformity with Ind AS requires the management to make use of judgements, estimates and assumptions, that affect the application of accounting policies and the reported amounts of assets and liabilities, revenue and expenses and disclosure of contingent liabilities. The estimates and assumptions used in accompanying Consolidated financial statements are based upon management's evaluation of the relevant facts and circumstances as of the date of the financial statements. Actual results may differ from the estimates and assumptions used in preparing the accompanying Consolidated financial statements and reviewed on an ongoing basis. Any revision to accounting estimates is recognized prospectively in current and future periods.

Assumptions and estimation uncertainties that have a significant risk of resulting in a material adjustment in the year ended 31 March 2025 are as follows:

a. Depreciation and amortisation

Depreciation and amortisation is based on management estimates of the future useful lives of the property, plant and equipment and intangible assets. The management estimates the useful lives of tangible assets similar to the useful life prescribed in Schedule II of the Act. In cases, where the useful lives are different from that prescribed in Schedule II, they are based on technical advice, taking into account the nature of the asset, the estimated usage of the asset, the operating conditions of the asset, past history of replacement, anticipated technological changes, manufacturers' warranties and maintenance support.

Estimates may change due to technological developments, competition, changes in market conditions and other factors and may result in changes in the estimated useful life and in the depreciation and amortisation charges.

b. Recognition and measurement of defined benefit obligations

The cost of the defined benefit gratuity plan and the present value of the gratuity obligation are determined using actuarial valuations. An actuarial valuation involves making various assumptions that may differ from actual developments in the future. These include the determination of the discount rate; future salary increases and mortality rates. Due to the complexities involved in the valuation and its long-term nature, a defined benefit obligation is highly sensitive to changes in these assumptions. In determining the appropriate discount rate for plans operated in India, the management considers the interest rates of government bonds where remaining maturity of such bond correspond to expected term of defined benefit obligation.

The mortality rate is based on publicly available mortality tables. Those mortality tables tend to change only at interval in response to demographic changes. Future salary increases and gratuity increases are based on expected future inflation rates.

All assumptions are reviewed at each reporting date

c. Provision for income tax and deferred tax assets

The Group uses judgements based on the relevant rulings in the areas of allowances and disallowances which is exercised while determining the provision for income tax. A deferred tax asset is recognised to the extent that it is probable that future taxable profit will be available against which the deductible temporary differences, tax losses and unabsorbed depreciation can be utilised. Accordingly, the Group exercises its judgement to reassess the carrying amount of deferred tax assets at the end of each reporting period.

d. Recognition and measurement of other provisions

The recognition and measurement of other provisions are based on the assessment of the probability of an outflow of resources, and on past experience and circumstances known at the balance sheet date.

Notes to the Consolidated Financial Statements

for the year ended 31 March 2025

(₹ in million)

The actual outflow of resources at a future date may therefore vary from the amount included in other provisions.

e. Provision for expected credit losses (ECL) of trade receivables

The Group uses a provision matrix to calculate ECLs for trade receivables. The provision rates are based on days past due for Groupings of various customer segments that have similar loss patterns (i.e., by aging of receivables after considering letters of credit and other forms of security). The provision matrix is initially based on the Group's historical observed default rates. At every reporting date, the historical observed default rates are updated. The Group's historical credit loss experience and forecast of economic conditions may also not be representative of customer's actual default in the future.

f. Measurement of fair values

The Group's accounting policies and disclosures require the measurement of fair values, for both financial and non-financial assets and liabilities.

The Group has an established control framework with respect to the measurement of fair values, which includes overseeing all significant fair value measurements, including Level 3 fair values by the management. The management regularly reviews significant unobservable inputs and valuation adjustments. If third party information, such as broker quotes or pricing services, is used to measure fair values, then the management assesses the evidence obtained from the third parties to support the conclusion that such valuations meet the requirements of Ind AS, including the level in the fair value hierarchy in which such valuations should be classified.

When measuring the fair value of a financial asset or a financial liability, the Group uses observable market data as far as possible. Fair values are categorised into different levels in a fair value hierarchy based on the inputs used in the valuation techniques as follows.

- Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities.
- Level 2: inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).
- Level 3: inputs for the asset or liability that are not based on observable market data (unobservable inputs).

If the inputs used to measure the fair value of an asset or a liability fall into different levels of the fair value hierarchy, then the fair value measurement is categorised in its entirety in the same level of the fair value hierarchy as the lowest level input that is significant to the entire measurement. The Group recognises transfers between levels of the fair value

hierarchy at the end of the reporting period during which the change has occurred.

3A Standards issued but not yet effective

Ministry of Corporate Affairs ("MCA") notifies new standard or amendments to the existing standards. For the year ended March 31, 2025, MCA has notified below new standards or amendments to the existing standards not applicable to the Group.

a. Ind AS 117, Insurance Contracts

Ministry of Corporate Affairs ("MCA") notifies new standards or amendments to the existing standards under Companies (Indian Accounting Standards) Rules as issued from time to time. For the year ended March 31, 2025, MCA has notified a new Accounting Standard Ind AS 117 on Insurance Contracts and a amendment to Ind AS 116 on Leases to existing standards however these are not applicable to the Group.

4 Principles of Consolidation

a Business combinations

As part of its transition to Ind AS, the group has elected to apply Ind AS 103, Business Combinations, to only those business combinations that occurred on or after the transition date i.e 1 April 2016. In accordance with Ind AS 103, the group accounts for these business combinations using the acquisition method when control is transferred to the group. The consideration transferred for the business combination is measured at fair value as at the date the control is acquired (acquisition date), as are the net identifiable assets acquired. Any goodwill that arises is tested annually for impairment. Any gain on a bargain purchase is recognised in Other Comprehensive Income (OCI) and accumulated in equity as capital reserve if there exists clear evidence of the underlying reasons for classifying the business combination as resulting in a bargain purchase; otherwise the gain is recognised directly in equity as capital reserve. Transaction costs are expensed as incurred, except to the extent related to the issue of debt or equity securities.

The consideration transferred does not include amounts related to the settlement of pre-existing relationships with the acquiree. Such amounts are recognised in the consolidated statement of profit and loss.

Any contingent consideration is measured at fair value at the date of acquisition. If an obligation to pay contingent consideration that meets the definition of a financial instrument is classified as equity, then it is not remeasured subsequently and settlement is accounted for within equity. Other contingent consideration is remeasured at fair value at each reporting date and changes in the fair value of the contingent consideration are recognised in the consolidated statement of profit and loss.

If a business combination is achieved in stages, any previously held equity interest in the acquiree is re-measured at its acquisition date fair value and any

Notes to the Consolidated Financial Statements

for the year ended 31 March 2025

(₹ in million)

resulting gain or loss is recognised in the consolidated statement of profit and loss or OCI, as appropriate.

b Subsidiaries

Subsidiaries are entities controlled by the Parent Company, directly or indirectly. The Group controls an entity when it is exposed to, or has rights to, variable returns from its involvement with the entity

and has the ability to affect those returns through its power over the entity. The financial statements of subsidiaries are included in the consolidated financial statements from the date on which control commences until the date on which control ceases.

The Subsidiary companies considered in the Consolidated Financial Statements are as follows:

Name of the Company	Country of incorporation	% age voting interest held as at 31 March 2025	% age voting interest held as at 31 March 2024
i. Advanced Bio-Agro Tech Limited	India	60.00%	60.00%
ii. JC Biotech Private Limited	India	95.72%	95.72%
iii. Advanced Enzytech Solutions Limited	India	100.00%	100.00%
iv. Advanced Enzymes USA, Inc.	USA	100.00%	100.00%
v. Advanced Enzymes Europe B.V. (Wholly owned subsidiary)	Netherlands	100.00%	100.00%
vi. Evoxx Technologies GmbH (Wholly owned subsidiary of Advanced Enzymes Europe B. V.)	Germany	100.00%	100.00%
vii. Cal India Foods International (Wholly owned subsidiary of Advanced Enzymes USA, Inc.)	USA	100.00%	100.00%
viii. Advanced Supplementary Technologies Corporation (Wholly owned subsidiary of Advanced Enzymes USA, Inc.) ("AST")	USA	100.00%	100.00%
ix. Enzyme Innovation, Inc. (Wholly owned subsidiary of Cal India Foods International)	USA	100.00%	100.00%
x. Dynamic Enzymes, Inc. (Wholly owned subsidiary of Advanced Enzymes USA, Inc.) (merged in AST w.e.f. 01 April 2023)	USA	Nil	Nil
xi. Starya Labs, Inc. (Wholly owned subsidiary of Advanced Enzymes USA, Inc.) (w.e.f. 09 December 2024)	USA	100.00%	Nil
xii. Advanced Enzymes (Malaysia) Sdn. Bhd. (Wholly owned subsidiary) (Voluntary strike off with effect from 8 November 2023)	Malaysia	Nil	Nil
xiii. Sci-Tech Specialties Private Limited	India	51.00%	51.00%
xiv. Saiganesh Enzytech Solutions Private Limited	India	50.00%	50.00%

c Non-controlling interests (NCI)

NCI are measured at their proportionate share of the acquiree's net identifiable assets at the date of acquisition.

Changes in the Group's equity interest in a subsidiary that do not result in a loss of control are accounted for as equity transactions.

d Loss of control

When the Group loses control over a subsidiary, it derecognises the assets and liabilities of the subsidiary, and any related NCI and other components of equity. Any interest retained in the former subsidiary is measured at fair value at the date the control is lost. Any resulting gain or loss is recognised in consolidated statement profit or loss.

e Transactions eliminated on consolidation

Intra-group balances and transactions, and any unrealised income and expenses arising from intra-group transactions, are eliminated.

5 Material accounting policies:

The accounting policies set out below have been applied consistently to the periods presented in the Consolidated financial statements.

a. Revenue recognition

i. Revenue from sale of products:

The Group recognises revenue from sale of goods measured upon satisfaction of performance obligation which is at a point of time when the control of goods is transferred to the customer. Revenue is measured based on transaction price, which is the consideration, adjusted for estimated returns and allowances, discounts and volume rebates, if any, as specified in the contracts with the customers. Sales are exclusive of Goods and Service Tax (GST).

ii. Revenue from sale of services:

The Group offers various services ranging from enzyme identification, enzyme optimisation,

Notes to the Consolidated Financial Statements

for the year ended 31 March 2025

(₹ in million)

enzyme and process development, scale-up and production ender fixed price contracts.

Revenue from providing services is recognised in the accounting period in which the services are rendered. For fixed-price contracts, revenue is recognised based on the actual service provided to the end of the reporting period as a proportion of the total services to be provided. This is determined based on the actual labour hours spent relative to the total expected labour hours.

- iii. Export incentives received pursuant to the Duty Drawback Scheme and Merchandise Export from India Scheme are accounted on an accrual basis, to the extent it is probable that realization is certain.

a.1 Other income

- i. Interest income is recognised on a time proportionate basis, taking into account the amount outstanding and the rates applicable.

b. Property, plant and equipment and depreciation

Recognition and measurement

- i. Items of property, plant and equipment are stated at cost less accumulated depreciation and amortisation and accumulated impairment losses, if any. Cost includes taxes, non refundable duties and taxes, freight and other incidental expenses directly related to acquisition/construction and installation of the assets. Any trade discounts and rebates are deducted in arriving the purchase price. Interest on borrowings to finance acquisition of property, plant and equipment during qualifying period is capitalized.
- ii. Leasehold improvements represent expenses incurred towards civil work and interior furnishings on the leased premises.
- iii. Asset is eliminated from the Consolidated financial statements on disposal or when no further benefit is expected from its use and disposal. Gains / losses arising from disposal of property, plant and equipment carried at cost are recognised in the Consolidated Statement of Profit and Loss.
- iv. Capital work-in-progress includes fixed assets not ready for their intended use and related incidental expenses and attributable interest.
- v. The Group has elected to continue with the carrying value of all its property, plant and equipment as recognized in the Consolidated financial statements as at the date of transition to Ind AS, measured as per the previous GAAP and use that as the deemed cost as at the transition date pursuant to the exemption under Ind AS 101

Subsequent expenditure

- vi. Subsequent expenditure is capitalised only if it is probable that the future economic benefits associated with the expenditure will flow to the Group.

Depreciation

- vii Depreciation on tangible fixed assets other than plant and equipment and residential flat included under buildings has been provided on Written Down Value method and on plant and equipment and on residential flat included under buildings on Straight Line Method. Depreciation is provided on a pro-rata basis, i.e. from the date on which asset is ready for use.

The estimated useful life of assets are as follows:

Particulars	Estimated useful life
Building	30 - 60 years
Plant and equipment	10 - 25 years
Furniture and fixture	3 - 10 years
Vehicles	8 years
Office equipments	5 years
Computer and data processing equipment	3 - 6 years

Depreciation method, useful lives and residual values are reviewed at each financial year-end and adjusted, if appropriate.

- viii Leasehold improvements and leasehold land are amortized over the unexpired primary period of lease.

c. Intangible assets

- i. Intangible assets are stated at cost of acquisition less accumulated amortisation and accumulated impairment losses, if any.
- ii. Costs relating to acquisition of technical know-how and software are capitalized as intangible assets. Further, the expenditure incurred towards product studies during the development of product dossiers are grouped under "Intangible assets under development" to the extent such expenditure meet the criteria of intangible asset.
- iii. Subsequent expenditure is capitalised only when it increases the future economic benefits embodied in the specific asset to which it relates.
- iv. An intangible asset is eliminated from the Consolidated financial statements on disposal or when no further benefit is expected from its use and disposal. Gains / losses arising from disposal are recognised in the Statement of Profit and Loss.

Notes to the Consolidated Financial Statements

for the year ended 31 March 2025

(₹ in million)

- v. Any expected loss is recognized immediately in the Statement of Profit and Loss.

Particulars	Estimated useful life
Computer software	1-5 years
Website domain	3 years
Technical Knowhow	7 years
Customer relationship	10 years
Developed technologies	15-25 years
Rights and Licences	10-15 years
Product Dossiers	10 years
Trade name	7 years

d. Impairment of non-financial assets

The carrying values of assets at each balance sheet date are reviewed for impairment if any indication of impairment exists.

If the carrying amount of the assets exceed the estimated recoverable amount, an impairment is recognized for such excess amount. The impairment loss is recognized as an expense in the Statement of Profit and Loss, unless the asset is carried at revalued amount, in which case any impairment loss of the revalued asset is treated as a revaluation decrease to the extent a revaluation reserve is available for that asset.

The recoverable amount is the greater of the net selling price and their value in use. Value in use is arrived at by discounting the future cash flows to their present value based on an appropriate discount factor.

When there is indication that an impairment loss recognized for an asset (other than a revalued asset) in earlier accounting periods no longer exists or may have decreased, such reversal of impairment loss is recognized in the Statement of Profit and Loss, to the extent the amount was previously charged to the Statement of Profit and Loss. In case of revalued assets such reversal is not recognized.

e. Foreign currency

Foreign currency transactions

- i. Initial recognition - Foreign currency transactions are recorded in the functional currency, by applying to the foreign currency amount the exchange rate between the functional currency and the foreign currency at the date of the transaction.
- ii. Subsequent measurement- Monetary assets and liabilities denominated in foreign currencies are translated into the functional currency at the exchange rate at the reporting date. Non-monetary assets and liabilities that are measured at fair value in a foreign currency are translated into the functional currency

at the exchange rate when the fair value was determined. Foreign currency differences are generally recognised in consolidated statement of Profit and Loss. Non-monetary items that are measured based on historical cost in a foreign currency are not translated.

- iii. Exchange differences - All exchange differences arising on settlement/conversion on foreign currency transactions are included in the consolidated statement of Profit and Loss in the period in which they arise.

Foreign operations

The assets and liabilities of foreign operations, including goodwill and fair value adjustments arising on acquisition, are translated into Indian rupee at the exchange rates at the reporting date. The income and expenses of foreign operations are translated into Indian rupee at the exchange rates at the dates of the transactions.

Foreign currency differences are recognised in other comprehensive income (OCI) and accumulated in the translation reserve, except to the extent that the translation difference is allocated to NCI.

When a foreign operation is disposed of in its entirety or partially such that control is lost, the cumulative amount in the translation reserve related to that foreign operation is reclassified to profit or loss as part of the gain or loss on disposal. If the Group disposes of part of its interest in a subsidiary but retains control, then the relevant proportion of the cumulative amount is reattributed to NCI.

f. Share based Compensation:

Employees Stock Option Plans ("ESOPs"):

Equity-settled plans are accounted at fair value as at the grant date. The fair value of the share-based option is determined at the grant date using a market-based option valuation model (Black Scholes Option Valuation Model). The fair value of the option is recorded as compensation expense amortized over the vesting period of the options, with a corresponding increase in Reserves and Surplus under the head "Employee Stock Option account". On exercise of the option, the proceeds are recorded as share capital.

The cumulative expense recognized for equity-settled transactions at each reporting date until the vesting date reflects the extent to which the vesting period has expired and the Group's best estimate of the number of equity instruments that will ultimately vest. The charge or credit to the consolidated statement of Profit and Loss for a period represents the movement in cumulative expense recognized as at the beginning and end of that period and is recognized in employee benefits expense.

Service and non-market performance conditions are not taken into account when determining the grant date fair value of awards, but the likelihood of the conditions being met is assessed as part of

Notes to the Consolidated Financial Statements
for the year ended 31 March 2025

(₹ in million)

the Group's best estimate of the number of equity instruments that will ultimately vest.

g. Inventories

- i. Inventories of raw materials, packing materials, consumables, finished goods and work in process are valued at lower of cost or net realizable value on an item-by-item basis.
- ii. Cost of raw materials, consumables and packing materials is determined on weighted average basis. Cost of finished goods and stock in process is determined by considering materials, labour costs, conversion costs, including an appropriate share of fixed production overheads based on normal operating capacity and other related costs incurred in bringing the inventories to their present condition and location.

Net realisable value is the estimated selling price in the ordinary course of business, less the estimated costs of completion and the estimated costs necessary to make the sale. Raw materials and other supplies held for use in the production of inventories are not written down below cost except in case where material prices have declined and it is estimated that the cost of the finished product will exceed its net realisable value.

h. Employee benefits

Employee benefits payable wholly within twelve months of receiving employees services are classified as short-term employee benefits. The short term employee benefits are accounted on undiscounted basis during the accounting period based on services rendered by employees.

i. Defined contribution plans

A defined contribution plan is a post-employment benefit plan under which an entity pays specified contributions to a separate entity and has no obligation to pay any further amounts. The Group contributes to statutory provident fund in accordance with Employees' Provident Fund and Miscellaneous Provisions Act, 1952 that is a defined contribution plan and contribution paid or payable is recognized as an expense in the period in which the employee renders services.

Superannuation benefits, a defined contribution plan, has been funded with Life Insurance Corporation of India and the contribution is charged to Statement of profit and loss, when the contribution to the Fund is due.

For the entities incorporated in U.S.A., the companies contributed towards the pension cum retirement benefit plan in accordance with 401(k) of the Internal Revenue Code and the contribution paid or payable is recognised as an expense in the period in which the employee renders services.

ii. Defined benefit plans

The Group provides for Gratuity benefit and Compensated Absences, which are defined benefit plans, covering all its eligible employees. Liability towards gratuity benefits and compensated absences expected to occur after twelve months, are determined using the Projected Unit Credit Method. Actuarial valuations are carried out at the balance sheet date. Remeasurements of the net defined benefit liability, which comprise actuarial gains and losses, the return on plan assets (excluding interest) and the effect of the asset ceiling (if any, excluding interest), are recognised in OCI. The retirement benefit obligation recognized in the balance sheet represents the present value of the defined benefit obligation as adjusted for unrecognized past service cost, and as reduced by the fair value of scheme assets. The gratuity benefit and compensated absences scheme is funded with the Life Insurance Corporation of India (LIC).

The short term provision for compensated absences has been calculated on undiscounted basis, based on the balance of leave available over and above the maximum accumulation allowed as per the Group's policy.

i. Income taxes

Income tax expense comprises current tax (i.e. amount of tax for the period determined in accordance with the income tax law), deferred tax charge or credit (reflecting the tax effects of timing differences between accounting income and taxable income for the period) and Minimum Alternate Tax (MAT) credit entitlement.

Current tax

Current income tax relating to items recognised outside profit or loss (either in other comprehensive income or in equity). Current tax items are recognised in correlation to the underlying transaction either in OCI or directly in equity. Management periodically evaluates positions taken in the tax returns with respect to situations in which applicable tax regulations are subject to interpretation and establishes provisions where appropriate.

Deferred tax

Deferred tax is recognised in respect of temporary difference between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the year when the asset is realised or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the reporting date.

Deferred tax assets are recognised for all deductible temporary differences, the carry forward of unused tax credits and any unused tax losses. Deferred tax

Notes to the Consolidated Financial Statements
for the year ended 31 March 2025

(₹ in million)

assets are recognised to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, and the carry forward of unused tax credits and unused tax losses can be utilised.

The carrying amount of deferred tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilised. Unrecognised deferred tax assets are re-assessed at each reporting date and are recognised to the extent that it has become probable that future taxable profits will allow the deferred tax asset to be recovered.

Deferred tax relating to items recognised outside profit or loss is recognised outside profit or loss (either in other comprehensive income or in equity). Deferred tax items are recognised in correlation to the underlying transaction either in OCI or directly in equity.

Deferred tax assets and deferred tax liabilities are offset if a legally enforceable right exists to set off current tax assets against current tax liabilities and the deferred taxes relate to the same taxable entity and the same taxation.

Deferred tax assets and liabilities are offset only if:

- a) The entity has a legally enforceable right to set off current tax assets against current tax liabilities; and
- b) The deferred tax assets and the deferred tax liabilities relate to income taxes levied by the same taxation authority on the same taxable entity.

Minimum Alternate Tax

Minimum Alternate Tax (MAT) under the provisions of Income Tax Act, 1961 is recognized as current tax in the the consolidated statement of Profit and Loss. The Group recognizes MAT credit available as an asset only when it is probable that the future economic benefit associated with it will flow to the Group i.e. the Group will pay normal income tax during the period for which MAT Credit is allowed to be carried forward. In the year in which the Group recognizes MAT Credit recognized as an asset in accordance with the Guidance Note on Accounting for Credit Available in respect of Minimum Alternate Tax under the Income Tax Act, 1961, by way of credit to the Statement of Profit and Loss and shown as "MAT Credit Entitlement." MAT credit recognized as an asset is reviewed at each balance sheet date and written down to the extent the aforesaid evidence no longer exists.

j. Borrowing costs

Borrowing costs are interest and other costs that the Group incurs in connection with the borrowing of funds and is measured with reference to the Effective Interest Rate (EIR) applicable to the respective borrowing. Borrowing cost include interest costs measured at EIR and exchange differences arising

from foreign currency borrowings to the extent they are regarded as an adjustment to the interest cost.

Borrowing costs incurred on constructing or acquiring a qualifying asset are capitalized as cost of that asset until it is ready for its intended use. A qualifying asset is an asset that necessarily takes a substantial period of time to get ready for its intended use or sale. All other borrowing costs are charged to revenue and recognized as an expense in the consolidated statement of Profit and Loss.

k. Research and development costs

Research and development costs incurred for development of products are expensed as incurred, except for development costs that relate to the design and testing of new or improved materials, products or processes, which are recognized as an intangible asset to the extent that it is technically feasible to complete the development of such asset and future economic benefits are expected to be generated from such assets. Capital expenditure on research and development is included as part of assets and depreciated on the same basis as other assets.

l. Provisions and contingencies

Provisions are determined by discounting the expected future cash flows specific to the liability. The unwinding of the discount is recognised as finance cost. A provision for onerous contracts is measured at the present value of the lower of the expected cost of terminating the contract and the expected net cost of continuing with the contract. Before a provision is established, the Group recognises any impairment loss on the assets associated with that contract.

A disclosure for a contingent liability is made when there is a possible obligation or a present obligation that may, but will probably not, require an outflow of resources. When there is a possible obligation or a present obligation in respect of which the likelihood of outflow of resources is remote, no provision or disclosure is made.

A contingent asset is not recognised but disclosed in the Consolidated financial statements where an inflow of economic benefit is probable.

m. Leases

The Group assesses whether a contract contains a lease, at inception of a contract. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. To assess whether a contract conveys the right to control the use of an identified assets, the Group assesses whether:

- (i) the contact involves the use of an identified asset
- (ii) the Group has substantially all of the economic benefits from use of the asset through the period of the lease and
- (iii) the Group has the right to direct the use of the asset.

Notes to the Consolidated Financial Statements
for the year ended 31 March 2025

(₹ in million)

As a lessee, the Group recognises a right-of-use asset and a lease liability at the lease commencement date. The right of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset or to restore the underlying asset or the site on which it is located, less any lease incentives received.

The right-of-use asset is subsequently depreciated using the straight-line method from the commencement date to the earlier of the end of the useful life of the rightof-use asset or the end of the lease term. The estimated useful lives of right-of-use assets are determined on the same basis as those of property and equipment. In addition, the right-of-use asset is periodically reduced by impairment losses, if any, and adjusted for certain remeasurements of the lease liability.

The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Group's incremental borrowing rate.

Generally, the Group uses its incremental borrowing rate as the discount rate. Lease payments included in the measurement of the lease liability comprise the fixed payments, including in substance fixed payments.

The lease liability is measured at amortised cost using the effective interest method.

The Group has elected not to recognise right-of-use assets and lease liabilities for short-term leases that have a lease term of 12 months or less and leases of low-value assets.

The Group's leases mainly comprise of Office premises and land and buildings for warehouse facilities. The Group also has leases for equipment.

n. Cash and cash equivalents

Cash comprises of cash at bank and in hand and cash equivalents comprise of short-term bank deposits with an original maturity of three months or less.

For the purpose of the statement of cash flows, cash and cash equivalents consist of cash and short term deposits, as defined above, net of outstanding bank overdrafts as they are considered an integral part of the Group's cash management.

o. Financial Instruments

a. Financial assets

i. Recognition and initial measurement

Trade receivables and debt instruments issued are initially recognised when they are originated. All other financial assets

are initially recognised when the Group becomes a party to the contractual provisions of the instrument.

A financial asset is initially measured at fair value. In the case of financial assets which are recognised at fair value through profit and loss (FVTPL), the transaction costs are recognised in the statement of profit and loss. In other cases, the transaction costs are attributed to the acquisition value of the financial asset.

ii. Classification

On initial recognition, a financial asset is classified as measured at

- amortised cost; or
- fair value through profit or loss (FVTPL); or
- fairvaluethroughothercomprehensive income (FVOCI) - debt investment or equity investment

Financial assets are not reclassified subsequent to their initial recognition, except if and in the period the Group changes its business model for managing financial assets.

A financial asset is measured at amortised cost if it meets both of the following conditions and is not designated as at FVTPL:

- the asset is held within a business model whose objective is to hold assets to collect contractual cash flows; and
- the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

A debt investment is measured at FVOCI if it meets both of the following conditions and is not designated as at FVTPL:

- the asset is held within a business model whose objective is achieved by both collecting contractual cash flows and selling financial assets; and
- the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

On initial recognition of an equity investment that is not held for trading, the Group may irrevocably elect to present subsequent changes in the investment's fair value in OCI (designated as FVOCI –

Notes to the Consolidated Financial Statements
for the year ended 31 March 2025

(₹ in million)

equity investment). This election is made on an investment- by- investment basis.

All financial assets not classified as measured at amortised cost or FVOCI as described above are measured at FVTPL. This includes all derivative financial assets. On initial recognition, the Company may irrevocably designate a financial asset that otherwise meets the requirements to be measured at amortised cost or at FVOCI as at FVTPL if doing so eliminates or significantly reduces an accounting mismatch that would otherwise arise.

Financial assets that are held for trading or are managed and whose performance is evaluated on a fair value basis are measured at FVTPL.

iii. Subsequent measurement and gains and losses

Financial assets at FVTPL

These assets are subsequently measured at fair value. Net gains and losses, including any interest or dividend income, are recognised in consolidated statement of Profit and Loss.

Financial assets at amortised cost

These assets are subsequently measured at amortised cost using the effective interest method. The amortised cost is reduced by impairment losses. Interest income, foreign exchange gains and losses and impairment are recognised in Statement of Profit and Loss. Any gain or loss on derecognition is recognised in consolidated statement of Profit and Loss.

Debt investments at FVOCI

These assets are subsequently measured at fair value. Interest income under the effective interest method, foreign exchange gains and losses and impairment are recognised in consolidated statement of Profit and Loss. Other net gains and losses are recognised in OCI. On derecognition, gains and losses accumulated in OCI are reclassified to consolidated statement of Profit and Loss.

Equity investments at FVOCI

These assets are subsequently measured at fair value. Dividends are recognised as income in Statement of Profit and Loss unless the dividend clearly represents a recovery of part of the cost of the investment. Other net gains and losses are recognised in OCI and are not reclassified to consolidated statement of Profit and Loss.

iv. Derecognition

The Group derecognises a financial asset when the contractual rights to the cash flows from the financial asset expire, or it transfers the rights to receive the contractual cash flows in a

transactionin which substantially all of the risks and rewards of ownership of the financial asset are transferred or in which the Group neither transfers nor retains substantially all of the risks and rewards of ownership and does not retain control of the financial asset.

If the Group enters into transactions whereby it transfers assets recognised on its balance sheet, but retains either all or substantially all of the risks and rewards of the transferred assets, the transferred assets are not derecognised.

v. Impairment of financial assets

In accordance with Ind AS 109, the Group applies Expected Credit Loss (ECL) model for measurement and recognition of impairment loss on the following financial assets and credit risk exposure:

i. Financial assets that are debt instruments, and are measured at amortised cost e.g., loans, debt securities,deposits, and bank balance.

ii. Trade receivables.

The application of simplified approach does not require the Group to track changes in credit risk. Rather,it recognises impairment loss allowance based on lifetime ECLs at each reporting date, right from its initial recognition.

b. Financial liabilities

i. Recognition and initial measurement

All financial liabilities are initially recognised when the Group becomes a party to the contractual provisions of the instrument.

A financial liability is initially measured at fair value. In the case of financial liabilities which are recognised at fair value through profit and loss (FVTPL), the transaction costs are recognised in the statement of consolidated Profit and Loss. In other cases, the transaction costs are attributed to the acquisition or issue of financial liability.

ii. Classification, subsequent measurement and gains and losses

Financial liabilities are classified as measured at amortised cost or FVTPL. A financial liability is classified as at FVTPL if it is classified as held-for- trading, or it is a derivative or it is designated as such on initial recognition. Financial liabilities at FVTPL are measured at fair value and net gains and losses, including any interest expense, are recognised in consolidated statement of profit and loss. Other financial liabilities are subsequently measured at amortised cost using the effective interest method. Interest expense and foreign exchange gains and losses are recognised in consolidated statement of profit and loss. Any gain or loss on derecognition is

Notes to the Consolidated Financial Statements
for the year ended 31 March 2025
(₹ in million)

also recognised in consolidated statement of profit and loss.

iii. Derecognition

The Group derecognises a financial liability when its contractual obligations are discharged or cancelled, or expire.

The Group also derecognises a financial liability when its terms are modified and the cash flows under the modified terms are substantially different. In this case, a new financial liability based on the modified terms is recognised at fair value. The difference between the carrying amount of the financial liability extinguished and the new financial liability with modified terms is recognised in consolidated statement of profit and loss.

iv. Offsetting

Financial assets and financial liabilities are offset and the net amount presented in the balance sheet when, and only when, the Group currently has a legally enforceable right to set off the amounts and it intends either to settle them on a net basis or to realise the asset and settle the liability simultaneously.

v. Derivative financial instruments

The Group uses derivative financial instruments, such as forward currency contracts to hedge its interest rate risk. Such derivative financial instruments are initially recognised at fair value on the date on which a derivative contract is entered into and are subsequently re-measured

at fair value at each reporting period. Any changes therein are generally recognised in the consolidated statement of profit and loss.

p. Government grants

Grants received from the government are recognized at their fair value where there is reasonable assurance that the grant will be received and the Group will comply with the conditions.

Government grants related to income are deferred and recognized in the consolidated statement of profit and loss over the period necessary to match them with the costs that they are intended to compensate and netted off with the expense in the consolidated statement of profit and loss.

Government grants related to purchase of property plant and equipment are recognised as deferred income and are credited to consolidated statement of profit and loss on a straight line basis over expected life of the related asset and presented within other income.

q. Earnings Per Share:

Basic earnings per share are calculated by dividing the net profit or loss for the period attributable to equity shareholders by the weighted average number of equity shares outstanding during the period.

For the purpose of calculating diluted earnings per share, the net profit or loss for the period attributable to equity shareholders and the weighted average number of shares outstanding during the period are adjusted for the effects of all dilutive potential equity shares.

Notes to the Consolidated Financial Statements
for the year ended 31 March 2025
(₹ in million)

6A Property, plant and equipment

Gross block	Land Freehold	Land Leasehold	Buildings	Plant and equipment	Furniture and fixtures	Vehicles	Office equipments	Leasehold improvements	Computer and data processing equipments	Right to use asset (Refer note b)	Total
Balance as at 1 April 2023	553.90	5.22	723.47	2,214.61	55.96	63.14	104.76	109.63	50.96	428.03	4,309.68
Additions	9.24	-	7.11	153.43	2.41	1.87	10.32	10.98	13.79	110.11	319.26
Disposals	-	-	-	7.04	0.14	1.33	0.09	-	0.93	-	9.53
Other adjustments	-	-	-	-	-	-	-	-	-	11.44	11.44
Reversal on account of assets written off	-	-	-	-	-	-	0.68	-	6.55	-	7.23
Balance as at 31 March 2024	563.14	5.22	730.58	2,361.00	58.23	63.68	114.31	120.61	57.27	526.70	4,600.74
Additions	6.07	-	112.54	282.63	4.57	14.05	6.79	0.15	5.37	20.05	452.22
Disposals	-	-	0.03	13.57	0.37	7.40	1.07	-	-	-	22.44
Other adjustments	-	-	-	-	-	-	-	-	-	0.69	0.69
Balance as at 31 March 2025	569.21	5.22	843.09	2,630.06	62.43	70.33	120.03	120.76	62.64	546.06	5,029.83
Accumulated depreciation and amortisation											
Balance as at 1 April 2023	-	0.49	229.80	852.62	33.49	33.37	93.25	101.34	42.18	233.94	1,620.48
Depreciation and amortisation	-	0.07	39.76	134.93	5.57	9.14	7.35	4.76	8.03	65.41	275.02
Reversal on disposal of assets	-	-	-	3.36	0.11	1.24	0.07	-	0.82	-	5.60
Other adjustments	-	-	-	-	-	-	-	-	-	2.49	2.49
Reversal on account of assets written off	-	-	-	0.02	-	-	0.62	-	5.93	-	6.57
Balance as at 31 March 2024	-	0.56	269.57	984.16	38.94	41.27	99.91	106.10	43.47	296.86	1,880.84
Depreciation and amortisation	-	0.07	39.32	145.07	4.96	9.74	7.51	5.22	7.55	70.51	289.95
Reversal on disposal of assets	-	-	0.03	11.39	0.34	6.57	1.01	-	-	-	19.34
Balance as at 31 March 2025	-	0.63	308.86	1,117.84	43.56	44.44	106.41	111.32	51.02	367.37	2,151.45
Other Adjustment											
Foreign currency translation adjustments as at 31 March 2024	-	-	-	9.15	0.05	-	1.59	5.90	0.55	28.14	45.38
Foreign currency translation adjustments during the year	-	-	-	1.47	-	-	0.04	0.39	0.02	3.73	5.65
Balance as at 31 March 2025	-	-	-	10.62	0.05	-	1.63	6.29	0.57	31.87	51.03
Net block											
Balance as at 31 March 2024	563.14	4.66	461.01	1,385.98	19.34	22.41	16.00	20.41	14.34	257.98	2,765.28
Balance as at 31 March 2025	569.21	4.59	534.23	1,522.84	18.92	25.89	15.24	15.72	12.20	210.56	2,929.41

Notes to the Consolidated Financial Statements

for the year ended 31 March 2025

(₹ in million)

6B Capital work-in-progress (CWIP)

	Amount
CWIP as at 1 April 2023	156.09
Additions during the year	339.73
Capitalised during the year	188.45
CWIP as at 31 March 2024	307.37
Additions during the year	259.31
Capitalised during the year	349.77
CWIP as at 31 March 2025	216.91

(a) For Capital-work-in progress ageing schedule

CWIP as at 31 March 2025	Amount in CWIP for a period of				Total
	Less than 1 year	1 - 2 years	2 - 3 years	More than 3 years	
Projects in progress	135.28	38.82	39.59	3.22	216.91
Projects temporarily suspended	-	-	-	-	-

CWIP as at 31 March 2024	Amount in CWIP for a period of				Total
	Less than 1 year	1 - 2 years	2 - 3 years	More than 3 years	
Projects in progress	214.03	90.12	0.36	2.86	307.37
Projects temporarily suspended	-	-	-	-	-

(b) For Right to use asset (refer note 43)

Gross block	Buildings	Land Leasehold	Total
Balance as at 1 April 2023	415.41	12.62	428.03
Additions	110.11	-	110.11
Other adjustment			
- Remeasurement impact of right to use asset	11.44	-	11.44
Balance as at 31 March 2024	514.08	12.62	526.70
Additions	20.05	-	20.05
Other adjustment			
- Remeasurement impact of right to use asset	0.69	-	0.69
Balance as at 31 March 2025	533.44	12.62	546.06
Accumulated depreciation and amortization			
Balance as at 1 April 2023	231.71	2.23	233.94
Depreciation and amortization	64.67	0.74	65.41
Other adjustment			
- Remeasurement impact of right to use asset	2.49	-	2.49
Balance as at 31 March 2024	293.89	2.97	296.86
Depreciation and amortization	69.77	0.74	70.51
Other adjustment			
- Remeasurement impact of right to use asset	-	-	-
Balance as at 31 March 2025	363.66	3.71	367.37
Other Adjustment			
Foreign currency translation adjustments as at 31 March 2024	28.14	-	28.14
Foreign currency translation adjustments during the year	3.73	-	3.73
	31.87	-	31.87
Net block			
Balance as at 31 March 2024	248.33	9.65	257.98
Balance as at 31 March 2025	201.65	8.91	210.56

Notes to the Consolidated Financial Statements

for the year ended 31 March 2025

(₹ in million)

6C Goodwill on consolidation (refer note 53)

	As at 31 March 2025	As at 31 March 2024
Advanced Enzymes USA, Inc.	2,898.81	2,824.04
JC Biotech Private Limited	123.65	123.65
Advanced Enzytech Solutions Limited	0.87	0.87
Advanced Enzymes Europe B.V.	292.68	286.00
Saiganesh Enzytech Solutions Private Limited	18.39	18.39
	3,334.40	3,252.95

6D Intangible assets

Gross block	Computer software	Customer relationship	Developed Technologies	Rights and Licences	Tradename	Website Domain	Product Dossiers	Technical Knowhow	Non-compete Fee	Total
Balance as at 1 April 2023	37.51	109.02	527.93	229.66	25.63	6.32	3.83	90.70	28.20	1,058.80
Additions	5.00	-	-	-	-	-	-	-	-	5.00
Balance as at 31 March 2024	42.51	109.02	527.93	229.66	25.63	6.32	3.83	90.70	28.20	1,063.80
Additions	60.06	-	-	0.61	-	-	53.69	-	-	114.36
Balance as at 31 March 2025	102.57	109.02	527.93	230.27	25.63	6.32	57.52	90.70	28.20	1,178.16
Accumulated amortisation										
Balance as at 1 April 2023	34.78	61.97	173.99	225.45	22.59	7.02	1.63	28.72	10.47	566.62
Amortisation	3.45	15.46	31.23	4.82	4.36	-	0.38	12.99	4.71	77.40
Balance as at 31 March 2024	38.23	77.43	205.22	230.27	26.95	7.02	2.01	41.71	15.18	644.02
Amortisation	4.40	15.56	31.41	3.74	1.65	-	1.15	12.99	4.71	75.61
Balance as at 31 March 2025	42.63	92.99	236.63	234.01	28.60	7.02	3.16	54.70	19.89	719.63
Other Adjustment										
Foreign currency translation adjustments as at 31 March 2024	0.18	11.02	40.76	3.83	2.96	0.71	-	-	-	59.46
Foreign currency translation adjustments during the year	0.68	0.58	3.63	0.02	0.01	-	-	-	-	4.92
Balance as at 31 March 2025	0.86	11.60	44.39	3.85	2.97	0.71	-	-	-	64.38
Net block										
Balance as at 31 March 2024	4.46	42.61	363.47	3.22	1.64	-	1.82	48.99	13.02	479.24
Balance as at 31 March 2025	60.80	27.63	335.69	0.11	0.00	-	54.36	36.00	8.31	522.91

Figures are below ₹ 0.01 Million, hence disclosed as ₹ 0.00

6E Intangible assets under development

	Amount
Balance as at 1 April 2023	58.86
Additions during the year	49.75
Capitalised during the year	4.99
Balance as at 31 March 2024	103.62
Additions during the year	10.29
Capitalised during the year	113.74
Balance as at 31 March 2025	0.17

Notes to the Consolidated Financial Statements

for the year ended 31 March 2025

(₹ in million)

(a) Intangible assets under development ("IAUD") ageing schedule

As at 31 Mar 2025	Amount in IAUD for a period of				Total
	Less than 1 year	1 - 2 years	2 - 3 years	More than 3 years	
Projects in progress	0.05	0.09	0.03	-	0.17
Projects temporarily suspended	-	-	-	-	-

As at 31 Mar 2024	Amount in IAUD for a period of				Total
	Less than 1 year	1 - 2 years	2 - 3 years	More than 3 years	
Projects in progress	49.59	0.04	0.30	53.69	103.62
Projects temporarily suspended	-	-	-	-	-

7 Non-current investments

	As at 31 March 2025	As at 31 March 2024
Other investments (unquoted)		
Equity shares at fair value through profit and loss		
19,100 Equity shares (31 March 2024 - 19,100) of ₹10 each fully paid up of Advenza Global Limited (Formerly known as Advanced Vital Enzymes Pvt Ltd) *	0.57	0.57
1,666 Equity shares (31 March 2024 - 1,666) of ₹30 each fully paid up of Bombay Mercantile Co-op. Bank Limited	0.05	0.05
2,520 Equity shares (31 March 2024 - 2,520) of ₹ 10 each fully paid up of Saraswat Coop Bank Ltd.	0.03	0.03
140 Equity shares (31 March 2024 - 140) of RAND 15,000 each fully paid up of Vecteng Scitech Property Limited	1.00	1.00
Less : Impairment in value of investments ^	(1.00)	-
	0.65	1.65
Aggregate value of unquoted investments	0.65	1.65

^ The impairment in value of investment pertains to investment made in Vecteng Scitech Property Limited.

* refer note 44

8 Long-term loans

(Unsecured considered good unless otherwise stated)

	As at 31 March 2025	As at 31 March 2024
Loans	0.02	-
Interest receivable	0.63	0.38
	0.65	0.38

9 Other non-current financial assets

(unsecured considered good unless otherwise stated)

	As at 31 March 2025	As at 31 March 2024
Non-current bank deposits	55.60	0.06
Security deposits	43.59	41.87
	99.19	41.93

Notes to the Consolidated Financial Statements

for the year ended 31 March 2025

(₹ in million)

10 Other non-current assets

(unsecured considered good unless otherwise stated)

	As at 31 March 2025	As at 31 March 2024
Prepaid expenses	14.04	13.89
Capital advances	16.54	24.47
Others	0.30	0.30
	30.88	38.66

11 Inventories

(valued at lower of cost and net realizable value)

	As at 31 March 2025	As at 31 March 2024
Raw materials and packing materials [including goods-in-transit of ₹ 2.84 million (31 March 2024 ₹ 37.77 million)]	624.74	637.08
Work-in-progress	436.20	363.41
Finished goods [including goods-in-transit of ₹ 67.54 million (31 March 2024 ₹ 36.64 million)]	382.86	357.87
Stores, consumables and fuel [including goods-in-transit of ₹ Nil (31 March 2024 ₹ 2.50 million)]	129.25	126.19
	1,573.05	1,484.55

As at 31 March 2025, the Group has written down the value for slow moving inventory aggregating ₹ 51.67 million (31 March 2024: ₹ 81.06 million). Reversal of charge during the year ended 31 March 2025 is ₹ 29.39 million (31 March 2024: ₹ 28.98 million) is included in cost of materials consumed and changes in inventories.

12 Current investments

Mutual funds (Quoted)

(carried at fair value through profit and loss)

	As at 31 March 2025	As at 31 March 2024
Fixed income securities	4,381.61	3,453.30
Aditya Birla Sun Life- Low Duration Fund Growth- Direct (No. of units 31 March 2025: Nil, 31 March 2024: 1,093.148) (Market value 31 March 2024: 659.142/unit)	-	0.72
Aditya Birla Sun Life- Overnight Growth- Direct (No. of units 31 March 2025: Nil, 31 March 2024: 15,614.253) (Market value 31 March 2024: 1,295.050/unit)	-	20.22
UTI Money Market Fund -Direct- Growth (No. of units 31 March 2025: 24,874.866, 31 March 2024: 67,752.111) (Market value 31 March 2025: 3,060.6445/unit; 31 March 2024: 2,837.2161/unit)	76.13	192.23
Aditya Birla Sunlife Limited Money Manager Fund - Growth - Direct (No. of units 31 March 2025: 32,554.191, 31 March 2024: 235,243.398) (Market value 31 March 2025: 367.6703/unit, 31 March 2024: 340.7909/unit)	11.97	80.17

Notes to the Consolidated Financial Statements

for the year ended 31 March 2025

(₹ in million)

	As at 31 March 2025	As at 31 March 2024
ICICI Prudential Mutual Fund- "ICICI Prudential Liquid - Growth"	12.84	11.95
(No. of units 31 March 2025: 33,438.884, 31 March 2024: 33,438.884)		
(Market value 31 March 2025: 383.8953/unit, 31 March 2024: 357.406/unit)		
UTI OVERNIGHT FUND -DIRECT - GROWTH	-	14.43
(No. of units 31 March 2025: Nil, 31 March 2024: 4,404.003)		
(Market value 31 March 2024: 3,277.4011/unit)		
TATA OVERNIGHT FUND - DIRECT - GROWTH	20.29	18.29
(No. of units 31 March 2025: 15,057.214, 31 March 2024: 14,478.958)		
(Market value 31 March 2025: 1,347.4855/unit, 31 March 2024: 1,263.236/unit)		
TATA MONEY MARKET FUND - DIRECT - GROWTH	201.81	139.20
(No. of units 31 March 2025: 42,789.255, 31 March 2024: 31,872.195)		
(Market value 31 March 2025: 9,432.6390/unit, 31 March 2024: 4,367.520/unit)		
HDFC OVERNIGHT FUND-DIRECT PLAN GROWTH	-	2.77
(No. of units 31 March 2025: Nil, 31 March 2024: 779.253)		
(Market value 31 March 2024: 3,553.188/unit)		
HDFC MONEY MARKET FUND - DIRECT PLAN GROWTH	89.92	68.52
(No. of units 31 March 2025: 15,728.622, 31 March 2024: 12,929.034)		
(Market value 31 March 2025: 5,716.8240/unit, 31 March 2024: 5,300.037/unit)		
ICICI Prudential Mutual Fund- "Liquid Fund- DP Growth"	8.01	26.46
(No. of units 31 March 2025: 5,824.962, 31 March 2024: 20,503.452)		
(Market value 31 March 2025: 1,375.9255/unit, 31 March 2024: 1,290.529/unit)		
ICICI Prudential Mutual Fund- "Floating Interest Fund- DP Growth"	-	0.19
(No. of units 31 March 2025: Nil, 31 March 2024: 456.948)		
(Market value 31 March 2024: 416.756/unit)		
Franklin India Ultra Short Bond Fund Super Institutional Plan - Direct Growth	-	0.05
(No. of units 31 March 2025: Nil, 31 March 2024: 145.782)		
(Market value 31 March 2024: 354.376/unit)		
	4,802.58	4,028.50

13 Trade receivables

	As at 31 March 2025	As at 31 March 2024
Secured, considered good	0.08	0.08
Unsecured, considered good	1,153.91	985.60
Unsecured, credit impaired	21.22	12.36
Less : Impairment loss allowance	(21.22)	(12.36)
	1,153.99	985.68
(refer note 54 for information about credit risk and market risk of trade receivables)		
The above balance includes amounts due by private companies in which KMPs/relative of KMPs are interested (Refer note 44)		

Notes to the Consolidated Financial Statements

for the year ended 31 March 2025

(₹ in million)

Outstanding as on 31 March 2025							
Particulars	Not due	Less than 6 months	6 months - 1 year	1 - 2 years	2 - 3 years	More than 3 years	Total
i) Undisputed Trade Receivables – considered good	531.85	596.26	16.57	6.80	1.30	1.21	1,153.99
ii) Undisputed Trade Receivables – which have significant increase in credit risk	-	-	-	-	-	-	-
iii) Undisputed Trade Receivables – credit impaired	1.45	3.74	1.15	4.72	5.01	5.15	21.22
iv) Disputed Trade Receivables – considered good	-	-	-	-	-	-	-
v) Disputed Trade Receivables – which have significant increase in credit risk	-	-	-	-	-	-	-
vi) Disputed Trade Receivables – credit impaired	-	-	-	-	-	-	-
Total trade receivables	533.30	600.00	17.72	11.52	6.31	6.36	1,175.21
Provision for doubtful trade receivables	(1.45)	(3.74)	(1.15)	(4.72)	(5.01)	(5.15)	(21.22)
Net receivable	531.85	596.26	16.57	6.80	1.30	1.21	1,153.99

Outstanding as on 31 March 2024							
Particulars	Not due	Less than 6 months	6 months - 1 year	1 - 2 years	2 - 3 years	More than 3 years	Total
i) Undisputed Trade Receivables – considered good	499.92	473.26	4.67	7.40	0.36	0.06	985.67
ii) Undisputed Trade Receivables – which have significant increase in credit risk	-	-	-	-	-	-	-
iii) Undisputed Trade Receivables – credit impaired	1.25	1.48	0.68	3.18	2.92	1.76	11.27
iv) Disputed Trade Receivables – considered good	-	-	-	-	-	1.10	1.10
v) Disputed Trade Receivables – which have significant increase in credit risk	-	-	-	-	-	-	-
vi) Disputed Trade Receivables – credit impaired	-	-	-	-	-	-	-
Total trade receivables	501.17	474.74	5.35	10.58	3.28	2.92	998.04
Provision for doubtful trade receivables	(1.24)	(1.48)	(0.68)	(3.18)	(2.92)	(2.86)	(12.36)
Net receivable	499.93	473.26	4.67	7.40	0.36	0.06	985.68

14 Cash and cash equivalents

	As at 31 March 2025	As at 31 March 2024
Cash on hand	0.96	0.52
Cheques, drafts on hand	-	5.40
Balances with banks		
- in current accounts	266.14	414.11
- in deposit account with original maturity upto three months	7.65	54.90
Money market deposits	667.50	662.58
	942.25	1,137.51

15 Other bank balances

	As at 31 March 2025	As at 31 March 2024
Unpaid dividend accounts	2.28	1.59
Bank deposits with original maturity more than three months but less than twelve months	132.32	129.70
Earmarked bank balances *	-	0.67
	134.60	131.96

* These balances represent unspent Corporate Social Responsibility (CSR) amount of prior years and are transferred to separate bank account as per Section 135(6) of the Companies Act, 2013.

Notes to the Consolidated Financial Statements

for the year ended 31 March 2025

(₹ in million)

16 Short-term loans

(unsecured considered good unless otherwise stated)

	As at 31 March 2025	As at 31 March 2024
Loan to employees	1.03	1.01
	1.03	1.01

17 Other current financial assets

(unsecured considered good unless otherwise stated)

	As at 31 March 2025	As at 31 March 2024
Interest receivable	4.11	6.86
Export incentives receivable	2.98	6.33
Bank deposits having original maturity of more than 12 months but remaining maturity is less than 12 months	45.66	165.50
Others	27.73	18.51
	80.48	197.20

18 Other current assets

(unsecured considered good unless otherwise stated)

	As at 31 March 2025	As at 31 March 2024
Prepaid expenses	36.24	39.63
Advance to suppliers	17.98	39.82
Excess of Planned Assets over Obligation - Gratuity	0.68	0.82
Balance with Government authorities	42.75	31.59
Others	13.06	16.44
	110.71	128.30

19 Equity share capital

	As at 31 March 2025		As at 31 March 2024	
	Number of shares	Amount	Number of shares	Amount
Authorised				
Equity shares of Face Value ₹ 2 each	175,000,000	350.00	175,000,000	350.00
	175,000,000	350.00	175,000,000	350.00
Issued, subscribed and fully paid up				
Equity shares of Face Value ₹ 2 each	111,881,150	223.76	111,824,075	223.65
Total	111,881,150	223.76	111,824,075	223.65

a) Reconciliation of equity share capital

	As at 31 March 2025		As at 31 March 2024	
	Number of shares	Amount	Number of shares	Amount
Balance at the beginning of the year	111,824,075	223.65	111,824,075	223.65
Add : Issued during the year (Refer note 19d)	57,075	0.11	-	-
Balance at the end of the year	111,881,150	223.76	111,824,075	223.65

Notes to the Consolidated Financial Statements

for the year ended 31 March 2025

(₹ in million)

b) Shareholders holding more than 5% of equity shares

	As at 31 March 2025		As at 31 March 2024	
	Number of shares	% of holding	Number of shares	% of holding
Equity shares of Face Value ₹ 2 each				
Mr. Vasant L. Rathī *	37,123,702	33.18%	37,053,702	33.14%
Nalanda India Equity Fund Limited	9,465,501	8.46%	9,963,685	8.91%
Orbimed Asia III Mauritius Limited	13,509,522	12.07%	11,053,245	9.88%
	60,098,725	53.71%	58,070,632	51.93%

*includes shares held by Vasant and Prabha Rathī Generation Trust – 31 March 2025: 7,500,000 shares (6.70%) [31 March 2024: 7,500,000 shares (6.71%)]

c) Rights, preferences and restrictions attached to equity shares

The Company has only one class of equity share having a par value of ₹ 2 per share. Each holder of equity share is entitled to one vote per share. All shares rank pari passu on repayment of capital and surplus assets in the event of liquidation. Dividend proposed by the Board of Directors is subject to the approval of shareholders in the ensuing Annual General Meeting except interim dividend.

d) Shares reserved for issue under “Employees Stock Option Scheme 2022 (ESOS 2022)”

The Company had reserved issuance of 1,088,500 Equity shares of ₹ 2 each for offering to eligible employees of the Company and subsidiary companies under Employees Stock Option Scheme (ESOS). The option would vest on graded basis over a maximum period of 5 years or such other period as may be decided by the Nomination and Remuneration Committee from the date of grant based on specific criteria (refer note 46 & 46A).

Equity share capital

Details of Shares held by Promoters and Promoter Group Members at the end of the year

No.	Promoter and Promoter Group Members name	As at 31 March 2025		As at 31 March 2024		% change between 31 Mar 25 vs 31 Mar 24	As at 31 March 2023		% change between 31 Mar 24 vs 31 Mar 23
		No. of shares	% of total shares	No. of shares	% of total shares		No. of shares	% of total shares	
1	Vasant Rathī *	37,123,702	33.18%	37,053,702	33.14%	0.04%	36,503,702	32.64%	0.49%
2	Chandrakumar Laxminarayan Rathī	-	0.00%	46,500	0.04%	-0.04%	46,500	0.04%	0.00%
3	Reshma Namita Rathī	2,646,858	2.37%	2,646,858	2.37%	0.00%	2,646,858	2.37%	0.00%
4	Rachana Vasant Rathī	2,641,500	2.36%	2,641,500	2.36%	0.00%	2,641,500	2.36%	0.00%
5	Rasika Vasant Rathī	2,665,825	2.38%	2,665,825	2.38%	0.00%	2,636,700	2.36%	0.03%
6	Prabhavati Vasant Rathī	913,000	0.82%	913,000	0.82%	0.00%	913,000	0.82%	0.00%
7	Kishor Laxminarayan Rathī	406,000	0.36%	1,466,000	1.31%	-0.95%	1,466,000	1.31%	0.00%
8	Kishor Laxminarayan Rathī HUF	1,100,000	0.98%	-	0.00%	0.98%	-	0.00%	0.00%
9	Madhusudan Kabra	615,600	0.55%	715,600	0.64%	-0.09%	715,600	0.64%	0.00%
10	Savita Chandrakumar Rathī	-	0.00%	-	0.00%	0.00%	-	0.00%	0.00%
11	Radhika Ashish Pujara	-	0.00%	-	0.00%	0.00%	-	0.00%	0.00%
12	Piyush Chandrakumar Rathī	-	0.00%	-	0.00%	0.00%	-	0.00%	0.00%
13	Jayesh Madhusudan Soni #	35,000	0.03%	-	0.00%	0.03%	10,000	0.01%	-0.01%
14	Sanju Madhusudan Soni #	-	0.00%	-	0.00%	0.00%	10,000	0.01%	-0.01%
15	Tejasvi Madhusudan Soni #	-	0.00%	-	0.00%	0.00%	10,000	0.01%	-0.01%
16	Abhijit Kishor Rathī #	-	0.00%	-	0.00%	0.00%	82,835	0.07%	-0.07%
17	Ankit Kishor Rathī #	-	0.00%	-	0.00%	0.00%	100,000	0.09%	-0.09%
18	Amit Kishor Rathī #	-	0.00%	-	0.00%	0.00%	75,001	0.07%	-0.07%

Notes to the Consolidated Financial Statements

for the year ended 31 March 2025

(₹ in million)

No.	Promoter and Promoter Group Members name	As at 31 March 2025		As at 31 March 2024		% change between 31 Mar 25 vs 31 Mar 24	As at 31 March 2023		% change between 31 Mar 24 vs 31 Mar 23
		No. of shares	% of total shares	No. of shares	% of total shares		No. of shares	% of total shares	
19	Sunita Sunil Attal #	-	0.00%	-	0.00%	0.00%	11,760	0.01%	-0.01%
20	Sunil Ramdayal Attal	5,000	0.00%	-	0.00%	0.00%	-	0.00%	0.00%
21	Anisha Sunil Attal #	-	0.00%	-	0.00%	0.00%	9,421	0.01%	-0.01%
22	Megha Jhawar #	20,000	0.02%	-	0.00%	0.02%	10,000	0.01%	-0.01%
23	Nikita Madhusudan Soni #	-	0.00%	-	0.00%	0.00%	10,000	0.01%	-0.01%
24	Payal Akshay Kulkarni #	7,500	0.01%	-	0.00%	0.01%	5,000	0.00%	0.00%
25	Pramila Shamsunder Soni .	5,000	0.00%	-	0.00%	0.00%	-	0.00%	0.00%
26	Snehal Shamsunder Soni #	15,000	0.01%	-	0.00%	0.01%	4,400	0.00%	0.00%
27	Advenza Global Limited (Formerly known as Advanced Vital Enzymes Pvt Ltd)	-	0.00%	487,609	0.44%	-0.44%	7,232,844	6.47%	-6.03%
28	Atharva Green Ecotech LLP	-	0.00%	-	0.00%	0.00%	629,000	0.56%	-0.56%
29	Mangala Madhusudan Kabra	-	-	-	-	0.00%	-	-	0.00%
Total		48,199,985	43.08%	48,636,594	43.49%	-0.42%	55,770,121	49.87%	-6.38%

*includes shares held by Vasant and Prabha Rathii Generation Trust – 31 March 2025: 7,500,000 shares (6.70%) [31 March 2024: 7,500,000 shares (6.71%)]

Reclassified from Promoter Group category to public category with effect from 17 April 2023

Snehal Shamsunder Soni, Pramila Shamsunder Soni, Sunil Ramdayal Attal, Megha Jhawar, Payal Akshay Kulkarni and Kishor Laxminarayan Rathii HUF are classified as promoter group members pursuant to gift of shares by promoter and promoter group members during the year.

20 Other equity

	As at 31 March 2025	As at 31 March 2024
Capital reserve		
Balance at the beginning of the year	6.74	6.74
Add : Additions made during the year	-	-
Less : Deletions made during the year	-	-
Balance at the end of the year	6.74	6.74
Securities premium account		
Balance at the beginning of the year	821.31	821.31
Add: Premium on issue of equity shares under ESOP scheme	18.91	-
Balance at the end of the year	840.22	821.31
Employee stock option reserve		
Balance at the beginning of the year	30.31	-
Add: Options granted during the year (refer note 46)	36.80	30.31
Less: Exercised during the year	(15.24)	-
Less: Lapsed during the year	(2.34)	-
Balance at the end of the year	49.53	30.31

Notes to the Consolidated Financial Statements

for the year ended 31 March 2025

(₹ in million)

	As at 31 March 2025	As at 31 March 2024
General reserve		
Balance at the beginning of the year	38.77	38.77
Add : Additions made during the year	-	-
Less : Deletions made during the year	-	-
Balance at the end of the year	38.77	38.77
Non controlling interest reserve		
Balance at the beginning of the year	(122.39)	(116.22)
Acquisition of non-controlling interests (refer note 49)	-	(6.17)
Balance at the end of the year	(122.39)	(122.39)
Retained earnings		
Balance at the beginning of the year	10,794.91	10,022.77
Add: Profit for the year	1,311.15	1,333.04
Add: Transferred from Other comprehensive income	(4.97)	(1.78)
Less: Dividend paid	(570.30)	(559.12)
Balance at the end of the year	11,530.79	10,794.91
Other Comprehensive Income		
Foreign currency translation reserve		
Balance at the beginning of the year	1,447.98	1,353.67
Add: Exchange rate difference in translation (net)	193.23	94.31
Balance at the end of the year	1,641.21	1,447.98
	13,984.87	13,017.63

Nature and purpose of reserves

Capital reserve

The reserve comprises of profits/gains of capital nature earned by the Company and credited directly to such reserve.

Securities premium

Securities premium is used to record the premium received on issue of shares. It is utilised in accordance with the provisions of the Companies Act, 2013.

Employee stock option reserve

This represents the fair value of options granted to eligible employees of the Company under the ESOS 2022 Scheme over the vesting period. This reserve will be utliised on exercise of options by the employees.

General reserve

General reserve is created out of the profits earned by the Company by way of transfer from surplus in the Statement of Profit and Loss. The Company can use this reserve for payment of dividend and issue of fully paid up and not paid up bonus shares.

Non controlling interest reserve

Non controlling interest reserve represent the difference between the consideration paid and the carrying value of non controlling interest acquired in subsidiaries.

Retained earnings

Retained earnings are the profits that the Group has earned till date, less any transfers to general reserve, dividends or other distributions paid to shareholders.

Foreign currency translation reserve

Exchange differences arising on translation of the foreign operations, if any, are recognised in other comprehensive income as described in accounting policy and accumulated in a separate reserve within equity.

Notes to the Consolidated Financial Statements

for the year ended 31 March 2025

(₹ in million)

21 Non-current borrowings

	As at 31 March 2025	As at 31 March 2024
Secured		
Term loans:		
From banks	90.29	66.52
Vehicle loans	1.54	3.08
	91.83	69.60

a) Details of security for each type of borrowings as at 31 March 2025

Scitech Specialities Private Limited:

- i) The term loan is secured by way of equitable mortgage of Building located at 501, DLH Park, S. V. Road, Goregaon (West), Mumbai, Maharashtra and personal guarantee by the directors. For terms of repayment (refer note 21(b)).
- ii) Vehicle loans availed from five banks and are secured by way of hypothecation of respective vehicle.

Advanced Bio Agro Tech Limited:

- i) Vehicle loans availed from one bank and are secured by way of hypothecation of respective vehicle.

b) Terms of repayment of term loans and other loans (including current borrowings)

Term loans	Interest rates	Repayment terms	Outstanding as at 31 March 2025	Outstanding as at 31 March 2024
From Banks				
Deutsche Bank AG	9.15%	173 equal monthly instalments of ₹ 0.58 million each along with interest up to 5 November 2034	100.84	70.11

Vehicle Loans (including current borrowings)

Interest rate	No. of installments	Date of last installment	Amount of installment	Outstanding as at 31 March 2025	Outstanding as at 31 March 2024
8.50%	4	05-Jul-25	0.03	0.11	0.41
9.10%	0	05-Nov-24	0.00	0.00	0.42
10.00%	0	15-Aug-24	0.00	0.00	0.07
6.80%	60	05-Mar-27	0.05	2.97	4.32
Total				3.08	5.22

22 Non current lease liabilities

	As at 31 March 2025	As at 31 March 2024
Lease liability (refer note 43)	117.34	158.56
	117.34	158.56

23 Non-current provisions

	As at 31 March 2025	As at 31 March 2024
Provision for employee benefits		
Compensated absences	1.56	1.71
Gratuity (refer note 41)	12.15	7.15
	13.71	8.86

Notes to the Consolidated Financial Statements

for the year ended 31 March 2025

(₹ in million)

24 Current borrowings

	As at 31 March 2025	As at 31 March 2024
Secured		
Loans repayable on demand:		
From banks in rupees	111.45	175.80
	111.45	175.80
Current maturities of long-term term loans (refer note 21)		
- From banks	10.54	3.58
	1.54	2.14
- Vehicle loans	12.08	5.72
	123.53	181.52

a) Details of security for each type of borrowings as at 31 March 2025

JC Biotech Private Limited:

- (i) The cash credit from bank is secured by way of hypothecation of first charge on entire current assets of the company both current and future. The loan is also supported by first charge by way of an equitable mortgage of industrial land (by deposit of title deeds) and subservient charge on entire unencumbered movable fixed assets of the company both present and future(excluding vehicles/assets under HP/lease) of the JC Biotech Private Limited.

Scitech Specialities Private Limited:

- (i) The working capital facility from bank are secured against the inventories and Trade receivables of of the Scitech Specialities Private Limited.

Saiganesh Enzytech Solutions Private Limited:

- (i) The working capital facility from bank are secured against the fixed deposit.

b) Terms of repayment of loans

Loan repayable on demand - from banks

Cash Credit from bank for ₹ 111.45 million (31 March 2024: ₹ 175.80 million) carries an interest rate of 7.50% to 9.50%.

25 Current lease liabilities

	As at 31 March 2025	As at 31 March 2024
Lease liability (refer note 43)	60.80	63.40
	60.80	63.40

26 Trade payables

	As at 31 March 2025	As at 31 March 2024
Total outstanding dues to micro and small enterprises (refer note below)	42.93	32.69
Total outstanding dues to others (refer note 44 for payable to related parties)	129.08	124.90
	172.01	157.59

Notes to the Consolidated Financial Statements

for the year ended 31 March 2025

(₹ in million)

Note:

Dues to micro, small and medium enterprises pursuant to section 22 of the Micro, Small and Medium Enterprises Development Act (MSMED), 2006

Principal amount remaining unpaid	42.93	32.69
Interest due thereon	-	-
Interest paid by the Company in terms of Section 16 of MSMED Act, 2006, along with the amount of the payment made to the suppliers and service providers beyond the appointed day during the year.	-	-
Interest due and payable for the period of delay in making payment (which has been paid but beyond the appointed day during the year) but without adding the interest specified under MSMED Act, 2006	-	-
Interest accrued and remaining unpaid as at balance sheet date	0.05	0.05
Further interest remaining due and payable even in the succeeding years, until such date when the interest dues as above are actually paid to the small enterprise for the purpose of disallowance as a deductible expenditure under section 23 of the MSMED Act, 2006.	0.05	0.05

The management has identified enterprises which have provided goods and services to the Companies within the Group which are incorporated in India and which qualify under the definition of micro and small enterprises, as defined under Micro, Small and Medium Enterprises Development Act, 2006 (MSMED). Accordingly, the disclosure in respect of the amounts payable to such enterprises has been made in the Consolidated financials statements based on information received and available with the Group.

Outstanding as at 31 March 2025						
Particulars	Not due	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
MSME	40.99	1.94	-	-	-	42.93
Others	65.18	53.41	7.94	2.43	0.12	129.08
Disputed dues (MSMEs) and	-	-	-	-	-	-
Disputed dues (Others)	-	-	-	-	-	-
Total	106.17	55.35	7.94	2.43	0.12	172.01

Outstanding as at 31 March 2024						
Particulars	Not due	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
MSME	31.49	1.20	-	-	-	32.69
Others	119.19	1.59	0.38	3.46	0.28	124.90
Disputed dues (MSMEs) and	-	-	-	-	-	-
Disputed dues (Others)	-	-	-	-	-	-
Total	150.68	2.79	0.38	3.46	0.28	157.59

Notes to the Consolidated Financial Statements

for the year ended 31 March 2025

(₹ in million)

27 Other current financial liabilities

	As at 31 March 2025	As at 31 March 2024
Unpaid dividends (refer note below)	2.28	1.59
Security deposits from customers	9.12	7.95
Payable for purchase of property, plant and equipment	28.89	31.57
Employee benefits payable	101.51	82.10
Other payables	124.53	113.78
	266.33	236.99

Note:

The amount due and paid during the year to “Investor Education and Protection Fund” is ₹ 0.18 million (31 March 2024: 0.11 million).

28 Other current liabilities

	As at 31 March 2025	As at 31 March 2024
Statutory dues:		
Provident fund payable	4.52	3.20
Employees' State Insurance Scheme contribution payable	0.08	0.03
Other dues payable	15.83	22.53
Advance from customers	62.85	89.34
Others	2.00	20.81
	85.28	135.91

29 Current provisions

	As at 31 March 2025	As at 31 March 2024
Provision for employee benefits		
Compensated absences	12.24	10.21
Gratuity (refer note 41)	15.03	8.36
Provision for 401(k) (refer note a below)	17.60	15.54
Provision for sales return (refer note b below)	12.40	10.26
Provision for claims and litigations (refer note c below and note 39)	156.41	152.38
	213.68	196.75

Note:

a) Advanced Enzymes USA, Inc.

The Company has maintained a 401(k) Safe Harbor Profit Sharing Plan (“Plan”) to provide retirement and incidental benefits for its eligible employees. Employees may contribute from 1% to 15% of their annual compensation to the Plan, limited to a maximum annual amount as set periodically by the Internal Revenue Service. The Company contributes 100% of each dollar of mandatory contributions each eligible participant makes each plan year. All safe harbor contributions vest immediately.

Movement in provision 401(k) during the year:

Provision at the beginning of the year	15.54	12.22
Contribution during the year	(15.37)	(19.11)
Provision created during the year	17.00	22.23
Foreign exchange currency translation	0.43	0.20
Provision at the end of the year	17.60	15.54

Notes to the Consolidated Financial Statements

for the year ended 31 March 2025

(₹ in million)

b) Provision for sales return

As per best estimate of the management, provision has been made towards probable return of goods from customers, as per Indian Accounting Standard (Ind AS) 37

Movement in provision for sales return

Provision at the beginning of the year	10.26	5.89
Provision created during the year	12.40	10.26
Provision reversed during the year	(10.26)	(5.89)
Provision at the end of the year	12.40	10.26

c) Movement in provision for claims and litigations

Provision at the beginning of the year	152.38	-
Provision created during the year	-	152.38
Provision reversed during the year	-	-
Foreign exchange currency translation	4.03	-
Provision at the end of the year	156.41	152.38

30 Revenue from contracts with customers

30.1 Disaggregated revenue information

	Year ended 31 March 2025	Year ended 31 March 2024
Sale of goods		
Export	3,407.63	3,072.66
Domestic	2,901.34	3,101.64
	6,308.97	6,174.30
Sale of services		
Export	56.10	60.47
	56.10	60.47
Other operating revenues		
Export incentives	4.03	3.91
	6,369.10	6,238.68

30.2 Disaggregation of revenue from contracts with customers and reconciliation:

Following table provides disaggregation of revenue and a reconciliation of product categorywise revenue and revenue recognised in Statement of Profit and Loss as revenue from contracts with customers:

Particulars of segment	31 March 2025	31 March 2024
Human nutrition	4,049.52	4,202.45
Animal nutrition	759.65	677.43
Bio-process	1,501.08	1,306.89
	6,310.25	6,186.77
Adjustments		
Provision for sales return	(2.14)	(4.37)
Discount reversal / (given)	0.86	(8.10)
	(1.28)	(12.47)
Total revenue from contract with customers	6,308.97	6,174.30

Notes to the Consolidated Financial Statements

for the year ended 31 March 2025

(₹ in million)

31 Other income

	Year ended 31 March 2025	Year ended 31 March 2024
Interest income		
- on bank deposits carried at amortised cost	12.42	11.99
- on other assets carried at amortised cost	185.64	121.27
Provision for doubtful debts written back	0.38	0.02
Profit on sale of property, plant and equipment (net)	2.29	0.16
Liabilities no longer required written back	1.98	48.20
Net gain on foreign currency transactions and translations	9.76	5.49
Mark to mark gain on marketable securities	59.01	86.13
Miscellaneous income	58.93	93.38
	330.41	366.64

32 Cost of materials consumed

	Year ended 31 March 2025	Year ended 31 March 2024
Opening stock		
Raw materials and packing materials (including goods-in-transit)	637.08	528.89
Add : Purchases during the year		
Raw materials and packing materials	1,607.37	1,662.69
Less : Closing stock		
Raw materials and packing materials (including goods-in-transit)	624.89	637.08
	1,619.56	1,554.50

33 Purchase of traded goods

	Year ended 31 March 2025	Year ended 31 March 2024
Purchase of traded goods	-	0.20
	-	0.20

34 Changes in inventories of finished goods, work-in-progress and stock-in- trade

	Year ended 31 March 2025	Year ended 31 March 2024
Opening stock		
- Finished goods	357.87	286.53
- Work-in-progress	363.41	325.84
	721.28	612.37
Closing stock		
- Finished goods	386.03	357.87
- Work-in-progress	436.20	363.41
	822.23	721.28
	(100.95)	(108.91)

Notes to the Consolidated Financial Statements

for the year ended 31 March 2025

(₹ in million)

35 Employee benefits expense

	Year ended 31 March 2025	Year ended 31 March 2024
Salaries, wages and bonus	1,230.38	1,102.20
Contribution to provident and other funds (refer note 41)	71.33	70.27
Retirement benefits expense (refer note 41)	45.24	38.87
Staff welfare expenses	34.01	36.19
Employee stock compensation expense (refer note 46)	34.46	30.31
	1,415.42	1,277.84

36 Finance costs

	Year ended 31 March 2025	Year ended 31 March 2024
Interest expenses on financial liabilities - borrowings carried at amortised cost	16.08	11.90
Interest on term loan - carried at amortised cost	7.44	7.61
Net loss on foreign currency transactions and translations#	-	0.00
Interest expenses on lease liabilities (refer note 43)	12.05	9.77
	35.57	29.28

37 Depreciation and amortisation expense

	Year ended 31 March 2025	Year ended 31 March 2024
Depreciation on property, plant and equipment (refer note 6A)	219.44	209.61
Amortisation of intangible assets (refer note 6D)	75.61	77.40
Amortisation of Right to use of assets (refer note 6A & 43)	70.51	65.41
	365.56	352.42

Figures are below ₹ 0.01 Million, hence disclosed as ₹ 0.00

38 Other expenses

	Year ended 31 March 2025	Year ended 31 March 2024
Consumption of stores and spare parts	129.81	148.32
Power and fuel	373.99	403.39
Water charges	5.56	5.83
Laboratory expenses	56.12	41.93
Analysis & Testing charges	7.07	7.20
Repairs and maintenance		
- Buildings	20.66	29.98
- Plant and equipments	69.17	58.06
- Others	44.38	42.13
Travel, conveyance and car hire	66.45	64.26
Commission	26.02	23.20
Sales promotion and advertisement	75.56	62.19
Freight outward and forwarding	109.13	71.70
Selling and distribution expenses	32.48	22.62
Rent (refer note 43 and 44)	10.24	15.27
Rates and taxes	64.56	60.16

Notes to the Consolidated Financial Statements

for the year ended 31 March 2025

(₹ in million)

	Year ended 31 March 2025	Year ended 31 March 2024
Insurance	35.91	33.67
Printing and stationary	5.37	5.33
Communication expenses	14.11	12.44
Directors' sitting fees (refer note 44)	1.09	1.74
Commission to Non Executive Directors	4.97	5.83
Legal and professional charges	147.46	185.08
Technical Services	26.04	17.10
Payments to Auditors (refer note 42)	11.44	9.52
Bad debts	6.43	11.32
Provisions for doubtful accounts receivables (net)	9.23	(3.10)
Advances/assets written off	9.41	9.63
Research and development expenses	8.75	8.12
Donation	1.12	0.65
Bank Charges	10.76	11.93
Net loss on foreign currency transactions and translations	0.01	-
Provision for diminution in values of shares	1.01	-
Loss on sale of property, plant and equipment (net)	-	3.21
Corporate Social Responsibility expenditure (refer note 58)	20.82	17.15
Commuting expenses	1.10	1.53
Miscellaneous expenses	84.48	83.07
	1,490.71	1,470.46

39 Exceptional items

The District of Arizona (U.S.A) pronounced an order in respect of lawsuit filed by a competitor against the Advanced Supplementary Technologies Corporation (U.S.A.) ("AST") wholly owned subsidiary of Advanced Enzymes USA, Inc. (U.S.A.) dated 27 February 2024. The Honorable Court after considering the counter claim by AST issued net monetary judgement in favor of the competitor for ₹ 151.32 million.

	Year ended 31 March 2025	Year ended 31 March 2024
Charge for claims and litigations	-	151.32
	-	151.32

Notes to the Consolidated Financial Statements

for the year ended 31 March 2025

(₹ in million)

40 Income taxes

Tax expense

(a) Income tax recognised in Statement of Profit and Loss

	Year ended 31 March 2025	Year ended 31 March 2024
Current income tax	495.59	565.52
Changes in estimates related to prior period #	2.18	0.69
Total current tax	497.77	566.21
Deferred income tax liability / (asset), net		
Origination and reversal of temporary differences	38.57	(53.30)
Minimum Alternate Tax credit	(2.44)	(4.21)
Tax expense for the year	533.90	508.70

(b) Income tax recognised in Other Comprehensive Income

	Year ended 31 March 2025			Year ended 31 March 2024		
	Before tax	Tax (expense) / benefit	Net of tax	Before tax	Tax (expense) / benefit	Net of tax
Items that will not be reclassified to profit and loss						
Remeasurements of the defined benefit plans	6.78	(1.77)	5.01	2.40	(0.58)	1.82
	6.78	(1.77)	5.01	2.40	(0.58)	1.82

(c) Reconciliation of effective tax rate

	Year ended 31 March 2025	Year ended 31 March 2024
Profit before tax	1,873.64	1,878.21
Tax using the Company's domestic tax rate (31 March 2025: 25.168%, 31 March 2024: 25.168%)	471.56	472.75
Tax effect of:		
Tax on losses on which no deferred tax is created	(5.12)	22.30
Non tax deductible items	39.52	52.30
Prior period tax	1.79	0.69
Tax rate differential	29.56	19.29
Deferred tax impact on Ind AS adjustments	(13.25)	(31.18)
Others	9.84	(27.45)
Tax expense as per profit and loss	533.90	508.70

Deferred tax assets (net) and liabilities (net)

Particulars	As at 31 March 2025	As at 31 March 2024
(a) Deferred tax assets (net)	101.92	142.82
(b) Deferred tax liabilities (net)	(336.34)	(343.24)
Net deferred tax assets/(liabilities)	(234.42)	(200.42)

Notes to the Consolidated Financial Statements

for the year ended 31 March 2025

(₹ in million)

Particulars	Balance 31 March 2024	Recognised in profit or loss	Recognised in OCI	Acquired on business combination	Others	Balance 31 March 2025
Deferred tax assets (net) in relation to:						
Property, plant and equipment and other intangible assets	8.11	(7.75)	-	-	(0.03)	0.33
Other items	45.81	(18.15)	-	-	1.01	28.67
Provision for employee benefits	1.26	0.16	(0.02)	-	-	1.40
Unrealised profits on unsold inventory	76.70	(8.20)	-	-	0.66	69.16
Carry forward business loss	9.23	(9.23)	-	-	-	-
Provision for doubtful trade receivable	1.71	0.65	-	-	-	2.36
	142.82	(42.52)	(0.02)	-	1.64	101.92
Deferred tax liabilities (net) in relation to:						
Property, plant and equipment and other intangible assets	(376.07)	6.86	-	-	(1.28)	(370.49)
Other items	13.08	(3.88)	-	-	-	9.20
Provision for employee benefits	10.26	0.97	1.79	-	-	13.02
MAT Credit	9.49	-	-	-	2.44	11.93
	(343.24)	3.95	1.79	-	1.16	(336.34)
	(200.42)	(38.57)	1.77	-	2.80	(234.42)

Particulars	Balance 31 March 2023	Recognised in profit or loss	Recognised in OCI	Acquired on business combination	Others	Balance 31 March 2024
Deferred tax assets (net) in relation to:						
Property, plant and equipment and other intangible assets	8.27	(0.17)	-	-	0.01	8.11
Other items	10.65	34.75	-	-	0.41	45.81
Provision for employee benefits	1.62	(0.30)	0.06	-	(0.12)	1.26
Unrealised profits on unsold inventory	68.43	7.91	-	-	0.36	76.70
MAT Credit	22.29	(13.06)	-	-	-	9.23
Provision for doubtful trade receivable	2.16	(0.45)	-	-	-	1.71
	113.42	28.68	0.06	-	0.66	142.82
Deferred tax liabilities (net) in relation to:						
Property, plant and equipment and other intangible assets	(400.22)	24.59	-	-	(0.44)	(376.07)
Other items	14.43	(1.35)	-	-	-	13.08
Provision for employee benefits	8.24	1.38	(0.64)	-	1.28	10.26
MAT Credit	5.28	-	-	-	4.21	9.49
Provision for doubtful trade receivable	-	-	-	-	-	-
	(372.27)	24.62	(0.64)	-	5.05	(343.24)
	(258.85)	53.30	(0.58)	-	5.71	(200.42)

As at year end, the Group has tax credits in respect of Minimum Alternative Tax (MAT credit) of ₹ 9.23 million (March 31, 2024 : ₹ 9.49 million). The Group is reasonably certain of availing the said MAT credit in future years against the normal tax expected to be paid in those years.

Given that the Group does not have any intention to dispose investments in subsidiaries in the foreseeable future, deferred tax asset on indexation benefit in relation to such investments has not been recognised.

Unrecognised deferred tax assets/ liabilities

As at 31 March 2025 undistributed earning of subsidiaries amounted to ₹ 7,248.15 millions (March 31, 2024: ₹ 6,999.77 millions). The corresponding deferred tax liability of ₹ 1,189.41 millions (March 31, 2024 ₹ 1,146.55 millions), was not recognised because the Company controls the dividend policy of its subsidiaries i.e. the Company controls the timing of reversal of the related taxable temporary differences and management is satisfied that they will not reverse in the foreseeable future.

Notes to the Consolidated Financial Statements

for the year ended 31 March 2025

(₹ in million)

41 Employee benefits

The Group contributes to the following post-employment plans in India.

(A) Defined Contribution Plans:

The Group makes contributions towards provident fund and superannuation fund which are in the nature of defined contribution post employment benefit plans. Under the plan, the Group is required to contribute a specified percentage of payroll cost to fund the benefits.

The Group recognised ₹ 68.33 million for the year ended 31 March 2025 (31 March 2024 ₹ 68.02 million) towards provident fund and other retirement benefits funds contribution and ₹ 3.38 million for the year ended 31 March 2025 (31 March 2024 ₹ 3.49 million) towards super-annuation fund contribution in the Statement of Profit and Loss.

The contributions payable to these plans by the Group are at rates specified in the rules of the schemes.

(B) Defined Benefit Plan:

The Group provides for gratuity benefit and compensated absences, which are defined benefit plans, covering all its eligible employees. The Group has taken a Group Gratuity and Compensated Absences policy for its employees with the Life Insurance Corporation of India (LIC). Under gratuity policy, the eligible employees are entitled to receive gratuity payments upon their resignation or death (subject to completion of 4.5 years of employment) in lumpsum after deduction of necessary taxes.

The most recent actuarial valuation of the defined benefit obligation along with the fair valuation of the plan assets in relation to the gratuity scheme was carried out as at 31 March 2025. The present value of the defined benefit obligations and the related current service cost and past service cost, were measured using the Projected Unit Credit Method.

These defined benefit plans expose the Group to actuarial risks, such as longevity risk, currency risk, interest rate risk and market (investment) risk.

Based on the actuarial valuation obtained in this respect, the following table sets out the details of the employee benefit obligation and the plan assets as at balance sheet date:

	31 March 2025	31 March 2024
Defined benefit obligation	130.89	107.31
Fair value of plan assets	104.39	92.62
Net defined benefit obligation/(assets)	(26.50)	(14.69)

i) Reconciliation in present value of obligations ('PVO') – defined benefit obligation:

	Defined benefit obligation	
	31 March 2025	31 March 2024
Opening balance	107.31	91.63
Included in profit and loss		
Current service cost	10.66	9.87
Past service cost	1.99	-
Interest cost	7.14	6.33
	127.10	107.83
Included in OCI		
Remeasurement loss/(gain):		
Actuarial loss/(gain) arising from:		
Financial assumptions	6.55	2.64
Experience adjustment	1.11	0.20
	134.76	110.67
Benefits paid	(3.87)	(3.36)
Closing balance	130.89	107.31

Notes to the Consolidated Financial Statements

for the year ended 31 March 2025

(₹ in million)

ii) Change in fair value of plan assets

	Fair value of plan assets	
	31 March 2025	31 March 2024
Opening balance	92.62	82.64
Included in profit and loss		
Expected return on plan assets	7.03	5.79
	99.64	88.42
Included in OCI		
Remeasurement (loss)/gain:		
Actuarial (loss)/gain arising from:		
Expected return on plan assets	0.88	0.44
	100.52	88.86
Other		
Contributions paid by the employer	7.36	6.26
Benefits paid	(3.49)	(2.50)
Closing balance	104.39	92.62

Impact on Consolidated Statement of Profit and Loss for the current year

	31 March 2025	31 March 2024
Service cost:		
Current service cost	10.66	9.87
Past service cost and loss/(gain) on curtailments and settlement	1.99	-
Net interest cost	0.12	0.54
Total included in Employee Benefit expenses	12.77	10.42

Impact on Other comprehensive income for the current year

	31 March 2025	31 March 2024
Components of actuarial gain/losses on obligations:		
Due to Change in financial assumptions	(6.55)	(2.64)
Due to change in demographic assumption	-	-
Due to experience adjustments	(1.11)	(0.20)
Return on plan assets excluding amounts included in interest income	0.88	0.44
Amounts recognized in Other Comprehensive Income	(6.78)	(2.40)

ii. Plan assets

Plan assets comprise the following

Gratuity	31 March 2025	31 March 2024
Policy of insurance	100%	100%
	100%	100%

Notes to the Consolidated Financial Statements

for the year ended 31 March 2025

(₹ in million)

iii. Actuarial assumptions

The following were the principal actuarial assumptions at the reporting date (expressed as weighted averages).

	31 March 2025	31 March 2024
Discount rate	6.60% - 7.00%	7.11% - 7.23%
Rate of return on plan assets	6.60% - 7.00%	7.11% - 7.23%
Salary Escalation	6.00% - 8.50%	6.00% - 8.50%
Withdrawal rates	12%-2% at younger ages reducing to 2%-1% at older ages	12%-2% at younger ages reducing to 2%-1% at older ages
Retirement age	58-65 years	58-65 years
Mortality rates	As published under the Indian assured lives mortality (2012-14) table	As published under the Indian assured lives mortality (2012-14) table

Assumptions regarding future mortality have been based on published statistics and mortality tables.

iv. Sensitivity analysis

Reasonably possible changes at the reporting date to one of the relevant actuarial assumptions, holding other assumptions constant, would have affected the defined benefit obligation as shown below.

	31 March 2025 Gratuity	31 March 2024 Gratuity
Increase in		
Discount rate (0.5% movement)	121.58	99.07
Future salary growth (0.5% movement)	133.08	107.86
Withdrawal rates (10% movement)	127.08	103.54

	31 March 2025 Gratuity	31 March 2024 Gratuity
Decrease in		
Discount rate (0.5% movement)	131.77	105.42
Future salary growth (0.5% movement)	121.89	99.09
Withdrawal rates (10% movement)	127.34	104.48

The sensitivity analyses above have been determined based on a method that extrapolates the impact on defined benefit obligation as a result of reasonable changes in key assumptions occurring at the end of the reporting period.

v. Expected future cash flows

Expected contribution

The expected contributions for the defined benefit plan for the next financial year is ₹ 13.28 million

Expected future benefit payments	Rs in million
31 March 2026	9.03
31 March 2027	17.96
31 March 2028	11.25
31 March 2029	12.45
31 March 2030	7.49
Thereafter	59.80

Notes to the Consolidated Financial Statements

for the year ended 31 March 2025

(₹ in million)

The trustees of the plan have outsourced the investment management of the fund to an insurance company. The insurance company in turn manages these funds as per the mandate provided to them by the trustees and the asset allocation which is within the permissible limits prescribed in the insurance regulations. Due to the restrictions in the type of investments that can be held by the fund, it may not be possible to explicitly follow an asset-liability matching strategy to manage risk actively in a conventional fund.

42 Payments to auditors (excluding taxes)

	Year ended 31 March 2025	Year ended 31 March 2024
As auditor		
Statutory audit	8.84	6.93
Limited review	1.56	2.19
Certification work	0.34	0.18
Tax audit fee	0.05	0.05
Reimbursement of expenses	0.65	0.17
	11.44	9.52

43 Leases

(a) Maturity analysis of lease liabilities– contractual undiscounted cash flows:

Particulars	Year Ended 31 March 2025	Year Ended 31 March 2024
Less than one year	83.27	73.29
One to five years	105.62	163.97
More than five years	3.47	5.19
Total undiscounted lease liabilities at 31 March	192.36	242.45
Discounted Lease liabilities included in the statement of financial position at 31 March		
Current lease liability	60.80	63.40
Non-current lease liability	117.34	158.56

- (b) The Weighted average incremental borrowing rate of ranges from 4% p.a. to 9.50% p.a. for local currency borrowings has been applied for measuring the lease liability at the date of initial application.
- (c) The Group incurred ₹ 92.81 million for the year ended 31 March 2025 (31 March 2024: ₹ 90.45 million) towards expenses relating to leases in statement of profit and loss. Lease rent incurred not falling under the scope of Ind AS 116 amounted to ₹ 10.24 million for the year ended 31 March 2025 (31 March 2024: ₹ 15.27 million), (refer note 38).
- (d) The total cash outflow for leases for year ended 31 March 2025 is ₹ 69.72 million (31 March 2024: ₹ 60.49 million)
- (e) General Description of leasing agreements:
- Leased Assets: Office Premises, Leasehold Land, Factory premises
 - Future Lease rentals are determined on the basis of agreed terms.
 - At the expiry of lease terms, the Company has an option to return the assets or extend the term by giving notice in writing.
 - Lease agreements are generally cancellable and are renewable by mutual consent on mutually agreed terms.
- (f) Please refer note 6A for carrying value of Right of Use Assets for the year ended 31 March 2025

Notes to the Consolidated Financial Statements

for the year ended 31 March 2025

(₹ in million)

(g) Changes in the lease liabilities

Particulars	Building	Leasehold land
Opening balance as at 1 April 2023	199.34	3.26
Add: Additions during the year	84.43	-
Add: Interest for the year	9.56	0.21
Less: Lease payments during the year	61.51	0.38
Less: Other adjustments including remeasurement	12.95	-
Closing balance as at 31 March 2024	218.87	3.09
Add: Additions during the year	20.05	-
Add: Interest for the year	11.85	0.20
Less: Lease payments during the year	77.37	0.38
Less: Other adjustments including remeasurement	(1.83)	-
Closing balance as at 31 March 2025	175.23	2.91

44 Related Party Disclosures

a Name of other related parties

II Key Management Personnel (KMP)

Mr. Vasant L. Rath	Chairman and Non-executive director
Mr. Mukund M. Kabra	Whole-time Director
Mr. Beni P. Rauka	Chief Financial Officer
Mr. Sanjay Basantani	Company Secretary
Mr. Kedar Desai (up to 31 March 2024)	Independent Director
Mr. Pramod Kasat	Independent Director
Mr. Rajesh Sharma (up to 10 August 2023)	Independent Director
Ms. Rasika Rath	Non-executive Director and daughter of Chairman
Mr. Vinodkumar Jajoo	Independent Director
Dr. Sunny Sharma	Non-executive Director
Mrs. Rajshree Patel	Independent Director
Mr. Nitin Jagannath Deshmukh	Independent Director
Mrs. Vandana Tilak (w.e.f. 01 July 2023)	Independent Director

Relatives of KMP :

Mrs. Prabha V. Rath	Wife of Chairman
Ms. Rachana Rath	Daughter of Chairman
Ms. Reshma Rath	Daughter of Chairman
Mr. Kishor L. Rath	Brother of Chairman

III Other related parties (entities in which either of the KMP's have significant influence) and with whom transactions have taken place during the year

Advenza Global Limited (Formerly known as Advanced Vital Enzymes Pvt Ltd)
Rathi Properties LLC
ServiceMob Inc.

Notes to the Consolidated Financial Statements

for the year ended 31 March 2025

(₹ in million)

b) Transactions with related parties

Transactions during the year	KMP and relatives		Other related parties	
	Year ended 31 March 2025	Year ended 31 March 2024	Year ended 31 March 2025	Year ended 31 March 2024
1 Sale of goods				
Advenza Global Limited (Formerly known as Advanced Vital Enzymes Pvt Ltd)	-	-	2.06	3.44
	-	-	2.06	3.44
2 Rent paid				
Rathi Properties LLC	-	-	32.42	30.15
Mr. Vasant L Rath	14.33	13.33	-	-
	14.33	13.33	32.42	30.15
3 Remuneration **				
Mr. Vasant L. Rath	46.51	43.05	-	-
Mr. Mukund M. Kabra	27.14	25.00	-	-
Mr. Kishor L. Rath	3.90	3.71	-	-
Mrs. Prabha V. Rath	25.37	23.18	-	-
Ms. Reshama Rath	16.07	14.49	-	-
Ms. Rachana Rath	14.38	12.83	-	-
Ms. Rasika Rath	17.76	17.39	-	-
Mr. Beni P. Rauka	15.94	14.56	-	-
Mr. Sanjay Basantani	5.50	4.79	-	-
	172.57	159.00	-	-
4 Commission				
Mr. Vasant L. Rath	8.02	7.23	-	-
Mr. Mukund Kabra	5.11	5.37	-	-
Ms. Rasika Rath	0.59	0.26	-	-
Mr. Kedar Desai	-	1.22	-	-
Mr. Pramod Kasat	0.89	0.87	-	-
Mr. Vinodkumar Jajoo	1.09	0.87	-	-
Mr. Sunny Sharma	0.30	0.35	-	-
Mrs. Rajshree Patel	0.30	0.52	-	-
Mr. Nitin Jagannath Deshmukh	0.59	0.44	-	-
Mrs. Vandana Tilak	-	0.17	-	-
	16.89	17.30	-	-
5 Sitting fees to Independent directors				
Mr. Kedar Desai	0.11	0.53	-	-
Mr. Pramod Kasat	0.40	0.41	-	-
Mr. Vinodkumar Jajoo	0.34	0.32	-	-
Mrs. Rajshree Patel	0.10	0.20	-	-
Mr. Nitin Jagannath Deshmukh	0.22	0.18	-	-
Mrs. Vandana Tilak	(0.08)	0.10	-	-
	1.09	1.74	-	-
6 Car hire charges				
Mrs. Prabha V. Rath	1.81	0.44	-	-
	1.81	0.44	-	-

Notes to the Consolidated Financial Statements

for the year ended 31 March 2025

(₹ in million)

Transactions during the year	KMP and relatives		Other related parties	
	Year ended 31 March 2025	Year ended 31 March 2024	Year ended 31 March 2025	Year ended 31 March 2024
7 Consultancy services				
ServiceMob Inc.	-	-	14.81	11.82
	-	-	14.81	11.82

* included in Employee benefit expense

^ The amount does not include gratuity and compensated absences which are actuarially determined on an overall basis for the Company and individual information in respect of the Key Management Personnel is not available.

c) Outstanding balances

	KMP and relatives		Other related parties	
	As on 31 March 2025	As on 31 March 2024	As on 31 March 2025	As on 31 March 2024
a. Investment				
Advenza Global Limited (Formerly known as Advanced Vital Enzymes Pvt Ltd)	-	-	0.57	0.57
	-	-	0.57	0.57
b. Remuneration payable				
Mr. Vasant L. Rathi	0.97	0.42		
Mr. Mukund M. Kabra	1.27	1.14	-	-
Mr. Kishor L. Rathi	0.22	0.21	-	-
Mrs. Prabha V. Rathi	0.53	0.26		
Ms. Reshama Rathi	0.33	0.31		
Ms. Rachana Rathi	0.30	0.78		
Ms. Rasika Rathi	0.37	0.23	-	-
Mr. Beni P. Rauka	0.52	0.51	-	-
Mr. Sanjay Basantani	0.21	0.22	-	-
	4.72	4.08	-	-
c. Commission payable				
Mr. Vasant L. Rathi	8.10	7.27	-	-
Mr. Mukund Kabra	5.11	5.37	-	-
Ms. Rasika Rathi	0.59	0.26	-	-
Mr. Kedar Desai	-	1.22	-	-
Mr. Pramod Kasat	0.89	0.87	-	-
Mr. Vinodkumar Jajoo	1.09	0.87	-	-
Mr. Sunny Sharma	0.30	0.35	-	-
Mrs. Rajshree Patel	0.30	0.52	-	-
Mr. Nitin Jagannath Deshmukh	0.59	0.44	-	-
Mrs. Vandana Tilak	-	0.17		
	16.97	17.34	-	-
d. Prepaid for car hire				
Mrs. Prabha V. Rathi	6.85	8.46	-	-
	6.85	8.46	-	-

Notes to the Consolidated Financial Statements

for the year ended 31 March 2025

(₹ in million)

	KMP and relatives		Other related parties	
	As on 31 March 2025	As on 31 March 2024	As on 31 March 2025	As on 31 March 2024
e. Directors' sitting fees payable				
Mr. Kedar Desai	-	0.02		
Mr. Pramod Kasat	0.02	0.02		
Mr. Vinodkumar Jajoo	0.02	0.02		
Mrs. Rajshree Patel	0.05	0.09		
Mr. Nitin Jagannath Deshmukh	0.02	0.02		
	0.11	0.17		

45 Segment reporting

Basis of segmentation

The Group operates only in one business segment viz. ‘manufacturing and sales of enzymes’ and hence no separate information for primary segment wise disclosure is required.

Geographic information

The geographic information analyses the Company’s revenues and non-current assets by the Company’s country of domicile and other countries. In presenting geographic information, segment revenue has been based on the selling location in relation to sale of goods and services to customers and segment assets are based on geographical location of assets.

	Year ended 31 March 2025	Year ended 31 March 2024
Segment revenue (based upon location of customers)		
India	2,905.47	3,102.66
Europe	335.36	397.80
USA	2,367.37	2,086.84
Asia	585.07	439.70
Others	171.80	207.77
	6,365.07	6,234.77

	31 March 2025	31 March 2024
Segment assets (based upon location of assets)		
India	3,514.49	3,353.40
Europe	591.08	636.28
USA	3,106.79	3,080.75
	7,212.36	7,070.43

Major customer

There are no customers from whom revenue is in excess of 10% of the Group’s revenue out of total revenue of the Group for financial year 2024-25 and financial year 2023-24 (refer note 30).

46 Employee share-based payment plans

a) Description of share-based payment arrangements:

As at 31 March 2025, the Company has the following share-based payment arrangements for employees.

‘AETL Employee Stock Option Scheme 2022’- (“AETL ESOS 2022”)

AETL ESOS 2022 provides for the grant of 576,000 stock options to specified employees on 12 August 2023. The AETL ESOS 2022 had been formulated by Board of Directors which was further adopted by Nomination and Remuneration committee.

Notes to the Consolidated Financial Statements

for the year ended 31 March 2025

(₹ in million)

The Shareholders approved the scheme on 12 August 2023. The plan entitles specified employees to purchase shares in the Company at the stipulated exercise price, subject to compliance with vesting conditions. As per the plan, holders of vested options are entitled to purchase one equity share of face value of ₹ 2 each for every option as per the scheme.

576,000 Equity Shares of Face Value of ₹ 2 each are reserved for issue under AETL Employee Stock Option Scheme 2022 (AETL ESOS-2022)

The terms and conditions related to the grant of the share options are as follows:

Employees entitled	Specified employees
Number of options	5,76,000
Scheme formulation	
Category I	First 500 Options at the Exercise Price of ₹ 2/- each
Category II	Employees who have been granted Options upto 5,000; First 500 Options at ₹ 2/- each and remaining Options at ₹ 141/-
Category III	Employees who have been granted Options more than 5,000; First 500 Options at ₹ 2/- each, Next 4,500 Option at ₹ 141/- and remaining Options at ₹ 188/-
Vesting conditions	
Category I	After 1 year of the date of grant
Category II	First 500 option after 1 year of the date of grant and
	for balance options
	After 1 year of the date of grant 5% vesting
	After 2 year of the date of grant 10% vesting
	After 3 year of the date of grant 20% vesting
	After 4 year of the date of grant 30% vesting
	After 5 year of the date of grant 35% vesting
Category III	After 1 year of the date of grant 5% vesting
	After 2 year of the date of grant 10% vesting
	After 3 year of the date of grant 20% vesting
	After 4 year of the date of grant 30% vesting
	After 5 year of the date of grant 35% vesting
Contractual life of options	Graded vesting over 5 years

b) Measurement of fair value :

The fair values are measured based on the Black-Scholes-option valuation model. Service and non-market performance conditions attached to the arrangements were not taken into account in measuring fair value.

The inputs used in the measurement of the fair values at grant date and measurement date of the stock options were as follows.

Particulars					
Vesting	1 Year	2 Year	3 Years	4 Years	5 Years
Share price at grant date (Face value - ₹ 2 per share)	₹ 329	₹ 329	₹ 329	₹ 329	₹ 329
Exercise price (Face value - ₹ 2 per share)					
Expected volatility (weighted average)	31.41%	33.82%	40.78%	43.12%	42.13%
Expected life (weighted average)	1.25 years	2.25 years	3.25 years	4.25 years	5.25 years
Expected dividend	0.30%	0.30%	0.30%	0.30%	0.30%
Risk-free interest rate (based on government bond)	6.69% p.a.	6.77% p.a.	6.80% p.a.	6.81% p.a.	6.82% p.a.

Weighted-average exercise prices and weighted-average fair values of options

Date of Vesting	1 Year	2 Year	3 Years	4 Years	5 Years
Weighted-average exercise prices	64	156	156	156	156
Weighted-average fair value of options	269	195	208	219	227

Notes to the Consolidated Financial Statements

for the year ended 31 March 2025

(₹ in million)

c) Reconciliation of outstanding stock options :

Particular	31 March 2025 No. of options	31 March 2024 No. of options
Outstanding at 1 April	5,70,000	-
Granted		5,76,000
Vested	-	-
Forfeited	-	-
Expired	14,175	6,000
Exercised	57,075	-
Outstanding at 31 March	4,98,750	5,70,000
Exercisable at 31 March	-	-

d) Expense recognized in the Consolidated Statement of Profit and Loss :

	31 March 2025	31 March 2024
AETL ESOS 2022	34.14	30.31
Total expense recognized in 'employee benefits'	34.14	30.31

46A Employee share-based payment plans

a) Description of share-based payment arrangements:

As at 31 March 2025, the Company has the following share-based payment arrangements for employees.

'AETL Employee Stock Option Scheme 2022'- ("AETL ESOS 2022")

AETL ESOS 2022 provides for the grant of 512,500 stock options to specified employees on 27 March 2025. The AETL ESOS 2022 had been formulated by Board of Directors which was further adopted by Nomination and Remuneration committee. The Shareholders approved the scheme on 12 August 2023. The plan entitles specified employees to purchase shares in the Company at the stipulated exercise price, subject to compliance with vesting conditions. As per the plan, holders of vested options are entitled to purchase one equity share of face value of ₹ 2 each for every option as per the scheme.

512,500 Equity Shares of Face Value of ₹ 2 each are reserved for issue under AETL Employee Stock Option Scheme 2022 (AETL ESOS-2022)

The terms and conditions related to the grant of the share options are as follows:

Employees entitled	Specified employees
Number of options	5,12,500
Scheme formulation	
Category I	First 500 Options at the Exercise Price of ₹ 2/- each
Category II	Employees who have been granted Options upto 5,000; First 500 Options at ₹ 2/- each and remaining Options at ₹ 166/-
Category III	Employees who have been granted Options more than 5,000; First 500 Options at ₹ 2/- each, Next 4,500 Option at ₹ 166/- and remaining Options at ₹ 221/-
Vesting conditions	
Category I	After 1 year of the date of grant
Category II	First 500 option after 1 year of the date of grant and
	for balance options
	After 1 year of the date of grant 5% vesting
	After 2 year of the date of grant 10% vesting
	After 3 year of the date of grant 20% vesting
	After 4 year of the date of grant 30% vesting
	After 5 year of the date of grant 35% vesting
Category III	After 1 year of the date of grant 5% vesting
	After 2 year of the date of grant 10% vesting
	After 3 year of the date of grant 20% vesting
	After 4 year of the date of grant 30% vesting
	After 5 year of the date of grant 35% vesting
Contractual life of options	Graded vesting over 5 years

Notes to the Consolidated Financial Statements

for the year ended 31 March 2025

(₹ in million)

b) Measurement of fair value :

The fair values are measured based on the Black-Scholes-option valuation model. Service and non-market performance conditions attached to the arrangements were not taken into account in measuring fair value. The inputs used in the measurement of the fair values at grant date and measurement date of the stock options were as follows.

Particulars					
Vesting	1 Year	2 Year	3 Years	4 Years	5 Years
Share price at grant date (Face value - ₹ 2 per share)	₹ 278.90	₹ 278.90	₹ 278.90	₹ 278.90	₹ 278.90
Exercise price (Face value - ₹ 2 per share)					
Expected volatility (weighted average)	38.44%	35.06%	35.64%	35.76%	41.78%
Expected life (weighted average)	1.25 years	2.25 years	3.25 years	4.25 years	5.25 years
Expected dividend	0.68%	0.78%	0.70%	0.62%	0.58%
Risk-free interest rate (based on government bond)	6.24% p.a.	6.21% p.a.	6.20% p.a.	6.21% p.a.	6.22% p.a.

Weighted-average exercise prices and weighted-average fair values of options

Date of Vesting	1 Year	2 Year	3 Years	4 Years	5 Years
Weighted-average exercise prices	81	184	184	184	184
Weighted-average fair value of options	205	125	136	146	162

c) Reconciliation of outstanding stock options :

Particular	31 March 2025 No. of options	31 March 2024 No. of options
Outstanding at 1 April	-	-
Granted	5,12,500	
Vested	-	-
Forfeited	-	-
Expired	-	-
Exercised	-	-
Outstanding at 31 March	5,12,500	-
Exercisable at 31 March	-	-

d) Expense recognized in the Consolidated Statement of Profit and Loss :

	31 March 2025	31 March 2024
AETL ESOS 2022	0.32	-
Total expense recognized in 'employee benefits'	0.32	-

47 Earnings per share (EPS)

Basic EPS amounts are calculated by dividing the profit for the year attributable to equity holders by the weighted average number of Equity shares outstanding during the year.

Diluted EPS amounts are calculated by dividing the profit attributable to equity holders by the weighted average number of Equity shares outstanding during the year plus the weighted average number of Equity shares that would be issued on conversion of all the dilutive potential Equity shares into Equity shares.

i. Profit attributable to Equity holders

	31 March 2025	31 March 2024
Profit attributable to equity holders	1,311.15	1,333.05

Notes to the Consolidated Financial Statements

for the year ended 31 March 2025

(₹ in million)

ii. Weighted average number of equity shares

	31 March 2025	31 March 2024
Issued equity shares at 1 April	111,824,075	111,824,075
Effect of fresh issue of shares for cash under ESOP scheme	28,071	-
Weighted average number of shares at 31 March for basic EPS	111,852,146	111,824,075
Effect of exercise of share options	138,199	55,236
Weighted average number of shares at 31 March for diluted EPS	111,990,345	111,879,311

Basic and Diluted earnings per share

	31 March 2025	31 March 2024
Basic earnings per share	11.72	11.92
Diluted earnings per share	11.71	11.92

Note 48

Additional information as required by Paragraph 2 of the General Instructions for Preparation of Consolidated Financial Statements to Schedule III to the Companies Act, 2013.

Particulars	As at 31 March 2025		Year ended 31 March 2025		Year ended 31 March 2025		Year ended 31 March 2025	
	Net assets i.e. total assets minus total liabilities		Share in profit or loss		Share of Other Comprehensive income		Share of Total Comprehensive income	
	As a % of consolidated net assets	₹ in million	As a % of consolidated profit and loss	₹ in million	As a % of OCI	₹ in million	As a % of Total Comprehensive income	₹ in million
Parent								
Advanced Enzyme Technologies Limited	44.29	6,293.41	78.11	1,024.20	(1.83)	(3.44)	68.08	1,020.76
Subsidiaries								
Indian								
Advanced Bio-Agro Tech Limited	1.63	231.89	2.77	36.27	0.03	0.06	2.42	36.32
Advanced EnzyTech Solutions Limited	0.38	54.61	1.68	22.09	(0.00)	(0.00)	1.47	22.09
JC Biotech Private Limited	4.44	630.20	0.92	12.11	(0.87)	(1.63)	0.70	10.46
Scitech Specialties Private Limited	3.48	494.49	2.81	36.83	0.00	0.01	2.46	36.84
Saiganesh EnzyTech Solutions Private Limited	0.83	117.23	1.20	15.71	-	-	1.05	15.71
Foreign								
Advanced Enzymes USA, Inc. (including its subsidiaries)	60.08	8,536.18	54.49	714.47	109.60	206.31	61.41	920.78
Advanced Enzymes Europe B.V. (including its subsidiaries)	3.64	516.87	2.27	29.75	8.60	16.20	3.06	45.95
Total eliminations/adjustments	(15.41)	(2,188.18)	(42.07)	(551.69)	(15.55)	(29.29)	(38.75)	(580.95)
Share of Non- controlling interest	(3.36)	(478.07)	(2.18)	(28.59)	0.02	0.04	(1.90)	(28.55)
Total	100.00	14,208.63	100.00	1,311.15	100.00	188.26	100.00	1,499.41

Notes to the Consolidated Financial Statements

for the year ended 31 March 2025

(₹ in million)

Particulars	As at 31 March 2024		Year ended 31 March 2024		Year ended 31 March 2024		Year ended 31 March 2024	
	Net assets i.e. total assets minus total liabilities		Share in profit or loss		Share of Other Comprehensive income		Share of Total Comprehensive income	
	As a % of consolidated net assets	₹ in million	As a % of consolidated profit and loss	₹ in million	As a % of OCI	₹ in million	As a % of Total Comprehensive income	₹ in million
Parent								
Advanced Enzyme Technologies Limited	43.84	5,804.74	81.11	1,081.24	(1.11)	(1.03)	75.77	1,080.21
Subsidiaries								
Indian								
Advanced Bio-Agro Tech Limited	1.78	235.58	3.02	40.23	0.21	0.20	2.84	40.43
Advanced EnzyTech Solutions Limited	0.40	53.53	1.44	19.23	(0.05)	(0.05)	1.35	19.18
JC Biotech Private Limited	4.68	619.09	1.37	18.31	(0.83)	(0.77)	1.23	17.54
Scitech Specialties Private Limited	3.46	457.65	2.78	37.07	(0.18)	(0.17)	2.59	36.90
Saiganesh EnzyTech Solutions Private Limited	0.83	109.53	1.98	26.44	-	-	1.85	26.44
Foreign								
Advanced Enzymes USA, Inc. (including its subsidiaries)	61.42	8,132.81	46.18	615.54	114.39	105.84	50.60	721.38
Advanced Enzymes (Malaysia) Sdn. Bhd. #	-	-	(0.00)	(0.00)	(0.00)	(0.00)	(0.00)	(0.00)
Advanced Enzymes Europe B.V. (including its subsidiaries)	(0.07)	(9.59)	(5.89)	(78.49)	(0.26)	(0.24)	(5.52)	(78.73)
Total eliminations/adjustments	(12.79)	(1,692.55)	(29.25)	(390.06)	(12.21)	(11.29)	(28.15)	(401.35)
Share of Non- controlling interest	(3.55)	(469.52)	(2.74)	(36.46)	0.04	0.04	(2.56)	(36.42)
Total	100.00	13,241.28	100.00	1,333.05	100.00	92.53	100.00	1,425.58

The above amounts/percentage of net assets and net profit or loss in respect of Advanced Enzyme Technologies Limited and its subsidiaries are determined based on the amount of the respective entities included in Consolidated Financial Statements before elimination of inter company transactions.

Figures are below ₹ 0.01 Million, hence disclosed as ₹ 0.00

49 Acquisition of additional 5.89% stake in JC Biotech Private Limited on 05 March 2024

On 05 March 2024, the Company had acquired additional stake of 5.89% in its subsidiary JC Biotech Private Limited for consideration of ₹ 56.07 million. Post this additional acquisition the Company holds 95.72% stake in the subsidiary. On account of acquisition of additional stake of 5.89% by the Company in JC Biotech Private Limited Non-controlling interest was reduced by ₹ 49.90 million and ₹ 6.17 million was adjusted in other equity. Impact of additional stake of 5.83% acquired in subsidiary JC Biotech Private Limited as on the date of acquisition of the additional stake is summarised as below-

Particulars	Amount
(A) Consideration paid to acquire additional 5.89% stake	56.07
(B) Value of 5.89% non-controlling interest acquired	49.90
(C) Adjusted in other equity (A-B)	6.17

50 Acquisiton of Shri Ganesh Industrial Enzymes on 01 April 2023

On 01 April 2023, the Group completed the acquisition of Shri Ganesh Industrial Enzymes (a partnership firm based in Burhanpur, Madhya Pradesh) ("SGIE"), through a slump sale for a total consideration of ₹ 9.00 million. The Group on finalising of purchase price allocation has recognised fair value of Net Assets acquired of ₹ 5.71 million resulting in Goodwill of ₹ 3.29 million.

Notes to the Consolidated Financial Statements

for the year ended 31 March 2025

(₹ in million)

51 Voluntary strike off of Advanced Enzymes Malaysia Sdn. Bhd. ('AEM')

Effective 8 November 2023, the wholly owned subsidiary AEM was struck off on 8 November 2023 after approval from Registrar of Companies, Malaysia , and status of AEM is now appearing as 'Dissolved'. Consequently, AEM ceases to be the subsidiary of the Company. The Company has written off its investment in equity share capital and loan given by the Company to AEM along with interest receivable and corresponding provision created against investment, loan and interest receivable is also released. There is no impact on the profitability of the Company in the current year.

52 Non controlling interest

Financial information of subsidiaries that have material non-controlling interests is provided below :

Name of the entity	Place of business / country of incorporation	Ownership interest held by the group		Ownership interest held by non-controlling interest	
		31 March 2025	31 March 2024	31 March 2025	31 March 2024
Advanced Bio-Agro Tech Limited	India	60.00%	60.00%	40.00%	40.00%
JC Biotech Private Limited	India	95.72%	95.72%	4.28%	4.28%
Scitech Specialities Private Limited	India	51.00%	51.00%	49.00%	49.00%
Saiganesh Enzytech Solutions Private Limited	India	50.00%	50.00%	50.00%	50.00%

The following table summarises information relating to each of the Group's subsidiary, before any inter-company eliminations:

I. Summarised statement of profit or loss

(a) Advanced Bio-Agro Tech Limited

	31 March 2025	31 March 2024
Total Revenue	478.82	448.28
Profit for the year	36.27	40.23
Other Comprehensive Income	0.06	(0.20)
Profit allocated to non-controlling interests	14.50	16.09
Total comprehensive income allocated to non-controlling interests	14.53	16.01
OCI allocated to non-controlling interests	0.02	(0.08)
Dividends paid to non-controlling interests	16.00	8.00

(b) JC Biotech Private Limited

	31 March 2025	31 March 2024
Total Revenue	599.78	626.26
Profit for the year	12.09	18.31
Other Comprehensive Income	(1.63)	0.77
Ind AS adjustments	(8.69)	(8.80)
Profit allocated to non-controlling interests	0.18	0.41
Total comprehensive income allocated to non-controlling interests	0.11	0.44
OCI allocated to non-controlling interests	(0.07)	0.03
Dividends paid to non-controlling interests	-	-

Notes to the Consolidated Financial Statements

for the year ended 31 March 2025

(₹ in million)

(c) Scitech Specialities Private Limited

	31 March 2025	31 March 2024
Total Revenue	541.93	417.74
Profit for the year	36.83	37.07
Other Comprehensive Income	0.01	0.17
Ind AS adjustments	(23.95)	(24.23)
Profit allocated to non-controlling interests	6.31	6.29
Total comprehensive income allocated to non-controlling interests	6.32	6.37
OCI allocated to non-controlling interests	0.00	0.08
Dividends paid to non-controlling interests	-	-

(d) Saiganesh Enzytech Solutions Private Limited

	31 March 2025	31 March 2024
Total Revenue	212.90	267.43
Profit for the year	15.71	26.44
Other Comprehensive Income	-	-
Ind AS adjustments	(0.51)	(0.51)
Profit allocated to non-controlling interests	7.60	12.96
Total comprehensive income allocated to non-controlling interests	7.60	12.96
OCI allocated to non-controlling interests	-	-
Dividends paid to non-controlling interests	4.00	-

II. Summarised balance sheet

(a) Advanced Bio-Agro Tech Limited

	31 March 2025	31 March 2024
Non-current liabilities	1.54	2.97
Current liabilities	37.83	47.01
	39.37	49.98
Non-current assets	31.76	30.99
Current assets	239.50	254.57
	271.26	285.56
Net assets	231.89	235.58
Net assets attributable to non-controlling interest	92.76	94.23

(b) JC Biotech Private Limited

	31 March 2025	31 March 2024
Non-current liabilities	48.49	43.62
Current liabilities	122.24	155.41
	170.73	199.03
Non-current assets	525.23	538.98
Current assets	275.70	279.14
	800.93	818.12
Net assets	630.20	619.09
Ind AS adjustments	236.54	245.23
Net assets attributable to non-controlling interest	37.09	36.99

Notes to the Consolidated Financial Statements

for the year ended 31 March 2025

(₹ in million)

(c) Scitech Specialities Private Limited

	31 March 2025	31 March 2024
Non-current liabilities	98.39	75.86
Current liabilities	78.37	99.26
	176.76	175.12
Non-current assets	477.30	456.16
Current assets	193.95	176.61
	671.25	632.77
Net assets	494.49	457.65
Ind AS adjustments	89.24	113.19
Net assets attributable to non-controlling interest	286.02	279.71

(d) Saiganesh Enzytech Solutions Private Limited

	31 March 2025	31 March 2024
Non-current liabilities	0.15	0.12
Current liabilities	35.79	54.93
	35.95	55.05
Non-current assets	29.38	23.70
Current assets	123.81	140.87
	153.19	164.57
Net assets	117.23	109.52
Ind AS adjustments	7.15	7.66
Net assets attributable to non-controlling interest	62.20	58.59

III. Summarised cash flow information

(a) Advanced Bio-Agro Tech Limited

	31 March 2025	31 March 2024
Cash flows from(used in) in operating activities	8.64	26.85
Cash flows from(used in) in investing activities	9.08	(16.36)
Cash flows from(used in) in financing activities	(16.65)	(8.64)
Net increase /(decrease) in cash and cash equivalents	1.07	1.85

(b) JC Biotech Private Limited

	31 March 2025	31 March 2024
Cash flows from(used in) in operating activities	2.33	0.12
Cash flows from(used in) in investing activities	(1.14)	(1.79)
Cash flows from(used in) in financing activities	(1.18)	1.66
Net increase /(decrease) in cash and cash equivalents	0.01	(0.01)

(c) Scitech Specialities Private Limited

	31 March 2025	31 March 2024
Cash flows from(used in) in operating activities	14.52	43.65
Cash flows from(used in) in investing activities	(33.37)	(54.08)
Cash flows from(used in) in financing activities	(4.43)	7.93
Net increase /(decrease) in cash and cash equivalents	(23.28)	(2.50)

Notes to the Consolidated Financial Statements

for the year ended 31 March 2025

(₹ in million)

(d) Saiganesh Enzytech Solutions Private Limited

	31 March 2025	31 March 2024
Cash flows from(used in) in operating activities	14.79	(15.85)
Cash flows from(used in) in investing activities	(2.53)	(8.76)
Cash flows from(used in) in financing activities	(15.33)	23.41
Net increase /(decrease) in cash and cash equivalents	(3.07)	(1.20)

53 Goodwill and other intangibles

Impairment testing of Goodwill

For the purposes of impairment testing, goodwill is allocated to the Group's operating divisions which represent the lowest level within the Group at which goodwill is monitored for internal management purposes, which is not higher than the Group's operating segments. The aggregate carrying amounts of goodwill allocated to each unit are as follows:

Particulars	31 March 2025	31 March 2024
Advanced Enzymes USA, Inc.	2,898.81	2,824.04
JC Biotech Private Limited	123.65	123.65
Advanced Enzymes Europe B.V.	292.68	286.00
Advanced EnzyTech Solutions Limited	0.87	0.87
Saiganesh Enzytech Solutions Private Limited (refer note 50)	18.39	18.39
	3,334.40	3,252.95

The recoverable amount of this cash generating unit was based on fair value less costs of disposal, estimated using discounted cash flows.The fair value measurement was categorised as a Level 3 fair value based on inputs in the valuation technique used.

The key assumptions used in the estimation of the recoverable amount are set out below. The values assigned to the key assumptions represent management's assessment of future trends in the relevant industries and have been based on historical data from both external and internal sources.

Particulars	31 March 2025	31 March 2024
Discount rate	8% - 15%	8% - 15%
Terminal value growth rate	3%-5%	3%-5%
Sales growth rate	10% - 20%	10% - 20%

The discount rate was post tax measure estimated based on the weighted-average cost of capital.

The cash flow projections include specific estimates for five years and a terminal growth rate thereafter. The terminal growth rate has been determined based on management's estimate of the long-term business growth rate, consistent with the assumptions that a market participant would make.

Sales growth rate has been considered based on past performance duly adjusted with new sales mix as envisaged by the management.

The Group has performed sensitivity analysis around the base assumptions and has concluded that there are no reasonably possible changes to key assumptions that would cause the carrying amount of the cash generating unit's to exceed its recoverable amount.

54 Financial instruments

i. Financial instruments – Fair values and risk management

A. Accounting classification and fair values

The following table shows the carrying amounts and fair values of financial assets and financial liabilities, including their levels are presented below. It does not include the fair value information for financial assets and financial liabilities not measured at fair value if their carrying amount is a reasonable approximation of fair value.

Notes to the Consolidated Financial Statements

for the year ended 31 March 2025

(₹ in million)

31 March 2025	Note No.	Carrying amount				Fair value			
		FVTPL	FVTOCI	Amortised Cost	Total	Quoted prices in active markets (Level 1)	Significant observable inputs (Level 2)	Significant unobservable inputs (Level 3)	Total
Financial assets									
Non-current investments	7	0.65	-	-	0.65	-	-	0.65	0.65
Long-term loans	8	-	-	0.65	0.65	-	-	-	-
Other non-current financial assets	9	-	-	99.19	99.19	-	-	-	-
Current investments	12	4,802.58	-	-	4,802.58	4,802.58	-	-	4,802.58
Trade receivables	13	-	-	1,153.99	1,153.99	-	-	-	-
Cash and cash equivalents	14	-	-	942.25	942.25	-	-	-	-
Other bank balances	15	-	-	134.60	134.60	-	-	-	-
Short-term loans	16	-	-	1.03	1.03	-	-	-	-
Other current financial assets	17	-	-	80.48	80.48	-	-	-	-
		4,803.23	-	2,412.19	7,215.42	4,802.58	-	0.65	4,803.23
Financial liabilities									
Long-term borrowings	21	-	-	91.83	91.83	-	-	-	-
Non-current lease liability	22	-	-	117.34	117.34	-	-	-	-
Short-term borrowings	24	-	-	123.53	123.53	-	-	-	-
Current lease liability	25	-	-	60.80	60.80	-	-	-	-
Trade payables	26	-	-	172.01	172.01	-	-	-	-
Other Current financial liabilities	27	-	-	266.33	266.33	-	-	-	-
		-	-	831.84	831.84	-	-	-	-

Note: There have been no transfers among Level 1, Level 2 and Level 3 during the year.

31 March 2024	Note No.	Carrying amount				Fair value			
		FVTPL	FVTOCI	Amortised Cost	Total	Quoted prices in active markets (Level 1)	Significant observable inputs (Level 2)	Significant unobservable inputs (Level 3)	Total
Financial assets									
Non-current investments	7	1.65	-	-	1.65	-	-	1.65	1.65
Long-term loans	8	-	-	0.38	0.38	-	-	-	-
Other non-current financial assets	9	-	-	41.93	41.93	-	-	-	-
Current investments	12	4,028.50	-	-	4,028.50	4,028.50	-	-	4,028.50
Trade receivables	13	-	-	985.68	985.68	-	-	-	-
Cash and cash equivalents	14	-	-	1,137.51	1,137.51	-	-	-	-
Other bank balances	15	-	-	131.96	131.96	-	-	-	-
Short-term loans	16	-	-	1.01	1.01	-	-	-	-
Other current financial assets	17	-	-	197.20	197.20	-	-	-	-
		4,030.15	-	2,495.67	6,525.82	4,028.50	-	1.65	4,030.15
Financial liabilities									
Long-term borrowings	21	-	-	69.60	69.60	-	-	-	-
Lease liability	22	-	-	158.56	158.56	-	-	-	-
Short-term borrowings	24	-	-	181.52	181.52	-	-	-	-
Current lease liability	25	-	-	63.40	63.40	-	-	-	-
Trade payables	26	-	-	157.59	157.59	-	-	-	-
Other Current financial liabilities	27	-	-	236.99	236.99	-	-	-	-
		-	-	867.66	867.66	-	-	-	-

Note: There have been no transfers among Level 1, Level 2 and Level 3 during the year.

Notes to the Consolidated Financial Statements

for the year ended 31 March 2025

(₹ in million)

B. Measurement of fair values

The fair value hierarchy is based on inputs to valuation techniques that are used to measure fair value that are either observable or unobservable and consists of the following three levels:

- Level 1 – Inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities.
- Level 2 – Inputs are other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).
- Level 3 – Inputs are not based on observable market data (unobservable inputs). Fair values are determined in whole or in part using a valuation model based on assumptions that are neither supported by prices from observable current market transactions in the same instrument nor are they based on available market data.

The cost of unquoted investments included in Level 3 of fair value hierarchy approximate their fair value because there is a wide range of possible fair value measurements and the cost represents estimate of fair value within that range.

C. Financial risk management

The Group has exposure to the following risks arising from financial instruments:

- Credit risk;
- Liquidity risk; and
- Market risk

i. Risk management framework

The Group's board of directors has overall responsibility for the establishment and oversight of the Group's risk management framework. The board of directors has established the Risk Management Committee, which is responsible for developing and monitoring the Group's risk management policies. The committee reports regularly to the board of directors on its activities

The Group's risk management policies are established to identify and analyse the risks faced by the Group, to set appropriate risk limits and controls and to monitor risks and adherence to limits. Risk management policies and systems are reviewed regularly to reflect changes in market conditions and the Group's activities. The Group, through its training and management standards and procedures, aims to maintain a disciplined and constructive control environment in which all employees understand their roles and obligations.

The audit committee oversees how management monitors compliance with the Group's risk management policies and procedures, and reviews the adequacy of the risk management framework in relation to the risks faced by the Group. The audit committee is assisted in its oversight role by internal audit. Internal audit undertakes both regular and ad hoc reviews of risk management controls and procedures, the results of which are reported to the audit committee.

ii. Credit risk

Credit risk is the risk of financial loss to the Group if a customer or counterparty to a financial instrument fails to meet its contractual obligations, and arises principally from the Group's receivables from customers and investment securities. Credit risk is managed through credit approvals, establishing credit limits and continuously monitoring the creditworthiness of customers to which the Group grants credit terms in the normal course of business. The Group establishes an allowance for doubtful debts and impairment that represents its estimate of incurred losses in respect of trade and other receivables and investments.

Trade and other receivables

The Group's exposure to credit risk is influenced mainly by the individual characteristics of each customer. The demographics of the customer, including the default risk of the industry and country in which the customer operates, also has an influence on credit risk assessment.

There is no concentration of risk for trade receivables.

Summary of the Group's exposure to credit risk by age of the outstanding from various customers is as follows:

	31 March 2025		
	Carrying Amount	Weighted Average Loss Rate	Loss Allowance
Not due	533.30	0.27%	1.45
0-90 days	581.53	0.35%	2.04
91-180 days	18.47	9.20%	1.70
181-270 days	15.04	4.05%	0.61
271-360 days	2.68	20.03%	0.54
More than 360 days	24.19	61.54%	14.88
	1,175.21		21.22

Notes to the Consolidated Financial Statements

for the year ended 31 March 2025

(₹ in million)

	31 March 2024		
	Carrying Amount	Weighted Average Loss Rate	Loss Allowance
Not due	644.11	0.19%	1.25
0-90 days	326.20	0.33%	1.09
91-180 days	5.93	6.53%	0.39
181-270 days	2.25	14.68%	0.33
271-360 days	1.51	23.25%	0.35
More than 360 days	18.04	49.62%	8.95
	998.04		12.36

Expected credit loss assessment for customers as at 31 March 2025 and 31 March 2024

The Group allocates each exposure to a credit risk grade based on a variety of data that is determined to be predictive of the risk of loss (e.g. timeliness of payments, available press information etc.) and applying experienced credit judgement.

Exposures to customers outstanding at the end of each reporting period are reviewed by the Group to determine incurred and expected credit losses. Historical trends of impairment of trade receivables do not reflect any significant credit losses. Given that the macro economic indicators affecting customers of the Group have not undergone any substantial change, the Group expects the historical trend of minimal credit losses to continue.

The movement in the allowance for impairment in respect of trade and other receivables during the year was as follows.

Particulars	Amount
Balance as at 31 March 2023	15.47
Impairment loss recognised	6.30
Less: Amounts written back	9.41
Balance as at 31 March 2024	12.36
Impairment loss recognised	13.85
Less: Amounts written off	4.99
Balance as at 31 March 2025	21.22

The impairment loss is related to several customers that have defaulted on their payments to the Group and are not expected to be able to pay their outstanding balances, mainly due to economic circumstances. Bad debts amounting to ₹ 1.44 million (March 2024: ₹ 1.91 million) have been directly recognised in the statement of profit and loss account.

Cash and cash equivalents

The Group held cash and cash equivalents of ₹ 942.25 million at 31 March 2025 (31 March 2024: ₹ 1,137.51 million). The cash and cash equivalents are held with bank and as money market deposits.

Derivatives

There are no derivatives contracts outstanding as on 31 March 2025.

Investments

The Group limits its exposure to credit risk by generally investing in liquid securities and only with counterparties that have a good credit rating. The Group does not expect any losses from non-performance by these counter-parties, and does not have any significant concentration of exposures to specific industry sectors or specific country risks.

Other than trade and other receivables, the Group has no other financial assets that are past due but not impaired

iii. Liquidity risk

Liquidity risk is the risk that the Group will encounter difficulty in meeting the obligations associated with its financial liabilities that are settled by delivering cash or another financial asset. The Group's approach to managing liquidity is to ensure, as far as possible, that it will have sufficient liquidity to meet its liabilities when they are due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the Group's reputation.

The Group has obtained fund and non-fund based working capital lines from various banks. The Group invests its surplus funds in bank fixed deposit which carry no/low mark-to-market risks. The Group monitors funding options available in the debt and capital markets with a view to maintaining financial flexibility

Notes to the Consolidated Financial Statements

for the year ended 31 March 2025

(₹ in million)

Exposure to liquidity risk:

The following are the remaining contractual maturities of financial liabilities at the reporting date. The amounts are gross and undiscounted except in case of lease liabilities where the amounts are mentioned on discounted basis, and include estimated interest payments:”

31 March 2025	Carrying amount	Contractual cash flows				
		Total	Upto 1 year	1-3 years	3-5 years	More than 5 years
Long-term borrowings	91.83	91.83	-	25.75	26.80	39.28
Interest payable on borrowings	-	28.42	19.38	2.50	2.65	3.89
Non-current lease liability	117.34	117.34	-	106.68	7.61	3.05
Short-term borrowings	123.53	123.53	123.53	-	-	-
Current lease liability	60.80	60.80	60.80	-	-	-
Trade payables	172.01	172.01	172.01	-	-	-
Other financial liabilities	266.33	266.33	266.33	-	-	-

31 March 2024	Carrying amount	Contractual cash flows				
		Total	Upto 1 year	1-3 years	3-5 years	More than 5 years
Long-term borrowings	69.60	69.61	-	11.39	10.11	48.11
Interest payable on borrowings	-	29.38	22.58	1.04	1.00	4.76
Non-current lease liability	158.56	158.56	-	129.91	24.01	4.64
Short-term borrowings	181.52	181.52	181.52	-	-	-
Current lease liability	63.40	63.40	63.40	-	-	-
Trade payables	157.59	157.59	157.59	-	-	-
Other financial liabilities	236.99	236.99	236.99	-	-	-

iv. Market risk

Market risk is the risk that changes in market prices – such as foreign exchange rates, interest rates and equity prices – will affect the Company’s income or the value of its holdings of financial instruments. Market risk is attributable to all market risk sensitive financial instruments including foreign currency receivables and payables and long term debt. We are exposed to market risk primarily related to foreign exchange rate risk. Thus, our exposure to market risk is a function of revenue generating and operating activities in foreign currency. The objective of market risk management is to avoid excessive exposure in our foreign currency revenues and costs.

Currency risk

The Company is exposed to currency risk on account of its operations in other countries. The functional currency of the Company is Indian Rupee. The exchange rate between the Indian rupee and foreign currencies has changed substantially in recent periods and may continue to fluctuate substantially in the future. Consequently, the Company uses derivative instruments, i.e. foreign exchange forward contracts to mitigate the risk of changes in foreign currency exchange rates in respect of its highly probable forecasted transactions and recognized assets and liabilities.

Exposure to currency risk

The currency profile of financial assets and financial liabilities as at 31 March 2025 and 31 March 2024 are as below:

	31 March 2025 USD	31 March 2025 EURO	31 March 2025 Others
Financial assets			
Cash and cash equivalents	0.03	0.06	0.03
Trade and other receivables	89.25	55.87	-
	89.28	55.93	0.03
Financial liabilities			
Trade and other payables	24.85	-	-
	24.85	-	-
Net exposure	64.43	55.93	0.03

Notes to the Consolidated Financial Statements

for the year ended 31 March 2025

(₹ in million)

	31 March 2024 USD	31 March 2024 EURO	31 March 2024 Others
Financial assets			
Cash and cash equivalents	0.02	0.08	0.03
Trade and other receivables	13.59	21.56	3.62
	13.61	21.64	3.65
Financial liabilities			
Trade payables	14.38	1.72	-
	14.38	1.72	-
Net exposure	(0.77)	19.92	3.65

Sensitivity analysis

A reasonably possible strengthening (weakening) of the Indian Rupee against US dollars and Euros at March 31 would have affected the measurement of financial instruments denominated in US dollars and Euros and affected equity and profit or loss by the amounts shown below. This analysis assumes that all other variables, in particular interest rates, remain constant and ignores any impact of forecast sales and purchases.

Effect in Rs	Profit or loss	
	Strengthening	Weakening
31 March 2025		
1% movement		
USD	(0.64)	0.64
EUR	(0.56)	0.56
Others #	(0.00)	0.00
	(1.20)	1.20

Effect in Rs	Profit or loss	
	Strengthening	Weakening
31 March 2024		
1% movement		
USD	0.01	(0.01)
EUR	(0.20)	0.20
Others #	(0.04)	0.04
	(0.23)	0.23

Figures are below ₹ 0.01 Million, hence disclosed as ₹ 0.00

Interest rate risk

Interest rate risk can be either fair value interest rate risk or cash flow interest rate risk. Fair value interest rate risk is the risk of changes in fair values of fixed interest bearing investments because of fluctuations in the interest rates. Cash flow interest rate risk is the risk that the future cash flows of floating interest bearing investments will fluctuate because of fluctuations in the interest rates.

Exposure to interest rate risk

Group’s interest rate risk arises from borrowings. Borrowings issued at fixed rates exposes to fair value interest rate risk. The interest rate profile of the Group’s interest-bearing financial instruments as reported to the management of the Group is as follows.

	31 March 2025	31 March 2024
Fixed-rate instruments		
Financial liabilities - measured at amortised cost		
Term Loan & vehicle loan	103.91	75.32
Floating-rate instruments		
Financial liabilities - measured at amortised cost		
From banks in rupees	111.45	175.80
Total	215.36	251.12

Notes to the Consolidated Financial Statements

for the year ended 31 March 2025

(₹ in million)

Fair value sensitivity analysis for fixed-rate instruments

The Group does not account for any fixed-rate financial assets or financial liabilities at fair value through profit or loss. Therefore, a change in interest rates at the reporting date would not affect profit or loss.

Cash flow sensitivity analysis for variable-rate instruments

The risk estimates provided assume a change of 25 basis points interest rate for the interest rate benchmark as applicable to the borrowings summarised above. This calculation assumes that the change occurs at the balance sheet date and has been calculated based on risk exposures outstanding as at that date assuming that all other variables, in particular foreign currency exchange rates, remain constant. The period end balances are not necessarily representative of the average debt outstanding during the period.

Cash flow sensitivity (net)	Profit or loss	
	25 bp increase	25 bp decrease
31 March 2025		
Variable-rate loan instruments	(0.28)	0.28
Cash flow sensitivity (net)	(0.28)	0.28
31 March 2024		
Variable-rate loan instruments	(0.44)	0.44
Cash flow sensitivity (net)	(0.44)	0.44

55 Capital Management

For the purpose of the Group’s capital management, capital includes issued capital and other equity reserves . The primary objective of the Group’s Capital Management is to maximise shareholders value. The Group manages its capital structure and makes adjustments in the light of changes in economic environment and the requirements of the financial covenants.

The Group monitors capital using adjusted net debt to equity ratio. For this purpose, adjusted net debt is defined as total debt less cash and bank balances.

	31 March 2025	31 March 2024
Non-current borrowings	91.83	69.60
Current borrowings	123.53	181.52
Gross debt	215.36	251.12
Less - Cash and cash equivalents	942.25	1,137.51
Less - Other bank deposits	134.60	131.96
Adjusted net debt	(861.49)	(1,018.35)
Total equity	14,208.63	13,241.28
Adjusted net debt to equity ratio	–*	–*

56 Contingent liabilities and commitments (to the extent not provided for)

	As at 31 March 2025	As at 31 March 2024
a) Contingent liabilities		
Pertains to income tax demand/ matters on account of deductions/ disallowances for earlier years, pending for appeals consequent to order passed against the Company/ demands raised by the Department under Income Tax Act, 1961. Amount paid and adjusted there against and included under Income tax asset ₹ 144.20 million (31 March 2024: ₹ 129.52 million).	53.81	26.00
Pertains to Excise Duty and Service Tax demand raised by Commissioner of Central Excise, Customs and Service tax on account of inadmissible CENVAT credit, incorrect product classification and service tax levy on directors' remuneration for various periods. Amount paid there against and included under note 17 'Other current assets'.	28.52	27.58

Notes to the Consolidated Financial Statements

for the year ended 31 March 2025

(₹ in million)

	As at 31 March 2025	As at 31 March 2024
The Andhra Pradesh Electricity Regulatory Commission (APERC) has issued an order and press release regarding the Fuel and Power Purchase Cost Adjustment (FPPCA) under OP No. 57 to 68 of 2024 for the year 2022-23 and OP No. 69, 70 and 71 of 2024 for the year 2023-24. As per this order, the DISCOM is required to recover the FPPCA true-up amounts for the years 2022-23 and 2023-24 from consumers, at rates determined by the commission spread over 15 and 24 monthly installments respectively.	10.74	-
"The Hon'ble Supreme Court of India (“SC”) by their order dated February 28, 2019, in the case of Surya Roshni Limited & others v/s EPFO, set out the principles based on which allowances paid to the employees should be identified for inclusion in basic wages for the purposes of computation of Provident Fund contribution. Subsequently, a review petition against this decision has been filed and is pending before the SC for disposal.	-	-
In view of the management, the liability for the period from date of the SC order to 31 March 2019 is not significant. Further, pending decision on the subject review petition and directions from the EPFO, the impact for the past period, if any, is not ascertainable and consequently no effect has been given in the accounts. Accordingly, this has been disclosed as a Contingent liability in the financial statements."	93.07	53.58

In respect of above contingent liabilities, it is not practicable for the Group to estimate the closure of these issues and the consequential timings of cash flows, if any, in respect of the same.

b) Commitments

Estimated amount of commitments remaining to be executed		
-Capital (net of advances)	123.81	150.02
	123.81	150.02
	216.88	203.60

57 Research and development

The Group has incurred the following expenditure on research and development activities:

	Year ended 31 March 2025	Year ended 31 March 2024
Revenue expenditure		
Laboratory expenses and consumables	33.13	24.35
Employee benefit expenses	113.05	97.31
Legal and professional charges	9.86	4.49
Technical services	24.64	17.10
Electricity	15.20	9.62
Rent, rates and taxes	2.34	2.22
Repairs and maintenance	11.57	11.47
Travelling and conveyance expenses	2.47	2.59
Other expenses	3.74	3.31
	216.00	172.46
Capital expenditure		
Plant and equipment	25.16	20.69
Furniture and fixture	0.39	0.49
Office equipment	2.82	1.87
Computer and data processing equipments	1.14	1.14
Vehicles	2.68	-
Building	0.15	-

Notes to the Consolidated Financial Statements

for the year ended 31 March 2025

(₹ in million)

	As at 31 March 2025	As at 31 March 2024
	32.34	24.19

58 Corporate Social Responsibility

As required by section 135 of Companies Act, 2013 and Rules therein, a Corporate social responsibility committee has been formed for the Parent Company and its subsidiary (Advanced Bio Agro Tech Limited, JC Biotech Private Limited and SciTech Specialities Private Limited). All the companies had spent the following amount during the year towards corporate social responsibility (CSR) for activities listed under schedule VII of the Companies Act, 2013.

Particulars	For the year ended 31 March 2025	For the year ended 31 March 2024
1) amount required to be spent by the company during the year	20.82	17.15
2) amount of expenditure incurred *	20.82	17.15
3) shortfall at the end of the year	-	-
4) total of previous years shortfall	-	-
5) reason for shortfall	Not applicable	Not applicable
6) nature of CSR activities	Promotion of education, Healthcare and skill development	
7) details of related party transactions, e.g., contribution to a trust controlled by the company in relation to CSR expenditure as per relevant Accounting Standard	-	-
8) where a provision is made with respect to a liability incurred by entering into a contractual obligation, the movements in the provision during the year should be shown separately.	10.77	5.73

*In Parent Company the Committee of Corporate Social Responsibility had approved the budget of ₹ 19.24 million (31 March 2024: ₹ 15.59 million), the Company contributes to the various projects undertaken by various organisations. During the year the amount spent is ₹ 7.97 million (31 March 2024: ₹ 11.28 million) on the ongoing projects and ₹ 0.50 million towards ongoing project (31 March 2024: Nil). The Company has deposited the balance unspent amount of ₹ 10.77 million (31 March 2024: ₹ 4.31 million) in a separate bank account.

During the year Advanced Bio-Agro Tech Limited has spent ₹ 1.53 million (31 March 2024: ₹ 0.15 million) and has transferred the balance unspent amount of ₹ Nil (31 March 2024: 1.42 million) in a separate bank account.

During the year Scitech Specialities Private Limited has spent ₹ 0.05 million (31 March 2024: Nil) and has transferred the balance unspent amount of ₹ Nil in a separate bank account.

During the immediate preceeding financial year JC Biotech Private Limited (“JCB”), Advanced Enzytech Solutions Limited (“AESL”) and Saiganesh Enzytech Solutions Private Limited (“SESPL”) were not having net worth of rupees five hundred crore or more, or turnover of rupees one thousand crore or more or a net profit of rupees five crore or more and hence, provisions of Section 135 of the Act are not applicable to JCB, AESL and SESPL during the year.

59 The Code on Social Security 2020

The Code on Social Security 2020 (‘the Code’) relating to employee benefits, during the employment and post-employment, has received Presidential assent on September 28, 2020. The Code has been published in the Gazette of India. Further, the Ministry of Labour and Employment has released draft rules for the Code on November 13, 2020. However, the effective date from which the changes are applicable is yet to be notified and rules for quantifying the financial impact are also not yet issued. The Company and its subsidiaries incorporated in India will assess the impact of the Code and will give appropriate impact in the financial statements in the period in which, the Code becomes effective and the related rules to determine the financial impact are published. Based on a preliminary assessment, the Company believes the impact of the change will not be significant.

60 Other Statutory Information

- (i) The Group does not have any Benami property, where any proceeding has been initiated or pending against the Group for holding any Benami property.

Notes to the Consolidated Financial Statements

for the year ended 31 March 2025

(₹ in million)

- (ii) The Group does not have any transactions with companies struck off.
- (iii) The Group does not have any charges or satisfaction which is yet to be registered with ROC beyond the statutory period.
- (iv) The Group has not traded or invested in Crypto currency or Virtual Currency during the financial year.
- (v) The Group has not advanced or loaned or invested funds to any other person(s) or entity(ies), including foreign entities (Intermediaries) with the understanding that the Intermediary shall:
- a. directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company (Ultimate Beneficiaries) or
- b. provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries
- (vi) The Group has not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Company shall:
- a. directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or
- b. provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries,
- (vii) The Group does not have any such transaction which is not recorded in the books of accounts that has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961.

61 Proposed Dividend

The Board of Directors recommended a final dividend for the financial year 2024-25 of ₹1.20 (31 March 2024: ₹1.10) per equity share of the face value of ₹2/- each, and the same will be paid after approval of shareholders in the Annual General Meeting of the Company.

62 Previous year amounts have been regrouped/ reclassified wherever necessary.

As per our report of even date attached
for **M S K A & Associates**
Chartered Accountants
Firm’s Registration No: 105047W

for and on behalf of the Board

Amrish Vaidya
Partner
Membership No.: 101739

Mukund Kabra
Wholetime Director
DIN : 00148294
Place: Thane

Vinodkumar Jajoo
Director
DIN : 08224980
Place: Nashik

Place: Thane
Date: 13 May 2025

Sanjay Basantani
Company Secretary
Membership No: A19637
Place: Thane

Beni P. Rauka
Chief Financial Officer
Membership No: 039980
Place: Thane

(Pursuant to first proviso to sub-section (3) of Section 129 read with Rule 5 of Companies (Accounts) Rules, 2014)

Statement containing salient features of the financial statement of subsidiaries/associate companies/joint ventures

FINANCIAL YEAR 2024-25

Part "A": Subsidiaries

(₹ in million except % shareholding & exchange rate)

Notes:-

- The financials of Advanced Enzymes USA are consolidated financials and includes financials of step-down subsidiaries of the Company viz.; Cal-India Foods International Inc., USA, Advanced Supplementary Technologies Corporation, USA and Enzyme Innovation, USA
- The financials of Advanced Enzymes Europe B.V. are consolidated financials and includes financials of evovx technologies GmbH, step down subsidiary of the Company.
- Names of the Subsidiaries which are yet to commence the operations: Starya Labs Inc. (wholly-owned subsidiary of Advanced Enzymes USA Inc.)
- Names of the Subsidiaries which have been sold or liquidated during the year - NIL
- The figures for foreign subsidiaries are arrived on the basis of exchange rate as on March 31, 2025:

#Exchange Rate on 31.03.2025:	Average Exchange Rate for financial year 2024-25:
1USD = ₹ 85.58	1USD = ₹ 84.57
1EUR = ₹ 92.32	1EUR = ₹ 90.76

Part “B” : Associates & Joint Ventures - NIL

For and on behalf of the Board of Directors

Mukund Kabra	Vinodkumar Jajoo	Beni P. Rauka	Sanjay Basantani
Whole-time Director	Director	Chief Financial Officer	Company Secretary
DIN: 00148294	DIN: 08224980	Membership No.: 039980	Membership No.: A19637
Place: Thane	Place: Nashik	Place: Thane	Place: Thane
Date: May 13, 2025			

Notes

[illegible]

Notes

[illegible]

CIN: L24200MH1989PLC051018

'A' Wing, 5th floor, Sun Magnetica, LIC Service Road,
Louiswadi, Thane (W) - 400 604, India.

Tel: +91 22 4170 3200 | **Fax:** +91 22 2583 5159,

Email: info@advancedenzymes.com

Website: www.advancedenzymes.com